data_2ljb_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ljb _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo . . . . . 0 N--CA 1.492 1.423 0 CA-C-O 120.788 0.245 . . . . 0.0 111.973 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.1 tp -63.52 -44.61 93.77 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.779 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.9 p -70.23 -37.76 72.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.436 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.08 -42.12 87.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.947 0.403 . . . . 0.0 110.663 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -43.85 46.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.007 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.3 -35.08 71.31 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.407 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.0 t -60.64 -43.24 97.77 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.027 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.7 mt -53.42 -37.85 30.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.079 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.91 -29.84 41.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.104 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.573 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -61.93 -47.66 88.65 Favored Glycine 0 C--N 1.302 -1.31 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.053 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.47 -29.37 38.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 122.382 -0.481 . . . . 0.0 110.775 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -61.24 -49.33 77.54 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.709 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.76 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.2 p80 -56.7 -28.95 61.87 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.968 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.76 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 78.1 t80 -63.78 -50.36 69.31 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.446 ' O ' ' OG1' ' A' ' 42' ' ' THR . 6.5 tt -57.85 -38.51 66.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.814 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -38.85 74.15 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.472 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -48.65 -32.44 8.29 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 120.847 0.356 . . . . 0.0 110.155 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.446 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 66.5 p -53.24 -42.47 66.44 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.319 179.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.413 ' H ' HD13 ' A' ' 43' ' ' ILE . 2.4 mp -60.95 -47.94 91.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.032 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.56 -29.34 5.56 Favored Glycine 0 C--N 1.303 -1.296 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 . . . . . 0 C--N 1.303 -1.45 0 O-C-N 122.779 -0.248 . . . . 0.0 111.377 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 CA-C-O 120.872 0.28 . . . . 0.0 111.938 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.8 tp -68.0 -43.96 77.68 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.666 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.05 -35.81 65.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.086 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 89.4 t -67.33 -44.02 87.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.53 -37.63 27.64 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.656 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.36 -34.02 75.86 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.948 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -60.05 -42.74 95.11 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.741 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.7 mm -49.96 -31.78 7.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.555 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -69.61 -29.61 42.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.333 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.17 -50.6 44.41 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 121.026 -0.607 . . . . 0.0 111.889 -179.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.0 pt -62.71 -29.8 47.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.88 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -61.16 -46.93 88.51 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.576 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.782 ' HE2' ' NE2' ' C' ' 37' ' ' HIS . 7.8 m-70 -51.53 -50.54 59.82 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -54.2 -44.67 71.82 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 81.9 mt -59.02 -50.24 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.507 -179.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -36.85 69.48 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 121.086 0.47 . . . . 0.0 111.424 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.408 ' O ' ' CD1' ' B' ' 41' ' ' TRP . 9.8 t-105 -49.35 -34.6 16.31 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 113.294 0.849 . . . . 0.0 113.294 -177.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 1.7 t -69.29 -29.31 67.14 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.048 -0.661 . . . . 0.0 110.709 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -61.99 -51.4 72.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.924 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.62 -29.83 19.01 Favored Glycine 0 C--N 1.306 -1.09 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -54.37 -27.47 36.61 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 120.88 0.371 . . . . 0.0 111.176 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -45.72 -29.83 1.4 Allowed 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.986 -176.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -58.29 -51.71 68.62 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.548 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -79.19 -58.91 2.99 Favored 'General case' 0 C--N 1.314 -0.959 0 O-C-N 121.871 -0.518 . . . . 0.0 111.741 -178.183 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 4.7 tt . . . . . 0 C--N 1.294 -1.837 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -179.195 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo . . . . . 0 N--CA 1.494 1.513 0 CA-C-O 120.748 0.228 . . . . 0.0 111.818 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 37.2 tp -65.81 -47.27 75.66 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -69.38 -40.88 80.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.918 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.4 t -67.39 -47.57 80.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.496 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.98 54.85 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.105 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.858 0.361 . . . . 0.0 111.009 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 8.9 t -50.48 -43.88 55.62 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.4 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.3 tp -49.69 -29.35 4.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-O 120.804 0.335 . . . . 0.0 111.279 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.96 -31.69 48.81 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -178.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.544 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.39 -50.28 45.48 Favored Glycine 0 C--N 1.303 -1.266 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.564 -178.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.85 -29.51 43.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-O 120.987 0.422 . . . . 0.0 110.452 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.3 tp -62.04 -50.78 70.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.066 -0.515 . . . . 0.0 112.13 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.782 ' NE2' ' HE2' ' B' ' 37' ' ' HIS . 1.8 p80 -57.79 -28.96 64.49 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.642 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.691 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 87.4 t80 -56.99 -44.24 82.52 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.228 -179.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.446 ' O ' ' OG1' ' C' ' 42' ' ' THR . 68.1 mt -55.1 -42.68 66.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.152 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.28 -38.16 75.01 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 120.967 0.413 . . . . 0.0 110.722 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . 0.424 ' CZ3' ' ND1' ' B' ' 37' ' ' HIS . 5.7 t-105 -49.59 -32.85 13.64 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.199 -179.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.446 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.2 p -65.58 -38.26 89.03 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.829 0.347 . . . . 0.0 110.961 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 29.5 mm -60.64 -50.43 80.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.021 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.21 -29.47 15.74 Favored Glycine 0 C--N 1.307 -1.066 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -50.19 -28.2 7.12 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp . . . . . 0 C--N 1.306 -1.322 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.934 -177.678 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 CA--C 1.533 0.307 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.03 41.48 0.66 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.087 1.858 . . . . 0.0 111.938 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -65.54 -48.69 71.62 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.672 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.32 -34.44 58.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.203 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 96.2 t -69.83 -45.62 76.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.524 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.44 -34.87 17.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.032 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.71 -29.74 69.8 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.062 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.4 t -55.04 -42.1 72.25 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.034 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -53.93 -31.84 21.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.73 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -70.98 -29.71 38.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.079 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.93 -45.0 90.7 Favored Glycine 0 C--N 1.306 -1.103 0 C-N-CA 121.26 -0.495 . . . . 0.0 112.392 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 16.5 pt -65.8 -38.42 82.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.038 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 47.5 tp -49.52 -40.34 37.43 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.551 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.479 ' HE2' ' NE2' ' A' ' 37' ' ' HIS . 2.1 m-70 -59.82 -39.16 84.12 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.687 -0.405 . . . . 0.0 111.739 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 79.7 t80 -61.24 -48.57 80.84 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -178.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.436 ' O ' ' OG1' ' D' ' 42' ' ' THR . 1.3 pp -66.02 -39.07 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.534 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.45 -41.31 72.97 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.803 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.02 -29.54 5.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.429 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.436 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 53.1 p -65.29 -30.3 71.15 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.537 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.4 mp -70.15 -51.48 38.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.397 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.83 -29.99 55.92 Favored Glycine 0 C--N 1.305 -1.158 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 27.0 t-80 -56.3 -28.32 58.4 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 122.866 -0.196 . . . . 0.0 111.515 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.308 -1.204 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.979 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo . . . . . 0 N--CA 1.493 1.488 0 CA-C-O 120.882 0.284 . . . . 0.0 112.085 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 12.4 tp -62.15 -48.88 78.15 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.186 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.0 p -70.33 -32.39 50.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.532 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.4 t -70.29 -43.33 78.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 120.78 0.324 . . . . 0.0 110.929 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.46 -40.06 58.7 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.158 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -31.23 69.74 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.362 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -62.38 -37.8 87.12 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.008 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -57.37 -35.04 47.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.075 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.7 mt -67.99 -32.42 56.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.539 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.498 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.48 -44.72 82.69 Favored Glycine 0 C--N 1.302 -1.329 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.425 -178.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 70.4 mt -70.14 -29.74 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.888 0.375 . . . . 0.0 111.202 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.72 -47.66 82.62 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.704 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.682 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -58.27 -28.69 65.18 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.468 -179.054 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.682 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 68.9 t80 -54.13 -44.06 71.03 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.426 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 8.9 tp -58.02 -43.12 84.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.378 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.426 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.5 -35.12 73.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.984 0.421 . . . . 0.0 110.976 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -49.21 -37.85 24.23 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.151 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.37 -29.53 68.99 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.287 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mm -60.42 -48.86 86.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.104 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.87 -32.28 11.28 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 121.294 -0.479 . . . . 0.0 112.015 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-160 . . . . . 0 C--N 1.304 -1.404 0 CA-C-N 116.865 0.333 . . . . 0.0 111.369 -179.549 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo . . . . . 0 N--CA 1.496 1.632 0 CA-C-O 120.743 0.226 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 tp -70.7 -42.98 69.94 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -70.35 -44.85 77.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.519 -179.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 39.8 t -68.82 -43.83 82.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.74 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -40.9 44.44 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.151 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -54.6 -28.57 47.36 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -48.77 -40.39 28.68 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 5.0 tp -49.2 -36.64 9.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.447 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -70.18 -29.54 40.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.54 -51.02 55.86 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.022 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 29.7 pt -65.46 -37.99 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.132 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 tt -59.68 -48.68 80.73 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 121.307 0.575 . . . . 0.0 109.547 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -48.98 -46.72 44.12 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.249 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -68.64 -39.17 80.83 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.946 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.477 ' O ' ' OG1' ' B' ' 42' ' ' THR . 80.1 mt -61.42 -46.33 96.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.04 -179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.12 -40.89 95.13 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.843 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 -48.42 -33.1 8.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.407 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.477 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 80.6 p -52.26 -49.51 63.92 Favored 'General case' 0 C--N 1.3 -1.575 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.266 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.16 -51.45 71.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 C-N-CA 121.004 -0.279 . . . . 0.0 111.416 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.12 -29.4 36.12 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 3.9 t-160 -60.72 -30.0 69.7 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 120.89 0.376 . . . . 0.0 110.996 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -48.67 -33.22 9.62 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.58 -178.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -64.37 -49.62 70.93 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.4 OUTLIER -59.79 -51.59 69.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-O 120.828 0.347 . . . . 0.0 111.928 -178.552 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 5.6 tt . . . . . 0 C--N 1.299 -1.618 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.529 -179.705 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo . . . . . 0 N--CA 1.493 1.443 0 CA-C-O 120.86 0.275 . . . . 0.0 112.039 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.3 mp -70.11 -40.59 74.8 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.835 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.16 -45.59 75.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.384 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.8 t -66.66 -45.41 88.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.902 0.382 . . . . 0.0 110.758 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.09 -44.24 87.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.84 -29.43 70.62 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.315 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 22.7 t -53.54 -41.3 66.29 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.328 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 11.3 tt -49.91 -29.15 4.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-O 120.94 0.4 . . . . 0.0 111.175 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 16.1 mt -64.55 -37.43 80.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.12 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.55 -47.8 83.69 Favored Glycine 0 C--N 1.302 -1.321 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.408 -178.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -69.58 -30.02 43.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.72 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -62.2 -50.62 71.08 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -178.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.673 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -52.92 -29.17 27.07 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.642 -178.523 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.673 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 42.7 t80 -61.16 -42.28 98.27 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.572 -0.285 . . . . 0.0 111.522 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' OG1' ' C' ' 42' ' ' THR . 76.9 mt -58.25 -49.72 80.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.824 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.59 -34.65 74.44 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.036 0.446 . . . . 0.0 110.649 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.1 -32.71 10.31 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.233 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.433 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.1 p -60.51 -36.08 77.51 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.258 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.39 -50.41 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.469 -179.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.89 -30.05 35.89 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 121.206 -0.521 . . . . 0.0 111.979 -179.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -50.87 -29.55 12.19 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 120.661 0.267 . . . . 0.0 111.627 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp . . . . . 0 C--N 1.304 -1.413 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.739 -177.666 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 t70 . . . . . 0 CA--C 1.538 0.489 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.33 55.97 3.73 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.015 1.81 . . . . 0.0 112.002 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.58 -45.51 68.49 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.597 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 t -70.48 -38.21 72.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.425 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 85.1 t -68.57 -43.22 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.848 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -31.9 12.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.021 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.09 69.5 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.959 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.2 t -54.22 -42.15 69.48 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.025 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 mm -50.7 -34.47 12.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.68 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -71.43 -29.27 34.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.358 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.59 -50.99 51.52 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.645 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 pp -62.87 -28.97 46.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.07 0.435 . . . . 0.0 110.628 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.5 tp -60.88 -41.61 96.32 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.305 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 25.2 m170 -56.07 -41.3 74.89 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.613 -179.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -61.43 -47.86 83.81 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -178.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.476 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.3 pt -63.46 -43.73 98.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.163 -178.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.87 98.99 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.967 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -49.67 -33.83 16.8 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.521 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.476 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 54.5 p -59.21 -42.18 90.34 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.785 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.441 HD13 ' H ' ' D' ' 43' ' ' ILE . 4.7 mp -71.56 -53.1 21.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.4 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.39 -29.07 10.26 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -58.72 -28.18 65.59 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.481 ' N ' HD12 ' D' ' 46' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.244 0 N-CA-C 112.654 0.613 . . . . 0.0 112.654 -177.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo . . . . . 0 N--CA 1.492 1.424 0 CA-C-O 120.765 0.235 . . . . 0.0 112.069 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.3 tp -66.84 -46.49 74.95 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.686 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.5 p -70.47 -38.46 73.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.373 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -70.03 -43.28 79.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.948 0.404 . . . . 0.0 110.674 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -36.47 25.73 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.096 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.43 -29.25 69.92 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -56.39 -43.83 79.65 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.4 pt -50.59 -29.51 6.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-O 120.746 0.308 . . . . 0.0 111.204 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -67.94 -29.95 46.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.592 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.99 -49.85 51.05 Favored Glycine 0 C--N 1.303 -1.275 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.181 -179.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.55 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 3.1 mp -66.4 -29.53 46.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-O 120.696 0.284 . . . . 0.0 111.063 -179.364 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 34.0 tp -62.02 -49.25 76.78 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.681 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.3 p80 -57.91 -29.21 64.92 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.937 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.681 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 68.1 t80 -59.31 -44.29 92.58 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.742 -0.383 . . . . 0.0 111.031 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.422 ' O ' ' OG1' ' A' ' 42' ' ' THR . 77.9 mt -57.34 -48.89 81.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.89 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.6 -35.49 77.41 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 120.911 0.386 . . . . 0.0 110.747 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.67 -33.31 9.77 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.788 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.422 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 54.1 p -62.42 -33.2 74.31 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.003 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' A' ' 45' ' ' HIS . 16.1 mm -70.12 -46.65 71.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.886 -0.325 . . . . 0.0 110.583 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.23 -24.28 0.56 Allowed Glycine 0 C--N 1.301 -1.379 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.423 ' N ' ' O ' ' A' ' 43' ' ' ILE . 5.7 t-80 . . . . . 0 C--N 1.299 -1.597 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo . . . . . 0 N--CA 1.495 1.584 0 CA-C-O 120.935 0.306 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 40.1 tp -69.55 -47.46 63.62 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.861 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -70.43 -35.14 60.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.03 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 45.5 t -70.15 -47.09 69.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.358 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -37.85 30.87 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.162 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.08 -31.61 69.04 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.667 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 5.7 t -57.09 -36.02 70.11 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.57 -35.11 37.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.5 mt -71.29 -29.69 36.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.471 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.68 -44.7 88.97 Favored Glycine 0 C--N 1.307 -1.058 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.017 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -64.46 -43.42 96.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.825 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.2 tp -57.45 -42.7 83.03 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.21 -47.64 46.05 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.101 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -70.06 -37.25 75.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' B' ' 42' ' ' THR . 96.1 mt -63.39 -43.59 98.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.587 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.63 -37.82 80.02 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 120.927 0.394 . . . . 0.0 110.681 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.63 -31.15 10.18 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.283 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 41.0 p -50.96 -36.06 36.87 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.158 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.516 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.5 mp -64.48 -50.29 76.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.66 -0.246 . . . . 0.0 111.078 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.3 -29.3 10.05 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.735 -0.546 . . . . 0.0 111.735 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-160 -53.56 -27.01 23.87 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 2.1 pp -48.92 -37.54 20.16 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -64.36 -51.15 64.75 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.569 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -68.45 -53.99 19.91 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -178.246 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 14.4 tt . . . . . 0 C--N 1.297 -1.691 0 C-N-CA 120.684 -0.407 . . . . 0.0 111.391 -178.639 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo . . . . . 0 N--CA 1.494 1.515 0 CA-C-O 120.961 0.317 . . . . 0.0 111.765 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.95 -47.16 81.54 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.368 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -69.67 -43.14 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.148 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -64.36 -43.32 97.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.575 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.13 -44.63 96.21 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.011 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.38 -29.49 70.56 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.789 0.328 . . . . 0.0 111.349 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -55.82 -43.02 76.54 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.432 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.4 tp -49.71 -28.9 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 120.804 0.335 . . . . 0.0 111.341 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.0 -31.03 46.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.104 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.99 -50.28 41.78 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.271 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 5.8 tp -68.41 -29.48 44.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.849 0.357 . . . . 0.0 110.482 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.16 -48.77 80.32 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.777 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.666 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -58.78 -29.24 66.65 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.561 -0.456 . . . . 0.0 111.886 -178.538 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.666 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 66.7 t80 -60.33 -45.49 93.27 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.939 -0.305 . . . . 0.0 111.361 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' OG1' ' C' ' 42' ' ' THR . 73.7 mt -54.98 -46.4 76.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.562 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -34.56 72.77 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.411 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -48.55 -29.69 4.49 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.879 -178.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.5 p -63.06 -33.21 74.95 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.743 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.526 ' N ' ' CD1' ' C' ' 43' ' ' ILE . 1.5 mp -65.28 -47.84 85.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.859 0.361 . . . . 0.0 110.598 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.78 -29.12 5.83 Favored Glycine 0 C--N 1.3 -1.466 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.504 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -53.41 -29.33 34.46 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.874 0.337 . . . . 0.0 111.732 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 7.5 mp . . . . . 0 C--N 1.308 -1.205 0 CA-C-O 120.415 0.15 . . . . 0.0 111.05 -178.401 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' D' ' 26' ' ' LEU . 6.8 m-20 . . . . . 0 CA--C 1.533 0.29 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -72.33 40.18 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.221 1.947 . . . . 0.0 111.968 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.421 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.5 tp -70.74 -43.59 68.54 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.908 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.68 -40.67 77.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.061 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.46 -42.25 78.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.599 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -56.51 -40.02 74.32 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.791 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.86 -29.37 70.14 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.649 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -49.32 -36.41 21.03 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.7 tp -53.75 -33.84 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 121.059 0.457 . . . . 0.0 110.397 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.6 mt -71.16 -29.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.429 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.51 -43.92 91.27 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 121.358 -0.449 . . . . 0.0 112.503 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 28.3 pt -68.39 -32.68 56.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.653 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -53.24 -41.44 65.42 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.621 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 18.7 m170 -54.48 -42.92 71.27 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.704 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -56.96 -47.19 81.3 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -178.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.7 pt -65.01 -46.04 92.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.932 -0.707 . . . . 0.0 111.503 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.43 -37.92 77.62 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.63 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.472 ' O ' ' CD1' ' D' ' 41' ' ' TRP . 13.1 t-105 -49.07 -28.46 4.15 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.35 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 4.0 m -59.61 -30.95 69.05 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 96.1 mt -62.46 -50.55 79.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.487 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.22 -29.48 9.77 Favored Glycine 0 C--N 1.303 -1.281 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -62.89 -29.13 70.53 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.76 0.281 . . . . 0.0 111.76 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.304 -1.396 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo . . . . . 0 N--CA 1.495 1.588 0 CA-C-O 120.9 0.292 . . . . 0.0 111.573 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.8 tp -70.16 -44.53 68.62 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.754 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.7 -36.27 64.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.122 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.07 -44.7 78.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.976 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.49 -31.05 9.25 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.582 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.5 -30.11 66.8 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 41.2 t -60.7 -44.45 96.54 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.592 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.526 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.1 mp -52.12 -29.79 12.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.804 0.335 . . . . 0.0 110.353 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.4 mt -70.6 -29.62 39.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.211 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.501 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -64.04 -45.93 92.62 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.416 HD11 ' H ' ' A' ' 35' ' ' ILE . 4.2 mp -69.9 -29.56 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.053 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.0 tt -61.84 -42.48 99.09 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.54 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.68 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -68.03 -28.59 67.53 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 120.239 -0.584 . . . . 0.0 111.456 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.68 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 76.7 t80 -66.49 -47.86 71.66 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' A' ' 42' ' ' THR . 7.2 tt -57.61 -35.9 52.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.24 -0.584 . . . . 0.0 110.442 -179.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.64 -36.11 73.25 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.659 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -52.95 -35.5 58.77 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.809 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 81.0 p -59.49 -37.12 77.43 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.669 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.545 ' CD1' ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -69.25 -50.9 48.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.673 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.68 -28.32 6.87 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 111.991 -0.444 . . . . 0.0 111.991 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 33.7 t-80 . . . . . 0 C--N 1.293 -1.859 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -179.382 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo . . . . . 0 N--CA 1.498 1.756 0 CA-C-O 121.213 0.422 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -70.85 -48.84 51.72 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.793 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 93.9 t -70.19 -39.43 76.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.095 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 53.1 t -70.17 -45.45 75.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.959 179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.07 -30.39 6.3 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.438 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.05 -29.54 69.79 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.057 0.456 . . . . 0.0 110.313 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -54.26 -37.23 64.46 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.649 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 70.4 mt -55.28 -33.9 32.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.1 mt -70.9 -31.5 45.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.223 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.71 -45.42 92.84 Favored Glycine 0 C--N 1.306 -1.127 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.045 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -65.59 -41.95 91.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.205 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -59.42 -46.39 88.86 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -49.87 -42.88 48.7 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.856 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -68.15 -39.07 82.75 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.364 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.432 ' O ' ' OG1' ' B' ' 42' ' ' THR . 92.9 mt -60.71 -40.97 86.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.919 -179.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.06 -40.85 74.81 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.023 0.44 . . . . 0.0 110.402 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.52 -31.09 9.5 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.858 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.432 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 62.7 p -60.77 -35.68 77.05 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.41 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.401 HG21 HD13 ' B' ' 43' ' ' ILE . 26.2 mm -67.38 -51.16 55.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.837 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.8 -39.38 31.88 Favored Glycine 0 C--N 1.305 -1.144 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -49.05 -26.55 2.7 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 120.741 0.305 . . . . 0.0 111.563 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.1 -32.55 6.98 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.778 -178.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' B' ' 44' ' ' GLY . 11.1 p30 -70.37 -50.32 40.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -177.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.522 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 4.1 pt20 -69.54 -52.43 26.33 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -177.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt . . . . . 0 C--N 1.296 -1.725 0 C-N-CA 120.661 -0.416 . . . . 0.0 110.638 -179.377 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo . . . . . 0 N--CA 1.493 1.448 0 CA-C-O 121.062 0.359 . . . . 0.0 111.919 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 45.8 tp -66.46 -47.72 72.23 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.471 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.5 t -69.98 -32.17 50.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.991 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.94 -49.5 56.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.588 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.25 -35.32 17.29 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.293 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.22 -29.79 71.06 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 120.915 0.388 . . . . 0.0 110.904 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 34.7 t -50.0 -38.91 39.43 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.157 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.1 tp -53.69 -29.47 17.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.187 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.24 -36.93 69.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.014 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' NE2' ' C' ' 37' ' ' HIS . . . -63.72 -49.4 68.98 Favored Glycine 0 C--N 1.305 -1.156 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.687 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 tp -70.05 -29.86 41.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 CA-C-O 121.032 0.444 . . . . 0.0 110.105 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 27.2 tp -59.81 -49.41 77.83 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.64 -179.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.707 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.3 p80 -59.62 -29.03 67.72 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.68 -178.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.707 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 65.0 t80 -61.16 -43.36 99.0 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.031 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' OG1' ' C' ' 42' ' ' THR . 66.2 mt -58.8 -45.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.087 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -38.96 75.55 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.585 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.6 -29.89 7.86 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.807 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.435 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 64.6 p -60.9 -37.7 83.16 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.748 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.5 mm -63.05 -50.54 79.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.31 -179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.12 -31.3 18.58 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 111.899 -0.48 . . . . 0.0 111.899 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -49.86 -28.09 6.03 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.0 pp . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 120.696 -0.401 . . . . 0.0 111.451 -178.458 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.499 ' C ' ' H ' ' D' ' 26' ' ' LEU . 10.5 m-20 . . . . . 0 CA--C 1.534 0.34 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.56 21.02 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.244 1.963 . . . . 0.0 111.752 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.499 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.9 tp -67.95 -47.15 69.44 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.532 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.97 -37.8 73.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 84.5 t -69.93 -43.57 79.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.525 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.39 -32.16 11.01 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.651 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.81 -29.68 69.68 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.964 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.0 t -56.27 -42.17 77.03 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.053 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.502 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 2.0 mp -55.32 -35.63 37.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.448 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -71.06 -32.58 48.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.412 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.74 -44.29 98.1 Favored Glycine 0 C--N 1.305 -1.141 0 C-N-CA 121.336 -0.459 . . . . 0.0 112.123 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.6 pt -68.44 -29.35 43.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.841 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.6 tp -57.35 -43.04 83.13 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.037 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 4.1 m170 -60.76 -35.02 75.35 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.123 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 t80 -62.34 -48.53 79.41 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.426 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.0 pt -61.6 -42.19 93.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.989 -178.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.21 -40.27 74.64 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.86 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -48.46 -29.81 4.49 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.605 -179.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 73.3 p -64.86 -30.87 71.89 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.5 mp -69.87 -51.74 37.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.26 -31.73 27.79 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.7 t-160 -60.4 -28.28 68.12 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.549 0.214 . . . . 0.0 111.276 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.306 -1.312 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.487 -177.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.494 1.509 0 CA-C-O 120.986 0.327 . . . . 0.0 111.594 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.476 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 8.9 mp -70.39 -43.83 69.25 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.043 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' A' ' 28' ' ' VAL . 13.6 p -70.89 -42.62 77.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.487 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.401 ' N ' ' CG1' ' A' ' 27' ' ' VAL . 66.1 t -68.41 -43.64 83.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.815 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.81 -34.45 53.74 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -30.54 67.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.5 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -60.36 -44.83 95.22 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.621 -179.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.565 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.2 mp -50.29 -29.08 5.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-O 120.825 0.345 . . . . 0.0 110.71 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.95 -29.32 39.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.809 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.54 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -68.61 -50.18 38.7 Favored Glycine 0 C--N 1.305 -1.172 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.324 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.417 HD12 ' H ' ' A' ' 35' ' ' ILE . 4.2 mp -65.98 -29.56 47.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.999 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.22 -46.02 88.96 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.679 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.7 OUTLIER -57.7 -28.35 63.74 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.625 -178.787 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.676 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 30.9 t80 -55.5 -45.76 77.02 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 3.4 tp -57.36 -44.56 84.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.299 -178.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.453 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.9 -35.4 72.28 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 120.824 0.345 . . . . 0.0 110.827 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.41 ' HE1' ' HB1' ' D' ' 40' ' ' ALA . 4.3 t-105 -48.95 -32.02 8.36 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.353 -178.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 61.2 p -57.56 -30.23 65.07 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.198 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 67.1 mt -64.2 -46.29 93.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.086 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.89 -27.56 3.4 Favored Glycine 0 C--N 1.297 -1.608 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.592 -178.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 t-80 . . . . . 0 C--N 1.304 -1.402 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -179.07 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_exo . . . . . 0 N--CA 1.496 1.641 0 CA-C-O 121.151 0.396 . . . . 0.0 111.91 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 tp -70.66 -49.15 50.36 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.417 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.3 -38.95 76.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.573 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 t -70.56 -45.24 75.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 120.602 -0.439 . . . . 0.0 109.891 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.63 -33.41 9.86 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.242 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.28 69.96 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.482 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.2 t -49.69 -41.82 44.1 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.032 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -50.97 -29.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-O 120.904 0.383 . . . . 0.0 110.456 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.16 -29.55 36.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.204 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.91 -47.08 89.38 Favored Glycine 0 C--N 1.307 -1.067 0 C-N-CA 121.308 -0.472 . . . . 0.0 112.06 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.1 pt -62.12 -44.87 99.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.861 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 55.4 tp -59.97 -45.9 91.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.997 0.427 . . . . 0.0 109.905 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 33.8 t-80 -50.39 -47.56 56.33 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.142 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -66.95 -38.81 86.82 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.516 -179.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.434 ' O ' ' OG1' ' B' ' 42' ' ' THR . 94.6 mt -62.08 -42.16 93.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.762 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.86 -39.74 76.17 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.964 0.412 . . . . 0.0 110.627 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -49.05 -29.32 4.9 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.956 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 77.8 p -54.67 -37.46 65.77 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 35.6 mm -61.16 -49.07 86.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.729 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.88 -29.91 8.66 Favored Glycine 0 C--N 1.305 -1.152 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.743 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -53.96 -27.48 31.49 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -46.43 -32.11 3.07 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -61.41 -50.31 73.38 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 120.705 -0.398 . . . . 0.0 112.039 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -56.26 -53.95 51.1 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -179.043 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 7.8 tt . . . . . 0 C--N 1.296 -1.761 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.31 -179.36 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo . . . . . 0 N--CA 1.492 1.424 0 CA-C-O 120.78 0.242 . . . . 0.0 112.211 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -60.0 -50.67 72.83 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.035 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -70.98 -33.76 53.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 120.937 0.399 . . . . 0.0 111.178 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.7 t -70.3 -42.91 78.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.912 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.98 -39.35 40.61 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.51 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.19 -29.48 69.84 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 120.842 0.353 . . . . 0.0 111.292 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -53.05 -40.87 64.29 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.395 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -49.68 -31.53 6.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.751 0.31 . . . . 0.0 111.428 -179.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -70.23 -29.84 41.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.94 -179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.526 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.26 -50.13 57.97 Favored Glycine 0 C--N 1.304 -1.218 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.908 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 36.8 pt -65.72 -29.65 47.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 120.776 0.322 . . . . 0.0 111.01 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 17.6 tp -61.29 -49.44 77.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.754 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.676 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.61 -29.69 62.42 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.767 -178.287 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.676 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 70.8 t80 -63.3 -44.37 95.21 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.258 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.432 ' O ' ' OG1' ' C' ' 42' ' ' THR . 72.5 mt -56.14 -48.21 79.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.155 -179.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.86 -35.97 81.25 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -50.29 -36.34 31.24 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.346 -179.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.432 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.4 p -54.28 -47.13 72.69 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 120.741 0.305 . . . . 0.0 111.009 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.408 ' H ' HD11 ' C' ' 43' ' ' ILE . 4.0 mp -62.44 -49.82 82.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.76 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.75 -29.74 13.39 Favored Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.031 -179.16 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -56.68 -29.02 61.9 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.8 pp . . . . . 0 C--N 1.305 -1.346 0 N-CA-C 111.625 0.231 . . . . 0.0 111.625 -177.811 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 22.0 t70 . . . . . 0 CA--C 1.537 0.477 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -75.09 43.87 1.07 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.069 1.846 . . . . 0.0 112.166 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.47 -45.79 65.05 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.82 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.67 -41.08 77.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.912 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.73 -41.83 77.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.334 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.8 -38.49 34.7 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.664 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.09 -31.54 72.8 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.258 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.5 t -56.22 -37.93 70.35 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.746 0.308 . . . . 0.0 110.793 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.413 HG23 HD13 ' D' ' 32' ' ' ILE . 19.2 mm -53.5 -29.59 17.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.387 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.4 mt -71.33 -29.24 34.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.465 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.33 -33.64 81.53 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 116.326 -0.397 . . . . 0.0 112.919 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -63.72 -38.48 82.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-N 117.402 0.601 . . . . 0.0 110.707 -179.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 43.6 tp -54.72 -43.09 72.28 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.8 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.679 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 19.3 m170 -51.13 -50.01 59.68 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.412 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -61.21 -42.45 98.61 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.557 -179.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' D' ' 42' ' ' THR . 83.2 mt -60.28 -48.17 89.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.913 -179.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . 0.41 ' HB1' ' HE1' ' A' ' 41' ' ' TRP . . . -70.56 -34.73 72.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.82 0.343 . . . . 0.0 111.178 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.0 t-105 -49.0 -28.04 3.62 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.141 0.496 . . . . 0.0 110.017 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 76.7 p -57.92 -34.88 70.33 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.522 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.4 mp -65.75 -50.92 67.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.759 0.314 . . . . 0.0 110.577 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.85 -29.67 62.08 Favored Glycine 0 C--N 1.302 -1.359 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.882 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -70.64 -32.91 70.39 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.306 -1.286 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.612 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo . . . . . 0 N--CA 1.495 1.581 0 CA-C-O 120.836 0.265 . . . . 0.0 111.755 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.4 tp -64.82 -44.89 88.4 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.202 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.29 -41.42 78.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.756 0.312 . . . . 0.0 111.307 -179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -63.32 -39.89 86.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-O 120.94 0.4 . . . . 0.0 110.921 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.08 -44.12 82.8 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.551 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.59 -37.13 75.16 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.785 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -57.84 -43.48 85.86 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.137 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 69.4 mt -49.32 -37.82 11.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 120.814 0.34 . . . . 0.0 110.778 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -64.77 -29.67 48.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.406 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.537 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -63.27 -50.04 65.94 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.164 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.561 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 2.8 mp -59.64 -29.62 43.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 122.686 -0.303 . . . . 0.0 111.34 -179.047 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tt -63.67 -50.83 67.71 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.67 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -51.26 -29.44 14.6 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.272 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.67 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 63.8 t80 -58.35 -48.1 81.67 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.718 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.6 tp -49.67 -43.53 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.252 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.432 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -72.88 -30.03 63.64 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.76 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.424 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 10.9 t-105 -49.02 -32.38 9.25 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -177.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.453 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -66.14 -33.01 74.79 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.463 -179.452 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -51.09 -43.86 27.51 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.03 0.443 . . . . 0.0 109.839 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.44 -28.71 4.93 Favored Glycine 0 C--N 1.299 -1.505 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.048 -178.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 . . . . . 0 C--N 1.307 -1.27 0 CA-C-N 117.251 0.526 . . . . 0.0 111.645 -179.485 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 N--CA 1.495 1.592 0 CA-C-O 121.15 0.396 . . . . 0.0 111.78 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 tp -70.13 -49.86 46.43 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.076 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -70.19 -33.02 52.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.943 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 87.7 t -69.68 -46.2 75.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.989 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.9 -33.02 9.93 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.639 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.26 -31.51 72.74 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.772 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 37.4 t -58.9 -40.93 85.96 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.623 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 mm -51.71 -29.23 10.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -70.41 -29.95 40.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.42 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.32 -48.4 69.72 Favored Glycine 0 C--N 1.307 -1.043 0 C-N-CA 121.185 -0.531 . . . . 0.0 111.948 -179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.8 pt -67.32 -29.79 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 120.871 0.367 . . . . 0.0 110.678 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.3 tp -59.45 -47.59 84.89 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.661 -179.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.844 ' HE2' ' NE2' ' C' ' 37' ' ' HIS . 7.2 m-70 -49.82 -49.78 47.65 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.648 -179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -50.92 -42.98 59.85 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.617 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.433 ' O ' ' OG1' ' B' ' 42' ' ' THR . 79.1 mt -61.12 -50.43 80.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.598 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.32 -38.4 74.92 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.949 0.404 . . . . 0.0 111.076 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.18 -28.73 4.72 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.035 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.433 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 44.1 p -59.9 -38.63 82.83 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.001 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 29.2 mm -65.77 -51.39 62.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 C-N-CA 120.836 -0.345 . . . . 0.0 111.379 -179.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.417 ' O ' ' OD1' ' B' ' 47' ' ' ASN . . . -50.21 -29.75 16.26 Favored Glycine 0 C--N 1.305 -1.193 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.6 t-160 -56.72 -27.66 59.59 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -47.78 -35.9 10.75 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.672 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.442 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 25.0 p-10 -63.26 -49.62 73.38 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 -178.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.442 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 1.4 tm0? -68.89 -57.45 5.52 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.298 -1.665 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -178.74 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo . . . . . 0 N--CA 1.493 1.452 0 CA-C-O 120.748 0.228 . . . . 0.0 111.999 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 59.7 tp -61.11 -42.21 98.1 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.739 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.2 t -70.13 -42.33 79.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.347 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 98.7 t -60.13 -43.48 93.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 120.955 0.407 . . . . 0.0 110.328 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -48.25 79.27 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.638 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.28 -35.05 69.3 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.847 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.9 t -56.8 -43.66 81.18 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.724 0.297 . . . . 0.0 111.453 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -48.66 -34.6 5.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-O 120.884 0.373 . . . . 0.0 110.459 -178.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.8 mt -64.18 -29.69 48.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.702 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.548 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.9 -51.37 35.06 Favored Glycine 0 C--N 1.306 -1.129 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.579 -178.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 tt -63.1 -29.29 46.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 122.419 -0.46 . . . . 0.0 111.195 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 55.9 tp -62.22 -51.4 67.95 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.589 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.844 ' NE2' ' HE2' ' B' ' 37' ' ' HIS . 1.2 p80 -53.92 -29.5 42.39 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.815 -178.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.743 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 68.9 t80 -57.17 -49.52 75.7 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.564 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -49.88 -43.38 19.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.505 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.77 -31.98 70.23 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.144 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -54.3 -42.68 70.38 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 116.592 -0.276 . . . . 0.0 111.309 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 17.3 p -56.58 -40.36 75.1 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.987 0.422 . . . . 0.0 110.434 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.4 mm -59.06 -50.86 78.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.318 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.8 -28.16 6.93 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -50.41 -40.13 49.22 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.308 -1.237 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 -177.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.9 m-20 . . . . . 0 CA--C 1.528 0.111 0 CA-C-O 120.699 0.285 . . . . 0.0 110.983 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.11 12.6 0.98 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.85 2.366 . . . . 0.0 111.447 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.45 ' H ' ' C ' ' D' ' 24' ' ' ASP . 39.3 tp -70.74 -44.75 66.17 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.607 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.4 p -70.54 -35.06 59.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.39 -50.04 49.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.528 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.66 -33.46 15.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.87 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.46 -34.77 74.87 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.865 0.364 . . . . 0.0 111.132 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 36.7 t -51.85 -38.47 56.08 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.161 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 mm -61.3 -29.64 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.89 0.376 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.405 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 5.1 mt -71.33 -39.17 71.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.418 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.38 -42.2 96.12 Favored Glycine 0 C--N 1.307 -1.068 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.198 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 9.9 tt -70.27 -39.27 76.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.301 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 44.3 tp -49.48 -36.36 22.62 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.437 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.642 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 45.6 m170 -49.93 -43.11 49.65 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.164 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -57.6 -38.29 74.66 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.442 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.427 ' O ' ' OG1' ' D' ' 42' ' ' THR . 6.3 mm -61.67 -50.81 78.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.157 -179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.68 -35.62 72.91 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.956 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.57 -28.65 3.56 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.109 0.48 . . . . 0.0 110.403 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 38.4 p -51.05 -36.66 41.05 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.057 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.408 HG21 HD12 ' D' ' 43' ' ' ILE . 32.2 mm -68.23 -51.13 51.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.127 -179.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.95 -29.48 55.39 Favored Glycine 0 C--N 1.305 -1.184 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -57.23 -27.57 62.14 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.298 -1.636 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.819 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 N--CA 1.492 1.41 0 CA-C-O 120.849 0.271 . . . . 0.0 112.123 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -66.52 -44.32 82.82 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.63 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.07 -35.14 62.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.311 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.9 t -69.63 -43.91 79.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.938 0.399 . . . . 0.0 110.762 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.67 -39.13 35.34 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.115 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.59 -34.38 76.86 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.726 0.298 . . . . 0.0 111.165 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.4 ' O ' ' CD1' ' A' ' 35' ' ' ILE . 33.5 t -59.88 -41.79 92.35 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.797 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.412 HD13 HG22 ' A' ' 32' ' ' ILE . 19.4 mm -52.55 -32.21 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.152 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.6 mt -70.25 -29.78 40.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.702 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.62 -45.1 93.92 Favored Glycine 0 C--N 1.304 -1.23 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.253 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.621 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 3.1 mp -66.82 -29.13 45.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 122.589 -0.359 . . . . 0.0 111.189 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -62.92 -46.96 85.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -178.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.7 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.4 p80 -58.96 -28.42 66.29 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 120.201 -0.6 . . . . 0.0 111.423 -178.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.7 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 33.7 t80 -56.74 -48.66 77.29 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.405 ' O ' ' OG1' ' A' ' 42' ' ' THR . 6.4 tt -59.4 -41.17 83.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.171 -178.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -35.94 73.88 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.47 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.67 -34.19 17.77 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.412 -179.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.405 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 40.2 p -62.19 -29.98 70.75 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.036 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 58.4 mt -61.33 -47.1 95.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.385 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.71 -28.36 5.19 Favored Glycine 0 C--N 1.307 -1.051 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.167 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 4.9 t-160 . . . . . 0 C--N 1.302 -1.496 0 CA-C-N 116.762 0.281 . . . . 0.0 111.271 -179.619 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.495 1.599 0 CA-C-O 120.903 0.293 . . . . 0.0 111.774 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -68.06 -47.96 66.89 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.695 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -70.52 -34.0 55.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -70.0 -45.88 75.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.265 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.04 -35.37 15.46 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.629 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.21 -29.81 70.64 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.679 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 7.0 t -57.88 -41.36 82.34 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.766 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 mm -50.44 -30.61 7.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.584 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.63 -29.34 37.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.4 -49.93 58.3 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 121.047 -0.596 . . . . 0.0 111.787 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.5 pt -63.42 -42.84 97.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.691 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 58.1 tp -60.26 -45.18 94.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.279 0.561 . . . . 0.0 109.615 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -61.08 -41.17 96.16 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.347 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 88.9 t80 -70.67 -46.58 62.94 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.474 ' O ' ' OG1' ' B' ' 42' ' ' THR . 18.0 tt -68.07 -29.97 46.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.317 -178.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -39.98 72.02 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.213 0.53 . . . . 0.0 110.139 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -54.35 -37.45 64.94 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.432 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 31.6 p -55.16 -36.58 65.97 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.603 -0.439 . . . . 0.0 110.934 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.49 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.8 mp -65.04 -50.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.015 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.542 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.51 -30.36 12.8 Favored Glycine 0 C--N 1.305 -1.185 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.43 ' CD2' ' CD ' ' B' ' 48' ' ' GLN . 31.7 t-80 -59.81 -27.04 66.26 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.7 0.286 . . . . 0.0 111.562 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.89 -31.65 12.69 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.774 -0.371 . . . . 0.0 111.943 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 6.9 p30 -68.95 -50.06 52.56 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -177.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.546 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 7.5 pt20 -69.28 -48.51 61.5 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 16.4 tt . . . . . 0 C--N 1.296 -1.744 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.214 -179.154 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo . . . . . 0 N--CA 1.494 1.516 0 CA-C-O 120.861 0.275 . . . . 0.0 111.885 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.3 tp -64.11 -48.44 76.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 59.5 t -70.42 -37.02 69.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 85.8 t -70.12 -43.71 78.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.742 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.48 -38.47 74.6 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.549 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.08 -30.38 71.45 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 120.906 0.384 . . . . 0.0 110.903 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -50.74 -36.47 36.61 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.178 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 11.8 tt -55.27 -29.76 23.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.603 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.41 -36.92 76.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.429 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.61 -46.41 84.49 Favored Glycine 0 C--N 1.303 -1.261 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.16 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 11.0 tt -70.28 -29.06 37.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.778 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 31.8 tp -61.94 -47.23 85.83 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.99 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -56.7 -29.94 62.95 Favored 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 120.421 -0.512 . . . . 0.0 111.876 -178.474 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 77.4 t80 -62.33 -40.63 96.99 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.393 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.458 ' O ' ' OG1' ' C' ' 42' ' ' THR . 96.6 mt -57.43 -46.93 85.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.54 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.18 -34.62 73.19 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 120.81 0.338 . . . . 0.0 110.812 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.2 -30.68 7.31 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.354 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.458 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 42.2 p -53.97 -44.02 70.41 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.923 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.401 ' H ' HD11 ' C' ' 43' ' ' ILE . 4.0 mp -63.66 -48.86 84.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.617 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.23 -33.56 15.67 Favored Glycine 0 C--N 1.304 -1.217 0 C-N-CA 121.259 -0.496 . . . . 0.0 111.881 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -50.58 -28.57 8.95 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 116.814 0.307 . . . . 0.0 111.628 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.2 pp . . . . . 0 C--N 1.308 -1.197 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.931 -177.782 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' D' ' 24' ' ' ASP . 4.2 p30 . . . . . 0 CA--C 1.533 0.296 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.72 45.56 0.9 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.322 2.015 . . . . 0.0 111.753 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 53.9 tp -69.97 -44.02 70.31 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.282 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.52 -38.62 74.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.979 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 95.6 t -67.08 -47.71 81.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.696 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.78 -34.37 19.18 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.015 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.31 -29.73 67.65 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.138 -179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.2 t -57.17 -42.79 81.8 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.127 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.419 HD12 HG23 ' D' ' 32' ' ' ILE . 18.0 mm -51.46 -33.34 14.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 120.881 0.372 . . . . 0.0 110.481 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 4.6 mt -71.51 -29.04 33.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.282 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.36 -47.47 79.08 Favored Glycine 0 C--N 1.309 -0.937 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.118 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -61.15 -42.07 91.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.786 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.5 tp -49.13 -32.24 9.63 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.667 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 29.5 m170 -65.35 -42.88 92.39 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.554 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.69 -50.07 66.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.3 pp -62.83 -39.04 83.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.847 -0.741 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.08 -40.75 78.24 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.335 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.1 t-105 -49.78 -30.2 9.18 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.73 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.2 m -69.59 -35.78 75.64 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 115.604 -0.726 . . . . 0.0 111.116 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 60.7 mt -70.6 -51.54 36.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.012 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.97 -27.8 65.19 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -55.99 -26.56 48.97 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.49 ' N ' HD12 ' D' ' 46' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -177.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo . . . . . 0 N--CA 1.494 1.523 0 CA-C-O 120.796 0.248 . . . . 0.0 111.991 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -67.75 -45.11 75.89 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.2 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.0 p -70.1 -37.2 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.655 -179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.6 t -68.91 -43.7 82.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 120.982 0.42 . . . . 0.0 110.989 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.82 -38.3 21.79 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.629 -179.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.08 -35.86 81.67 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.32 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.8 t -60.4 -44.75 95.41 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.333 -179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.0 mm -50.01 -29.72 5.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.042 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.9 mt -70.5 -30.96 44.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.813 -179.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.53 -48.49 72.82 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.379 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.437 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.4 mp -68.07 -29.5 44.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.74 0.305 . . . . 0.0 111.057 -179.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 45.2 tp -61.8 -47.43 85.17 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.464 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.698 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.1 -28.59 69.2 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.243 -0.583 . . . . 0.0 111.41 -178.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.698 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 51.4 t80 -60.18 -48.74 80.47 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.8 tt -60.73 -39.96 83.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -39.47 72.44 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 120.926 0.393 . . . . 0.0 110.968 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -48.94 -30.83 6.42 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.856 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -57.83 -37.54 73.99 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.8 mm -61.04 -48.88 87.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.804 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.27 -28.12 6.01 Favored Glycine 0 C--N 1.305 -1.163 0 N-CA-C 111.709 -0.557 . . . . 0.0 111.709 -179.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 . . . . . 0 C--N 1.301 -1.507 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.515 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo . . . . . 0 N--CA 1.497 1.689 0 CA-C-O 121.034 0.348 . . . . 0.0 111.567 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 18.1 tp -70.27 -45.07 67.12 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.013 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 95.5 t -70.64 -38.12 72.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.545 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.44 -42.47 78.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.739 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.17 -29.74 14.76 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.595 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.74 -31.55 69.59 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.702 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.5 t -52.17 -40.25 61.2 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.749 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -51.37 -32.79 13.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-O 121.224 0.535 . . . . 0.0 110.368 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -72.35 -29.17 30.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.36 -52.01 24.12 Favored Glycine 0 CA--C 1.528 0.899 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.731 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -70.95 -29.48 37.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 117.971 0.886 . . . . 0.0 110.267 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 57.4 tp -64.7 -44.97 88.56 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.167 0.508 . . . . 0.0 110.113 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -52.91 -43.24 66.07 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.547 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -69.8 -36.7 75.9 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.406 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.465 ' O ' ' OG1' ' B' ' 42' ' ' THR . 88.2 mt -63.33 -42.94 98.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.978 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.41 -36.04 78.53 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.85 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -53.44 -33.48 54.2 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.087 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.465 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 68.0 p -54.91 -40.12 69.51 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.775 -179.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.52 -47.64 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.614 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.12 -29.35 9.04 Favored Glycine 0 C--N 1.305 -1.161 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -49.46 -27.06 3.82 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.551 0.215 . . . . 0.0 111.484 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -47.43 -38.2 13.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.45 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -48.42 -51.06 28.51 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.315 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.42 ' O ' ' CG2' ' B' ' 49' ' ' ILE . 16.4 tt0 -82.08 -143.99 0.06 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.052 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.42 ' CG2' ' O ' ' B' ' 48' ' ' GLN . 12.4 tt . . . . . 0 C--N 1.308 -1.2 0 N-CA-C 113.085 0.772 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo . . . . . 0 N--CA 1.494 1.53 0 CA-C-O 120.788 0.245 . . . . 0.0 111.988 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 30.8 tp -70.0 -44.71 68.83 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.721 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.8 t -70.68 -39.33 75.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.348 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 13.6 t -69.7 -44.56 79.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.92 -39.15 88.29 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.265 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.85 -29.92 71.11 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.975 0.417 . . . . 0.0 110.786 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -50.51 -34.23 24.45 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.949 -0.568 . . . . 0.0 111.255 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.9 tp -53.18 -30.23 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.449 -179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.53 -32.03 51.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.013 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.58 -47.46 62.07 Favored Glycine 0 C--N 1.304 -1.233 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.312 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 13.1 tt -69.4 -29.82 43.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.026 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 28.5 tp -62.62 -48.95 77.13 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -53.42 -29.44 35.14 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.59 -178.7 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 58.0 t80 -61.57 -41.42 97.37 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.403 HD11 HG22 ' C' ' 39' ' ' ILE . 92.4 mt -57.61 -48.86 82.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.535 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.45 -32.83 72.02 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.967 0.413 . . . . 0.0 110.316 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.8 -35.03 21.28 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.145 -179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -58.77 -32.31 69.17 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.372 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.1 -48.66 80.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.309 -179.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.93 -36.56 27.28 Favored Glycine 0 C--N 1.305 -1.141 0 CA-C-N 116.387 -0.37 . . . . 0.0 112.721 -178.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -51.47 -27.84 11.58 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 117.296 0.548 . . . . 0.0 111.283 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.7 pp . . . . . 0 C--N 1.303 -1.432 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.187 -177.766 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.517 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.0 m-20 . . . . . 0 CA--C 1.532 0.271 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.83 22.0 0.21 Allowed 'Trans proline' 0 N--CA 1.495 1.573 0 C-N-CA 122.1 1.867 . . . . 0.0 111.972 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.517 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.5 tp -71.87 -39.93 69.31 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.923 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.7 t -70.03 -45.24 77.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -178.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 17.1 m -67.91 -35.87 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.059 0.457 . . . . 0.0 110.439 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.66 -36.36 56.77 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.302 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.67 -39.46 73.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.316 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -61.86 -48.59 79.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 12.5 pt -50.35 -28.21 5.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.751 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.77 -28.69 34.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.301 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -44.55 84.49 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 116.337 -0.392 . . . . 0.0 113.632 -178.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' D' ' 36' ' ' LEU . 0.0 OUTLIER -56.36 -28.43 26.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-N 117.411 0.605 . . . . 0.0 110.516 -178.954 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . 0.523 ' N ' ' CD1' ' D' ' 35' ' ' ILE . 4.1 tp -60.47 -43.1 97.3 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 120.892 0.377 . . . . 0.0 110.565 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.638 ' HE2' ' CE1' ' A' ' 37' ' ' HIS . 7.0 m170 -55.14 -49.16 72.52 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.526 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -56.46 -50.08 72.75 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -178.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.45 ' O ' ' OG1' ' D' ' 42' ' ' THR . 11.6 pt -61.29 -44.93 99.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.919 -0.712 . . . . 0.0 111.045 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.3 -37.51 74.79 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.187 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.7 t-105 -48.63 -30.13 5.09 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.843 0.354 . . . . 0.0 110.653 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.45 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 60.4 p -60.09 -36.75 78.11 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.842 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.517 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.6 mp -69.23 -51.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.231 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.44 -28.74 37.11 Favored Glycine 0 C--N 1.304 -1.228 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.6 t-80 -65.29 -33.33 75.72 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -177.762 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 CA-C-O 120.752 0.23 . . . . 0.0 112.031 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.3 tp -66.12 -46.61 76.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.956 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.0 p -70.34 -36.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.649 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.55 -42.27 80.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 120.918 0.389 . . . . 0.0 110.855 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.55 -38.12 29.8 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.828 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.42 75.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.303 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -59.93 -42.74 94.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.112 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.6 mm -49.69 -31.49 6.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.876 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -70.48 -29.59 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.547 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -65.57 -49.83 58.07 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.461 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.621 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 3.1 mp -65.64 -29.73 47.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 122.576 -0.367 . . . . 0.0 111.089 -179.187 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 56.5 tp -61.41 -46.11 91.5 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.643 -179.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.682 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.0 OUTLIER -61.34 -28.99 69.61 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 120.195 -0.602 . . . . 0.0 111.358 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.682 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 91.6 t80 -62.78 -50.16 72.12 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.444 ' O ' ' OG1' ' A' ' 42' ' ' THR . 5.8 tt -57.79 -40.38 75.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 C-N-CA 120.089 -0.644 . . . . 0.0 110.521 -178.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -36.15 72.37 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.629 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -48.83 -34.08 11.76 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.744 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 38.1 p -58.9 -33.67 70.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.814 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.605 ' CG2' ' NE2' ' B' ' 48' ' ' GLN . 96.6 mt -65.36 -44.24 94.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.201 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.0 -26.13 1.15 Allowed Glycine 0 C--N 1.306 -1.124 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 . . . . . 0 C--N 1.299 -1.625 0 O-C-N 123.016 -0.108 . . . . 0.0 111.104 179.846 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 N--CA 1.499 1.84 0 CA-C-O 121.147 0.395 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 20.6 tp -71.47 -50.88 27.28 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.504 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 t -70.69 -35.5 61.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-O 121.127 0.489 . . . . 0.0 111.514 -179.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 99.3 t -70.39 -44.18 77.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.274 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -29.52 5.71 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.813 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.53 -29.71 69.18 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.939 0.4 . . . . 0.0 110.524 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.0 t -49.98 -37.13 31.08 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.828 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -54.7 -29.51 21.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 120.978 0.418 . . . . 0.0 110.443 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -71.02 -29.84 38.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.323 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.45 -46.6 76.31 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.17 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 12.3 pt -66.01 -42.35 91.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.164 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.4 tp -62.32 -46.54 88.28 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.143 0.497 . . . . 0.0 109.818 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.4 t-80 -51.6 -42.03 61.65 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.444 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.13 -36.03 74.5 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.539 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.464 ' O ' ' OG1' ' B' ' 42' ' ' THR . 94.5 mt -64.96 -41.85 93.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.129 -179.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.41 -40.42 77.32 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.01 0.434 . . . . 0.0 110.817 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.26 -32.05 10.0 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.067 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 68.8 p -51.38 -33.91 32.02 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.264 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 34.3 mm -65.74 -50.46 70.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.61 -30.11 26.6 Favored Glycine 0 C--N 1.306 -1.089 0 C-N-CA 121.232 -0.509 . . . . 0.0 111.928 -179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.443 ' O ' ' OE1' ' B' ' 48' ' ' GLN . 0.1 OUTLIER -63.78 -27.73 69.39 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 122.574 0.349 . . . . 0.0 111.342 -179.286 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.75 -29.03 4.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -58.18 -51.7 68.66 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -177.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.605 ' NE2' ' CG2' ' A' ' 43' ' ' ILE . 0.0 OUTLIER -75.38 -47.82 25.78 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.25 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.409 ' H ' ' HG2' ' B' ' 48' ' ' GLN . 8.6 tt . . . . . 0 C--N 1.295 -1.771 0 C-N-CA 120.301 -0.56 . . . . 0.0 110.474 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo . . . . . 0 N--CA 1.494 1.54 0 CA-C-O 120.787 0.244 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -69.35 -47.97 62.73 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.49 -36.61 66.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.058 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 64.2 t -70.33 -46.74 70.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -36.61 27.38 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.18 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.5 -29.64 67.32 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.787 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -51.7 -41.94 61.85 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.278 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 7.4 tt -53.93 -27.13 15.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.018 0.437 . . . . 0.0 111.031 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 1.6 mm -59.89 -37.72 73.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.754 -178.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.446 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.4 -46.66 76.3 Favored Glycine 0 C--N 1.304 -1.212 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.991 -178.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -70.16 -29.13 38.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.533 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 34.4 tp -61.64 -50.62 71.79 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.667 -179.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.67 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -57.62 -29.0 64.17 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.652 -178.741 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.67 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 42.2 t80 -59.94 -42.64 94.44 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.638 0.256 . . . . 0.0 111.294 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' C' ' 42' ' ' THR . 19.6 mm -58.14 -45.71 88.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.071 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.01 -30.28 65.06 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.225 0.536 . . . . 0.0 111.056 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -52.6 -38.02 59.28 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -57.77 -29.99 65.27 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.48 -178.262 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.497 ' N ' ' CD1' ' C' ' 43' ' ' ILE . 1.6 mp -61.24 -48.97 86.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.165 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.42 -29.74 11.32 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -50.84 -28.09 8.73 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.69 0.281 . . . . 0.0 111.207 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.3 pp . . . . . 0 C--N 1.305 -1.35 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.892 -177.544 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.41 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.1 m-20 . . . . . 0 CA--C 1.534 0.34 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.54 42.23 0.56 Allowed 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.201 1.934 . . . . 0.0 111.743 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.41 ' H ' ' C ' ' D' ' 24' ' ' ASP . 59.4 tp -70.15 -47.08 63.2 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.574 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.3 t -70.68 -34.42 56.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.093 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 91.8 t -69.96 -47.67 67.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.648 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -31.45 10.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.839 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.01 -33.76 74.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -58.06 -41.21 82.85 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 68.3 mt -58.36 -30.15 39.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-O 120.976 0.417 . . . . 0.0 110.816 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.441 ' O ' ' NE2' ' D' ' 37' ' ' HIS . 6.0 mt -71.43 -31.96 44.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.515 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.6 -39.61 90.68 Favored Glycine 0 C--N 1.307 -1.07 0 C-N-CA 121.429 -0.415 . . . . 0.0 112.579 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 19.9 pt -69.99 -35.76 65.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.601 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 27.6 tp -49.34 -36.09 20.39 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.484 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 8.7 m170 -58.99 -34.73 72.18 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -62.05 -45.96 91.25 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.472 ' O ' ' OG1' ' D' ' 42' ' ' THR . 1.5 pp -67.22 -40.23 84.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.522 -178.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.87 -41.28 71.59 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.211 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -48.96 -28.72 4.07 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 60.1 p -60.3 -32.5 71.26 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.87 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 84.8 mt -66.01 -51.57 58.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.174 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.84 -29.5 42.35 Favored Glycine 0 C--N 1.304 -1.215 0 N-CA-C 111.685 -0.566 . . . . 0.0 111.685 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 9.0 t-80 -55.77 -28.21 54.91 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.253 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.522 -177.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo . . . . . 0 N--CA 1.493 1.497 0 CA-C-O 120.847 0.27 . . . . 0.0 112.024 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.3 tp -66.48 -48.52 69.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.03 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.34 -35.56 63.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.586 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.0 t -70.36 -43.63 78.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 120.868 0.366 . . . . 0.0 110.684 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -35.82 18.13 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.997 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.14 -35.26 79.69 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 120.734 0.302 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -61.07 -41.78 97.27 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.124 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.419 HG23 HD12 ' A' ' 32' ' ' ILE . 20.8 mm -55.92 -29.76 26.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.114 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.3 mt -70.39 -32.47 50.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.397 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -61.21 -40.24 98.3 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.375 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 mt -69.98 -29.6 40.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.937 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 tt -60.6 -47.83 84.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.314 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.667 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.5 p80 -61.61 -28.76 69.59 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.45 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.667 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 56.1 t80 -60.97 -48.24 82.76 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.449 ' O ' ' OG1' ' A' ' 42' ' ' THR . 10.2 pt -62.64 -40.53 88.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.074 -0.65 . . . . 0.0 111.098 -178.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -39.58 75.31 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.69 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.6 t-105 -49.09 -30.96 7.1 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.016 -179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.449 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 70.4 p -63.78 -30.9 71.94 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 76.7 mt -59.69 -49.57 83.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.815 0.341 . . . . 0.0 111.016 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.26 -28.99 9.45 Favored Glycine 0 C--N 1.305 -1.175 0 N-CA-C 111.618 -0.593 . . . . 0.0 111.618 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 . . . . . 0 C--N 1.304 -1.398 0 CA-C-O 120.764 0.316 . . . . 0.0 110.897 -179.764 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo . . . . . 0 N--CA 1.495 1.583 0 CA-C-O 120.97 0.321 . . . . 0.0 111.753 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 tp -70.44 -46.14 64.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.039 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 91.9 t -70.28 -38.69 75.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.323 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -70.35 -45.95 73.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.56 -35.38 20.35 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.656 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -36.8 77.99 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.5 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -51.57 -37.48 49.89 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.311 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.6 -36.12 47.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.847 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -70.63 -33.12 51.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.481 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.86 -44.72 78.5 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.284 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 16.6 pt -70.04 -37.41 72.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.553 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -42.63 40.26 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.035 -179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 0.5 OUTLIER -53.2 -45.79 68.74 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.783 -179.761 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -57.85 -45.07 86.8 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.464 ' N ' ' CD1' ' B' ' 39' ' ' ILE . 1.6 mp -61.28 -45.72 98.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.838 -179.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.33 -39.92 74.44 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.181 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.58 -28.64 5.91 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.435 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 43.4 p -62.01 -38.62 89.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.43 -179.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.48 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.8 mp -62.45 -50.17 80.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.607 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.74 -29.65 58.6 Favored Glycine 0 C--N 1.304 -1.218 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -56.0 -28.41 57.12 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.412 ' CD1' ' C ' ' B' ' 46' ' ' LEU . 1.9 pp -47.61 -29.44 2.91 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.738 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -62.92 -45.58 91.83 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -61.29 -53.11 60.96 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.011 0.434 . . . . 0.0 111.86 -179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 1.5 tp . . . . . 0 C--N 1.295 -1.778 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.566 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo . . . . . 0 N--CA 1.49 1.273 0 CA-C-O 120.744 0.227 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.24 -50.31 69.79 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.762 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 80.0 t -69.87 -39.91 78.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.829 0.347 . . . . 0.0 111.198 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 66.9 t -62.3 -44.21 98.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.618 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.19 69.43 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.609 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.43 -29.34 67.7 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.488 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -54.71 -42.6 71.69 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.448 -179.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.7 tp -50.75 -30.58 8.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.97 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -70.45 -34.26 57.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.342 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.49 -49.25 57.53 Favored Glycine 0 C--N 1.303 -1.291 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.128 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.4 tt -64.81 -37.45 80.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 122.52 -0.4 . . . . 0.0 110.713 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . 0.458 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.1 OUTLIER -53.29 -47.11 69.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.151 -178.807 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.709 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -61.0 -28.58 69.14 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.555 -178.258 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.709 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 57.2 t80 -58.88 -48.01 82.9 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.615 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.419 ' H ' HD12 ' C' ' 39' ' ' ILE . 4.3 mp -60.73 -45.58 97.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.484 -0.487 . . . . 0.0 111.078 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -29.88 65.92 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.472 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' C' ' 41' ' ' TRP . 10.7 t-105 -48.93 -50.36 35.71 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.769 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 12.2 t -47.79 -28.05 2.34 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.515 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tp -49.83 -49.32 20.83 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 120.299 -0.56 . . . . 0.0 110.358 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . 0.515 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -54.18 -28.44 42.1 Favored Glycine 0 C--N 1.302 -1.321 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.93 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.66 -33.39 15.48 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.818 0.309 . . . . 0.0 111.415 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.0 pp . . . . . 0 C--N 1.306 -1.311 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.868 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 t70 . . . . . 0 CA--C 1.538 0.484 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -74.55 45.36 1.24 Allowed 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.979 1.786 . . . . 0.0 111.935 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 41.6 tp -70.52 -44.39 67.65 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.0 t -70.7 -41.96 77.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.164 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.75 -38.39 72.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.329 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -35.13 21.41 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.69 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.17 -29.41 70.76 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.022 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.0 t -52.71 -42.54 64.93 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.199 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.473 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 1.9 mp -54.97 -37.35 41.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.733 0.301 . . . . 0.0 110.5 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.412 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 6.0 mt -71.45 -29.71 36.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.401 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.5 -48.92 47.97 Favored Glycine 0 C--N 1.306 -1.108 0 C-N-CA 121.361 -0.447 . . . . 0.0 113.025 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 pp -66.34 -32.47 58.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 117.194 0.497 . . . . 0.0 110.579 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 tp -51.06 -37.68 46.98 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.198 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.624 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 20.3 m170 -58.63 -40.44 83.37 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.858 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.02 -48.27 82.56 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.439 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.6 pt -61.53 -41.88 91.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.175 -0.61 . . . . 0.0 111.422 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.6 -38.34 73.99 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.083 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.4 -30.77 8.39 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 77.7 p -64.65 -34.11 77.52 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.252 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.6 mp -70.49 -52.08 32.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.688 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.52 -29.35 24.01 Favored Glycine 0 C--N 1.306 -1.105 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -56.4 -27.03 55.21 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 111.528 0.195 . . . . 0.0 111.528 -179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.273 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.429 -177.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.493 1.458 0 CA-C-O 121.075 0.365 . . . . 0.0 111.599 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.9 tp -70.52 -42.85 70.71 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.21 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.15 -40.92 78.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.589 -179.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.7 t -68.16 -46.21 81.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.822 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -38.43 34.96 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.879 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.47 79.01 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.428 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.29 -39.92 80.59 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.949 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -51.26 -29.67 9.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.263 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.9 mt -69.75 -29.82 42.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.623 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.26 -48.17 66.27 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 121.182 -0.532 . . . . 0.0 112.287 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.515 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 4.1 mp -67.14 -29.68 46.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 120.681 -0.407 . . . . 0.0 111.126 -179.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.73 -46.3 90.94 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.574 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.676 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.78 -28.79 69.7 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.385 -178.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.676 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 64.1 t80 -60.62 -50.14 74.72 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.8 -39.17 69.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.007 -178.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.42 -36.04 73.77 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.891 0.377 . . . . 0.0 110.944 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.8 t-105 -49.68 -38.05 31.22 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.103 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.1 p -52.47 -39.76 61.52 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.91 -49.32 84.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.834 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.36 -28.6 9.49 Favored Glycine 0 C--N 1.304 -1.205 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 . . . . . 0 C--N 1.303 -1.427 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -179.307 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo . . . . . 0 N--CA 1.496 1.651 0 CA-C-O 121.065 0.361 . . . . 0.0 111.681 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -70.42 -46.62 63.56 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.067 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 48.7 t -70.42 -37.55 70.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.582 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.17 -44.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.598 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -33.22 12.04 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.356 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.92 -33.67 76.59 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.766 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -57.56 -41.03 80.23 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.782 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -56.71 -35.94 47.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.279 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.57 -33.74 50.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.441 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.17 73.38 Favored Glycine 0 C--N 1.305 -1.183 0 C-N-CA 121.249 -0.5 . . . . 0.0 111.898 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 tp -68.47 -43.99 83.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.745 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.9 tp -49.97 -38.12 35.42 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.136 0.493 . . . . 0.0 110.078 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -49.64 -41.9 43.73 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.012 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -67.41 -38.71 85.04 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.726 -179.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.509 ' N ' ' CD1' ' B' ' 39' ' ' ILE . 1.5 mp -62.01 -43.91 98.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.65 -179.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.56 74.96 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.152 0.501 . . . . 0.0 110.788 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.49 -29.56 6.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.819 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.3 p -61.62 -36.14 79.89 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.464 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -63.67 -50.79 76.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.093 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.21 -29.48 29.48 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.478 ' CD2' ' CD ' ' B' ' 48' ' ' GLN . 29.2 t-80 -61.46 -28.92 69.62 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 120.616 0.246 . . . . 0.0 111.327 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -49.4 -34.66 16.83 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.397 -178.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -64.45 -50.43 67.53 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.478 ' CD ' ' CD2' ' B' ' 45' ' ' HIS . 9.5 pt20 -69.66 -50.05 47.8 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.41 ' H ' ' HG3' ' B' ' 48' ' ' GLN . 15.9 tt . . . . . 0 C--N 1.297 -1.705 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.93 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.494 1.529 0 CA-C-O 120.847 0.27 . . . . 0.0 112.116 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.8 tp -66.6 -45.07 80.4 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.994 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.22 -34.34 58.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.301 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.57 -47.3 80.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -37.38 26.42 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.788 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.4 -29.8 70.85 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.47 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.4 t -57.26 -42.85 82.34 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.693 0.283 . . . . 0.0 111.321 -179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.52 ' H ' ' CD1' ' C' ' 32' ' ' ILE . 2.2 mp -54.77 -30.28 22.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 mt -68.14 -36.38 75.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.525 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.61 -45.29 94.96 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.396 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 tp -69.96 -29.6 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 116.964 0.382 . . . . 0.0 110.824 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 33.0 tp -61.75 -49.26 77.13 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.916 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.689 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -55.66 -28.83 57.62 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 120.566 -0.454 . . . . 0.0 111.552 -178.61 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.689 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 51.4 t80 -61.07 -42.44 98.5 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.696 -0.229 . . . . 0.0 111.509 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.409 ' O ' ' OG1' ' C' ' 42' ' ' THR . 57.2 mt -58.1 -45.36 88.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.348 -178.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.26 -35.4 76.05 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.854 0.359 . . . . 0.0 110.743 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -49.47 -35.26 19.13 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.409 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.1 p -55.42 -39.07 69.79 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.031 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 85.1 mt -62.1 -48.49 88.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.901 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.17 -27.79 5.58 Favored Glycine 0 C--N 1.305 -1.189 0 N-CA-C 111.613 -0.595 . . . . 0.0 111.613 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -47.71 -28.1 2.28 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 122.744 -0.268 . . . . 0.0 111.511 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 pp . . . . . 0 C--N 1.305 -1.368 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.323 -178.044 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.515 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.2 m-20 . . . . . 0 CA--C 1.533 0.293 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.8 34.59 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 122.081 1.854 . . . . 0.0 111.841 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.515 ' H ' ' C ' ' D' ' 24' ' ' ASP . 48.4 tp -71.99 -38.25 69.7 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.801 179.05 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.73 -40.7 77.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 31.0 m -70.11 -40.23 78.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 CA-C-O 120.687 0.28 . . . . 0.0 110.836 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.45 -30.93 32.19 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.48 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.19 -34.61 68.53 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.237 179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.4 t -63.68 -44.85 92.49 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 pt -56.71 -28.17 27.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 120.852 0.358 . . . . 0.0 110.696 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.97 -29.02 35.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.315 179.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.07 -38.5 95.45 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 116.36 -0.382 . . . . 0.0 113.263 -178.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -68.96 -29.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 117.49 0.645 . . . . 0.0 110.366 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.31 -29.49 63.97 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.382 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.674 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 8.7 m170 -69.75 -35.6 75.09 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.539 -179.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -66.18 -46.68 76.51 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -178.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.468 ' O ' ' OG1' ' D' ' 42' ' ' THR . 2.2 pp -66.33 -39.14 83.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.416 -178.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -38.92 74.6 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.054 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -52.96 -30.74 36.58 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.952 0.406 . . . . 0.0 111.0 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.468 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 67.6 p -63.95 -32.08 73.49 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.023 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 18.1 mm -70.66 -51.63 35.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.461 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.42 -29.74 31.68 Favored Glycine 0 C--N 1.307 -1.082 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 t-80 -54.62 -27.19 37.65 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 120.715 0.293 . . . . 0.0 111.137 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.303 -1.44 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.668 -178.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo . . . . . 0 N--CA 1.494 1.51 0 CA-C-O 120.821 0.259 . . . . 0.0 111.912 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.4 tt -65.32 -49.54 69.06 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 -179.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.9 p -70.6 -39.43 75.97 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.005 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 69.0 t -62.95 -29.95 48.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.754 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.87 69.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.522 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.34 -36.0 80.53 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.596 -179.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.2 t -56.52 -46.19 80.72 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.565 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.526 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.1 mp -51.35 -39.85 22.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.935 0.398 . . . . 0.0 110.166 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -70.46 -28.61 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.289 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.96 -50.68 56.81 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.199 -0.524 . . . . 0.0 112.796 -178.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 pp -66.04 -29.15 45.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.065 0.432 . . . . 0.0 111.413 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.2 tt -62.74 -41.13 99.05 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.451 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.691 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -65.56 -28.74 69.37 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.659 -178.976 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.691 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 60.3 t80 -64.49 -50.44 67.42 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -178.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.4 pt -51.56 -40.46 25.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.149 -179.024 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.32 -33.25 65.05 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 120.97 0.414 . . . . 0.0 111.272 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.453 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 11.8 t-105 -49.23 -31.06 7.99 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -177.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -69.39 -29.6 67.4 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.331 -179.443 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.495 ' CD1' ' N ' ' A' ' 43' ' ' ILE . 1.5 mp -56.17 -44.98 80.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.847 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.15 -28.43 4.25 Favored Glycine 0 C--N 1.304 -1.236 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -178.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 . . . . . 0 C--N 1.301 -1.511 0 CA-C-O 120.806 0.336 . . . . 0.0 110.398 179.799 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo . . . . . 0 N--CA 1.493 1.482 0 CA-C-O 120.879 0.283 . . . . 0.0 111.618 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 52.2 tp -70.23 -43.21 71.08 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.503 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 96.3 t -70.16 -41.77 78.99 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.738 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 50.2 t -70.21 -41.11 78.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.176 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.8 -37.31 18.82 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.349 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.9 -29.52 65.14 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.72 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.6 t -58.64 -41.73 86.66 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.409 HD13 HG22 ' B' ' 32' ' ' ILE . 23.9 mm -50.66 -36.65 14.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.684 -179.698 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -69.99 -29.76 41.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.15 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.68 -50.16 63.61 Favored Glycine 0 C--N 1.306 -1.131 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.622 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.0 pt -62.5 -43.65 98.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.998 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.5 tp -62.28 -49.16 76.76 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.019 0.438 . . . . 0.0 109.828 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -49.79 -39.45 38.21 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.95 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 74.8 t80 -69.99 -39.74 75.71 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.48 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.443 ' O ' ' OG1' ' B' ' 42' ' ' THR . 85.3 mt -60.37 -43.67 94.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.968 -179.253 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.05 -40.76 91.23 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.995 0.426 . . . . 0.0 110.594 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.81 -32.74 14.74 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.285 -179.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.443 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 58.0 p -60.98 -38.16 84.99 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.993 -179.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.505 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.6 mp -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.503 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.19 -29.81 16.24 Favored Glycine 0 C--N 1.304 -1.224 0 C-N-CA 121.335 -0.46 . . . . 0.0 112.089 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -58.07 -28.5 64.62 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -47.03 -32.22 3.83 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.321 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 -62.29 -44.99 95.26 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -61.74 -53.33 57.43 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 120.916 0.389 . . . . 0.0 112.027 -178.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 1.9 tp . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.135 -179.142 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo . . . . . 0 N--CA 1.495 1.602 0 CA-C-O 120.911 0.296 . . . . 0.0 111.729 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 41.4 tp -70.07 -43.68 70.68 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.754 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.36 -40.92 78.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.923 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.2 -47.76 80.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -37.18 28.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.976 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.97 -29.55 70.49 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-O 120.83 0.347 . . . . 0.0 111.07 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -52.49 -43.72 65.19 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.2 tp -50.1 -29.1 5.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-O 120.75 0.31 . . . . 0.0 111.324 -179.281 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.1 -31.83 48.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.116 -179.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.62 -50.16 38.78 Favored Glycine 0 C--N 1.303 -1.267 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.753 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 tp -69.54 -29.49 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 120.852 0.358 . . . . 0.0 110.281 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.11 -48.86 79.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.79 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.68 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -55.59 -29.14 58.55 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 120.646 -0.422 . . . . 0.0 111.935 -178.491 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.68 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 61.3 t80 -59.04 -42.61 90.67 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.375 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' C' ' 42' ' ' THR . 3.8 mp -58.38 -47.57 87.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.577 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.93 78.63 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.889 -0.325 . . . . 0.0 110.847 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -49.13 -29.99 6.06 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.439 ' HG1' ' N ' ' C' ' 43' ' ' ILE . 67.7 p -57.13 -37.39 71.94 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.248 179.57 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.439 ' N ' ' HG1' ' C' ' 42' ' ' THR . 75.9 mt -63.22 -50.23 79.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.912 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.15 -28.83 6.3 Favored Glycine 0 C--N 1.305 -1.182 0 N-CA-C 112.059 -0.416 . . . . 0.0 112.059 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -49.12 -27.96 3.89 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.856 0.328 . . . . 0.0 111.341 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 C--N 1.306 -1.3 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.917 -177.943 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' D' ' 26' ' ' LEU . 4.1 m-20 . . . . . 0 CA--C 1.533 0.307 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -72.21 27.08 0.26 Allowed 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 122.218 1.945 . . . . 0.0 111.829 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.503 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.7 tp -70.17 -44.86 67.91 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.582 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -70.17 -36.97 70.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.998 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 87.9 t -67.97 -46.76 81.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.67 -34.35 11.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.46 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.96 -29.65 69.56 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 34.6 t -58.82 -43.72 90.69 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.218 -179.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.515 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 2.0 mp -53.98 -29.9 19.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 120.835 0.35 . . . . 0.0 110.351 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.36 -29.91 37.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.265 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.93 -43.94 95.26 Favored Glycine 0 C--N 1.308 -1.024 0 C-N-CA 121.34 -0.457 . . . . 0.0 112.188 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -67.19 -37.64 79.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.499 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.1 tt -49.81 -43.31 48.55 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.674 ' HE2' ' CE1' ' A' ' 37' ' ' HIS . 26.4 m170 -57.8 -44.19 86.14 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.923 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -61.56 -47.26 86.34 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -178.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.438 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.6 pt -63.79 -41.76 93.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.301 -0.56 . . . . 0.0 111.425 -178.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -40.76 74.53 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.804 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.53 -29.32 6.65 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.042 0.449 . . . . 0.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.438 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.2 p -62.25 -33.21 74.18 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.345 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 90.7 mt -65.56 -50.72 70.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.03 -28.15 47.84 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -56.85 -28.06 61.17 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 112.628 0.603 . . . . 0.0 112.628 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.546 HD11 ' N ' ' D' ' 46' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -178.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo . . . . . 0 N--CA 1.493 1.46 0 CA-C-O 120.931 0.305 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.2 tp -70.14 -42.89 71.98 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.084 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.69 -39.19 75.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.65 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.0 t -66.77 -42.57 89.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.85 0.357 . . . . 0.0 110.971 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -34.54 18.85 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.683 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.61 82.54 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.739 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -59.31 -44.03 92.6 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.392 -179.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -49.81 -34.68 9.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 120.95 0.405 . . . . 0.0 110.759 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.0 mt -69.8 -29.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.555 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.13 -50.27 52.6 Favored Glycine 0 C--N 1.306 -1.109 0 C-N-CA 121.105 -0.569 . . . . 0.0 112.363 -179.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 40.5 mt -61.04 -29.63 46.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 122.509 -0.407 . . . . 0.0 110.918 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 46.3 tp -61.88 -44.43 96.83 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.361 -179.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.77 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -61.56 -28.83 69.62 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.501 -178.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.77 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 40.4 t80 -63.19 -50.63 69.54 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.253 0.464 . . . . 0.0 112.253 -178.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 42' ' ' THR . 5.8 tt -57.07 -38.83 62.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.23 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -30.62 64.77 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 120.936 0.398 . . . . 0.0 111.448 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -55.09 -36.49 65.7 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 -177.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.52 ' O ' ' ND1' ' A' ' 45' ' ' HIS . 0.1 OUTLIER -59.06 -34.01 71.45 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.995 -178.946 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 mp -60.68 -38.21 77.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.114 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.87 -25.81 1.75 Allowed Glycine 0 C--N 1.306 -1.111 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.52 ' ND1' ' O ' ' A' ' 42' ' ' THR . 39.1 m170 . . . . . 0 C--N 1.3 -1.55 0 C-N-CA 122.77 0.428 . . . . 0.0 111.173 179.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 CA-C-O 121.027 0.345 . . . . 0.0 111.549 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 tt -63.35 -49.62 73.18 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.69 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.08 -33.77 56.52 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.375 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.6 t -69.93 -44.5 78.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.516 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.86 -39.37 39.01 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.672 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.25 -33.47 74.67 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.846 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 6.8 t -57.8 -41.82 82.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.849 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.404 HG23 HD11 ' B' ' 32' ' ' ILE . 19.1 mm -51.79 -34.33 16.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.727 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.88 -29.76 38.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.224 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.15 -48.74 62.54 Favored Glycine 0 C--N 1.305 -1.159 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 11.3 mm -61.54 -46.22 97.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.64 -179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.3 tp -52.39 -42.49 64.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.019 0.438 . . . . 0.0 109.933 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -49.92 -44.67 50.38 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.835 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -66.65 -41.6 87.98 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.555 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.48 ' O ' ' OG1' ' B' ' 42' ' ' THR . 93.3 mt -60.85 -45.16 98.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.899 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.81 -36.88 81.18 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.467 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.66 -34.85 19.57 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.534 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.0 p -52.43 -41.05 62.92 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.349 -179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.481 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.8 mp -62.66 -50.3 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.929 -0.308 . . . . 0.0 111.121 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.16 -29.72 15.88 Favored Glycine 0 C--N 1.305 -1.167 0 C-N-CA 121.187 -0.53 . . . . 0.0 111.964 -179.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -60.69 -28.1 68.37 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -46.81 -31.08 2.79 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.863 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -60.0 -48.96 79.54 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -63.14 -54.48 37.09 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -178.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 2.6 tt . . . . . 0 C--N 1.297 -1.684 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.07 -179.22 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.495 1.6 0 CA-C-O 120.715 0.215 . . . . 0.0 112.156 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 40.5 tp -64.21 -48.33 76.28 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.097 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 23.4 t -70.22 -40.21 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.222 -179.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.4 t -69.47 -44.18 80.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.806 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.25 -43.1 61.43 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.957 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.44 69.37 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.093 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 5.8 t -51.22 -43.42 61.43 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.493 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.2 tp -49.5 -29.61 4.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.344 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.5 mt -69.03 -30.55 47.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.912 -179.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.546 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.64 -49.71 58.38 Favored Glycine 0 C--N 1.303 -1.292 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.312 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -66.41 -29.34 46.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.841 -179.444 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 10.4 tp -62.02 -50.71 70.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.528 -0.306 . . . . 0.0 111.823 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.637 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -52.51 -29.24 24.11 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.665 -178.401 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 57.7 t80 -58.06 -44.5 87.5 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 120.578 0.228 . . . . 0.0 111.481 -179.488 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.0 mt -54.55 -48.99 69.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.587 -178.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.53 -30.49 67.25 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.994 0.426 . . . . 0.0 110.761 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -49.28 -36.67 21.3 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 33.6 p -59.23 -36.94 76.34 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.088 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -63.16 -50.98 77.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.283 -179.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.55 -29.8 25.4 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.916 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -51.76 -29.73 19.92 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp . . . . . 0 C--N 1.306 -1.303 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.472 -177.543 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.8 m-20 . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.12 42.52 0.64 Allowed 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.164 1.909 . . . . 0.0 111.745 179.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.4 ' H ' ' C ' ' D' ' 24' ' ' ASP . 51.7 tp -70.22 -47.92 59.32 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.649 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 10.5 t -70.87 -35.97 62.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.145 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -70.14 -46.29 72.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.659 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -29.8 7.71 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.005 -179.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.72 66.86 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.22 -40.38 81.52 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.22 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -55.22 -29.77 23.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.899 0.38 . . . . 0.0 110.836 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.23 -29.67 37.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.49 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.74 -44.43 80.87 Favored Glycine 0 C--N 1.307 -1.04 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.444 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.0 pt -67.03 -36.15 76.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.64 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -49.91 -36.68 28.37 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.457 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.712 ' HE2' ' CE1' ' A' ' 37' ' ' HIS . 32.8 m170 -59.17 -47.04 86.79 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.85 -179.185 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -57.54 -46.14 84.24 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.455 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.9 pt -66.39 -43.14 91.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.436 -178.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -39.78 72.87 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.367 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 t-105 -49.39 -28.86 5.53 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 120.974 0.416 . . . . 0.0 110.673 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.455 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 81.5 p -62.0 -29.92 70.59 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.755 179.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 82.1 mt -70.21 -52.25 31.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-O 121.025 0.44 . . . . 0.0 111.053 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.09 -28.21 32.79 Favored Glycine 0 C--N 1.302 -1.321 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -68.22 -29.34 68.14 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 C--N 1.309 -1.171 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.478 -179.021 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo . . . . . 0 N--CA 1.493 1.477 0 CA-C-O 120.841 0.267 . . . . 0.0 112.003 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 57.7 tp -63.69 -45.73 88.72 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.83 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 p -70.37 -37.61 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.453 -179.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.6 t -70.08 -35.99 66.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 CA-C-O 120.982 0.42 . . . . 0.0 110.784 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -38.16 31.66 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.62 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.57 -34.0 76.16 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.341 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.2 t -63.01 -50.34 71.11 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -178.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 11.2 pt -51.99 -29.49 11.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.636 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -67.25 -29.58 46.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -59.76 -46.24 94.38 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.4 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' D' ' 33' ' ' ILE . 10.0 mm -61.24 -35.75 68.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 CA-C-O 120.77 0.319 . . . . 0.0 111.145 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.65 -49.75 76.4 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.954 -178.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.692 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -57.72 -28.86 64.25 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.812 -178.768 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.692 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 71.2 t80 -59.63 -50.11 75.16 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 1.5 pp -59.22 -41.67 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.768 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.92 -34.03 68.76 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.106 0.479 . . . . 0.0 111.002 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.474 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 10.1 t-105 -48.23 -35.3 11.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.517 -178.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.9 t -56.86 -29.34 62.81 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.508 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 80.0 mt -55.28 -46.08 77.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.04 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.5 -28.63 2.42 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 120.762 -0.733 . . . . 0.0 111.534 -177.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 116.928 0.364 . . . . 0.0 110.79 179.299 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo . . . . . 0 N--CA 1.495 1.595 0 CA-C-O 121.071 0.363 . . . . 0.0 111.63 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 37.4 tp -69.35 -45.93 68.24 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.535 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 79.9 t -70.43 -41.1 78.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 57.3 t -68.65 -46.85 79.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.321 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.76 -38.37 33.72 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.663 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.89 -31.53 72.18 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.31 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 31.9 t -56.04 -42.11 76.05 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.991 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.6 mm -49.67 -29.86 4.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.649 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.9 mt -71.92 -29.82 34.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.51 -50.61 42.34 Favored Glycine 0 C--N 1.307 -1.076 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.324 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -64.53 -47.1 90.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.831 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -51.51 -41.26 60.87 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.059 0.457 . . . . 0.0 110.074 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -49.58 -39.79 36.38 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.813 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.46 -40.03 92.71 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.688 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' B' ' 42' ' ' THR . 1.7 mp -57.48 -42.84 81.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.51 -179.26 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.98 -37.18 69.93 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.228 0.537 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.8 t-105 -54.91 -39.65 69.02 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.453 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -57.69 -34.14 69.11 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.243 -178.903 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.8 mm -62.14 -47.72 91.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.603 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.09 -28.67 8.2 Favored Glycine 0 C--N 1.306 -1.089 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -61.23 -27.05 68.17 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.527 HD11 ' N ' ' B' ' 46' ' ' LEU . 0.0 OUTLIER -47.71 -30.63 3.98 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.676 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.494 ' N ' ' CD1' ' B' ' 46' ' ' LEU . 29.4 p-10 -61.5 -50.5 72.47 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -59.27 -53.07 62.47 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 120.978 0.418 . . . . 0.0 112.112 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 2.5 tp . . . . . 0 C--N 1.295 -1.763 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.162 -179.192 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo . . . . . 0 N--CA 1.493 1.452 0 CA-C-O 120.995 0.331 . . . . 0.0 111.738 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 44.5 tp -70.13 -42.64 72.33 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.091 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 92.8 t -70.12 -44.22 78.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.192 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.09 -46.64 84.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.545 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -54.87 -44.37 73.99 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.941 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.54 -29.63 70.71 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 120.777 0.322 . . . . 0.0 110.925 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 7.1 t -50.56 -41.86 54.68 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.181 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -49.8 -29.06 4.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-O 120.851 0.357 . . . . 0.0 111.295 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.9 mt -65.81 -33.45 63.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.144 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.57 -50.33 37.93 Favored Glycine 0 C--N 1.303 -1.256 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.202 -178.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.05 -29.48 44.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-O 120.868 0.366 . . . . 0.0 110.529 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -61.28 -50.62 72.26 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.782 -179.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.698 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -55.08 -28.65 54.06 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.742 -178.577 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.698 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 43.9 t80 -57.9 -44.38 86.72 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 121.031 -0.268 . . . . 0.0 111.456 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.43 ' O ' ' OG1' ' C' ' 42' ' ' THR . 79.4 mt -56.34 -48.37 79.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.943 -179.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.05 -34.28 73.02 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.855 0.359 . . . . 0.0 110.755 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 -48.4 -30.25 4.83 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.565 -179.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.7 p -56.38 -38.74 71.89 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.634 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.496 ' N ' ' CD1' ' C' ' 43' ' ' ILE . 1.7 mp -64.05 -49.93 79.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.013 -179.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.82 -28.28 5.34 Favored Glycine 0 C--N 1.304 -1.198 0 C-N-CA 121.301 -0.476 . . . . 0.0 112.024 -178.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -49.07 -27.84 3.64 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 pp . . . . . 0 C--N 1.307 -1.253 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.399 -177.543 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 CA--C 1.532 0.273 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.69 33.6 0.37 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.189 1.926 . . . . 0.0 111.756 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.445 ' H ' ' C ' ' D' ' 24' ' ' ASP . 2.1 tt -63.9 -50.54 68.32 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.613 -179.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 t -70.49 -33.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.113 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 92.5 t -69.95 -45.1 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.692 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.58 -32.71 8.51 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.718 -178.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.31 -32.17 73.69 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 120.769 0.319 . . . . 0.0 110.912 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 43.0 t -60.4 -42.93 96.95 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.217 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 mm -58.05 -35.21 51.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 121.148 0.499 . . . . 0.0 110.346 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' A' ' 35' ' ' ILE . 8.8 mt -71.67 -29.98 36.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.303 179.243 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.36 91.73 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.589 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 12.8 pt -68.51 -38.13 78.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.782 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tp -49.69 -38.63 33.76 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 120.946 0.403 . . . . 0.0 110.455 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.533 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 16.4 m170 -57.53 -39.78 77.36 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.371 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -58.23 -46.55 85.72 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.6 pt -66.63 -42.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.125 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -41.96 77.18 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.723 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -48.74 -29.46 4.5 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.745 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.5 m -66.8 -29.85 69.89 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.515 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.405 HD11 HG22 ' D' ' 43' ' ' ILE . 30.0 mm -65.48 -50.8 70.22 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.988 -0.285 . . . . 0.0 111.181 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.48 -34.17 63.34 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.7 t-80 -55.98 -28.05 55.44 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 120.653 0.263 . . . . 0.0 111.522 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.303 -1.434 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo . . . . . 0 N--CA 1.493 1.47 0 CA-C-O 120.843 0.268 . . . . 0.0 112.04 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.3 mp -69.5 -40.91 76.71 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.711 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.417 ' CG1' ' N ' ' A' ' 28' ' ' VAL . 12.4 p -70.76 -44.15 76.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.475 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.417 ' N ' ' CG1' ' A' ' 27' ' ' VAL . 88.5 t -63.63 -41.75 93.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.737 -179.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -37.38 29.53 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.476 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.76 -36.8 84.24 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.471 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -53.81 -47.14 71.13 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.994 -0.283 . . . . 0.0 111.233 -179.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.527 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.1 mp -51.56 -40.17 24.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.462 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.87 -29.5 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.1 -50.66 44.37 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.907 -179.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 57.3 mt -64.74 -29.71 48.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 122.652 -0.322 . . . . 0.0 111.047 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 33.4 tp -61.47 -45.18 95.33 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.331 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.683 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.6 OUTLIER -61.66 -28.79 69.64 Favored 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 120.151 -0.62 . . . . 0.0 111.497 -178.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.683 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 78.2 t80 -63.47 -50.82 68.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.4 tt -54.91 -39.67 49.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.135 -178.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -35.3 69.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.922 0.392 . . . . 0.0 111.215 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.462 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 11.3 t-105 -49.78 -35.07 21.2 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 t -65.4 -29.4 70.1 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 36.5 mm -60.87 -45.15 98.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.777 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.16 -27.03 2.44 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.037 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 . . . . . 0 C--N 1.304 -1.38 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.562 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.493 1.464 0 CA-C-O 121.055 0.356 . . . . 0.0 111.574 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.01 -48.74 67.49 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.552 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.59 -30.35 42.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.14 -46.7 71.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.392 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.11 -31.5 8.2 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.613 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.69 -29.64 70.22 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.538 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.6 t -54.44 -38.08 65.89 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.796 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 25.8 mm -55.6 -36.94 44.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-O 120.923 0.392 . . . . 0.0 110.456 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.24 -29.98 38.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.337 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.96 -48.41 54.47 Favored Glycine 0 C--N 1.306 -1.11 0 N-CA-C 111.659 -0.576 . . . . 0.0 111.659 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -63.93 -42.44 95.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.611 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -60.61 -44.26 96.51 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 24.2 t-80 -49.86 -44.36 49.68 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.696 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -70.12 -37.55 75.34 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.272 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' B' ' 42' ' ' THR . 91.8 mt -63.41 -42.64 97.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.856 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.66 -37.47 70.78 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.009 0.433 . . . . 0.0 111.297 -179.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -49.55 -44.84 46.94 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.81 -27.83 5.55 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.655 -178.528 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 9.3 tp -56.17 -48.57 79.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.252 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.517 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -57.65 -29.73 61.58 Favored Glycine 0 C--N 1.304 -1.229 0 C-N-CA 121.32 -0.466 . . . . 0.0 111.963 -179.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -53.17 -29.53 32.11 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.411 ' CD1' ' C ' ' B' ' 46' ' ' LEU . 2.7 pp -50.58 -34.0 24.13 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.836 -0.346 . . . . 0.0 111.519 -178.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -63.19 -50.38 70.55 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -67.41 -55.89 11.88 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.142 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 7.7 tp . . . . . 0 C--N 1.297 -1.714 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -178.599 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 N--CA 1.494 1.526 0 CA-C-O 120.861 0.275 . . . . 0.0 111.97 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.419 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -67.1 -42.71 84.13 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.637 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 p -70.28 -40.9 78.46 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.206 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 92.2 t -64.47 -46.63 92.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.746 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.69 73.6 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.92 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.56 -29.65 70.67 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.746 0.308 . . . . 0.0 111.138 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 15.1 t -52.56 -44.27 65.76 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.617 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.3 tt -49.68 -29.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.269 -179.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.4 mt -69.02 -31.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.037 -179.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.15 -50.43 39.79 Favored Glycine 0 C--N 1.306 -1.085 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.016 -179.214 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -66.72 -29.48 46.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.722 -179.76 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.4 tp -60.72 -48.77 80.31 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.687 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.79 -29.99 63.24 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.863 -178.367 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.2 t80 -62.18 -44.26 96.99 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.098 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.44 ' O ' ' OG1' ' C' ' 42' ' ' THR . 96.6 mt -55.65 -45.61 79.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.723 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.15 -33.79 72.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.015 0.436 . . . . 0.0 110.779 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.29 -34.68 16.0 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.173 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.44 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 18.5 p -57.3 -45.05 84.53 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.376 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 4.2 mp -66.45 -51.09 61.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.603 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.47 -29.52 17.42 Favored Glycine 0 C--N 1.303 -1.267 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -59.77 -28.96 67.85 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.116 0.414 . . . . 0.0 112.116 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.301 -1.527 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 . . . . . 0 CA--C 1.535 0.378 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.34 41.0 0.64 Allowed 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.1 1.867 . . . . 0.0 111.872 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.3 tp -63.85 -48.97 74.63 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.617 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 47.3 t -70.42 -34.21 57.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 57.6 t -70.05 -44.14 78.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.584 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -35.08 19.7 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.722 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.23 -29.63 70.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.2 t -55.54 -41.5 73.28 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.035 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.484 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 2.0 mp -54.87 -35.62 34.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.491 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.76 -30.05 40.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.352 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.25 -46.02 88.88 Favored Glycine 0 C--N 1.306 -1.096 0 C-N-CA 121.249 -0.501 . . . . 0.0 112.07 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.1 pt -66.68 -29.79 47.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-O 120.815 0.341 . . . . 0.0 110.753 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tp -56.29 -42.39 77.46 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.708 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 15.3 m170 -56.62 -43.52 80.28 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -59.52 -47.09 86.88 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.451 ' O ' ' OG1' ' D' ' 42' ' ' THR . 13.4 pt -64.03 -43.8 97.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.491 -178.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.12 -39.37 75.5 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.058 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -48.81 -29.4 4.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.859 0.361 . . . . 0.0 110.502 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.451 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 64.8 p -61.99 -31.51 71.88 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.769 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 33.7 mm -67.38 -51.33 53.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.76 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.99 -29.95 21.66 Favored Glycine 0 C--N 1.304 -1.245 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -59.02 -29.61 67.39 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 120.648 0.261 . . . . 0.0 111.274 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 pp . . . . . 0 C--N 1.305 -1.357 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.395 -178.949 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.1 m . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -172.0 61.04 0.3 Allowed Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.949 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -79.96 8.68 3.92 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.819 2.346 . . . . 0.0 111.973 179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.1 tp -63.52 -44.61 93.77 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.779 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.9 p -70.23 -37.76 72.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.436 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.08 -42.12 87.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.947 0.403 . . . . 0.0 110.663 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -43.85 46.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.007 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.3 -35.08 71.31 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.407 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.0 t -60.64 -43.24 97.77 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.027 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.7 mt -53.42 -37.85 30.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.079 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.91 -29.84 41.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.104 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.573 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -61.93 -47.66 88.65 Favored Glycine 0 C--N 1.302 -1.31 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.053 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.47 -29.37 38.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 122.382 -0.481 . . . . 0.0 110.775 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -61.24 -49.33 77.54 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.709 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.76 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.2 p80 -56.7 -28.95 61.87 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.968 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.76 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 78.1 t80 -63.78 -50.36 69.31 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.446 ' O ' ' OG1' ' A' ' 42' ' ' THR . 6.5 tt -57.85 -38.51 66.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.814 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -38.85 74.15 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.472 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -48.65 -32.44 8.29 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 120.847 0.356 . . . . 0.0 110.155 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.446 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 66.5 p -53.24 -42.47 66.44 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.319 179.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.413 ' H ' HD13 ' A' ' 43' ' ' ILE . 2.4 mp -60.95 -47.94 91.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.032 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.56 -29.34 5.56 Favored Glycine 0 C--N 1.303 -1.296 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.528 ' HE2' HE21 ' A' ' 48' ' ' GLN . 9.9 t-80 -49.74 -27.92 5.49 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 122.779 -0.248 . . . . 0.0 111.377 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.8 pp -44.99 -41.96 7.82 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.511 -176.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -50.19 -45.46 53.58 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.528 HE21 ' HE2' ' A' ' 45' ' ' HIS . 0.6 OUTLIER -73.34 -57.88 3.7 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.217 0.532 . . . . 0.0 111.255 -179.38 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.414 HD13 HG22 ' A' ' 49' ' ' ILE . 0.4 OUTLIER -48.68 -14.52 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.079 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 33.5 ttpt -109.48 -59.46 1.9 Allowed 'General case' 0 C--N 1.32 -0.712 0 O-C-N 122.092 -0.38 . . . . 0.0 110.739 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -84.04 104.9 14.49 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.823 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.108 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 179.783 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 11.1 m . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' B' ' 26' ' ' LEU . 12.4 m-20 52.62 58.0 14.9 Favored Pre-proline 0 C--N 1.304 -1.376 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.481 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.45 24.89 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.644 2.229 . . . . 0.0 111.938 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.505 ' H ' ' C ' ' B' ' 24' ' ' ASP . 49.8 tp -68.0 -43.96 77.68 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.666 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.05 -35.81 65.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.086 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 89.4 t -67.33 -44.02 87.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.53 -37.63 27.64 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.656 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.36 -34.02 75.86 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.948 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -60.05 -42.74 95.11 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.741 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.7 mm -49.96 -31.78 7.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.555 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -69.61 -29.61 42.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.333 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.17 -50.6 44.41 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 121.026 -0.607 . . . . 0.0 111.889 -179.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.0 pt -62.71 -29.8 47.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.88 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -61.16 -46.93 88.51 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.576 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.782 ' HE2' ' NE2' ' C' ' 37' ' ' HIS . 7.8 m-70 -51.53 -50.54 59.82 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -54.2 -44.67 71.82 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 81.9 mt -59.02 -50.24 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.507 -179.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -36.85 69.48 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 121.086 0.47 . . . . 0.0 111.424 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.408 ' O ' ' CD1' ' B' ' 41' ' ' TRP . 9.8 t-105 -49.35 -34.6 16.31 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 113.294 0.849 . . . . 0.0 113.294 -177.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 1.7 t -69.29 -29.31 67.14 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.048 -0.661 . . . . 0.0 110.709 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -61.99 -51.4 72.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.924 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.62 -29.83 19.01 Favored Glycine 0 C--N 1.306 -1.09 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -54.37 -27.47 36.61 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 120.88 0.371 . . . . 0.0 111.176 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -45.72 -29.83 1.4 Allowed 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.986 -176.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' B' ' 50' ' ' LYS . 29.3 m120 -58.29 -51.71 68.62 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.585 ' C ' ' H ' ' B' ' 50' ' ' LYS . 0.0 OUTLIER -79.19 -58.91 2.99 Favored 'General case' 0 C--N 1.314 -0.959 0 O-C-N 121.871 -0.518 . . . . 0.0 111.741 -178.183 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 4.7 tt -49.62 -2.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -179.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.585 ' H ' ' C ' ' B' ' 48' ' ' GLN . 22.2 ttpp -176.38 147.9 0.72 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 62.4 ttm-85 -155.54 99.18 2.01 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 120.866 0.365 . . . . 0.0 110.64 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -173.23 58.97 0.23 Allowed Pre-proline 0 C--N 1.306 -1.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.716 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.82 8.2 3.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.837 2.358 . . . . 0.0 111.818 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 37.2 tp -65.81 -47.27 75.66 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -69.38 -40.88 80.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.918 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.4 t -67.39 -47.57 80.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.496 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.98 54.85 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.105 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.858 0.361 . . . . 0.0 111.009 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 8.9 t -50.48 -43.88 55.62 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.4 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.3 tp -49.69 -29.35 4.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-O 120.804 0.335 . . . . 0.0 111.279 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.96 -31.69 48.81 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -178.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.544 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.39 -50.28 45.48 Favored Glycine 0 C--N 1.303 -1.266 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.564 -178.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.85 -29.51 43.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-O 120.987 0.422 . . . . 0.0 110.452 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.3 tp -62.04 -50.78 70.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.066 -0.515 . . . . 0.0 112.13 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.782 ' NE2' ' HE2' ' B' ' 37' ' ' HIS . 1.8 p80 -57.79 -28.96 64.49 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.642 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.691 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 87.4 t80 -56.99 -44.24 82.52 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.228 -179.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.446 ' O ' ' OG1' ' C' ' 42' ' ' THR . 68.1 mt -55.1 -42.68 66.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.152 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.28 -38.16 75.01 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 120.967 0.413 . . . . 0.0 110.722 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . 0.424 ' CZ3' ' ND1' ' B' ' 37' ' ' HIS . 5.7 t-105 -49.59 -32.85 13.64 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.199 -179.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.446 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.2 p -65.58 -38.26 89.03 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.829 0.347 . . . . 0.0 110.961 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 29.5 mm -60.64 -50.43 80.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.021 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.467 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -50.21 -29.47 15.74 Favored Glycine 0 C--N 1.307 -1.066 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -50.19 -28.2 7.12 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -45.94 -32.61 2.8 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.934 -177.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.664 ' ND2' ' H ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -60.85 -42.74 98.42 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.544 179.986 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.664 ' H ' ' ND2' ' C' ' 47' ' ' ASN . 54.3 tt0 -87.14 72.15 10.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.523 HG22 ' H ' ' C' ' 50' ' ' LYS . 1.7 tt 178.83 -79.4 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 O-C-N 122.346 -0.221 . . . . 0.0 110.467 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.55 ' C ' ' H ' ' C' ' 52' ' ' GLY . 15.0 ptpt -60.2 134.64 57.25 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 31.3 ttm180 63.24 -4.91 0.25 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.919 0.39 . . . . 0.0 110.481 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.108 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 55.7 m . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.17 149.89 70.33 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.283 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.03 41.48 0.66 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.087 1.858 . . . . 0.0 111.938 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -65.54 -48.69 71.62 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.672 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.32 -34.44 58.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.203 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 96.2 t -69.83 -45.62 76.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.524 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.44 -34.87 17.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.032 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.71 -29.74 69.8 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.062 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.4 t -55.04 -42.1 72.25 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.034 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -53.93 -31.84 21.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.73 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -70.98 -29.71 38.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.079 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.93 -45.0 90.7 Favored Glycine 0 C--N 1.306 -1.103 0 C-N-CA 121.26 -0.495 . . . . 0.0 112.392 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 16.5 pt -65.8 -38.42 82.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.038 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 47.5 tp -49.52 -40.34 37.43 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.551 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.479 ' HE2' ' NE2' ' A' ' 37' ' ' HIS . 2.1 m-70 -59.82 -39.16 84.12 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.687 -0.405 . . . . 0.0 111.739 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 79.7 t80 -61.24 -48.57 80.84 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -178.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.436 ' O ' ' OG1' ' D' ' 42' ' ' THR . 1.3 pp -66.02 -39.07 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.534 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.45 -41.31 72.97 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.803 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.02 -29.54 5.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.429 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.436 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 53.1 p -65.29 -30.3 71.15 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.537 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.4 mp -70.15 -51.48 38.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.397 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' D' ' 47' ' ' ASN . . . -55.83 -29.99 55.92 Favored Glycine 0 C--N 1.305 -1.158 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 27.0 t-80 -56.3 -28.32 58.4 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 122.866 -0.196 . . . . 0.0 111.515 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -48.4 -36.62 15.09 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.979 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' D' ' 48' ' ' GLN . 6.6 p30 -67.23 -44.18 80.1 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.93 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.538 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 37.8 mt-30 -63.87 -55.18 24.72 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-O 121.109 0.48 . . . . 0.0 111.635 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.594 ' CG2' ' H ' ' D' ' 50' ' ' LYS . 4.8 tp -59.07 -68.63 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.11 -179.334 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.594 ' H ' ' CG2' ' D' ' 49' ' ' ILE . 9.2 ptmm? -166.73 122.01 1.14 Allowed 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.007 0.432 . . . . 0.0 110.473 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -80.35 4.9 16.41 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.683 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.897 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.6 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -162.35 58.84 0.87 Allowed Pre-proline 0 C--N 1.308 -1.222 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -77.73 -3.15 13.28 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.785 2.323 . . . . 0.0 112.085 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 12.4 tp -62.15 -48.88 78.15 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.186 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.0 p -70.33 -32.39 50.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.532 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.4 t -70.29 -43.33 78.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 120.78 0.324 . . . . 0.0 110.929 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.46 -40.06 58.7 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.158 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -31.23 69.74 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.362 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -62.38 -37.8 87.12 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.008 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -57.37 -35.04 47.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.075 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.7 mt -67.99 -32.42 56.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.539 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.498 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.48 -44.72 82.69 Favored Glycine 0 C--N 1.302 -1.329 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.425 -178.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 70.4 mt -70.14 -29.74 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.888 0.375 . . . . 0.0 111.202 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.72 -47.66 82.62 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.704 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.682 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -58.27 -28.69 65.18 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.468 -179.054 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.682 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 68.9 t80 -54.13 -44.06 71.03 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.426 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 8.9 tp -58.02 -43.12 84.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.378 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.426 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.5 -35.12 73.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.984 0.421 . . . . 0.0 110.976 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -49.21 -37.85 24.23 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.151 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.37 -29.53 68.99 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.287 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mm -60.42 -48.86 86.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.104 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.87 -32.28 11.28 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 121.294 -0.479 . . . . 0.0 112.015 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-160 -49.39 -28.37 5.02 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.865 0.333 . . . . 0.0 111.369 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 pp -46.03 -40.84 11.17 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -177.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -56.09 -43.71 78.29 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 120.399 -0.52 . . . . 0.0 111.493 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -64.78 -59.12 4.59 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 120.896 0.379 . . . . 0.0 111.098 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.51 ' CG1' ' N ' ' A' ' 50' ' ' LYS . 1.1 pt -58.14 -51.73 67.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.51 ' N ' ' CG1' ' A' ' 49' ' ' ILE . 54.2 tttp -49.13 -74.95 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 120.721 0.296 . . . . 0.0 110.768 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -72.42 139.69 47.92 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.654 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.223 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.809 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' SER . . . . . 0.425 ' OG ' ' N ' ' B' ' 24' ' ' ASP . 46.5 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.564 ' C ' ' H ' ' B' ' 26' ' ' LEU . 3.8 m-20 41.08 71.43 1.29 Allowed Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.528 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -66.69 30.07 0.11 Allowed 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.779 2.319 . . . . 0.0 111.647 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.564 ' H ' ' C ' ' B' ' 24' ' ' ASP . 22.7 tp -70.7 -42.98 69.94 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -70.35 -44.85 77.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.519 -179.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 39.8 t -68.82 -43.83 82.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.74 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -40.9 44.44 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.151 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -54.6 -28.57 47.36 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -48.77 -40.39 28.68 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 5.0 tp -49.2 -36.64 9.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.447 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -70.18 -29.54 40.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.54 -51.02 55.86 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.022 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 29.7 pt -65.46 -37.99 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.132 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 tt -59.68 -48.68 80.73 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 121.307 0.575 . . . . 0.0 109.547 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -48.98 -46.72 44.12 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.249 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -68.64 -39.17 80.83 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.946 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.477 ' O ' ' OG1' ' B' ' 42' ' ' THR . 80.1 mt -61.42 -46.33 96.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.04 -179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.12 -40.89 95.13 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.843 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 -48.42 -33.1 8.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.407 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.477 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 80.6 p -52.26 -49.51 63.92 Favored 'General case' 0 C--N 1.3 -1.575 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.266 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.16 -51.45 71.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 C-N-CA 121.004 -0.279 . . . . 0.0 111.416 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.12 -29.4 36.12 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 3.9 t-160 -60.72 -30.0 69.7 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 120.89 0.376 . . . . 0.0 110.996 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -48.67 -33.22 9.62 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.58 -178.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.465 ' ND2' ' OD1' ' C' ' 47' ' ' ASN . 20.5 m120 -64.37 -49.62 70.93 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -178.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.4 OUTLIER -59.79 -51.59 69.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-O 120.828 0.347 . . . . 0.0 111.928 -178.552 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.437 HG21 ' H ' ' B' ' 50' ' ' LYS . 5.6 tt -56.09 -67.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.529 -179.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.437 ' H ' HG21 ' B' ' 49' ' ' ILE . 20.0 pttp -136.75 172.21 13.36 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 120.874 0.368 . . . . 0.0 110.426 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.604 HH22 HD22 ' C' ' 47' ' ' ASN . 60.7 ttm-85 -152.22 147.73 26.74 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.367 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.22 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.927 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.9 m . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -172.6 60.23 0.27 Allowed Pre-proline 0 C--N 1.306 -1.285 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.689 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -77.52 15.46 1.23 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.836 2.357 . . . . 0.0 112.039 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.3 mp -70.11 -40.59 74.8 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.835 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.16 -45.59 75.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.384 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.8 t -66.66 -45.41 88.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.902 0.382 . . . . 0.0 110.758 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.09 -44.24 87.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.84 -29.43 70.62 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.315 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 22.7 t -53.54 -41.3 66.29 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.328 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 11.3 tt -49.91 -29.15 4.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-O 120.94 0.4 . . . . 0.0 111.175 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 16.1 mt -64.55 -37.43 80.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.12 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.55 -47.8 83.69 Favored Glycine 0 C--N 1.302 -1.321 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.408 -178.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -69.58 -30.02 43.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.72 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -62.2 -50.62 71.08 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -178.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.673 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -52.92 -29.17 27.07 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.642 -178.523 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.673 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 42.7 t80 -61.16 -42.28 98.27 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.572 -0.285 . . . . 0.0 111.522 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' OG1' ' C' ' 42' ' ' THR . 76.9 mt -58.25 -49.72 80.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.824 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.59 -34.65 74.44 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.036 0.446 . . . . 0.0 110.649 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.1 -32.71 10.31 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.233 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.433 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.1 p -60.51 -36.08 77.51 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.258 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.39 -50.41 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.469 -179.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.89 -30.05 35.89 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 121.206 -0.521 . . . . 0.0 111.979 -179.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -50.87 -29.55 12.19 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 120.661 0.267 . . . . 0.0 111.627 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.529 ' CD2' HE21 ' D' ' 48' ' ' GLN . 1.6 pp -47.46 -34.95 7.9 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.739 -177.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.604 HD22 HH22 ' B' ' 51' ' ' ARG . 30.8 t-20 -50.24 -50.17 50.75 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.552 -179.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.6 tp-100 -56.47 -47.38 79.32 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 9.5 tt -102.2 96.21 4.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.432 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.593 ' HZ3' ' HE ' ' C' ' 51' ' ' ARG . 49.2 tttm -158.5 -74.9 0.08 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.349 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.593 ' HE ' ' HZ3' ' C' ' 50' ' ' LYS . 1.5 mpt_? -62.02 -41.81 98.48 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.028 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.103 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 179.863 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.1 p . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -70.51 138.79 86.29 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.363 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.33 55.97 3.73 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.015 1.81 . . . . 0.0 112.002 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.58 -45.51 68.49 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.597 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 t -70.48 -38.21 72.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.425 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 85.1 t -68.57 -43.22 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.848 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -31.9 12.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.021 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.09 69.5 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.959 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.2 t -54.22 -42.15 69.48 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.025 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 mm -50.7 -34.47 12.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.68 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -71.43 -29.27 34.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.358 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.59 -50.99 51.52 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.645 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 pp -62.87 -28.97 46.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.07 0.435 . . . . 0.0 110.628 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.5 tp -60.88 -41.61 96.32 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.305 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 25.2 m170 -56.07 -41.3 74.89 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.613 -179.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -61.43 -47.86 83.81 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -178.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.476 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.3 pt -63.46 -43.73 98.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.163 -178.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.87 98.99 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.967 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -49.67 -33.83 16.8 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.521 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.476 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 54.5 p -59.21 -42.18 90.34 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.785 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.441 HD13 ' H ' ' D' ' 43' ' ' ILE . 4.7 mp -71.56 -53.1 21.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.4 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.39 -29.07 10.26 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -58.72 -28.18 65.59 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -48.26 -32.31 7.08 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 112.654 0.613 . . . . 0.0 112.654 -177.543 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.507 ' N ' ' CD1' ' D' ' 46' ' ' LEU . 4.7 t-20 -62.32 -50.79 70.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.529 HE21 ' CD2' ' C' ' 46' ' ' LEU . 4.2 mm100 -59.53 -50.35 74.23 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 12.6 tt -70.78 89.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 CA-C-O 121.588 0.708 . . . . 0.0 110.408 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 26.4 ttmt 45.62 -139.3 0.46 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.474 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 ptt-85 -174.11 -15.92 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 120.846 0.355 . . . . 0.0 110.6 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.916 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.0 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -168.9 62.16 0.48 Allowed Pre-proline 0 C--N 1.306 -1.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.5 7.16 4.65 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.817 2.345 . . . . 0.0 112.069 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.3 tp -66.84 -46.49 74.95 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.686 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.5 p -70.47 -38.46 73.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.373 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -70.03 -43.28 79.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.948 0.404 . . . . 0.0 110.674 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -36.47 25.73 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.096 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.43 -29.25 69.92 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -56.39 -43.83 79.65 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.4 pt -50.59 -29.51 6.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-O 120.746 0.308 . . . . 0.0 111.204 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -67.94 -29.95 46.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.592 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.99 -49.85 51.05 Favored Glycine 0 C--N 1.303 -1.275 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.181 -179.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.55 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 3.1 mp -66.4 -29.53 46.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-O 120.696 0.284 . . . . 0.0 111.063 -179.364 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 34.0 tp -62.02 -49.25 76.78 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.681 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.3 p80 -57.91 -29.21 64.92 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.937 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.681 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 68.1 t80 -59.31 -44.29 92.58 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.742 -0.383 . . . . 0.0 111.031 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.422 ' O ' ' OG1' ' A' ' 42' ' ' THR . 77.9 mt -57.34 -48.89 81.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.89 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.6 -35.49 77.41 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 120.911 0.386 . . . . 0.0 110.747 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.67 -33.31 9.77 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.788 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.422 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 54.1 p -62.42 -33.2 74.31 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.003 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' A' ' 45' ' ' HIS . 16.1 mm -70.12 -46.65 71.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.886 -0.325 . . . . 0.0 110.583 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.23 -24.28 0.56 Allowed Glycine 0 C--N 1.301 -1.379 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.423 ' N ' ' O ' ' A' ' 43' ' ' ILE . 5.7 t-80 -46.3 -26.54 0.83 Allowed 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.4 ' N ' HD23 ' A' ' 46' ' ' LEU . 4.2 mm? -44.15 -49.8 8.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 118.73 0.695 . . . . 0.0 110.602 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -50.21 -33.86 20.86 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.173 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -73.69 -58.57 3.22 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.868 0.366 . . . . 0.0 111.734 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 1.7 pt -58.42 -26.37 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.0 tttp -87.37 -69.56 0.68 Allowed 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.869 0.366 . . . . 0.0 110.232 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -85.27 147.25 26.65 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.448 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.215 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.982 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.469 ' C ' ' H ' ' B' ' 26' ' ' LEU . 1.4 m-20 -88.05 150.98 48.69 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.115 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -71.92 37.43 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 122.281 1.987 . . . . 0.0 111.676 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.469 ' H ' ' C ' ' B' ' 24' ' ' ASP . 40.1 tp -69.55 -47.46 63.62 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.861 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -70.43 -35.14 60.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.03 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 45.5 t -70.15 -47.09 69.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.358 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -37.85 30.87 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.162 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.08 -31.61 69.04 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.667 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 5.7 t -57.09 -36.02 70.11 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.57 -35.11 37.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.5 mt -71.29 -29.69 36.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.471 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.68 -44.7 88.97 Favored Glycine 0 C--N 1.307 -1.058 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.017 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -64.46 -43.42 96.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.825 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.2 tp -57.45 -42.7 83.03 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.21 -47.64 46.05 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.101 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -70.06 -37.25 75.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' B' ' 42' ' ' THR . 96.1 mt -63.39 -43.59 98.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.587 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.63 -37.82 80.02 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 120.927 0.394 . . . . 0.0 110.681 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.63 -31.15 10.18 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.283 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 41.0 p -50.96 -36.06 36.87 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.158 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.516 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.5 mp -64.48 -50.29 76.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.66 -0.246 . . . . 0.0 111.078 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.3 -29.3 10.05 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.735 -0.546 . . . . 0.0 111.735 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-160 -53.56 -27.01 23.87 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' B' ' 50' ' ' LYS . 2.1 pp -48.92 -37.54 20.16 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -64.36 -51.15 64.75 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.569 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -68.45 -53.99 19.91 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -178.246 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.648 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -50.04 -71.93 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 C-N-CA 120.684 -0.407 . . . . 0.0 111.391 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.648 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 81.2 tttt -139.73 154.69 47.5 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 120.899 0.381 . . . . 0.0 110.905 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 8.6 tpp85 -152.22 83.11 1.26 Allowed 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.292 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.201 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.44 ' C ' ' H ' ' C' ' 26' ' ' LEU . 23.1 t70 -172.23 57.27 0.23 Allowed Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.933 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.59 20.24 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.576 2.184 . . . . 0.0 111.765 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.44 ' H ' ' C ' ' C' ' 24' ' ' ASP . 0.2 OUTLIER -63.95 -47.16 81.54 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.368 -179.718 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -69.67 -43.14 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.148 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -64.36 -43.32 97.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.575 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.13 -44.63 96.21 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.011 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.38 -29.49 70.56 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.789 0.328 . . . . 0.0 111.349 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -55.82 -43.02 76.54 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.432 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.4 tp -49.71 -28.9 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 120.804 0.335 . . . . 0.0 111.341 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.0 -31.03 46.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.104 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.99 -50.28 41.78 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.271 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 5.8 tp -68.41 -29.48 44.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.849 0.357 . . . . 0.0 110.482 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.16 -48.77 80.32 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.777 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.666 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -58.78 -29.24 66.65 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.561 -0.456 . . . . 0.0 111.886 -178.538 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.666 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 66.7 t80 -60.33 -45.49 93.27 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.939 -0.305 . . . . 0.0 111.361 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' OG1' ' C' ' 42' ' ' THR . 73.7 mt -54.98 -46.4 76.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.562 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -34.56 72.77 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.411 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -48.55 -29.69 4.49 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.879 -178.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.5 p -63.06 -33.21 74.95 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.743 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.526 ' N ' ' CD1' ' C' ' 43' ' ' ILE . 1.5 mp -65.28 -47.84 85.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.859 0.361 . . . . 0.0 110.598 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.78 -29.12 5.83 Favored Glycine 0 C--N 1.3 -1.466 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.504 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -53.41 -29.33 34.46 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.874 0.337 . . . . 0.0 111.732 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 7.5 mp -46.33 -45.39 17.51 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 120.415 0.15 . . . . 0.0 111.05 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.44 HD22 ' CB ' ' D' ' 47' ' ' ASN . 18.1 m120 -52.02 -50.25 61.78 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 120.511 -0.476 . . . . 0.0 111.615 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 43.7 tt0 -96.84 59.26 1.69 Allowed 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -178.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.525 ' O ' ' CG2' ' C' ' 49' ' ' ILE . 0.1 OUTLIER -171.71 91.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 CA-C-O 121.889 0.852 . . . . 0.0 110.079 178.355 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.6 pttt -179.92 -43.65 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.671 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 82.6 mtt85 -70.08 173.46 6.53 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.861 0.362 . . . . 0.0 110.751 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.177 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.825 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' D' ' 26' ' ' LEU . 6.8 m-20 -75.64 151.19 84.78 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.204 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -72.33 40.18 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.221 1.947 . . . . 0.0 111.968 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.421 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.5 tp -70.74 -43.59 68.54 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.908 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.68 -40.67 77.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.061 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.46 -42.25 78.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.599 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -56.51 -40.02 74.32 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.791 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.86 -29.37 70.14 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.649 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -49.32 -36.41 21.03 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.7 tp -53.75 -33.84 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 121.059 0.457 . . . . 0.0 110.397 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.6 mt -71.16 -29.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.429 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.51 -43.92 91.27 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 121.358 -0.449 . . . . 0.0 112.503 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 28.3 pt -68.39 -32.68 56.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.653 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -53.24 -41.44 65.42 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.621 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 18.7 m170 -54.48 -42.92 71.27 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.704 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -56.96 -47.19 81.3 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -178.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.7 pt -65.01 -46.04 92.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.932 -0.707 . . . . 0.0 111.503 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.43 -37.92 77.62 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.63 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.472 ' O ' ' CD1' ' D' ' 41' ' ' TRP . 13.1 t-105 -49.07 -28.46 4.15 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.35 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 4.0 m -59.61 -30.95 69.05 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 96.1 mt -62.46 -50.55 79.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.487 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.22 -29.48 9.77 Favored Glycine 0 C--N 1.303 -1.281 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -62.89 -29.13 70.53 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.76 0.281 . . . . 0.0 111.76 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -47.99 -34.27 9.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -177.426 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.44 ' CB ' HD22 ' C' ' 47' ' ' ASN . 3.7 m120 -58.87 -52.29 66.36 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.166 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.563 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -92.04 66.93 5.04 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 122.237 -0.289 . . . . 0.0 111.647 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.442 ' O ' ' N ' ' D' ' 51' ' ' ARG . 1.6 tp -175.66 103.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 121.187 0.517 . . . . 0.0 110.409 179.051 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' D' ' 51' ' ' ARG . 19.1 tptp 61.88 -76.38 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.258 179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' D' ' 49' ' ' ILE . 17.3 ptt180 38.45 -162.32 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.325 -179.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.893 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.481 ' C ' ' H ' ' A' ' 26' ' ' LEU . 5.8 p-10 -173.39 56.53 0.2 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.23 18.55 0.32 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.813 2.342 . . . . 0.0 111.573 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.481 ' H ' ' C ' ' A' ' 24' ' ' ASP . 50.8 tp -70.16 -44.53 68.62 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.754 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.7 -36.27 64.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.122 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.07 -44.7 78.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.976 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.49 -31.05 9.25 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.582 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.5 -30.11 66.8 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 41.2 t -60.7 -44.45 96.54 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.592 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.526 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.1 mp -52.12 -29.79 12.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.804 0.335 . . . . 0.0 110.353 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.4 mt -70.6 -29.62 39.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.211 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.501 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -64.04 -45.93 92.62 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.416 HD11 ' H ' ' A' ' 35' ' ' ILE . 4.2 mp -69.9 -29.56 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.053 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.0 tt -61.84 -42.48 99.09 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.54 -179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.68 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -68.03 -28.59 67.53 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 120.239 -0.584 . . . . 0.0 111.456 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.68 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 76.7 t80 -66.49 -47.86 71.66 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' A' ' 42' ' ' THR . 7.2 tt -57.61 -35.9 52.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.24 -0.584 . . . . 0.0 110.442 -179.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.64 -36.11 73.25 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.659 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -52.95 -35.5 58.77 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.809 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 81.0 p -59.49 -37.12 77.43 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.669 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.545 ' CD1' ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -69.25 -50.9 48.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.673 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.68 -28.32 6.87 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 111.991 -0.444 . . . . 0.0 111.991 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.544 ' CD2' ' OE1' ' A' ' 48' ' ' GLN . 33.7 t-80 -49.54 -27.31 4.26 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -179.382 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -47.99 -33.93 8.57 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -176.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -48.56 -52.87 20.63 Favored 'General case' 0 C--N 1.311 -1.084 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.403 -178.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.629 ' C ' ' H ' ' A' ' 50' ' ' LYS . 4.6 mp0 -67.52 -140.8 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 178.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER 54.14 -8.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.629 ' H ' ' C ' ' A' ' 48' ' ' GLN . 61.4 pttt -171.89 -163.94 0.28 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 118.217 0.462 . . . . 0.0 110.648 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.646 HH21 ' NH2' ' C' ' 51' ' ' ARG . 25.4 tpt85 47.79 96.56 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.256 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.879 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' SER . . . . . 0.433 ' O ' ' CB ' ' B' ' 24' ' ' ASP . 34.1 t . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.512 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.9 m-20 81.1 52.04 0.08 OUTLIER Pre-proline 0 C--N 1.31 -1.145 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.06 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . 0.472 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 17.9 Cg_endo -58.26 68.79 0.05 OUTLIER 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.85 2.367 . . . . 0.0 112.113 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' B' ' 24' ' ' ASP . 51.6 tp -70.85 -48.84 51.72 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.793 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 93.9 t -70.19 -39.43 76.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.095 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 53.1 t -70.17 -45.45 75.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.959 179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.07 -30.39 6.3 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.438 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.05 -29.54 69.79 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.057 0.456 . . . . 0.0 110.313 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -54.26 -37.23 64.46 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.649 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 70.4 mt -55.28 -33.9 32.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.1 mt -70.9 -31.5 45.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.223 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.71 -45.42 92.84 Favored Glycine 0 C--N 1.306 -1.127 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.045 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -65.59 -41.95 91.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.205 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -59.42 -46.39 88.86 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -49.87 -42.88 48.7 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.856 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -68.15 -39.07 82.75 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.364 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.432 ' O ' ' OG1' ' B' ' 42' ' ' THR . 92.9 mt -60.71 -40.97 86.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.919 -179.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.06 -40.85 74.81 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.023 0.44 . . . . 0.0 110.402 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.52 -31.09 9.5 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.858 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.432 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 62.7 p -60.77 -35.68 77.05 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.41 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.401 HG21 HD13 ' B' ' 43' ' ' ILE . 26.2 mm -67.38 -51.16 55.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.837 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.8 -39.38 31.88 Favored Glycine 0 C--N 1.305 -1.144 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -49.05 -26.55 2.7 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 120.741 0.305 . . . . 0.0 111.563 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.1 -32.55 6.98 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.778 -178.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' B' ' 44' ' ' GLY . 11.1 p30 -70.37 -50.32 40.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -177.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.522 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 4.1 pt20 -69.54 -52.43 26.33 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -177.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.605 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 10.6 tt -45.47 -71.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 C-N-CA 120.661 -0.416 . . . . 0.0 110.638 -179.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.605 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 18.0 pttp -148.7 149.27 31.15 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 120.803 0.335 . . . . 0.0 110.316 179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.477 ' CZ ' ' O ' ' C' ' 51' ' ' ARG . 0.0 OUTLIER -163.55 106.26 0.98 Allowed 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.996 -179.951 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.907 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.1 t . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -133.41 65.79 73.02 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.349 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -78.9 46.21 2.12 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.834 2.356 . . . . 0.0 111.919 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 45.8 tp -66.46 -47.72 72.23 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.471 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.5 t -69.98 -32.17 50.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.991 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.94 -49.5 56.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.588 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.25 -35.32 17.29 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.293 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.22 -29.79 71.06 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 120.915 0.388 . . . . 0.0 110.904 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 34.7 t -50.0 -38.91 39.43 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.157 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.1 tp -53.69 -29.47 17.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.187 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.24 -36.93 69.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.014 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' NE2' ' C' ' 37' ' ' HIS . . . -63.72 -49.4 68.98 Favored Glycine 0 C--N 1.305 -1.156 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.687 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 tp -70.05 -29.86 41.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 CA-C-O 121.032 0.444 . . . . 0.0 110.105 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 27.2 tp -59.81 -49.41 77.83 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.64 -179.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.707 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.3 p80 -59.62 -29.03 67.72 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.68 -178.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.707 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 65.0 t80 -61.16 -43.36 99.0 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.031 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' OG1' ' C' ' 42' ' ' THR . 66.2 mt -58.8 -45.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.087 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -38.96 75.55 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.585 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.6 -29.89 7.86 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.807 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.435 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 64.6 p -60.9 -37.7 83.16 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.748 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.5 mm -63.05 -50.54 79.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.31 -179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.434 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -50.12 -31.3 18.58 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 111.899 -0.48 . . . . 0.0 111.899 -179.061 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -49.86 -28.09 6.03 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.438 ' O ' ' O ' ' C' ' 49' ' ' ILE . 2.0 pp -48.58 -38.88 21.84 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.696 -0.401 . . . . 0.0 111.451 -178.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.453 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 9.7 p30 -51.94 -49.26 63.51 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.594 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.453 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 4.1 tp-100 -46.92 -38.57 10.75 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.042 0.449 . . . . 0.0 110.956 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.519 ' O ' ' CB ' ' C' ' 50' ' ' LYS . 12.8 tt -112.52 112.49 40.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.727 -179.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.55 ' O ' ' N ' ' C' ' 52' ' ' GLY . 0.8 OUTLIER 94.32 119.34 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.497 -1.228 . . . . 0.0 110.713 179.591 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.646 ' NH2' HH21 ' A' ' 51' ' ' ARG . 62.4 ttt180 38.78 -86.89 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.553 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.307 -1.053 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 36.0 m . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.499 ' C ' ' H ' ' D' ' 26' ' ' LEU . 10.5 m-20 -161.82 151.06 13.32 Favored Pre-proline 0 C--N 1.306 -1.297 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.144 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.56 21.02 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.244 1.963 . . . . 0.0 111.752 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.499 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.9 tp -67.95 -47.15 69.44 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.532 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.97 -37.8 73.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 84.5 t -69.93 -43.57 79.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.525 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.39 -32.16 11.01 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.651 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.81 -29.68 69.68 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.964 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.0 t -56.27 -42.17 77.03 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.053 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.502 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 2.0 mp -55.32 -35.63 37.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.448 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -71.06 -32.58 48.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.412 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.74 -44.29 98.1 Favored Glycine 0 C--N 1.305 -1.141 0 C-N-CA 121.336 -0.459 . . . . 0.0 112.123 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.6 pt -68.44 -29.35 43.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.841 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.6 tp -57.35 -43.04 83.13 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.037 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 4.1 m170 -60.76 -35.02 75.35 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.123 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 t80 -62.34 -48.53 79.41 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.426 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.0 pt -61.6 -42.19 93.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.989 -178.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.21 -40.27 74.64 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.86 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -48.46 -29.81 4.49 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.605 -179.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 73.3 p -64.86 -30.87 71.89 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.5 mp -69.87 -51.74 37.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.26 -31.73 27.79 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.7 t-160 -60.4 -28.28 68.12 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.549 0.214 . . . . 0.0 111.276 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -46.61 -31.23 2.71 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.487 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.437 ' ND2' ' OE1' ' D' ' 48' ' ' GLN . 37.9 t30 -61.03 -50.7 72.26 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.095 0.406 . . . . 0.0 112.095 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.534 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -74.04 -68.39 0.52 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.187 0.517 . . . . 0.0 111.427 -178.718 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.475 ' CG2' ' O ' ' D' ' 49' ' ' ILE . 20.6 tt -54.24 88.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.643 -179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' D' ' 48' ' ' GLN . 7.1 tppt? 58.12 116.72 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.734 179.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.03 129.38 34.45 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.32 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.772 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.414 ' C ' ' H ' ' A' ' 26' ' ' LEU . 4.1 p-10 -170.34 58.73 0.3 Allowed Pre-proline 0 C--N 1.306 -1.307 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.951 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -78.22 25.51 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.818 2.345 . . . . 0.0 111.594 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.476 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 8.9 mp -70.39 -43.83 69.25 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.043 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' A' ' 28' ' ' VAL . 13.6 p -70.89 -42.62 77.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.487 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.401 ' N ' ' CG1' ' A' ' 27' ' ' VAL . 66.1 t -68.41 -43.64 83.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.815 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.81 -34.45 53.74 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -30.54 67.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.5 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -60.36 -44.83 95.22 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.621 -179.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.565 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.2 mp -50.29 -29.08 5.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-O 120.825 0.345 . . . . 0.0 110.71 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.95 -29.32 39.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.809 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.54 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -68.61 -50.18 38.7 Favored Glycine 0 C--N 1.305 -1.172 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.324 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.417 HD12 ' H ' ' A' ' 35' ' ' ILE . 4.2 mp -65.98 -29.56 47.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.999 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.22 -46.02 88.96 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.679 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.7 OUTLIER -57.7 -28.35 63.74 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.625 -178.787 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.676 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 30.9 t80 -55.5 -45.76 77.02 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 3.4 tp -57.36 -44.56 84.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.299 -178.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.453 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.9 -35.4 72.28 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 120.824 0.345 . . . . 0.0 110.827 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.41 ' HE1' ' HB1' ' D' ' 40' ' ' ALA . 4.3 t-105 -48.95 -32.02 8.36 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.353 -178.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 61.2 p -57.56 -30.23 65.07 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.198 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 67.1 mt -64.2 -46.29 93.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.086 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.89 -27.56 3.4 Favored Glycine 0 C--N 1.297 -1.608 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.592 -178.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.596 ' NE2' ' NE2' ' A' ' 48' ' ' GLN . 13.4 t-80 -49.76 -32.91 14.8 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.4 mp -46.02 -40.15 10.14 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.938 -0.476 . . . . 0.0 111.633 -177.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -47.47 -52.68 16.41 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.455 -177.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.6 ' C ' ' H ' ' A' ' 50' ' ' LYS . 6.8 pt20 -72.41 -130.11 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.477 ' CG1' ' O ' ' A' ' 48' ' ' GLN . 3.8 pt 56.93 -13.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -179.129 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.6 ' H ' ' C ' ' A' ' 48' ' ' GLN . 42.6 pttt -170.12 19.94 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.012 0.434 . . . . 0.0 110.05 179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.471 HH21 ' CB ' ' D' ' 51' ' ' ARG . 64.9 ttt180 -150.22 80.36 1.36 Allowed 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.236 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.151 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.864 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 73.39 73.18 0.23 Allowed Pre-proline 0 C--N 1.307 -1.271 0 CA-C-O 121.059 0.457 . . . . 0.0 110.389 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_exo -53.35 89.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.641 0 C-N-CA 122.72 2.28 . . . . 0.0 111.91 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 tp -70.66 -49.15 50.36 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.417 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.3 -38.95 76.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.573 -179.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 t -70.56 -45.24 75.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 120.602 -0.439 . . . . 0.0 109.891 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.63 -33.41 9.86 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.242 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.28 69.96 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.482 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.2 t -49.69 -41.82 44.1 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.032 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -50.97 -29.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-O 120.904 0.383 . . . . 0.0 110.456 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.16 -29.55 36.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.204 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.91 -47.08 89.38 Favored Glycine 0 C--N 1.307 -1.067 0 C-N-CA 121.308 -0.472 . . . . 0.0 112.06 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.1 pt -62.12 -44.87 99.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.861 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 55.4 tp -59.97 -45.9 91.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.997 0.427 . . . . 0.0 109.905 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 33.8 t-80 -50.39 -47.56 56.33 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.142 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -66.95 -38.81 86.82 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.516 -179.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.434 ' O ' ' OG1' ' B' ' 42' ' ' THR . 94.6 mt -62.08 -42.16 93.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.762 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.86 -39.74 76.17 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.964 0.412 . . . . 0.0 110.627 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -49.05 -29.32 4.9 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.956 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 77.8 p -54.67 -37.46 65.77 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 35.6 mm -61.16 -49.07 86.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.729 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.88 -29.91 8.66 Favored Glycine 0 C--N 1.305 -1.152 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.743 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -53.96 -27.48 31.49 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -46.43 -32.11 3.07 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -61.41 -50.31 73.38 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 120.705 -0.398 . . . . 0.0 112.039 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -56.26 -53.95 51.1 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -179.043 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.429 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 7.8 tt -60.59 -66.6 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.761 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.31 -179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.429 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 15.9 ttpp -117.85 134.51 54.86 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.815 0.34 . . . . 0.0 110.585 -179.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 11.5 tpp180 -158.78 117.76 3.03 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.124 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.189 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 179.972 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -172.91 61.04 0.27 Allowed Pre-proline 0 C--N 1.306 -1.286 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.512 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -78.78 4.02 6.82 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.822 2.348 . . . . 0.0 112.211 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -60.0 -50.67 72.83 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.035 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -70.98 -33.76 53.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 120.937 0.399 . . . . 0.0 111.178 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.7 t -70.3 -42.91 78.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.912 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.98 -39.35 40.61 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.51 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.19 -29.48 69.84 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 120.842 0.353 . . . . 0.0 111.292 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -53.05 -40.87 64.29 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.395 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -49.68 -31.53 6.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.751 0.31 . . . . 0.0 111.428 -179.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -70.23 -29.84 41.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.94 -179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.526 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.26 -50.13 57.97 Favored Glycine 0 C--N 1.304 -1.218 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.908 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 36.8 pt -65.72 -29.65 47.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 120.776 0.322 . . . . 0.0 111.01 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 17.6 tp -61.29 -49.44 77.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.754 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.676 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.61 -29.69 62.42 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.767 -178.287 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.676 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 70.8 t80 -63.3 -44.37 95.21 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.258 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.432 ' O ' ' OG1' ' C' ' 42' ' ' THR . 72.5 mt -56.14 -48.21 79.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.155 -179.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.86 -35.97 81.25 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -50.29 -36.34 31.24 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.346 -179.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.432 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.4 p -54.28 -47.13 72.69 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 120.741 0.305 . . . . 0.0 111.009 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.408 ' H ' HD11 ' C' ' 43' ' ' ILE . 4.0 mp -62.44 -49.82 82.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.76 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.448 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -49.75 -29.74 13.39 Favored Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.031 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . 0.403 ' C ' HD21 ' C' ' 47' ' ' ASN . 56.3 t-80 -56.68 -29.02 61.9 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.414 ' O ' ' CG2' ' C' ' 49' ' ' ILE . 3.8 pp -47.12 -35.91 7.72 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.625 0.231 . . . . 0.0 111.625 -177.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.673 HD21 ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -48.51 -40.59 27.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.599 -0.841 . . . . 0.0 110.365 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.606 ' H ' ' ND2' ' C' ' 47' ' ' ASN . 49.4 tt0 -90.53 67.1 6.45 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.845 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.507 ' O ' ' CG2' ' C' ' 49' ' ' ILE . 17.7 tt -160.7 86.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 121.401 0.619 . . . . 0.0 111.285 179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -175.06 160.91 2.83 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.786 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 65.8 mtp85 47.97 -121.54 1.37 Allowed 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.433 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.153 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.976 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 69.4 p . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -76.32 136.76 68.37 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -75.09 43.87 1.07 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.069 1.846 . . . . 0.0 112.166 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.47 -45.79 65.05 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.82 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.67 -41.08 77.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.912 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.73 -41.83 77.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.334 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.8 -38.49 34.7 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.664 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.09 -31.54 72.8 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.258 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.5 t -56.22 -37.93 70.35 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.746 0.308 . . . . 0.0 110.793 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.413 HG23 HD13 ' D' ' 32' ' ' ILE . 19.2 mm -53.5 -29.59 17.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.387 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.4 mt -71.33 -29.24 34.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.465 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.33 -33.64 81.53 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 116.326 -0.397 . . . . 0.0 112.919 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -63.72 -38.48 82.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-N 117.402 0.601 . . . . 0.0 110.707 -179.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 43.6 tp -54.72 -43.09 72.28 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.8 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.679 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 19.3 m170 -51.13 -50.01 59.68 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.412 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -61.21 -42.45 98.61 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.557 -179.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' D' ' 42' ' ' THR . 83.2 mt -60.28 -48.17 89.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.913 -179.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . 0.41 ' HB1' ' HE1' ' A' ' 41' ' ' TRP . . . -70.56 -34.73 72.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.82 0.343 . . . . 0.0 111.178 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.0 t-105 -49.0 -28.04 3.62 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.141 0.496 . . . . 0.0 110.017 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 76.7 p -57.92 -34.88 70.33 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.522 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.4 mp -65.75 -50.92 67.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.759 0.314 . . . . 0.0 110.577 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.85 -29.67 62.08 Favored Glycine 0 C--N 1.302 -1.359 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.882 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -70.64 -32.91 70.39 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' D' ' 50' ' ' LYS . 0.7 OUTLIER -53.29 -30.18 37.38 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.612 -178.542 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -63.38 -50.26 70.6 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -178.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.532 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -67.1 -61.13 2.08 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.293 0.568 . . . . 0.0 111.632 -178.561 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.619 ' CG2' ' H ' ' D' ' 50' ' ' LYS . 7.2 tp -52.88 -67.17 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.975 -178.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.619 ' H ' ' CG2' ' D' ' 49' ' ' ILE . 34.7 ttpt -106.9 154.91 20.36 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 120.809 0.338 . . . . 0.0 110.545 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.471 ' CB ' HH21 ' A' ' 51' ' ' ARG . 0.0 OUTLIER -162.13 9.49 0.07 Allowed 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.782 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.202 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 179.935 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.423 ' C ' ' H ' ' A' ' 26' ' ' LEU . 16.6 p-10 -173.3 57.75 0.22 Allowed Pre-proline 0 C--N 1.306 -1.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.081 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -77.38 25.74 0.47 Allowed 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.763 2.309 . . . . 0.0 111.755 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.423 ' H ' ' C ' ' A' ' 24' ' ' ASP . 39.4 tp -64.82 -44.89 88.4 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.202 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.29 -41.42 78.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.756 0.312 . . . . 0.0 111.307 -179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -63.32 -39.89 86.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-O 120.94 0.4 . . . . 0.0 110.921 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.08 -44.12 82.8 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.551 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.59 -37.13 75.16 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.785 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -57.84 -43.48 85.86 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.137 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 69.4 mt -49.32 -37.82 11.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 120.814 0.34 . . . . 0.0 110.778 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -64.77 -29.67 48.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.406 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.537 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -63.27 -50.04 65.94 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.164 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.561 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 2.8 mp -59.64 -29.62 43.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 122.686 -0.303 . . . . 0.0 111.34 -179.047 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tt -63.67 -50.83 67.71 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.67 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -51.26 -29.44 14.6 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.272 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.67 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 63.8 t80 -58.35 -48.1 81.67 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.718 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.6 tp -49.67 -43.53 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.252 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -72.88 -30.03 63.64 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.76 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.424 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 10.9 t-105 -49.02 -32.38 9.25 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -177.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.453 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -66.14 -33.01 74.79 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.463 -179.452 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -51.09 -43.86 27.51 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.03 0.443 . . . . 0.0 109.839 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.44 -28.71 4.93 Favored Glycine 0 C--N 1.299 -1.505 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.048 -178.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -51.7 -33.78 35.69 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 117.251 0.526 . . . . 0.0 111.645 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.5 mp -45.69 -45.21 14.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 119.551 -0.262 . . . . 0.0 111.531 -177.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -46.65 -49.86 18.55 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.201 -178.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.411 ' O ' ' C ' ' A' ' 49' ' ' ILE . 28.4 mm-40 -67.28 -130.11 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.411 ' C ' ' O ' ' A' ' 48' ' ' GLN . 4.9 tt 35.78 56.28 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-O 121.373 0.606 . . . . 0.0 111.867 179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -169.27 4.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.799 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt180 -145.47 152.27 39.52 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.854 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.174 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 54.2 m . . . . . 0 N--CA 1.488 1.465 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.403 ' O ' ' OD2' ' B' ' 24' ' ' ASP . 5.6 p-10 -140.21 60.69 15.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.484 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.32 56.95 1.69 Allowed 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.602 2.201 . . . . 0.0 111.78 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 tp -70.13 -49.86 46.43 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.076 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -70.19 -33.02 52.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.943 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 87.7 t -69.68 -46.2 75.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.989 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.9 -33.02 9.93 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.639 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.26 -31.51 72.74 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.772 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 37.4 t -58.9 -40.93 85.96 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.623 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 mm -51.71 -29.23 10.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -70.41 -29.95 40.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.42 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.32 -48.4 69.72 Favored Glycine 0 C--N 1.307 -1.043 0 C-N-CA 121.185 -0.531 . . . . 0.0 111.948 -179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.8 pt -67.32 -29.79 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 120.871 0.367 . . . . 0.0 110.678 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.3 tp -59.45 -47.59 84.89 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.661 -179.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.844 ' HE2' ' NE2' ' C' ' 37' ' ' HIS . 7.2 m-70 -49.82 -49.78 47.65 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.648 -179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -50.92 -42.98 59.85 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.617 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.433 ' O ' ' OG1' ' B' ' 42' ' ' THR . 79.1 mt -61.12 -50.43 80.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.598 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.32 -38.4 74.92 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.949 0.404 . . . . 0.0 111.076 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.18 -28.73 4.72 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.035 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.433 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 44.1 p -59.9 -38.63 82.83 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.001 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 29.2 mm -65.77 -51.39 62.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 C-N-CA 120.836 -0.345 . . . . 0.0 111.379 -179.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.417 ' O ' ' OD1' ' B' ' 47' ' ' ASN . . . -50.21 -29.75 16.26 Favored Glycine 0 C--N 1.305 -1.193 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.6 t-160 -56.72 -27.66 59.59 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.41 ' O ' ' O ' ' B' ' 50' ' ' LYS . 1.5 pp -47.78 -35.9 10.75 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.672 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.442 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 25.0 p-10 -63.26 -49.62 73.38 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 -178.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.442 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 1.4 tm0? -68.89 -57.45 5.52 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.642 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 13.0 tt -51.13 -71.35 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -178.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.642 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 33.5 ttpt -111.78 147.3 35.96 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-O 120.827 0.346 . . . . 0.0 110.63 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 63.3 ttm-85 -146.49 143.33 28.88 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.387 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.92 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.18 61.83 1.93 Allowed Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.444 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -78.32 0.34 10.0 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.894 2.396 . . . . 0.0 111.999 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 59.7 tp -61.11 -42.21 98.1 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.739 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.2 t -70.13 -42.33 79.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.347 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 98.7 t -60.13 -43.48 93.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 120.955 0.407 . . . . 0.0 110.328 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -48.25 79.27 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.638 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.28 -35.05 69.3 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.847 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.9 t -56.8 -43.66 81.18 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.724 0.297 . . . . 0.0 111.453 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -48.66 -34.6 5.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-O 120.884 0.373 . . . . 0.0 110.459 -178.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.8 mt -64.18 -29.69 48.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.702 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.548 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.9 -51.37 35.06 Favored Glycine 0 C--N 1.306 -1.129 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.579 -178.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 tt -63.1 -29.29 46.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 122.419 -0.46 . . . . 0.0 111.195 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 55.9 tp -62.22 -51.4 67.95 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.589 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.844 ' NE2' ' HE2' ' B' ' 37' ' ' HIS . 1.2 p80 -53.92 -29.5 42.39 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.815 -178.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.743 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 68.9 t80 -57.17 -49.52 75.7 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.564 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -49.88 -43.38 19.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.505 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.77 -31.98 70.23 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.144 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -54.3 -42.68 70.38 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 116.592 -0.276 . . . . 0.0 111.309 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 17.3 p -56.58 -40.36 75.1 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.987 0.422 . . . . 0.0 110.434 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.4 mm -59.06 -50.86 78.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.318 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.8 -28.16 6.93 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -50.41 -40.13 49.22 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.482 HD11 ' H ' ' C' ' 47' ' ' ASN . 0.1 OUTLIER -56.27 -28.05 57.31 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 -177.77 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.482 ' H ' HD11 ' C' ' 46' ' ' LEU . 25.0 p-10 -45.81 -51.5 12.71 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -174.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -141.27 49.83 1.63 Allowed 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 119.205 0.911 . . . . 0.0 112.392 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.2 tp -96.68 41.12 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.56 0.695 . . . . 0.0 109.207 178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.63 25.58 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.942 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 11.1 tpt180 -155.38 126.14 6.96 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.855 0.36 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.7 m . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.9 m-20 47.7 57.73 17.69 Favored Pre-proline 0 C--N 1.304 -1.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.983 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.11 12.6 0.98 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.85 2.366 . . . . 0.0 111.447 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.45 ' H ' ' C ' ' D' ' 24' ' ' ASP . 39.3 tp -70.74 -44.75 66.17 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.607 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.4 p -70.54 -35.06 59.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.39 -50.04 49.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.528 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.66 -33.46 15.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.87 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.46 -34.77 74.87 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.865 0.364 . . . . 0.0 111.132 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 36.7 t -51.85 -38.47 56.08 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.161 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 mm -61.3 -29.64 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.89 0.376 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.405 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 5.1 mt -71.33 -39.17 71.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.418 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.38 -42.2 96.12 Favored Glycine 0 C--N 1.307 -1.068 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.198 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 9.9 tt -70.27 -39.27 76.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.301 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 44.3 tp -49.48 -36.36 22.62 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.437 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.642 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 45.6 m170 -49.93 -43.11 49.65 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.164 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -57.6 -38.29 74.66 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.442 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.427 ' O ' ' OG1' ' D' ' 42' ' ' THR . 6.3 mm -61.67 -50.81 78.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.157 -179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.68 -35.62 72.91 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.956 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.57 -28.65 3.56 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.109 0.48 . . . . 0.0 110.403 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 38.4 p -51.05 -36.66 41.05 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.057 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.408 HG21 HD12 ' D' ' 43' ' ' ILE . 32.2 mm -68.23 -51.13 51.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.127 -179.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.95 -29.48 55.39 Favored Glycine 0 C--N 1.305 -1.184 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -57.23 -27.57 62.14 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -47.3 -28.94 2.18 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.819 -178.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -50.74 -52.57 39.27 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 120.36 -0.536 . . . . 0.0 112.302 -178.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.55 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -84.32 -64.22 1.2 Allowed 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 120.68 0.276 . . . . 0.0 111.64 -179.001 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.402 ' H ' ' HG2' ' D' ' 48' ' ' GLN . 15.4 tt -62.77 14.54 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -178.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' D' ' 48' ' ' GLN . 12.2 ttmm -169.62 121.55 0.71 Allowed 'General case' 0 C--N 1.308 -1.22 0 O-C-N 121.844 -0.535 . . . . 0.0 110.524 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 20.9 tpt85 -162.95 80.62 0.48 Allowed 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.546 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.969 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 23' ' ' SER . 24.4 p . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.95 60.93 0.24 Allowed Pre-proline 0 C--N 1.305 -1.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.709 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -79.11 10.04 3.11 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.821 2.347 . . . . 0.0 112.123 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -66.52 -44.32 82.82 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.63 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.07 -35.14 62.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.311 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.9 t -69.63 -43.91 79.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.938 0.399 . . . . 0.0 110.762 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.67 -39.13 35.34 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.115 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.59 -34.38 76.86 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.726 0.298 . . . . 0.0 111.165 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.4 ' O ' ' CD1' ' A' ' 35' ' ' ILE . 33.5 t -59.88 -41.79 92.35 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.797 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.412 HD13 HG22 ' A' ' 32' ' ' ILE . 19.4 mm -52.55 -32.21 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.152 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.6 mt -70.25 -29.78 40.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.702 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.62 -45.1 93.92 Favored Glycine 0 C--N 1.304 -1.23 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.253 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.621 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 3.1 mp -66.82 -29.13 45.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 122.589 -0.359 . . . . 0.0 111.189 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -62.92 -46.96 85.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -178.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.7 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.4 p80 -58.96 -28.42 66.29 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 120.201 -0.6 . . . . 0.0 111.423 -178.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.7 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 33.7 t80 -56.74 -48.66 77.29 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.405 ' O ' ' OG1' ' A' ' 42' ' ' THR . 6.4 tt -59.4 -41.17 83.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.171 -178.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -35.94 73.88 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.47 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.67 -34.19 17.77 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.412 -179.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.405 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 40.2 p -62.19 -29.98 70.75 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.036 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 58.4 mt -61.33 -47.1 95.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.385 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.71 -28.36 5.19 Favored Glycine 0 C--N 1.307 -1.051 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.167 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.448 ' O ' ' O ' ' A' ' 48' ' ' GLN . 4.9 t-160 -48.88 -27.71 3.26 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 116.762 0.281 . . . . 0.0 111.271 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 pp -45.47 -41.89 9.98 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.54 -0.3 . . . . 0.0 111.745 -177.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.412 ' CG ' HD22 ' D' ' 47' ' ' ASN . 5.8 m120 -48.22 -50.22 30.21 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.454 ' C ' ' H ' ' A' ' 50' ' ' LYS . 2.4 tt0 -93.65 175.39 6.76 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.433 HG23 HD12 ' A' ' 49' ' ' ILE . 0.4 OUTLIER 75.7 -30.58 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 CA-C-N 118.154 0.433 . . . . 0.0 111.434 179.805 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.454 ' H ' ' C ' ' A' ' 48' ' ' GLN . 36.1 ttpt -92.09 -62.75 1.35 Allowed 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 120.558 0.218 . . . . 0.0 111.1 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -67.24 -38.33 85.02 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.507 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.266 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.835 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.495 ' N ' ' OD1' ' B' ' 24' ' ' ASP . 1.5 p30 -85.83 151.95 55.88 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.079 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -71.33 38.6 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.365 2.043 . . . . 0.0 111.774 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.456 ' H ' ' C ' ' B' ' 24' ' ' ASP . 43.9 tp -68.06 -47.96 66.89 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.695 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -70.52 -34.0 55.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -70.0 -45.88 75.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.265 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.04 -35.37 15.46 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.629 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.21 -29.81 70.64 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.679 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 7.0 t -57.88 -41.36 82.34 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.766 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 mm -50.44 -30.61 7.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.584 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.63 -29.34 37.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.4 -49.93 58.3 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 121.047 -0.596 . . . . 0.0 111.787 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.5 pt -63.42 -42.84 97.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.691 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 58.1 tp -60.26 -45.18 94.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.279 0.561 . . . . 0.0 109.615 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -61.08 -41.17 96.16 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.347 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 88.9 t80 -70.67 -46.58 62.94 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.474 ' O ' ' OG1' ' B' ' 42' ' ' THR . 18.0 tt -68.07 -29.97 46.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.317 -178.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -39.98 72.02 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.213 0.53 . . . . 0.0 110.139 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -54.35 -37.45 64.94 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.432 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 31.6 p -55.16 -36.58 65.97 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.603 -0.439 . . . . 0.0 110.934 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.49 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.8 mp -65.04 -50.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.015 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.542 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.51 -30.36 12.8 Favored Glycine 0 C--N 1.305 -1.185 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.43 ' CD2' ' CD ' ' B' ' 48' ' ' GLN . 31.7 t-80 -59.81 -27.04 66.26 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.7 0.286 . . . . 0.0 111.562 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.89 -31.65 12.69 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.774 -0.371 . . . . 0.0 111.943 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 6.9 p30 -68.95 -50.06 52.56 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -177.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.546 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 7.5 pt20 -69.28 -48.51 61.5 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.607 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 16.4 tt -53.95 -67.18 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.214 -179.154 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.607 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 1.5 pptp? -131.07 164.06 26.26 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 120.853 0.359 . . . . 0.0 110.762 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 60.1 ttm-85 -153.52 -48.33 0.09 Allowed 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.543 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.164 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 -179.96 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 91.0 p . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -173.08 60.13 0.25 Allowed Pre-proline 0 C--N 1.305 -1.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.788 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -77.31 6.34 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.767 2.311 . . . . 0.0 111.885 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.3 tp -64.11 -48.44 76.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 59.5 t -70.42 -37.02 69.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 85.8 t -70.12 -43.71 78.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.742 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.48 -38.47 74.6 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.549 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.08 -30.38 71.45 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 120.906 0.384 . . . . 0.0 110.903 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -50.74 -36.47 36.61 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.178 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 11.8 tt -55.27 -29.76 23.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.603 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.41 -36.92 76.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.429 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.61 -46.41 84.49 Favored Glycine 0 C--N 1.303 -1.261 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.16 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 11.0 tt -70.28 -29.06 37.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.778 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 31.8 tp -61.94 -47.23 85.83 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.99 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -56.7 -29.94 62.95 Favored 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 120.421 -0.512 . . . . 0.0 111.876 -178.474 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 77.4 t80 -62.33 -40.63 96.99 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.393 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.458 ' O ' ' OG1' ' C' ' 42' ' ' THR . 96.6 mt -57.43 -46.93 85.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.54 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.18 -34.62 73.19 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 120.81 0.338 . . . . 0.0 110.812 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.2 -30.68 7.31 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.354 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.458 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 42.2 p -53.97 -44.02 70.41 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.923 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.401 ' H ' HD11 ' C' ' 43' ' ' ILE . 4.0 mp -63.66 -48.86 84.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.617 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.23 -33.56 15.67 Favored Glycine 0 C--N 1.304 -1.217 0 C-N-CA 121.259 -0.496 . . . . 0.0 111.881 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -50.58 -28.57 8.95 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 116.814 0.307 . . . . 0.0 111.628 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.2 pp -46.82 -39.55 12.11 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.931 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 32.1 p30 -49.95 -35.03 22.63 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.191 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.524 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 1.9 tm0? -73.91 -53.4 10.23 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 112.473 0.545 . . . . 0.0 112.473 -178.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.504 ' CG2' ' N ' ' C' ' 50' ' ' LYS . 13.2 tt -62.7 -56.74 15.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' C' ' 52' ' ' GLY . 52.5 pttt -37.51 147.46 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 117.934 0.333 . . . . 0.0 111.287 -179.31 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.466 ' N ' ' CD ' ' C' ' 51' ' ' ARG . 10.5 mpt_? 45.79 -90.72 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.593 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.163 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 14.9 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' D' ' 24' ' ' ASP . 4.2 p30 -71.65 151.81 93.57 Favored Pre-proline 0 C--N 1.305 -1.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.223 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.72 45.56 0.9 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.322 2.015 . . . . 0.0 111.753 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 53.9 tp -69.97 -44.02 70.31 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.282 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.52 -38.62 74.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.979 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 95.6 t -67.08 -47.71 81.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.696 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.78 -34.37 19.18 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.015 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.31 -29.73 67.65 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.138 -179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.2 t -57.17 -42.79 81.8 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.127 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.419 HD12 HG23 ' D' ' 32' ' ' ILE . 18.0 mm -51.46 -33.34 14.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 120.881 0.372 . . . . 0.0 110.481 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 4.6 mt -71.51 -29.04 33.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.282 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.36 -47.47 79.08 Favored Glycine 0 C--N 1.309 -0.937 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.118 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -61.15 -42.07 91.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.786 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.5 tp -49.13 -32.24 9.63 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.667 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 29.5 m170 -65.35 -42.88 92.39 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.554 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.69 -50.07 66.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.3 pp -62.83 -39.04 83.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.847 -0.741 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.08 -40.75 78.24 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.335 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.1 t-105 -49.78 -30.2 9.18 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.73 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.2 m -69.59 -35.78 75.64 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 115.604 -0.726 . . . . 0.0 111.116 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 60.7 mt -70.6 -51.54 36.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.012 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.97 -27.8 65.19 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -55.99 -26.56 48.97 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.49 ' N ' HD12 ' D' ' 46' ' ' LEU . 0.0 OUTLIER -47.07 -25.11 0.77 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -177.642 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.434 ' N ' HD11 ' D' ' 46' ' ' LEU . 13.7 m120 -49.23 -51.51 32.81 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.066 -0.654 . . . . 0.0 111.402 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.526 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -85.07 -69.32 0.66 Allowed 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.997 0.427 . . . . 0.0 111.098 -179.443 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.431 ' O ' ' O ' ' D' ' 50' ' ' LYS . 7.3 tp -57.94 92.45 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 CA-C-O 121.546 0.689 . . . . 0.0 110.603 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' D' ' 46' ' ' LEU . 17.2 ttpp 59.13 145.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.928 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 25.1 ptt-85 -152.5 -22.69 0.17 Allowed 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.429 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.261 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.981 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.5 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -174.37 57.58 0.2 Allowed Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.38 9.74 2.41 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.828 2.352 . . . . 0.0 111.991 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -67.75 -45.11 75.89 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.2 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.0 p -70.1 -37.2 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.655 -179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.6 t -68.91 -43.7 82.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 120.982 0.42 . . . . 0.0 110.989 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.82 -38.3 21.79 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.629 -179.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.08 -35.86 81.67 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.32 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.8 t -60.4 -44.75 95.41 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.333 -179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.0 mm -50.01 -29.72 5.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.042 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.9 mt -70.5 -30.96 44.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.813 -179.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.53 -48.49 72.82 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.379 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.437 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.4 mp -68.07 -29.5 44.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.74 0.305 . . . . 0.0 111.057 -179.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 45.2 tp -61.8 -47.43 85.17 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.464 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.698 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.1 -28.59 69.2 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.243 -0.583 . . . . 0.0 111.41 -178.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.698 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 51.4 t80 -60.18 -48.74 80.47 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.8 tt -60.73 -39.96 83.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -39.47 72.44 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 120.926 0.393 . . . . 0.0 110.968 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -48.94 -30.83 6.42 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.856 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -57.83 -37.54 73.99 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.8 mm -61.04 -48.88 87.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.804 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.27 -28.12 6.01 Favored Glycine 0 C--N 1.305 -1.163 0 N-CA-C 111.709 -0.557 . . . . 0.0 111.709 -179.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 -48.2 -27.87 2.68 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 pp -45.8 -37.46 6.1 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.732 -0.387 . . . . 0.0 111.656 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -55.77 -50.24 70.97 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.431 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -86.52 68.44 10.18 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 111.612 0.227 . . . . 0.0 111.612 -179.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.3 pt -110.22 -122.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.619 0.247 . . . . 0.0 111.083 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -63.54 -36.66 84.53 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 120.837 0.351 . . . . 0.0 110.693 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -69.41 -21.54 63.75 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.95 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.216 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.988 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 27.2 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.461 ' C ' ' H ' ' B' ' 26' ' ' LEU . 21.4 m-20 50.01 56.13 17.38 Favored Pre-proline 0 C--N 1.304 -1.409 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.974 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 60.7 Cg_endo -71.53 38.68 0.35 Allowed 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.731 2.288 . . . . 0.0 111.567 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.461 ' H ' ' C ' ' B' ' 24' ' ' ASP . 18.1 tp -70.27 -45.07 67.12 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.013 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 95.5 t -70.64 -38.12 72.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.545 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.44 -42.47 78.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.739 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.17 -29.74 14.76 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.595 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.74 -31.55 69.59 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.702 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.5 t -52.17 -40.25 61.2 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.749 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -51.37 -32.79 13.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-O 121.224 0.535 . . . . 0.0 110.368 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -72.35 -29.17 30.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.36 -52.01 24.12 Favored Glycine 0 CA--C 1.528 0.899 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.731 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -70.95 -29.48 37.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 117.971 0.886 . . . . 0.0 110.267 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 57.4 tp -64.7 -44.97 88.56 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.167 0.508 . . . . 0.0 110.113 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -52.91 -43.24 66.07 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.547 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -69.8 -36.7 75.9 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.406 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.465 ' O ' ' OG1' ' B' ' 42' ' ' THR . 88.2 mt -63.33 -42.94 98.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.978 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.41 -36.04 78.53 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.85 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -53.44 -33.48 54.2 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.087 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.465 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 68.0 p -54.91 -40.12 69.51 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.775 -179.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.52 -47.64 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.614 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.12 -29.35 9.04 Favored Glycine 0 C--N 1.305 -1.161 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -49.46 -27.06 3.82 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.551 0.215 . . . . 0.0 111.484 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -47.43 -38.2 13.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.45 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -48.42 -51.06 28.51 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.315 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.579 ' C ' ' H ' ' B' ' 50' ' ' LYS . 16.4 tt0 -82.08 -143.99 0.06 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.052 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.42 ' CG2' ' O ' ' B' ' 48' ' ' GLN . 12.4 tt 46.57 1.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 N-CA-C 113.085 0.772 . . . . 0.0 113.085 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.579 ' H ' ' C ' ' B' ' 48' ' ' GLN . 20.7 pttp -175.18 132.1 0.3 Allowed 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 56.6 ttm-85 -164.95 123.73 1.75 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.848 0.356 . . . . 0.0 110.969 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.081 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.781 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 26.3 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -162.09 58.8 0.9 Allowed Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.491 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -76.17 8.02 3.05 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.841 2.361 . . . . 0.0 111.988 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 30.8 tp -70.0 -44.71 68.83 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.721 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.8 t -70.68 -39.33 75.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.348 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 13.6 t -69.7 -44.56 79.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.92 -39.15 88.29 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.265 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.85 -29.92 71.11 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.975 0.417 . . . . 0.0 110.786 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -50.51 -34.23 24.45 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.949 -0.568 . . . . 0.0 111.255 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.9 tp -53.18 -30.23 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.449 -179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.53 -32.03 51.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.013 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.58 -47.46 62.07 Favored Glycine 0 C--N 1.304 -1.233 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.312 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 13.1 tt -69.4 -29.82 43.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.026 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 28.5 tp -62.62 -48.95 77.13 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -53.42 -29.44 35.14 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.59 -178.7 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 58.0 t80 -61.57 -41.42 97.37 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.403 HD11 HG22 ' C' ' 39' ' ' ILE . 92.4 mt -57.61 -48.86 82.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.535 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.45 -32.83 72.02 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.967 0.413 . . . . 0.0 110.316 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.8 -35.03 21.28 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.145 -179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -58.77 -32.31 69.17 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.372 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.1 -48.66 80.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.309 -179.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.447 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -49.93 -36.56 27.28 Favored Glycine 0 C--N 1.305 -1.141 0 CA-C-N 116.387 -0.37 . . . . 0.0 112.721 -178.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -51.47 -27.84 11.58 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 117.296 0.548 . . . . 0.0 111.283 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.7 pp -45.95 -41.22 11.35 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.187 -177.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.657 HD21 ' N ' ' C' ' 48' ' ' GLN . 0.5 OUTLIER -54.14 -39.0 66.1 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.017 179.744 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.657 ' N ' HD21 ' C' ' 47' ' ' ASN . 5.3 tp-100 -63.73 -51.59 64.26 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.007 0.432 . . . . 0.0 111.408 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.686 ' CG1' ' H ' ' C' ' 50' ' ' LYS . 0.6 OUTLIER -96.54 -144.62 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.935 -179.344 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.686 ' H ' ' CG1' ' C' ' 49' ' ' ILE . 46.9 tttp 53.57 161.03 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.754 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 50.38 69.46 0.62 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.442 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.17 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.946 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.517 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.0 m-20 -153.84 150.64 23.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.139 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.83 22.0 0.21 Allowed 'Trans proline' 0 N--CA 1.495 1.573 0 C-N-CA 122.1 1.867 . . . . 0.0 111.972 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.517 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.5 tp -71.87 -39.93 69.31 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.923 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.7 t -70.03 -45.24 77.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -178.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 17.1 m -67.91 -35.87 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.059 0.457 . . . . 0.0 110.439 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.66 -36.36 56.77 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.302 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.67 -39.46 73.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.316 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -61.86 -48.59 79.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 12.5 pt -50.35 -28.21 5.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.751 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.77 -28.69 34.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.301 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -44.55 84.49 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 116.337 -0.392 . . . . 0.0 113.632 -178.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' D' ' 36' ' ' LEU . 0.0 OUTLIER -56.36 -28.43 26.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-N 117.411 0.605 . . . . 0.0 110.516 -178.954 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . 0.523 ' N ' ' CD1' ' D' ' 35' ' ' ILE . 4.1 tp -60.47 -43.1 97.3 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 120.892 0.377 . . . . 0.0 110.565 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.638 ' HE2' ' CE1' ' A' ' 37' ' ' HIS . 7.0 m170 -55.14 -49.16 72.52 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.526 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -56.46 -50.08 72.75 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -178.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.45 ' O ' ' OG1' ' D' ' 42' ' ' THR . 11.6 pt -61.29 -44.93 99.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.919 -0.712 . . . . 0.0 111.045 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.3 -37.51 74.79 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.187 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.7 t-105 -48.63 -30.13 5.09 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.843 0.354 . . . . 0.0 110.653 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.45 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 60.4 p -60.09 -36.75 78.11 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.842 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.517 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.6 mp -69.23 -51.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.231 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' D' ' 47' ' ' ASN . . . -53.44 -28.74 37.11 Favored Glycine 0 C--N 1.304 -1.228 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.6 t-80 -65.29 -33.33 75.72 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -59.41 -41.33 89.23 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.446 ' OD1' ' O ' ' D' ' 44' ' ' GLY . 0.7 OUTLIER -64.43 -50.33 67.97 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.948 -178.771 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -63.63 -61.56 2.24 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.955 0.407 . . . . 0.0 111.233 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.531 ' CG2' ' H ' ' D' ' 50' ' ' LYS . 4.2 tp -47.42 -60.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.126 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.531 ' H ' ' CG2' ' D' ' 49' ' ' ILE . 46.4 mtpt -125.86 153.53 44.01 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.91 21.63 1.12 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.838 0.351 . . . . 0.0 110.403 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.898 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.4 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 43.2 m . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-20 -161.62 64.0 1.73 Allowed Pre-proline 0 C--N 1.307 -1.246 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.638 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -79.55 0.48 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 122.876 2.384 . . . . 0.0 112.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.3 tp -66.12 -46.61 76.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.956 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.0 p -70.34 -36.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.649 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.55 -42.27 80.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 120.918 0.389 . . . . 0.0 110.855 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.55 -38.12 29.8 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.828 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.42 75.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.303 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -59.93 -42.74 94.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.112 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.6 mm -49.69 -31.49 6.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.876 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -70.48 -29.59 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.547 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -65.57 -49.83 58.07 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.461 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.621 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 3.1 mp -65.64 -29.73 47.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 122.576 -0.367 . . . . 0.0 111.089 -179.187 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 56.5 tp -61.41 -46.11 91.5 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.643 -179.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.682 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.0 OUTLIER -61.34 -28.99 69.61 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 120.195 -0.602 . . . . 0.0 111.358 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.682 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 91.6 t80 -62.78 -50.16 72.12 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.444 ' O ' ' OG1' ' A' ' 42' ' ' THR . 5.8 tt -57.79 -40.38 75.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 C-N-CA 120.089 -0.644 . . . . 0.0 110.521 -178.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -36.15 72.37 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.629 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -48.83 -34.08 11.76 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.744 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 38.1 p -58.9 -33.67 70.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.814 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.605 ' CG2' ' NE2' ' B' ' 48' ' ' GLN . 96.6 mt -65.36 -44.24 94.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.201 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.0 -26.13 1.15 Allowed Glycine 0 C--N 1.306 -1.124 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -46.94 -25.02 0.7 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 123.016 -0.108 . . . . 0.0 111.104 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.567 ' CD1' ' NE2' ' B' ' 48' ' ' GLN . 1.1 mt -44.34 -50.58 9.02 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.208 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -56.94 -42.28 79.78 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.564 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.413 ' O ' ' OE1' ' A' ' 48' ' ' GLN . 0.1 OUTLIER -66.47 -57.67 6.86 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 120.897 0.38 . . . . 0.0 111.62 -179.054 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.546 ' CG2' ' H ' ' A' ' 50' ' ' LYS . 7.3 tp -59.91 -64.03 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.221 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.546 ' H ' ' CG2' ' A' ' 49' ' ' ILE . 34.4 ttmt -47.02 146.5 1.69 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 49.7 ptt85 37.74 -154.66 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.983 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.729 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' SER . . . . . 0.49 ' O ' ' CB ' ' B' ' 24' ' ' ASP . 14.9 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' B' ' 26' ' ' LEU . 4.0 t70 84.79 52.58 0.04 OUTLIER Pre-proline 0 C--N 1.312 -1.044 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.38 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . 0.466 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 13.5 Cg_endo -56.06 70.46 0.03 OUTLIER 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 122.985 2.457 . . . . 0.0 112.29 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' B' ' 24' ' ' ASP . 20.6 tp -71.47 -50.88 27.28 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.504 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 t -70.69 -35.5 61.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-O 121.127 0.489 . . . . 0.0 111.514 -179.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 99.3 t -70.39 -44.18 77.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.274 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -29.52 5.71 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.813 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.53 -29.71 69.18 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.939 0.4 . . . . 0.0 110.524 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.0 t -49.98 -37.13 31.08 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.828 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -54.7 -29.51 21.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 120.978 0.418 . . . . 0.0 110.443 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -71.02 -29.84 38.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.323 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.45 -46.6 76.31 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.17 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 12.3 pt -66.01 -42.35 91.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.164 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.4 tp -62.32 -46.54 88.28 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.143 0.497 . . . . 0.0 109.818 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.4 t-80 -51.6 -42.03 61.65 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.444 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.13 -36.03 74.5 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.539 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.464 ' O ' ' OG1' ' B' ' 42' ' ' THR . 94.5 mt -64.96 -41.85 93.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.129 -179.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.41 -40.42 77.32 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.01 0.434 . . . . 0.0 110.817 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.26 -32.05 10.0 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.067 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 68.8 p -51.38 -33.91 32.02 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.264 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 34.3 mm -65.74 -50.46 70.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.61 -30.11 26.6 Favored Glycine 0 C--N 1.306 -1.089 0 C-N-CA 121.232 -0.509 . . . . 0.0 111.928 -179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.443 ' O ' ' OE1' ' B' ' 48' ' ' GLN . 0.1 OUTLIER -63.78 -27.73 69.39 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 122.574 0.349 . . . . 0.0 111.342 -179.286 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.75 -29.03 4.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -58.18 -51.7 68.66 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -177.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.605 ' NE2' ' CG2' ' A' ' 43' ' ' ILE . 0.0 OUTLIER -75.38 -47.82 25.78 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.25 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.582 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 8.6 tt -55.05 -73.41 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 C-N-CA 120.301 -0.56 . . . . 0.0 110.474 -179.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.582 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 0.0 OUTLIER -147.84 149.41 32.25 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.015 0.436 . . . . 0.0 110.939 179.672 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 57.8 ttm-85 -141.47 -53.45 0.45 Allowed 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.086 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.931 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 16.8 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -175.34 57.99 0.18 Allowed Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.39 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -75.68 7.58 3.06 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.881 2.387 . . . . 0.0 112.061 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -69.35 -47.97 62.73 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.49 -36.61 66.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.058 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 64.2 t -70.33 -46.74 70.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -36.61 27.38 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.18 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.5 -29.64 67.32 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.787 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -51.7 -41.94 61.85 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.278 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 7.4 tt -53.93 -27.13 15.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.018 0.437 . . . . 0.0 111.031 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 1.6 mm -59.89 -37.72 73.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.754 -178.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.446 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.4 -46.66 76.3 Favored Glycine 0 C--N 1.304 -1.212 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.991 -178.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -70.16 -29.13 38.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.533 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 34.4 tp -61.64 -50.62 71.79 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.667 -179.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.67 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -57.62 -29.0 64.17 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.652 -178.741 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.67 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 42.2 t80 -59.94 -42.64 94.44 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.638 0.256 . . . . 0.0 111.294 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' C' ' 42' ' ' THR . 19.6 mm -58.14 -45.71 88.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.071 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.01 -30.28 65.06 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.225 0.536 . . . . 0.0 111.056 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -52.6 -38.02 59.28 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -57.77 -29.99 65.27 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.48 -178.262 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.497 ' N ' ' CD1' ' C' ' 43' ' ' ILE . 1.6 mp -61.24 -48.97 86.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.165 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.42 -29.74 11.32 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -50.84 -28.09 8.73 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.69 0.281 . . . . 0.0 111.207 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.3 pp -45.85 -33.6 3.28 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.892 -177.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -62.36 -49.03 77.18 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.732 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -82.04 71.03 9.08 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-O 120.604 0.24 . . . . 0.0 111.58 -178.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.517 HG23 ' H ' ' C' ' 50' ' ' LYS . 1.5 tp -179.51 -78.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 O-C-N 122.088 -0.382 . . . . 0.0 110.687 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.517 ' H ' HG23 ' C' ' 49' ' ' ILE . 51.5 pttt -50.86 -27.12 6.76 Favored 'General case' 0 C--N 1.309 -1.191 0 O-C-N 122.067 -0.395 . . . . 0.0 110.457 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -156.69 145.3 19.91 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.205 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.218 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 60.3 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.41 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.1 m-20 -81.6 150.02 65.7 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.316 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.54 42.23 0.56 Allowed 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.201 1.934 . . . . 0.0 111.743 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.41 ' H ' ' C ' ' D' ' 24' ' ' ASP . 59.4 tp -70.15 -47.08 63.2 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.574 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.3 t -70.68 -34.42 56.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.093 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 91.8 t -69.96 -47.67 67.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.648 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -31.45 10.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.839 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.01 -33.76 74.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -58.06 -41.21 82.85 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 68.3 mt -58.36 -30.15 39.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-O 120.976 0.417 . . . . 0.0 110.816 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.441 ' O ' ' NE2' ' D' ' 37' ' ' HIS . 6.0 mt -71.43 -31.96 44.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.515 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.6 -39.61 90.68 Favored Glycine 0 C--N 1.307 -1.07 0 C-N-CA 121.429 -0.415 . . . . 0.0 112.579 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 19.9 pt -69.99 -35.76 65.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.601 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 27.6 tp -49.34 -36.09 20.39 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.484 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 8.7 m170 -58.99 -34.73 72.18 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -62.05 -45.96 91.25 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.472 ' O ' ' OG1' ' D' ' 42' ' ' THR . 1.5 pp -67.22 -40.23 84.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.522 -178.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.87 -41.28 71.59 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.211 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -48.96 -28.72 4.07 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 60.1 p -60.3 -32.5 71.26 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.87 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 84.8 mt -66.01 -51.57 58.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.174 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.84 -29.5 42.35 Favored Glycine 0 C--N 1.304 -1.215 0 N-CA-C 111.685 -0.566 . . . . 0.0 111.685 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 9.0 t-80 -55.77 -28.21 54.91 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.436 ' O ' ' O ' ' D' ' 50' ' ' LYS . 1.0 OUTLIER -47.02 -31.81 3.52 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.522 -177.618 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 19.5 p-10 -54.07 -48.25 70.82 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.107 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . . . . . . . . . 36.2 mm-40 -65.02 -53.33 47.64 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-O 120.936 0.398 . . . . 0.0 111.006 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.401 ' H ' HG23 ' D' ' 49' ' ' ILE . 3.6 tp -87.35 95.59 5.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-O 121.797 0.808 . . . . 0.0 110.389 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' D' ' 46' ' ' LEU . 5.7 ttpm? 64.32 161.42 0.11 Allowed 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.645 -1.161 . . . . 0.0 111.234 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.12 3.11 0.44 Allowed 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.771 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.28 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 79.2 p . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -177.73 60.28 0.15 Allowed Pre-proline 0 C--N 1.307 -1.244 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.847 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -78.62 4.1 6.68 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.891 2.394 . . . . 0.0 112.024 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.3 tp -66.48 -48.52 69.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.03 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.34 -35.56 63.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.586 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.0 t -70.36 -43.63 78.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 120.868 0.366 . . . . 0.0 110.684 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -35.82 18.13 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.997 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.14 -35.26 79.69 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 120.734 0.302 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -61.07 -41.78 97.27 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.124 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.419 HG23 HD12 ' A' ' 32' ' ' ILE . 20.8 mm -55.92 -29.76 26.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.114 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.3 mt -70.39 -32.47 50.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.397 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -61.21 -40.24 98.3 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.375 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 mt -69.98 -29.6 40.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.937 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 tt -60.6 -47.83 84.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.314 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.667 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.5 p80 -61.61 -28.76 69.59 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.45 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.667 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 56.1 t80 -60.97 -48.24 82.76 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.449 ' O ' ' OG1' ' A' ' 42' ' ' THR . 10.2 pt -62.64 -40.53 88.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.074 -0.65 . . . . 0.0 111.098 -178.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -39.58 75.31 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.69 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.6 t-105 -49.09 -30.96 7.1 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.016 -179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.449 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 70.4 p -63.78 -30.9 71.94 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 76.7 mt -59.69 -49.57 83.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.815 0.341 . . . . 0.0 111.016 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.26 -28.99 9.45 Favored Glycine 0 C--N 1.305 -1.175 0 N-CA-C 111.618 -0.593 . . . . 0.0 111.618 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.479 ' CD2' ' NE2' ' A' ' 48' ' ' GLN . 3.1 t-80 -49.76 -27.63 5.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 120.764 0.316 . . . . 0.0 110.897 -179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.505 ' O ' ' CD1' ' A' ' 49' ' ' ILE . 2.5 pp -44.63 -36.96 3.33 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 52' ' ' GLY . 21.0 m120 -70.5 -36.19 73.67 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.605 ' C ' ' H ' ' A' ' 50' ' ' LYS . 11.0 tt0 -67.55 -57.92 5.62 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.505 ' CD1' ' O ' ' A' ' 46' ' ' LEU . 0.0 OUTLIER -60.63 15.39 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -177.658 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.612 ' CG ' ' H ' ' A' ' 51' ' ' ARG . 0.4 OUTLIER -164.2 -80.45 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 178.686 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.612 ' H ' ' CG ' ' A' ' 50' ' ' LYS . 60.8 ttt180 -57.18 -9.09 0.83 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.975 0.417 . . . . 0.0 110.166 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 47' ' ' ASN . . . . . . . . 0 C--N 1.308 -0.996 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 32.9 t . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' B' ' 26' ' ' LEU . 6.1 p-10 42.09 57.56 10.27 Favored Pre-proline 0 C--N 1.306 -1.309 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.963 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.27 12.1 0.52 Allowed 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.744 2.296 . . . . 0.0 111.753 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.455 ' H ' ' C ' ' B' ' 24' ' ' ASP . 36.0 tp -70.44 -46.14 64.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.039 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 91.9 t -70.28 -38.69 75.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.323 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -70.35 -45.95 73.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.56 -35.38 20.35 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.656 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -36.8 77.99 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.5 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -51.57 -37.48 49.89 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.311 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.6 -36.12 47.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.847 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -70.63 -33.12 51.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.481 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.86 -44.72 78.5 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.284 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 16.6 pt -70.04 -37.41 72.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.553 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -42.63 40.26 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.035 -179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 0.5 OUTLIER -53.2 -45.79 68.74 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.783 -179.761 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -57.85 -45.07 86.8 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.464 ' N ' ' CD1' ' B' ' 39' ' ' ILE . 1.6 mp -61.28 -45.72 98.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.838 -179.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.33 -39.92 74.44 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.181 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.58 -28.64 5.91 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.435 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 43.4 p -62.01 -38.62 89.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.43 -179.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.48 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.8 mp -62.45 -50.17 80.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.607 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.74 -29.65 58.6 Favored Glycine 0 C--N 1.304 -1.218 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -56.0 -28.41 57.12 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.54 ' CD2' HE21 ' C' ' 48' ' ' GLN . 1.9 pp -47.61 -29.44 2.91 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.738 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.491 ' OD1' ' NH2' ' B' ' 51' ' ' ARG . 83.5 m-20 -62.92 -45.58 91.83 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -61.29 -53.11 60.96 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.011 0.434 . . . . 0.0 111.86 -179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.424 HG23 ' H ' ' B' ' 50' ' ' LYS . 1.5 tp -55.85 -66.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.424 ' H ' HG23 ' B' ' 49' ' ' ILE . 18.0 pttp -150.89 172.23 15.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.995 0.426 . . . . 0.0 110.71 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.491 ' NH2' ' OD1' ' B' ' 47' ' ' ASN . 32.9 ttm-85 -152.23 135.21 15.65 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.233 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.227 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.932 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 41.6 t . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -106.08 100.05 26.48 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.372 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -83.12 10.51 3.62 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 122.145 1.897 . . . . 0.0 112.37 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.24 -50.31 69.79 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.762 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 80.0 t -69.87 -39.91 78.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.829 0.347 . . . . 0.0 111.198 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 66.9 t -62.3 -44.21 98.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.618 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.19 69.43 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.609 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.43 -29.34 67.7 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.488 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -54.71 -42.6 71.69 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.448 -179.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.7 tp -50.75 -30.58 8.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.97 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -70.45 -34.26 57.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.342 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.49 -49.25 57.53 Favored Glycine 0 C--N 1.303 -1.291 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.128 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.4 tt -64.81 -37.45 80.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 122.52 -0.4 . . . . 0.0 110.713 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . 0.458 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.1 OUTLIER -53.29 -47.11 69.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.151 -178.807 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.709 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -61.0 -28.58 69.14 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.555 -178.258 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.709 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 57.2 t80 -58.88 -48.01 82.9 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.615 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.419 ' H ' HD12 ' C' ' 39' ' ' ILE . 4.3 mp -60.73 -45.58 97.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.484 -0.487 . . . . 0.0 111.078 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -29.88 65.92 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.472 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' C' ' 41' ' ' TRP . 10.7 t-105 -48.93 -50.36 35.71 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.769 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 12.2 t -47.79 -28.05 2.34 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.515 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tp -49.83 -49.32 20.83 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 120.299 -0.56 . . . . 0.0 110.358 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.515 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -54.18 -28.44 42.1 Favored Glycine 0 C--N 1.302 -1.321 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.93 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.66 -33.39 15.48 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.818 0.309 . . . . 0.0 111.415 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.405 ' CD1' ' N ' ' C' ' 47' ' ' ASN . 2.0 pp -60.7 -44.56 96.42 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.56 HD22 ' NE2' ' C' ' 48' ' ' GLN . 0.5 OUTLIER -61.57 -49.69 75.63 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 120.188 -0.605 . . . . 0.0 111.143 -178.976 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.56 ' NE2' HD22 ' C' ' 47' ' ' ASN . 1.9 mm100 -44.64 -15.63 0.02 OUTLIER 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.834 0.35 . . . . 0.0 111.096 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.545 ' CG2' ' H ' ' C' ' 50' ' ' LYS . 2.0 tt -136.43 -98.37 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -179.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.545 ' H ' ' CG2' ' C' ' 49' ' ' ILE . 58.7 pttt 42.7 32.89 0.42 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.764 0.316 . . . . 0.0 111.005 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -141.99 87.43 2.04 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.408 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.987 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 12.6 p . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -63.85 137.1 97.0 Favored Pre-proline 0 C--N 1.305 -1.365 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.213 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -74.55 45.36 1.24 Allowed 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.979 1.786 . . . . 0.0 111.935 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 41.6 tp -70.52 -44.39 67.65 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.0 t -70.7 -41.96 77.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.164 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.75 -38.39 72.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.329 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -35.13 21.41 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.69 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.17 -29.41 70.76 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.022 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.0 t -52.71 -42.54 64.93 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.199 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.473 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 1.9 mp -54.97 -37.35 41.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.733 0.301 . . . . 0.0 110.5 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.412 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 6.0 mt -71.45 -29.71 36.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.401 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.5 -48.92 47.97 Favored Glycine 0 C--N 1.306 -1.108 0 C-N-CA 121.361 -0.447 . . . . 0.0 113.025 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 pp -66.34 -32.47 58.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 117.194 0.497 . . . . 0.0 110.579 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 tp -51.06 -37.68 46.98 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.198 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.624 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 20.3 m170 -58.63 -40.44 83.37 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.858 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.02 -48.27 82.56 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.439 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.6 pt -61.53 -41.88 91.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.175 -0.61 . . . . 0.0 111.422 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.6 -38.34 73.99 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.083 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.4 -30.77 8.39 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 77.7 p -64.65 -34.11 77.52 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.252 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' D' ' 43' ' ' ILE . 1.6 mp -70.49 -52.08 32.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.688 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.52 -29.35 24.01 Favored Glycine 0 C--N 1.306 -1.105 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -56.4 -27.03 55.21 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 111.528 0.195 . . . . 0.0 111.528 -179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -46.3 -31.9 2.82 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.429 -177.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 30.5 t-20 -59.49 -50.86 72.29 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.767 -0.373 . . . . 0.0 111.558 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.551 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -73.31 -66.22 0.71 Allowed 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.159 0.504 . . . . 0.0 111.417 -178.789 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.477 ' CG2' ' O ' ' D' ' 49' ' ' ILE . 17.9 tt -63.63 93.6 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 CA-C-O 121.717 0.77 . . . . 0.0 110.046 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 33.5 ttpt 60.6 106.67 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.62 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -76.51 -169.17 1.15 Allowed 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.496 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.989 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.6 m . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -129.45 65.4 74.44 Favored Pre-proline 0 C--N 1.312 -1.032 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.153 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -78.65 48.41 2.75 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.767 2.311 . . . . 0.0 111.599 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.9 tp -70.52 -42.85 70.71 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.21 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.15 -40.92 78.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.589 -179.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.7 t -68.16 -46.21 81.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.822 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -38.43 34.96 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.879 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.47 79.01 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.428 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.29 -39.92 80.59 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.949 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -51.26 -29.67 9.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.263 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.9 mt -69.75 -29.82 42.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.623 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.26 -48.17 66.27 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 121.182 -0.532 . . . . 0.0 112.287 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.515 ' H ' ' CD1' ' A' ' 35' ' ' ILE . 4.1 mp -67.14 -29.68 46.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 120.681 -0.407 . . . . 0.0 111.126 -179.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.73 -46.3 90.94 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.574 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.676 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.78 -28.79 69.7 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.385 -178.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.676 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 64.1 t80 -60.62 -50.14 74.72 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.8 -39.17 69.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.007 -178.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.42 -36.04 73.77 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.891 0.377 . . . . 0.0 110.944 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.8 t-105 -49.68 -38.05 31.22 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.103 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.1 p -52.47 -39.76 61.52 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.91 -49.32 84.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.834 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.36 -28.6 9.49 Favored Glycine 0 C--N 1.304 -1.205 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 -48.85 -28.22 3.59 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.4 pp -46.15 -33.77 3.8 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.292 -177.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 11.2 m-20 -46.12 -28.03 1.12 Allowed 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.597 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.539 ' O ' ' N ' ' A' ' 50' ' ' LYS . 12.1 tt0 -92.26 -45.62 8.13 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 120.66 0.267 . . . . 0.0 111.25 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 1.8 tp -42.62 -15.19 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.539 ' N ' ' O ' ' A' ' 48' ' ' GLN . 0.0 OUTLIER -94.65 -74.76 0.53 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 120.86 0.362 . . . . 0.0 110.034 179.336 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -52.31 -71.03 0.07 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.707 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.074 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -179.866 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 34.3 p . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' B' ' 26' ' ' LEU . 0.9 OUTLIER -77.86 152.17 79.88 Favored Pre-proline 0 C--N 1.304 -1.377 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.147 179.853 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 35.43 0.24 Allowed 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.14 1.893 . . . . 0.0 111.681 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.51 ' H ' ' C ' ' B' ' 24' ' ' ASP . 48.4 tp -70.42 -46.62 63.56 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.067 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 48.7 t -70.42 -37.55 70.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.582 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.17 -44.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.598 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -33.22 12.04 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.356 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.92 -33.67 76.59 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.766 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -57.56 -41.03 80.23 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.782 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -56.71 -35.94 47.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.279 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.57 -33.74 50.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.441 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.17 73.38 Favored Glycine 0 C--N 1.305 -1.183 0 C-N-CA 121.249 -0.5 . . . . 0.0 111.898 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.7 tp -68.47 -43.99 83.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.745 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.9 tp -49.97 -38.12 35.42 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.136 0.493 . . . . 0.0 110.078 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -49.64 -41.9 43.73 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.012 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -67.41 -38.71 85.04 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.726 -179.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.509 ' N ' ' CD1' ' B' ' 39' ' ' ILE . 1.5 mp -62.01 -43.91 98.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.65 -179.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.56 74.96 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.152 0.501 . . . . 0.0 110.788 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.49 -29.56 6.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.819 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.3 p -61.62 -36.14 79.89 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.464 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -63.67 -50.79 76.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.093 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.21 -29.48 29.48 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.478 ' CD2' ' CD ' ' B' ' 48' ' ' GLN . 29.2 t-80 -61.46 -28.92 69.62 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 120.616 0.246 . . . . 0.0 111.327 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -49.4 -34.66 16.83 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.397 -178.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -64.45 -50.43 67.53 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.478 ' CD ' ' CD2' ' B' ' 45' ' ' HIS . 9.5 pt20 -69.66 -50.05 47.8 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.634 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 15.9 tt -58.43 -68.88 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.93 -179.272 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.634 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 17.8 ptmt -114.84 155.39 26.88 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.671 0.272 . . . . 0.0 110.442 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 61.5 ttm-85 -147.54 -61.42 0.27 Allowed 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.362 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.135 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 93.3 p . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 m-20 -162.32 57.32 0.72 Allowed Pre-proline 0 C--N 1.307 -1.262 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -76.21 0.78 9.01 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.723 2.282 . . . . 0.0 112.116 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.8 tp -66.6 -45.07 80.4 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.994 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.22 -34.34 58.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.301 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.57 -47.3 80.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -37.38 26.42 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.788 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.4 -29.8 70.85 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.47 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.4 t -57.26 -42.85 82.34 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.693 0.283 . . . . 0.0 111.321 -179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.52 ' H ' ' CD1' ' C' ' 32' ' ' ILE . 2.2 mp -54.77 -30.28 22.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 mt -68.14 -36.38 75.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.525 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.61 -45.29 94.96 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.396 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 tp -69.96 -29.6 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 116.964 0.382 . . . . 0.0 110.824 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 33.0 tp -61.75 -49.26 77.13 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.916 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.689 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -55.66 -28.83 57.62 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 120.566 -0.454 . . . . 0.0 111.552 -178.61 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.689 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 51.4 t80 -61.07 -42.44 98.5 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.696 -0.229 . . . . 0.0 111.509 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.409 ' O ' ' OG1' ' C' ' 42' ' ' THR . 57.2 mt -58.1 -45.36 88.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.348 -178.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.26 -35.4 76.05 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.854 0.359 . . . . 0.0 110.743 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -49.47 -35.26 19.13 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.409 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.1 p -55.42 -39.07 69.79 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.031 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 85.1 mt -62.1 -48.49 88.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.901 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.517 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -48.17 -27.79 5.58 Favored Glycine 0 C--N 1.305 -1.189 0 N-CA-C 111.613 -0.595 . . . . 0.0 111.613 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -47.71 -28.1 2.28 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 122.744 -0.268 . . . . 0.0 111.511 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 pp -46.15 -43.73 15.29 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.323 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.699 ' ND2' ' H ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -50.14 -37.93 36.72 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.24 179.704 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.699 ' H ' ' ND2' ' C' ' 47' ' ' ASN . 44.9 tt0 -63.19 -49.1 75.58 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.921 0.391 . . . . 0.0 111.445 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.661 ' CG1' ' H ' ' C' ' 50' ' ' LYS . 0.5 OUTLIER -94.56 -142.7 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.474 -179.499 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.661 ' H ' ' CG1' ' C' ' 49' ' ' ILE . 8.4 mtpm? 39.72 26.55 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.727 -179.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' C' ' 49' ' ' ILE . 11.3 tpt180 -157.31 112.22 2.75 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.177 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.086 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 95.8 p . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.515 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.2 m-20 -53.11 150.94 9.84 Favored Pre-proline 0 C--N 1.306 -1.314 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.058 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.8 34.59 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 122.081 1.854 . . . . 0.0 111.841 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.515 ' H ' ' C ' ' D' ' 24' ' ' ASP . 48.4 tp -71.99 -38.25 69.7 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.801 179.05 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.73 -40.7 77.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 31.0 m -70.11 -40.23 78.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 CA-C-O 120.687 0.28 . . . . 0.0 110.836 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.45 -30.93 32.19 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.48 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.19 -34.61 68.53 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.237 179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.4 t -63.68 -44.85 92.49 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 pt -56.71 -28.17 27.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 120.852 0.358 . . . . 0.0 110.696 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.97 -29.02 35.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.315 179.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.07 -38.5 95.45 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 116.36 -0.382 . . . . 0.0 113.263 -178.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -68.96 -29.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 117.49 0.645 . . . . 0.0 110.366 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.31 -29.49 63.97 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.382 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.674 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 8.7 m170 -69.75 -35.6 75.09 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.539 -179.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -66.18 -46.68 76.51 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -178.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.468 ' O ' ' OG1' ' D' ' 42' ' ' THR . 2.2 pp -66.33 -39.14 83.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.416 -178.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -38.92 74.6 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.054 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -52.96 -30.74 36.58 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.952 0.406 . . . . 0.0 111.0 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.468 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 67.6 p -63.95 -32.08 73.49 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.023 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 18.1 mm -70.66 -51.63 35.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.461 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.42 -29.74 31.68 Favored Glycine 0 C--N 1.307 -1.082 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . 0.435 ' O ' ' OE1' ' D' ' 48' ' ' GLN . 6.2 t-80 -54.62 -27.19 37.65 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 120.715 0.293 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.83 -33.38 10.43 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.668 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 51.0 t-20 -48.72 -51.82 26.75 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.733 -178.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.435 ' OE1' ' O ' ' D' ' 45' ' ' HIS . 3.0 pm0 -88.46 -132.53 0.08 Allowed 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.503 ' CG2' ' O ' ' D' ' 49' ' ' ILE . 0.2 OUTLIER 29.78 89.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.959 0.885 . . . . 0.0 112.203 179.139 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt 42.83 77.68 0.06 Allowed 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.835 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 33.7 ptt-85 -49.29 -38.7 28.23 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.153 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.84 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.4 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.434 ' C ' ' H ' ' A' ' 26' ' ' LEU . 49.5 m-20 -160.85 58.25 0.98 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.761 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.89 20.33 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.761 2.307 . . . . 0.0 111.912 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.434 ' H ' ' C ' ' A' ' 24' ' ' ASP . 1.4 tt -65.32 -49.54 69.06 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 -179.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.9 p -70.6 -39.43 75.97 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.005 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 69.0 t -62.95 -29.95 48.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.754 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.87 69.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.522 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.34 -36.0 80.53 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.596 -179.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.2 t -56.52 -46.19 80.72 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.565 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.526 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.1 mp -51.35 -39.85 22.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.935 0.398 . . . . 0.0 110.166 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -70.46 -28.61 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.289 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.96 -50.68 56.81 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.199 -0.524 . . . . 0.0 112.796 -178.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 pp -66.04 -29.15 45.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.065 0.432 . . . . 0.0 111.413 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.2 tt -62.74 -41.13 99.05 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.451 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.691 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -65.56 -28.74 69.37 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.659 -178.976 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.691 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 60.3 t80 -64.49 -50.44 67.42 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -178.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.4 pt -51.56 -40.46 25.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.149 -179.024 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.32 -33.25 65.05 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 120.97 0.414 . . . . 0.0 111.272 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.453 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 11.8 t-105 -49.23 -31.06 7.99 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -177.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -69.39 -29.6 67.4 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.331 -179.443 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.495 ' CD1' ' N ' ' A' ' 43' ' ' ILE . 1.5 mp -56.17 -44.98 80.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.847 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.15 -28.43 4.25 Favored Glycine 0 C--N 1.304 -1.236 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -178.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 -48.88 -28.48 3.81 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 120.806 0.336 . . . . 0.0 110.398 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.425 ' HG ' ' H ' ' A' ' 47' ' ' ASN . 2.8 pp -45.44 -44.22 12.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.905 -177.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.425 ' H ' ' HG ' ' A' ' 46' ' ' LEU . 55.8 m-20 -49.98 -51.76 39.05 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.689 -0.632 . . . . 0.0 111.102 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.408 ' OE1' ' CG2' ' D' ' 43' ' ' ILE . 1.7 pt20 -96.94 59.46 1.68 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -178.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.616 ' CD1' ' H ' ' A' ' 49' ' ' ILE . 0.1 OUTLIER -64.1 -55.2 23.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.585 179.299 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -12.87 1.4 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 120.854 0.359 . . . . 0.0 110.073 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -67.73 -22.54 65.24 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.561 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.095 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 80.5 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.473 ' C ' ' H ' ' B' ' 26' ' ' LEU . 48.7 m-20 54.02 57.54 12.88 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.818 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.49 24.55 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.702 2.268 . . . . 0.0 111.618 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.473 ' H ' ' C ' ' B' ' 24' ' ' ASP . 52.2 tp -70.23 -43.21 71.08 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.503 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 96.3 t -70.16 -41.77 78.99 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.738 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 50.2 t -70.21 -41.11 78.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.176 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.8 -37.31 18.82 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.349 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.9 -29.52 65.14 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.72 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.6 t -58.64 -41.73 86.66 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.409 HD13 HG22 ' B' ' 32' ' ' ILE . 23.9 mm -50.66 -36.65 14.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.684 -179.698 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -69.99 -29.76 41.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.15 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.68 -50.16 63.61 Favored Glycine 0 C--N 1.306 -1.131 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.622 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.0 pt -62.5 -43.65 98.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.998 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.5 tp -62.28 -49.16 76.76 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.019 0.438 . . . . 0.0 109.828 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -49.79 -39.45 38.21 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.95 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 74.8 t80 -69.99 -39.74 75.71 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.48 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.443 ' O ' ' OG1' ' B' ' 42' ' ' THR . 85.3 mt -60.37 -43.67 94.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.968 -179.253 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.05 -40.76 91.23 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.995 0.426 . . . . 0.0 110.594 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.81 -32.74 14.74 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.285 -179.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.443 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 58.0 p -60.98 -38.16 84.99 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.993 -179.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.505 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.6 mp -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.503 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.19 -29.81 16.24 Favored Glycine 0 C--N 1.304 -1.224 0 C-N-CA 121.335 -0.46 . . . . 0.0 112.089 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -58.07 -28.5 64.62 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.554 ' CD1' HH21 ' B' ' 51' ' ' ARG . 1.0 OUTLIER -47.03 -32.22 3.83 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.321 -177.605 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.586 HD22 HD21 ' C' ' 47' ' ' ASN . 86.6 m-20 -62.29 -44.99 95.26 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -61.74 -53.33 57.43 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 120.916 0.389 . . . . 0.0 112.027 -178.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.424 HG22 ' H ' ' B' ' 50' ' ' LYS . 1.9 tp -58.75 -67.53 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.135 -179.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.424 ' H ' HG22 ' B' ' 49' ' ' ILE . 24.0 pttm -136.15 149.3 48.57 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.959 0.409 . . . . 0.0 110.709 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.554 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.3 tpm_? -153.93 -43.93 0.09 Allowed 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.314 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.223 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -172.0 56.18 0.22 Allowed Pre-proline 0 C--N 1.306 -1.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.956 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -76.21 11.57 1.76 Allowed 'Trans proline' 0 N--CA 1.495 1.602 0 C-N-CA 122.747 2.298 . . . . 0.0 111.729 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 41.4 tp -70.07 -43.68 70.68 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.754 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.36 -40.92 78.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.923 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.2 -47.76 80.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -37.18 28.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.976 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.97 -29.55 70.49 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-O 120.83 0.347 . . . . 0.0 111.07 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -52.49 -43.72 65.19 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.2 tp -50.1 -29.1 5.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-O 120.75 0.31 . . . . 0.0 111.324 -179.281 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.1 -31.83 48.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.116 -179.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.62 -50.16 38.78 Favored Glycine 0 C--N 1.303 -1.267 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.753 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 tp -69.54 -29.49 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 120.852 0.358 . . . . 0.0 110.281 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.11 -48.86 79.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.79 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.68 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -55.59 -29.14 58.55 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 120.646 -0.422 . . . . 0.0 111.935 -178.491 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.68 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 61.3 t80 -59.04 -42.61 90.67 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.375 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.423 ' O ' ' OG1' ' C' ' 42' ' ' THR . 3.8 mp -58.38 -47.57 87.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.577 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.93 78.63 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.889 -0.325 . . . . 0.0 110.847 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -49.13 -29.99 6.06 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.439 ' HG1' ' N ' ' C' ' 43' ' ' ILE . 67.7 p -57.13 -37.39 71.94 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.248 179.57 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.439 ' N ' ' HG1' ' C' ' 42' ' ' THR . 75.9 mt -63.22 -50.23 79.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.912 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.41 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -48.15 -28.83 6.3 Favored Glycine 0 C--N 1.305 -1.182 0 N-CA-C 112.059 -0.416 . . . . 0.0 112.059 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -49.12 -27.96 3.89 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.856 0.328 . . . . 0.0 111.341 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.406 ' HG ' ' H ' ' C' ' 47' ' ' ASN . 3.4 pp -46.04 -44.39 15.26 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.917 -177.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.586 HD21 HD22 ' B' ' 47' ' ' ASN . 28.4 p-10 -52.05 -46.54 65.13 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.046 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.459 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 7.4 tm0? -53.84 -48.14 70.24 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.645 -179.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.689 ' CG1' ' H ' ' C' ' 50' ' ' LYS . 0.9 OUTLIER -94.43 -143.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.637 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.689 ' H ' ' CG1' ' C' ' 49' ' ' ILE . 50.1 mttm 43.0 -167.19 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 120.663 0.268 . . . . 0.0 110.31 -179.222 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -43.09 133.28 3.89 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.839 0.352 . . . . 0.0 110.878 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . 0.468 ' C ' ' NH1' ' B' ' 51' ' ' ARG . . . . . . . . 0 C--N 1.305 -1.163 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' D' ' 26' ' ' LEU . 4.1 m-20 -67.92 151.13 97.43 Favored Pre-proline 0 C--N 1.306 -1.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.124 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -72.21 27.08 0.26 Allowed 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 122.218 1.945 . . . . 0.0 111.829 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.503 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.7 tp -70.17 -44.86 67.91 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.582 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -70.17 -36.97 70.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.998 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 87.9 t -67.97 -46.76 81.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.67 -34.35 11.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.46 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.96 -29.65 69.56 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 34.6 t -58.82 -43.72 90.69 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.218 -179.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.515 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 2.0 mp -53.98 -29.9 19.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 120.835 0.35 . . . . 0.0 110.351 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.36 -29.91 37.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.265 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.93 -43.94 95.26 Favored Glycine 0 C--N 1.308 -1.024 0 C-N-CA 121.34 -0.457 . . . . 0.0 112.188 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -67.19 -37.64 79.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.499 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.1 tt -49.81 -43.31 48.55 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.674 ' HE2' ' CE1' ' A' ' 37' ' ' HIS . 26.4 m170 -57.8 -44.19 86.14 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.923 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -61.56 -47.26 86.34 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -178.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.438 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.6 pt -63.79 -41.76 93.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.301 -0.56 . . . . 0.0 111.425 -178.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -40.76 74.53 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.804 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.53 -29.32 6.65 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.042 0.449 . . . . 0.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.438 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.2 p -62.25 -33.21 74.18 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.345 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.408 ' CG2' ' OE1' ' A' ' 48' ' ' GLN . 90.7 mt -65.56 -50.72 70.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.03 -28.15 47.84 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -56.85 -28.06 61.17 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 112.628 0.603 . . . . 0.0 112.628 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.546 HD11 ' N ' ' D' ' 46' ' ' LEU . 0.0 OUTLIER -49.21 -28.08 4.23 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -178.342 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.432 ' N ' HD13 ' D' ' 46' ' ' LEU . 16.0 m120 -65.09 -50.61 65.47 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.732 ' N ' HE21 ' D' ' 48' ' ' GLN . 0.0 OUTLIER -64.21 -53.79 43.64 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -177.904 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.636 ' CG2' ' H ' ' D' ' 50' ' ' LYS . 14.7 tt -55.6 -68.63 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.237 -179.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.636 ' H ' ' CG2' ' D' ' 49' ' ' ILE . 14.7 tptm -121.79 156.03 34.05 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 120.814 0.34 . . . . 0.0 110.497 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 37.8 ptt-85 -151.02 16.94 0.76 Allowed 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.406 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.165 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.978 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 68.7 m . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -173.58 60.55 0.25 Allowed Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.41 24.7 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.716 2.277 . . . . 0.0 111.851 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.2 tp -70.14 -42.89 71.98 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.084 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.69 -39.19 75.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.65 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.0 t -66.77 -42.57 89.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.85 0.357 . . . . 0.0 110.971 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -34.54 18.85 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.683 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.61 82.54 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.739 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -59.31 -44.03 92.6 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.392 -179.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -49.81 -34.68 9.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 120.95 0.405 . . . . 0.0 110.759 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.0 mt -69.8 -29.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.555 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.13 -50.27 52.6 Favored Glycine 0 C--N 1.306 -1.109 0 C-N-CA 121.105 -0.569 . . . . 0.0 112.363 -179.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 40.5 mt -61.04 -29.63 46.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 122.509 -0.407 . . . . 0.0 110.918 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 46.3 tp -61.88 -44.43 96.83 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.361 -179.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.77 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -61.56 -28.83 69.62 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.501 -178.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.77 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 40.4 t80 -63.19 -50.63 69.54 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.253 0.464 . . . . 0.0 112.253 -178.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 42' ' ' THR . 5.8 tt -57.07 -38.83 62.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.23 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -30.62 64.77 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 120.936 0.398 . . . . 0.0 111.448 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -55.09 -36.49 65.7 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 -177.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.52 ' O ' ' ND1' ' A' ' 45' ' ' HIS . 0.1 OUTLIER -59.06 -34.01 71.45 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.995 -178.946 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 mp -60.68 -38.21 77.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.114 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.87 -25.81 1.75 Allowed Glycine 0 C--N 1.306 -1.111 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.52 ' ND1' ' O ' ' A' ' 42' ' ' THR . 39.1 m170 -46.96 -23.65 0.49 Allowed 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 122.77 0.428 . . . . 0.0 111.173 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mt -42.21 -47.32 4.67 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.984 -0.287 . . . . 0.0 110.504 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -53.59 -51.1 64.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -178.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.408 ' HG3' ' H ' ' A' ' 49' ' ' ILE . 8.5 pt20 -69.74 -55.16 10.68 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -178.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.408 ' H ' ' HG3' ' A' ' 48' ' ' GLN . 4.5 pt -54.23 -38.31 38.88 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.998 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -76.03 -72.61 0.31 Allowed 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.834 0.35 . . . . 0.0 110.527 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.707 HH22 ' HZ1' ' C' ' 50' ' ' LYS . 98.8 mtt180 -83.26 139.53 33.04 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.431 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.125 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.974 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 71.9 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.447 ' C ' ' H ' ' B' ' 26' ' ' LEU . 51.8 m-20 -77.74 149.6 77.78 Favored Pre-proline 0 C--N 1.305 -1.359 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.203 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -72.7 39.55 0.44 Allowed 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.104 1.87 . . . . 0.0 111.549 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.447 ' H ' ' C ' ' B' ' 24' ' ' ASP . 1.6 tt -63.35 -49.62 73.18 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.69 -179.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.08 -33.77 56.52 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.375 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.6 t -69.93 -44.5 78.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.516 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.86 -39.37 39.01 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.672 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.25 -33.47 74.67 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.846 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 6.8 t -57.8 -41.82 82.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.849 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.404 HG23 HD11 ' B' ' 32' ' ' ILE . 19.1 mm -51.79 -34.33 16.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.727 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.88 -29.76 38.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.224 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.15 -48.74 62.54 Favored Glycine 0 C--N 1.305 -1.159 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 11.3 mm -61.54 -46.22 97.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.64 -179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.3 tp -52.39 -42.49 64.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.019 0.438 . . . . 0.0 109.933 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -49.92 -44.67 50.38 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.835 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -66.65 -41.6 87.98 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.555 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.48 ' O ' ' OG1' ' B' ' 42' ' ' THR . 93.3 mt -60.85 -45.16 98.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.899 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.81 -36.88 81.18 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.467 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.66 -34.85 19.57 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.534 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.0 p -52.43 -41.05 62.92 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.349 -179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.481 ' CD1' ' N ' ' B' ' 43' ' ' ILE . 1.8 mp -62.66 -50.3 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.929 -0.308 . . . . 0.0 111.121 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.16 -29.72 15.88 Favored Glycine 0 C--N 1.305 -1.167 0 C-N-CA 121.187 -0.53 . . . . 0.0 111.964 -179.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -60.69 -28.1 68.37 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.48 ' CD1' HH21 ' B' ' 51' ' ' ARG . 1.0 OUTLIER -46.81 -31.08 2.79 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.863 -177.364 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -60.0 -48.96 79.54 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -63.14 -54.48 37.09 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -178.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.463 HG21 ' H ' ' B' ' 50' ' ' LYS . 2.6 tt -58.42 -68.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.07 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.463 ' H ' HG21 ' B' ' 49' ' ' ILE . 60.7 pttt -121.85 161.77 22.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.846 0.355 . . . . 0.0 110.668 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.48 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.6 tpm_? -167.92 -57.61 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.611 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.173 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.953 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 40.9 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -174.92 56.42 0.17 Allowed Pre-proline 0 C--N 1.307 -1.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.708 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.07 11.49 1.45 Allowed 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 122.692 2.261 . . . . 0.0 112.156 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 40.5 tp -64.21 -48.33 76.28 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.097 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 23.4 t -70.22 -40.21 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.222 -179.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.4 t -69.47 -44.18 80.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.806 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.25 -43.1 61.43 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.957 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.44 69.37 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.093 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 5.8 t -51.22 -43.42 61.43 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.493 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 10.2 tp -49.5 -29.61 4.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.344 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.5 mt -69.03 -30.55 47.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.912 -179.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.546 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.64 -49.71 58.38 Favored Glycine 0 C--N 1.303 -1.292 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.312 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -66.41 -29.34 46.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.841 -179.444 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 10.4 tp -62.02 -50.71 70.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.528 -0.306 . . . . 0.0 111.823 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.637 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -52.51 -29.24 24.11 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.665 -178.401 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 57.7 t80 -58.06 -44.5 87.5 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 120.578 0.228 . . . . 0.0 111.481 -179.488 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.0 mt -54.55 -48.99 69.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.587 -178.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.53 -30.49 67.25 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.994 0.426 . . . . 0.0 110.761 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -49.28 -36.67 21.3 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 33.6 p -59.23 -36.94 76.34 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.088 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -63.16 -50.98 77.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.283 -179.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.55 -29.8 25.4 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.916 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -51.76 -29.73 19.92 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -46.54 -35.8 6.13 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.472 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.443 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 7.5 p30 -48.96 -44.86 41.17 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.371 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.443 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 5.5 tp-100 -63.15 -48.71 77.28 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.695 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 tp -111.58 101.13 12.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 121.452 0.644 . . . . 0.0 110.252 -179.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.707 ' HZ1' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER -170.1 -39.76 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.682 179.605 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -74.81 -43.93 52.06 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.496 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.209 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.903 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 46.9 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.8 m-20 -82.22 149.92 63.2 Favored Pre-proline 0 C--N 1.307 -1.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.347 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.12 42.52 0.64 Allowed 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.164 1.909 . . . . 0.0 111.745 179.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.4 ' H ' ' C ' ' D' ' 24' ' ' ASP . 51.7 tp -70.22 -47.92 59.32 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.649 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 10.5 t -70.87 -35.97 62.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.145 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -70.14 -46.29 72.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.659 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -29.8 7.71 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.005 -179.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.72 66.86 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.22 -40.38 81.52 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.22 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -55.22 -29.77 23.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.899 0.38 . . . . 0.0 110.836 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.23 -29.67 37.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.49 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.74 -44.43 80.87 Favored Glycine 0 C--N 1.307 -1.04 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.444 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.0 pt -67.03 -36.15 76.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.64 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -49.91 -36.68 28.37 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.457 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.712 ' HE2' ' CE1' ' A' ' 37' ' ' HIS . 32.8 m170 -59.17 -47.04 86.79 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.85 -179.185 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -57.54 -46.14 84.24 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.455 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.9 pt -66.39 -43.14 91.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.436 -178.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -39.78 72.87 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.367 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 t-105 -49.39 -28.86 5.53 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 120.974 0.416 . . . . 0.0 110.673 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.455 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 81.5 p -62.0 -29.92 70.59 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.755 179.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 82.1 mt -70.21 -52.25 31.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-O 121.025 0.44 . . . . 0.0 111.053 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.538 ' O ' ' ND2' ' D' ' 47' ' ' ASN . . . -53.09 -28.21 32.79 Favored Glycine 0 C--N 1.302 -1.321 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -68.22 -29.34 68.14 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.423 ' HG ' ' H ' ' D' ' 47' ' ' ASN . 2.4 pp -52.76 -46.67 67.61 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.478 -179.021 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.538 ' ND2' ' O ' ' D' ' 44' ' ' GLY . 0.2 OUTLIER -60.8 -45.63 93.67 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.609 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.464 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 2.1 mm100 -67.42 -110.57 0.0 OUTLIER 'General case' 0 N--CA 1.429 -1.517 0 C-N-CA 122.287 0.235 . . . . 0.0 111.214 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' D' ' 50' ' ' LYS . 32.1 pt 32.69 50.59 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.379 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' D' ' 49' ' ' ILE . 50.5 mtpt 47.99 -178.11 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.422 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 ppt_? -158.51 -3.29 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.761 0.315 . . . . 0.0 110.51 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.252 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 179.956 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 49.9 m . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -161.64 59.17 1.0 Allowed Pre-proline 0 C--N 1.306 -1.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.735 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -77.55 -3.38 13.55 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.754 2.303 . . . . 0.0 112.003 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 57.7 tp -63.69 -45.73 88.72 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.83 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 p -70.37 -37.61 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.453 -179.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.6 t -70.08 -35.99 66.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 CA-C-O 120.982 0.42 . . . . 0.0 110.784 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -38.16 31.66 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.62 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.57 -34.0 76.16 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.341 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.2 t -63.01 -50.34 71.11 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -178.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 11.2 pt -51.99 -29.49 11.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.636 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -67.25 -29.58 46.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -59.76 -46.24 94.38 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.4 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' D' ' 33' ' ' ILE . 10.0 mm -61.24 -35.75 68.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 CA-C-O 120.77 0.319 . . . . 0.0 111.145 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.65 -49.75 76.4 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.954 -178.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.692 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -57.72 -28.86 64.25 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.812 -178.768 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.692 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 71.2 t80 -59.63 -50.11 75.16 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 1.5 pp -59.22 -41.67 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.768 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.92 -34.03 68.76 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.106 0.479 . . . . 0.0 111.002 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.474 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 10.1 t-105 -48.23 -35.3 11.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.517 -178.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.9 t -56.86 -29.34 62.81 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.508 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 80.0 mt -55.28 -46.08 77.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.04 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' O ' ' OD1' ' A' ' 47' ' ' ASN . . . -45.5 -28.63 2.42 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 120.762 -0.733 . . . . 0.0 111.534 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 -48.59 -25.98 2.0 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.928 0.364 . . . . 0.0 110.79 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -45.2 -50.21 11.69 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.399 -178.175 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.549 ' OD1' ' NE2' ' A' ' 48' ' ' GLN . 0.1 OUTLIER -59.41 -44.02 92.92 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.507 -179.024 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.549 ' NE2' ' OD1' ' A' ' 47' ' ' ASN . 9.0 mm-40 -85.0 68.18 10.47 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.652 ' CD1' ' H ' ' A' ' 49' ' ' ILE . 0.0 OUTLIER -115.93 -137.63 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 CA-C-O 120.873 0.368 . . . . 0.0 111.972 -179.699 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.402 ' N ' HG12 ' A' ' 49' ' ' ILE . 22.4 pttp -102.94 12.31 36.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.156 -179.227 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.8 ttt-85 -63.51 -41.04 98.54 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.23 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.146 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 179.651 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 41.2 m . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' B' ' 26' ' ' LEU . 0.8 OUTLIER -79.77 152.22 74.66 Favored Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.167 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 40.72 0.32 Allowed 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.226 1.951 . . . . 0.0 111.63 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.466 ' H ' ' C ' ' B' ' 24' ' ' ASP . 37.4 tp -69.35 -45.93 68.24 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.535 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 79.9 t -70.43 -41.1 78.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 57.3 t -68.65 -46.85 79.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.321 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.76 -38.37 33.72 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.663 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.89 -31.53 72.18 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.31 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 31.9 t -56.04 -42.11 76.05 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.991 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.6 mm -49.67 -29.86 4.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.649 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.9 mt -71.92 -29.82 34.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.51 -50.61 42.34 Favored Glycine 0 C--N 1.307 -1.076 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.324 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -64.53 -47.1 90.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.831 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -51.51 -41.26 60.87 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.059 0.457 . . . . 0.0 110.074 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -49.58 -39.79 36.38 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.813 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.46 -40.03 92.71 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.688 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' B' ' 42' ' ' THR . 1.7 mp -57.48 -42.84 81.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.51 -179.26 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.98 -37.18 69.93 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.228 0.537 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.8 t-105 -54.91 -39.65 69.02 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.453 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -57.69 -34.14 69.11 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.243 -178.903 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.8 mm -62.14 -47.72 91.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.603 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.09 -28.67 8.2 Favored Glycine 0 C--N 1.306 -1.089 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -61.23 -27.05 68.17 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.527 HD11 ' N ' ' B' ' 46' ' ' LEU . 0.0 OUTLIER -47.71 -30.63 3.98 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.676 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.494 ' N ' ' CD1' ' B' ' 46' ' ' LEU . 29.4 p-10 -61.5 -50.5 72.47 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -59.27 -53.07 62.47 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 120.978 0.418 . . . . 0.0 112.112 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.474 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 2.5 tp -60.67 -67.2 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.162 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.474 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 57.4 mttp -71.57 116.21 11.65 Favored 'General case' 0 C--N 1.309 -1.175 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.149 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -166.3 129.61 2.02 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.474 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.16 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.938 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -162.02 56.37 0.66 Allowed Pre-proline 0 C--N 1.306 -1.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -77.82 8.57 3.36 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.692 2.261 . . . . 0.0 111.738 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 44.5 tp -70.13 -42.64 72.33 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.091 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 92.8 t -70.12 -44.22 78.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.192 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.09 -46.64 84.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.545 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -54.87 -44.37 73.99 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.941 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.54 -29.63 70.71 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 120.777 0.322 . . . . 0.0 110.925 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 7.1 t -50.56 -41.86 54.68 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.181 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -49.8 -29.06 4.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-O 120.851 0.357 . . . . 0.0 111.295 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.9 mt -65.81 -33.45 63.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.144 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.57 -50.33 37.93 Favored Glycine 0 C--N 1.303 -1.256 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.202 -178.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.05 -29.48 44.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-O 120.868 0.366 . . . . 0.0 110.529 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -61.28 -50.62 72.26 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.782 -179.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.698 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -55.08 -28.65 54.06 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.742 -178.577 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.698 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 43.9 t80 -57.9 -44.38 86.72 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 121.031 -0.268 . . . . 0.0 111.456 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.43 ' O ' ' OG1' ' C' ' 42' ' ' THR . 79.4 mt -56.34 -48.37 79.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.943 -179.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.05 -34.28 73.02 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.855 0.359 . . . . 0.0 110.755 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 -48.4 -30.25 4.83 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.565 -179.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.7 p -56.38 -38.74 71.89 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.634 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.496 ' N ' ' CD1' ' C' ' 43' ' ' ILE . 1.7 mp -64.05 -49.93 79.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.013 -179.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -47.82 -28.28 5.34 Favored Glycine 0 C--N 1.304 -1.198 0 C-N-CA 121.301 -0.476 . . . . 0.0 112.024 -178.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -49.07 -27.84 3.64 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.4 ' O ' ' O ' ' C' ' 49' ' ' ILE . 3.0 pp -46.04 -41.41 12.02 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.399 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.451 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 20.8 p-10 -49.13 -50.24 38.32 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.174 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -58.09 -49.14 77.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.162 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.491 ' O ' ' CG2' ' C' ' 49' ' ' ILE . 0.1 OUTLIER -120.8 110.39 28.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.909 -179.565 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -131.78 -76.74 0.51 Allowed 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.12 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 84.3 mtt85 -89.24 9.55 25.4 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.485 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.963 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 74.1 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.4 m-20 -88.5 150.89 47.42 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.232 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.69 33.6 0.37 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.189 1.926 . . . . 0.0 111.756 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.445 ' H ' ' C ' ' D' ' 24' ' ' ASP . 2.1 tt -63.9 -50.54 68.32 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.613 -179.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 t -70.49 -33.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.113 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 92.5 t -69.95 -45.1 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.692 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.58 -32.71 8.51 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.718 -178.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.31 -32.17 73.69 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 120.769 0.319 . . . . 0.0 110.912 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 43.0 t -60.4 -42.93 96.95 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.217 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 mm -58.05 -35.21 51.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 121.148 0.499 . . . . 0.0 110.346 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' A' ' 35' ' ' ILE . 8.8 mt -71.67 -29.98 36.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.303 179.243 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.36 91.73 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.589 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 12.8 pt -68.51 -38.13 78.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.782 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tp -49.69 -38.63 33.76 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 120.946 0.403 . . . . 0.0 110.455 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.533 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 16.4 m170 -57.53 -39.78 77.36 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.371 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -58.23 -46.55 85.72 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.6 pt -66.63 -42.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.125 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -41.96 77.18 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.723 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -48.74 -29.46 4.5 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.745 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.5 m -66.8 -29.85 69.89 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.515 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.405 HD11 HG22 ' D' ' 43' ' ' ILE . 30.0 mm -65.48 -50.8 70.22 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.988 -0.285 . . . . 0.0 111.181 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.48 -34.17 63.34 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . 0.451 ' O ' ' OE1' ' D' ' 48' ' ' GLN . 10.7 t-80 -55.98 -28.05 55.44 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 120.653 0.263 . . . . 0.0 111.522 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.58 -29.82 39.26 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.17 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.537 ' OD1' ' N ' ' D' ' 48' ' ' GLN . 6.5 p30 -59.75 -49.88 76.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.405 -0.518 . . . . 0.0 112.313 -178.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.537 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 0.1 OUTLIER -83.31 53.02 2.35 Favored 'General case' 0 C--N 1.309 -1.184 0 O-C-N 122.208 -0.307 . . . . 0.0 111.616 -179.056 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.418 ' O ' ' O ' ' D' ' 50' ' ' LYS . 0.0 OUTLIER -177.2 127.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.119 0 CA-C-O 121.18 0.515 . . . . 0.0 110.229 179.085 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' D' ' 49' ' ' ILE . 54.1 tttp 60.18 131.01 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.833 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -161.46 136.57 7.47 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.467 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.173 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.919 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -171.23 60.11 0.31 Allowed Pre-proline 0 C--N 1.305 -1.329 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.827 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.68 28.68 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.788 2.325 . . . . 0.0 112.04 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.3 mp -69.5 -40.91 76.71 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.711 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.417 ' CG1' ' N ' ' A' ' 28' ' ' VAL . 12.4 p -70.76 -44.15 76.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.475 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.417 ' N ' ' CG1' ' A' ' 27' ' ' VAL . 88.5 t -63.63 -41.75 93.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.737 -179.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -37.38 29.53 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.476 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.76 -36.8 84.24 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.471 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -53.81 -47.14 71.13 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.994 -0.283 . . . . 0.0 111.233 -179.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.527 ' CD1' ' H ' ' A' ' 32' ' ' ILE . 2.1 mp -51.56 -40.17 24.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.462 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.87 -29.5 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.1 -50.66 44.37 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.907 -179.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 57.3 mt -64.74 -29.71 48.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 122.652 -0.322 . . . . 0.0 111.047 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 33.4 tp -61.47 -45.18 95.33 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.331 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.683 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.6 OUTLIER -61.66 -28.79 69.64 Favored 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 120.151 -0.62 . . . . 0.0 111.497 -178.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.683 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 78.2 t80 -63.47 -50.82 68.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.4 tt -54.91 -39.67 49.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.135 -178.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -35.3 69.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.922 0.392 . . . . 0.0 111.215 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.462 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 11.3 t-105 -49.78 -35.07 21.2 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 t -65.4 -29.4 70.1 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 36.5 mm -60.87 -45.15 98.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.777 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.16 -27.03 2.44 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.037 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -49.41 -29.62 6.69 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 mp -46.06 -43.17 14.33 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 121.181 -0.208 . . . . 0.0 111.036 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.72 HD22 HD21 ' B' ' 47' ' ' ASN . 18.9 m120 -58.02 -51.92 67.65 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.905 -0.718 . . . . 0.0 112.122 -178.166 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.527 ' C ' ' H ' ' A' ' 50' ' ' LYS . 0.6 OUTLIER -61.89 -53.22 58.72 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -177.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 40.1 pt -48.64 -3.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -177.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 48' ' ' GLN . 17.9 pttp -143.78 -44.85 0.27 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 118.301 0.5 . . . . 0.0 111.077 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -76.69 -143.27 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.797 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.133 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.765 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -133.72 62.63 59.73 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.498 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -76.1 45.32 1.51 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.75 2.3 . . . . 0.0 111.574 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.01 -48.74 67.49 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.552 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.59 -30.35 42.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.14 -46.7 71.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.392 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.11 -31.5 8.2 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.613 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.69 -29.64 70.22 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.538 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.6 t -54.44 -38.08 65.89 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.796 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 25.8 mm -55.6 -36.94 44.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-O 120.923 0.392 . . . . 0.0 110.456 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.24 -29.98 38.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.337 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.96 -48.41 54.47 Favored Glycine 0 C--N 1.306 -1.11 0 N-CA-C 111.659 -0.576 . . . . 0.0 111.659 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -63.93 -42.44 95.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.611 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -60.61 -44.26 96.51 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 24.2 t-80 -49.86 -44.36 49.68 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.696 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -70.12 -37.55 75.34 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.272 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' B' ' 42' ' ' THR . 91.8 mt -63.41 -42.64 97.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.856 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.66 -37.47 70.78 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.009 0.433 . . . . 0.0 111.297 -179.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -49.55 -44.84 46.94 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.81 -27.83 5.55 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.655 -178.528 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 9.3 tp -56.17 -48.57 79.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.252 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.517 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -57.65 -29.73 61.58 Favored Glycine 0 C--N 1.304 -1.229 0 C-N-CA 121.32 -0.466 . . . . 0.0 111.963 -179.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -53.17 -29.53 32.11 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.433 ' O ' ' O ' ' B' ' 50' ' ' LYS . 2.7 pp -50.58 -34.0 24.13 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.836 -0.346 . . . . 0.0 111.519 -178.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.72 HD21 HD22 ' A' ' 47' ' ' ASN . 5.3 m120 -63.19 -50.38 70.55 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.096 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -67.41 -55.89 11.88 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.142 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.617 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 7.7 tp -50.51 -67.71 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.617 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 23.0 ttpp -139.82 146.49 39.48 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.997 0.427 . . . . 0.0 111.114 -179.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.666 HH21 ' ND2' ' B' ' 47' ' ' ASN . 48.2 ttm-85 -162.53 115.06 1.66 Allowed 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.383 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.978 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.424 ' C ' ' H ' ' C' ' 26' ' ' LEU . 4.6 p-10 -175.74 59.68 0.19 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.778 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.95 19.74 0.57 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.862 2.375 . . . . 0.0 111.97 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.424 ' H ' ' C ' ' C' ' 24' ' ' ASP . 10.3 mp -67.1 -42.71 84.13 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.637 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 p -70.28 -40.9 78.46 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.206 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 92.2 t -64.47 -46.63 92.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.746 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.69 73.6 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.92 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.56 -29.65 70.67 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.746 0.308 . . . . 0.0 111.138 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 15.1 t -52.56 -44.27 65.76 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.617 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.3 tt -49.68 -29.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.269 -179.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.4 mt -69.02 -31.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.037 -179.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.15 -50.43 39.79 Favored Glycine 0 C--N 1.306 -1.085 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.016 -179.214 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -66.72 -29.48 46.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.722 -179.76 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.4 tp -60.72 -48.77 80.31 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.687 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.79 -29.99 63.24 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.863 -178.367 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.2 t80 -62.18 -44.26 96.99 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.098 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.44 ' O ' ' OG1' ' C' ' 42' ' ' THR . 96.6 mt -55.65 -45.61 79.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.723 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.15 -33.79 72.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.015 0.436 . . . . 0.0 110.779 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.29 -34.68 16.0 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.173 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.44 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 18.5 p -57.3 -45.05 84.53 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.376 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 4.2 mp -66.45 -51.09 61.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.603 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.47 -29.52 17.42 Favored Glycine 0 C--N 1.303 -1.267 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -59.77 -28.96 67.85 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.116 0.414 . . . . 0.0 112.116 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.433 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 0.9 OUTLIER -46.1 -28.27 1.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.446 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.584 HD22 HE22 ' D' ' 48' ' ' GLN . 28.0 m120 -47.43 -51.48 19.95 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.383 -178.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.672 ' H ' ' NE2' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -73.24 -45.74 54.24 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.269 -179.622 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 1.1 tp -47.93 -5.73 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.54 ' H ' ' C ' ' C' ' 48' ' ' GLN . 49.8 mttm -92.08 153.65 19.25 Favored 'General case' 0 C--N 1.317 -0.833 0 O-C-N 122.046 -0.408 . . . . 0.0 110.234 179.425 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.428 ' O ' ' O ' ' C' ' 50' ' ' LYS . 2.1 mpt_? 48.28 -176.96 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.162 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 47.2 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -76.82 148.35 79.05 Favored Pre-proline 0 C--N 1.305 -1.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.113 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.34 41.0 0.64 Allowed 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.1 1.867 . . . . 0.0 111.872 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.3 tp -63.85 -48.97 74.63 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.617 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 47.3 t -70.42 -34.21 57.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 57.6 t -70.05 -44.14 78.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.584 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -35.08 19.7 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.722 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.23 -29.63 70.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.2 t -55.54 -41.5 73.28 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.035 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.484 ' CD1' ' H ' ' D' ' 32' ' ' ILE . 2.0 mp -54.87 -35.62 34.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.491 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.76 -30.05 40.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.352 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.25 -46.02 88.88 Favored Glycine 0 C--N 1.306 -1.096 0 C-N-CA 121.249 -0.501 . . . . 0.0 112.07 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.1 pt -66.68 -29.79 47.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-O 120.815 0.341 . . . . 0.0 110.753 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tp -56.29 -42.39 77.46 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.708 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 15.3 m170 -56.62 -43.52 80.28 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -59.52 -47.09 86.88 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.451 ' O ' ' OG1' ' D' ' 42' ' ' THR . 13.4 pt -64.03 -43.8 97.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.491 -178.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.12 -39.37 75.5 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.058 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -48.81 -29.4 4.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.859 0.361 . . . . 0.0 110.502 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.451 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 64.8 p -61.99 -31.51 71.88 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.769 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 33.7 mm -67.38 -51.33 53.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.76 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.99 -29.95 21.66 Favored Glycine 0 C--N 1.304 -1.245 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -59.02 -29.61 67.39 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 120.648 0.261 . . . . 0.0 111.274 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.443 ' CD1' ' N ' ' D' ' 47' ' ' ASN . 2.6 pp -49.52 -43.49 45.68 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.395 -178.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.446 ' C ' ' ND2' ' D' ' 47' ' ' ASN . 0.9 OUTLIER -62.32 -49.42 75.68 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 -179.055 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.69 ' N ' HE21 ' D' ' 48' ' ' GLN . 2.9 mm-40 -54.22 -40.27 67.5 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-O 120.943 0.402 . . . . 0.0 111.603 -179.401 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 20.4 tt -102.55 113.24 38.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-O 121.531 0.681 . . . . 0.0 109.973 -179.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt 62.76 144.98 0.02 OUTLIER 'General case' 0 C--N 1.292 -1.914 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.805 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.95 18.96 1.44 Allowed 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.315 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.16 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.999 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo . . . . . 0 N--CA 1.492 1.423 0 CA-C-O 120.788 0.245 . . . . 0.0 111.973 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.1 tp -63.52 -44.61 93.77 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.779 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.9 p -70.23 -37.76 72.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.436 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.427 ' N ' HG13 ' A' ' 27' ' ' VAL . 97.3 t -67.08 -42.12 87.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.947 0.403 . . . . 0.0 110.663 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -43.85 46.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.007 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.3 -35.08 71.31 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.407 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.0 t -60.64 -43.24 97.77 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.027 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.7 mt -53.42 -37.85 30.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.079 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.91 -29.84 41.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.104 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.573 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -61.93 -47.66 88.65 Favored Glycine 0 C--N 1.302 -1.31 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.053 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.47 -29.37 38.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 122.382 -0.481 . . . . 0.0 110.775 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.518 ' O ' HD23 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -61.24 -49.33 77.54 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.709 -178.978 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.606 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.2 p80 -56.7 -28.95 61.87 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.968 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.606 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.1 t80 -63.78 -50.36 69.31 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.517 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.5 tt -57.85 -38.51 66.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.814 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -38.85 74.15 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.472 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -48.65 -32.44 8.29 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 120.847 0.356 . . . . 0.0 110.155 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -53.24 -42.47 66.44 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.319 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.4 mp -60.95 -47.94 91.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.032 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.56 -29.34 5.56 Favored Glycine 0 C--N 1.303 -1.296 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 . . . . . 0 C--N 1.303 -1.45 0 O-C-N 122.779 -0.248 . . . . 0.0 111.377 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 CA-C-O 120.872 0.28 . . . . 0.0 111.938 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.8 tp -68.0 -43.96 77.68 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.666 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.05 -35.81 65.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.086 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 89.4 t -67.33 -44.02 87.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.53 -37.63 27.64 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.656 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.36 -34.02 75.86 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.948 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -60.05 -42.74 95.11 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.741 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.7 mm -49.96 -31.78 7.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.555 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -69.61 -29.61 42.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.333 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.17 -50.6 44.41 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 121.026 -0.607 . . . . 0.0 111.889 -179.472 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.0 pt -62.71 -29.8 47.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.88 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -61.16 -46.93 88.51 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.576 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' C' ' 37' ' ' HIS . 7.8 m-70 -51.53 -50.54 59.82 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -54.2 -44.67 71.82 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.615 ' O ' HG22 ' B' ' 42' ' ' THR . 81.9 mt -59.02 -50.24 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.507 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.401 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -72.14 -36.85 69.48 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 121.086 0.47 . . . . 0.0 111.424 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.408 ' O ' ' CD1' ' B' ' 41' ' ' TRP . 9.8 t-105 -49.35 -34.6 16.31 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 113.294 0.849 . . . . 0.0 113.294 -177.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.615 HG22 ' O ' ' B' ' 39' ' ' ILE . 1.7 t -69.29 -29.31 67.14 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.048 -0.661 . . . . 0.0 110.709 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -61.99 -51.4 72.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.924 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.62 -29.83 19.01 Favored Glycine 0 C--N 1.306 -1.09 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -54.37 -27.47 36.61 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 120.88 0.371 . . . . 0.0 111.176 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -45.72 -29.83 1.4 Allowed 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.986 -176.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -58.29 -51.71 68.62 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.584 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -79.19 -58.91 2.99 Favored 'General case' 0 C--N 1.314 -0.959 0 O-C-N 121.871 -0.518 . . . . 0.0 111.741 -178.183 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 4.7 tt . . . . . 0 C--N 1.294 -1.837 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -179.195 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo . . . . . 0 N--CA 1.494 1.513 0 CA-C-O 120.748 0.228 . . . . 0.0 111.818 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 37.2 tp -65.81 -47.27 75.66 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -69.38 -40.88 80.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.918 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.4 t -67.39 -47.57 80.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.496 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.526 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -50.44 -42.98 54.85 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.105 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.858 0.361 . . . . 0.0 111.009 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 8.9 t -50.48 -43.88 55.62 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.4 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.526 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.3 tp -49.69 -29.35 4.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-O 120.804 0.335 . . . . 0.0 111.279 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.96 -31.69 48.81 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -178.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.544 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.39 -50.28 45.48 Favored Glycine 0 C--N 1.303 -1.266 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.564 -178.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.85 -29.51 43.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-O 120.987 0.422 . . . . 0.0 110.452 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.3 tp -62.04 -50.78 70.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.066 -0.515 . . . . 0.0 112.13 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' B' ' 37' ' ' HIS . 1.8 p80 -57.79 -28.96 64.49 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.642 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 87.4 t80 -56.99 -44.24 82.52 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.228 -179.308 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.401 ' O ' ' OG1' ' C' ' 42' ' ' THR . 68.1 mt -55.1 -42.68 66.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.152 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.28 -38.16 75.01 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 120.967 0.413 . . . . 0.0 110.722 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 41' ' ' TRP . . . . . 0.424 ' CZ3' ' ND1' ' B' ' 37' ' ' HIS . 5.7 t-105 -49.59 -32.85 13.64 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.199 -179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.2 p -65.58 -38.26 89.03 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.829 0.347 . . . . 0.0 110.961 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 29.5 mm -60.64 -50.43 80.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.021 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.21 -29.47 15.74 Favored Glycine 0 C--N 1.307 -1.066 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -50.19 -28.2 7.12 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp . . . . . 0 C--N 1.306 -1.322 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.934 -177.678 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 CA--C 1.533 0.307 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.03 41.48 0.66 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.087 1.858 . . . . 0.0 111.938 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -65.54 -48.69 71.62 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.672 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.32 -34.44 58.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.203 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 96.2 t -69.83 -45.62 76.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.524 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.44 -34.87 17.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.032 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.71 -29.74 69.8 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.062 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.4 t -55.04 -42.1 72.25 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.034 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -53.93 -31.84 21.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.73 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -70.98 -29.71 38.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.079 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.93 -45.0 90.7 Favored Glycine 0 C--N 1.306 -1.103 0 C-N-CA 121.26 -0.495 . . . . 0.0 112.392 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 16.5 pt -65.8 -38.42 82.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.038 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 47.5 tp -49.52 -40.34 37.43 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.551 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.422 ' ND1' ' N ' ' D' ' 37' ' ' HIS . 2.1 m-70 -59.82 -39.16 84.12 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.687 -0.405 . . . . 0.0 111.739 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 79.7 t80 -61.24 -48.57 80.84 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -178.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.3 pp -66.02 -39.07 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.534 -178.488 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.45 -41.31 72.97 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.803 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.02 -29.54 5.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.429 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 53.1 p -65.29 -30.3 71.15 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -70.15 -51.48 38.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.397 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.83 -29.99 55.92 Favored Glycine 0 C--N 1.305 -1.158 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 27.0 t-80 -56.3 -28.32 58.4 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 122.866 -0.196 . . . . 0.0 111.515 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.43 HD12 ' C ' ' D' ' 46' ' ' LEU . 0.9 OUTLIER . . . . . 0 C--N 1.308 -1.204 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.979 -178.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo . . . . . 0 N--CA 1.493 1.488 0 CA-C-O 120.882 0.284 . . . . 0.0 112.085 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 12.4 tp -62.15 -48.88 78.15 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.186 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.0 p -70.33 -32.39 50.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.532 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.4 t -70.29 -43.33 78.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 120.78 0.324 . . . . 0.0 110.929 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.46 -40.06 58.7 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.158 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -31.23 69.74 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.362 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -62.38 -37.8 87.12 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.008 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -57.37 -35.04 47.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.075 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.7 mt -67.99 -32.42 56.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.539 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.498 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.48 -44.72 82.69 Favored Glycine 0 C--N 1.302 -1.329 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.425 -178.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 70.4 mt -70.14 -29.74 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.888 0.375 . . . . 0.0 111.202 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.438 ' O ' HG22 ' A' ' 39' ' ' ILE . 54.5 tp -62.72 -47.66 82.62 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.704 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -58.27 -28.69 65.18 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.468 -179.054 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.9 t80 -54.13 -44.06 71.03 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 36' ' ' LEU . 8.9 tp -58.02 -43.12 84.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.378 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.426 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.5 -35.12 73.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.984 0.421 . . . . 0.0 110.976 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.484 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 3.2 t-105 -49.21 -37.85 24.23 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.151 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.37 -29.53 68.99 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.287 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mm -60.42 -48.86 86.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.104 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.87 -32.28 11.28 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 121.294 -0.479 . . . . 0.0 112.015 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-160 . . . . . 0 C--N 1.304 -1.404 0 CA-C-N 116.865 0.333 . . . . 0.0 111.369 -179.549 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo . . . . . 0 N--CA 1.496 1.632 0 CA-C-O 120.743 0.226 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 tp -70.7 -42.98 69.94 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -70.35 -44.85 77.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.519 -179.077 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 39.8 t -68.82 -43.83 82.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.74 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.483 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -49.89 -40.9 44.44 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.151 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -54.6 -28.57 47.36 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -48.77 -40.39 28.68 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.483 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.0 tp -49.2 -36.64 9.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.447 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.401 ' N ' HG23 ' B' ' 32' ' ' ILE . 8.3 mt -70.18 -29.54 40.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.532 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.54 -51.02 55.86 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.022 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 29.7 pt -65.46 -37.99 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.132 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.508 ' O ' HD23 ' B' ' 36' ' ' LEU . 1.7 tt -59.68 -48.68 80.73 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 121.307 0.575 . . . . 0.0 109.547 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -48.98 -46.72 44.12 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.249 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -68.64 -39.17 80.83 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.946 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 80.1 mt -61.42 -46.33 96.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.04 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.12 -40.89 95.13 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.843 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 -48.42 -33.1 8.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.407 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -52.26 -49.51 63.92 Favored 'General case' 0 C--N 1.3 -1.575 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.266 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.16 -51.45 71.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 C-N-CA 121.004 -0.279 . . . . 0.0 111.416 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.12 -29.4 36.12 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 3.9 t-160 -60.72 -30.0 69.7 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 120.89 0.376 . . . . 0.0 110.996 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.525 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.6 OUTLIER -48.67 -33.22 9.62 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.58 -178.49 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -64.37 -49.62 70.93 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.4 OUTLIER -59.79 -51.59 69.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-O 120.828 0.347 . . . . 0.0 111.928 -178.552 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 5.6 tt . . . . . 0 C--N 1.299 -1.618 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.529 -179.705 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo . . . . . 0 N--CA 1.493 1.443 0 CA-C-O 120.86 0.275 . . . . 0.0 112.039 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.509 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -70.11 -40.59 74.8 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.835 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.16 -45.59 75.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.384 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.8 t -66.66 -45.41 88.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.902 0.382 . . . . 0.0 110.758 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -58.09 -44.24 87.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.57 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.84 -29.43 70.62 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.315 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 22.7 t -53.54 -41.3 66.29 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.328 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.3 tt -49.91 -29.15 4.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-O 120.94 0.4 . . . . 0.0 111.175 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 16.1 mt -64.55 -37.43 80.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.12 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.55 -47.8 83.69 Favored Glycine 0 C--N 1.302 -1.321 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.408 -178.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -69.58 -30.02 43.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.72 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -62.2 -50.62 71.08 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -178.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -52.92 -29.17 27.07 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.642 -178.523 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.636 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.7 t80 -61.16 -42.28 98.27 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.572 -0.285 . . . . 0.0 111.522 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 76.9 mt -58.25 -49.72 80.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.824 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.59 -34.65 74.44 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.036 0.446 . . . . 0.0 110.649 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.1 -32.71 10.31 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.233 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -60.51 -36.08 77.51 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.258 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.39 -50.41 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.469 -179.201 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.89 -30.05 35.89 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 121.206 -0.521 . . . . 0.0 111.979 -179.109 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -50.87 -29.55 12.19 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 120.661 0.267 . . . . 0.0 111.627 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp . . . . . 0 C--N 1.304 -1.413 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.739 -177.666 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 t70 . . . . . 0 CA--C 1.538 0.489 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.33 55.97 3.73 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.015 1.81 . . . . 0.0 112.002 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.58 -45.51 68.49 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.597 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 t -70.48 -38.21 72.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.425 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 85.1 t -68.57 -43.22 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.848 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -31.9 12.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.021 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.09 69.5 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.959 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.2 t -54.22 -42.15 69.48 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.025 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 mm -50.7 -34.47 12.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.68 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -71.43 -29.27 34.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.358 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.59 -50.99 51.52 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.645 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 35' ' ' ILE . . . . . 0.833 HD12 ' N ' ' D' ' 36' ' ' LEU . 2.8 pp -62.87 -28.97 46.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.07 0.435 . . . . 0.0 110.628 -179.442 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 36' ' ' LEU . . . . . 0.833 ' N ' HD12 ' D' ' 35' ' ' ILE . 4.5 tp -60.88 -41.61 96.32 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.305 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 25.2 m170 -56.07 -41.3 74.89 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.613 -179.276 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -61.43 -47.86 83.81 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -178.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 12.3 pt -63.46 -43.73 98.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.163 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.484 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -63.33 -42.87 98.99 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.967 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -49.67 -33.83 16.8 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.521 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 54.5 p -59.21 -42.18 90.34 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.785 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.542 ' O ' HD12 ' D' ' 46' ' ' LEU . 4.7 mp -71.56 -53.1 21.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.4 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.39 -29.07 10.26 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -58.72 -28.18 65.59 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.593 HD22 ' C ' ' D' ' 46' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.244 0 N-CA-C 112.654 0.613 . . . . 0.0 112.654 -177.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo . . . . . 0 N--CA 1.492 1.424 0 CA-C-O 120.765 0.235 . . . . 0.0 112.069 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.3 tp -66.84 -46.49 74.95 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.686 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.5 p -70.47 -38.46 73.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.373 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.457 ' N ' HG13 ' A' ' 27' ' ' VAL . 89.0 t -70.03 -43.28 79.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.948 0.404 . . . . 0.0 110.674 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -36.47 25.73 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.096 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.43 -29.25 69.92 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -56.39 -43.83 79.65 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.4 pt -50.59 -29.51 6.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-O 120.746 0.308 . . . . 0.0 111.204 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -67.94 -29.95 46.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.592 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.99 -49.85 51.05 Favored Glycine 0 C--N 1.303 -1.275 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.181 -179.205 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.778 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.4 -29.53 46.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-O 120.696 0.284 . . . . 0.0 111.063 -179.364 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 34.0 tp -62.02 -49.25 76.78 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.634 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.3 p80 -57.91 -29.21 64.92 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.937 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.634 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.1 t80 -59.31 -44.29 92.58 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.742 -0.383 . . . . 0.0 111.031 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 77.9 mt -57.34 -48.89 81.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.89 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.6 -35.49 77.41 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 120.911 0.386 . . . . 0.0 110.747 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.67 -33.31 9.77 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.788 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 54.1 p -62.42 -33.2 74.31 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.003 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' A' ' 45' ' ' HIS . 16.1 mm -70.12 -46.65 71.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.886 -0.325 . . . . 0.0 110.583 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.23 -24.28 0.56 Allowed Glycine 0 C--N 1.301 -1.379 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.423 ' N ' ' O ' ' A' ' 43' ' ' ILE . 5.7 t-80 . . . . . 0 C--N 1.299 -1.597 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo . . . . . 0 N--CA 1.495 1.584 0 CA-C-O 120.935 0.306 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 40.1 tp -69.55 -47.46 63.62 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.861 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -70.43 -35.14 60.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.03 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 45.5 t -70.15 -47.09 69.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.358 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -37.85 30.87 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.162 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.08 -31.61 69.04 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.667 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 5.7 t -57.09 -36.02 70.11 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.57 -35.11 37.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.5 mt -71.29 -29.69 36.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.471 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.68 -44.7 88.97 Favored Glycine 0 C--N 1.307 -1.058 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.017 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -64.46 -43.42 96.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.825 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.2 tp -57.45 -42.7 83.03 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.21 -47.64 46.05 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.101 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -70.06 -37.25 75.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.421 ' O ' ' OG1' ' B' ' 42' ' ' THR . 96.1 mt -63.39 -43.59 98.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.587 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.63 -37.82 80.02 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 120.927 0.394 . . . . 0.0 110.681 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.63 -31.15 10.18 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.283 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 41.0 p -50.96 -36.06 36.87 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.158 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.5 mp -64.48 -50.29 76.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.66 -0.246 . . . . 0.0 111.078 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.3 -29.3 10.05 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.735 -0.546 . . . . 0.0 111.735 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.582 ' O ' HG22 ' B' ' 49' ' ' ILE . 7.7 t-160 -53.56 -27.01 23.87 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 2.1 pp -48.92 -37.54 20.16 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -64.36 -51.15 64.75 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.586 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -68.45 -53.99 19.91 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -178.246 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.582 HG22 ' O ' ' B' ' 45' ' ' HIS . 14.4 tt . . . . . 0 C--N 1.297 -1.691 0 C-N-CA 120.684 -0.407 . . . . 0.0 111.391 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo . . . . . 0 N--CA 1.494 1.515 0 CA-C-O 120.961 0.317 . . . . 0.0 111.765 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.503 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -63.95 -47.16 81.54 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.368 -179.718 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -69.67 -43.14 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.148 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -64.36 -43.32 97.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.575 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.579 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -62.13 -44.63 96.21 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.011 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.38 -29.49 70.56 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.789 0.328 . . . . 0.0 111.349 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -55.82 -43.02 76.54 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.432 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.579 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.4 tp -49.71 -28.9 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 120.804 0.335 . . . . 0.0 111.341 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.0 -31.03 46.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.104 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.99 -50.28 41.78 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.271 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 5.8 tp -68.41 -29.48 44.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.849 0.357 . . . . 0.0 110.482 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.16 -48.77 80.32 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.777 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -58.78 -29.24 66.65 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.561 -0.456 . . . . 0.0 111.886 -178.538 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 66.7 t80 -60.33 -45.49 93.27 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.939 -0.305 . . . . 0.0 111.361 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.414 ' O ' ' OG1' ' C' ' 42' ' ' THR . 73.7 mt -54.98 -46.4 76.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.562 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -34.56 72.77 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.411 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -48.55 -29.69 4.49 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.879 -178.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.5 p -63.06 -33.21 74.95 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.743 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.615 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.5 mp -65.28 -47.84 85.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.859 0.361 . . . . 0.0 110.598 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.78 -29.12 5.83 Favored Glycine 0 C--N 1.3 -1.466 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.504 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -53.41 -29.33 34.46 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.874 0.337 . . . . 0.0 111.732 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.601 HD13 ' O ' ' C' ' 43' ' ' ILE . 7.5 mp . . . . . 0 C--N 1.308 -1.205 0 CA-C-O 120.415 0.15 . . . . 0.0 111.05 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 . . . . . 0 CA--C 1.533 0.29 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -72.33 40.18 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.221 1.947 . . . . 0.0 111.968 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.74 -43.59 68.54 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.68 -40.67 77.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.061 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 28' ' ' VAL . . . . . 0.469 HG13 ' N ' ' D' ' 29' ' ' ALA . 14.3 p -70.46 -42.25 78.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.599 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.489 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -56.51 -40.02 74.32 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.791 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.86 -29.37 70.14 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.649 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -49.32 -36.41 21.03 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.489 HG22 ' O ' ' D' ' 29' ' ' ALA . 3.7 tp -53.75 -33.84 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 121.059 0.457 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.6 mt -71.16 -29.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.429 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.51 -43.92 91.27 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 121.358 -0.449 . . . . 0.0 112.503 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 28.3 pt -68.39 -32.68 56.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.653 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -53.24 -41.44 65.42 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 18.7 m170 -54.48 -42.92 71.27 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.704 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -56.96 -47.19 81.3 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -178.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.7 pt -65.01 -46.04 92.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.932 -0.707 . . . . 0.0 111.503 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.43 -37.92 77.62 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.63 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.472 ' O ' ' CD1' ' D' ' 41' ' ' TRP . 13.1 t-105 -49.07 -28.46 4.15 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.35 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 4.0 m -59.61 -30.95 69.05 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 96.1 mt -62.46 -50.55 79.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.487 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.22 -29.48 9.77 Favored Glycine 0 C--N 1.303 -1.281 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -62.89 -29.13 70.53 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.76 0.281 . . . . 0.0 111.76 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.304 -1.396 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo . . . . . 0 N--CA 1.495 1.588 0 CA-C-O 120.9 0.292 . . . . 0.0 111.573 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.8 tp -70.16 -44.53 68.62 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.754 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.7 -36.27 64.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.122 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.07 -44.7 78.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.976 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.49 -31.05 9.25 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.582 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.5 -30.11 66.8 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 35' ' ' ILE . 41.2 t -60.7 -44.45 96.54 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.592 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.682 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -52.12 -29.79 12.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.804 0.335 . . . . 0.0 110.353 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.4 mt -70.6 -29.62 39.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.211 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.501 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -64.04 -45.93 92.62 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.555 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -69.9 -29.56 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.053 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 39' ' ' ILE . 8.0 tt -61.84 -42.48 99.09 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.54 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -68.03 -28.59 67.53 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 120.239 -0.584 . . . . 0.0 111.456 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 76.7 t80 -66.49 -47.86 71.66 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.434 HG22 ' O ' ' A' ' 36' ' ' LEU . 7.2 tt -57.61 -35.9 52.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.24 -0.584 . . . . 0.0 110.442 -179.149 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.64 -36.11 73.25 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.659 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -52.95 -35.5 58.77 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.809 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.0 p -59.49 -37.12 77.43 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.669 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.604 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -69.25 -50.9 48.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.673 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.68 -28.32 6.87 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 111.991 -0.444 . . . . 0.0 111.991 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 33.7 t-80 . . . . . 0 C--N 1.293 -1.859 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -179.382 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 25' ' ' PRO . . . . . 0.432 ' O ' ' HB2' ' B' ' 29' ' ' ALA . 17.9 Cg_endo . . . . . 0 N--CA 1.498 1.756 0 CA-C-O 121.213 0.422 . . . . 0.0 112.113 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -70.85 -48.84 51.72 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.793 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 93.9 t -70.19 -39.43 76.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.095 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 53.1 t -70.17 -45.45 75.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.959 179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -49.07 -30.39 6.3 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.438 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.05 -29.54 69.79 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.057 0.456 . . . . 0.0 110.313 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -54.26 -37.23 64.46 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.649 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 70.4 mt -55.28 -33.9 32.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.1 mt -70.9 -31.5 45.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.223 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.71 -45.42 92.84 Favored Glycine 0 C--N 1.306 -1.127 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.045 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -65.59 -41.95 91.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.205 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -59.42 -46.39 88.86 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -49.87 -42.88 48.7 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.856 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -68.15 -39.07 82.75 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.364 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.71 -40.97 86.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.919 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.06 -40.85 74.81 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.023 0.44 . . . . 0.0 110.402 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.52 -31.09 9.5 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.858 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 62.7 p -60.77 -35.68 77.05 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.41 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.2 mm -67.38 -51.16 55.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.837 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.8 -39.38 31.88 Favored Glycine 0 C--N 1.305 -1.144 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.575 ' O ' HG22 ' B' ' 49' ' ' ILE . 40.2 t60 -49.05 -26.55 2.7 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 120.741 0.305 . . . . 0.0 111.563 -179.648 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.1 -32.55 6.98 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.778 -178.485 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' B' ' 44' ' ' GLY . 11.1 p30 -70.37 -50.32 40.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -177.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.522 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 4.1 pt20 -69.54 -52.43 26.33 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -177.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.575 HG22 ' O ' ' B' ' 45' ' ' HIS . 10.6 tt . . . . . 0 C--N 1.296 -1.725 0 C-N-CA 120.661 -0.416 . . . . 0.0 110.638 -179.377 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo . . . . . 0 N--CA 1.493 1.448 0 CA-C-O 121.062 0.359 . . . . 0.0 111.919 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 45.8 tp -66.46 -47.72 72.23 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.471 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.5 t -69.98 -32.17 50.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.991 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.94 -49.5 56.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.588 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.25 -35.32 17.29 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.293 -179.007 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.22 -29.79 71.06 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 120.915 0.388 . . . . 0.0 110.904 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 34.7 t -50.0 -38.91 39.43 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.157 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.1 tp -53.69 -29.47 17.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.187 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.24 -36.93 69.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.014 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' NE2' ' C' ' 37' ' ' HIS . . . -63.72 -49.4 68.98 Favored Glycine 0 C--N 1.305 -1.156 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.687 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 tp -70.05 -29.86 41.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 CA-C-O 121.032 0.444 . . . . 0.0 110.105 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 27.2 tp -59.81 -49.41 77.83 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.64 -179.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.3 p80 -59.62 -29.03 67.72 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.68 -178.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 65.0 t80 -61.16 -43.36 99.0 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.031 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 66.2 mt -58.8 -45.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.087 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -38.96 75.55 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.585 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.6 -29.89 7.86 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.807 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 64.6 p -60.9 -37.7 83.16 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.748 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.5 mm -63.05 -50.54 79.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.31 -179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.12 -31.3 18.58 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 111.899 -0.48 . . . . 0.0 111.899 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -49.86 -28.09 6.03 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.0 pp . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 120.696 -0.401 . . . . 0.0 111.451 -178.458 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' D' ' 26' ' ' LEU . 10.5 m-20 . . . . . 0 CA--C 1.534 0.34 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.56 21.02 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.244 1.963 . . . . 0.0 111.752 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.462 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.9 tp -67.95 -47.15 69.44 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.532 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.97 -37.8 73.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 84.5 t -69.93 -43.57 79.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.525 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.39 -32.16 11.01 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.651 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.81 -29.68 69.68 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.964 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.0 t -56.27 -42.17 77.03 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.053 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.678 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -55.32 -35.63 37.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.448 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -71.06 -32.58 48.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.412 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.74 -44.29 98.1 Favored Glycine 0 C--N 1.305 -1.141 0 C-N-CA 121.336 -0.459 . . . . 0.0 112.123 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.6 pt -68.44 -29.35 43.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.841 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.6 tp -57.35 -43.04 83.13 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.037 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 4.1 m170 -60.76 -35.02 75.35 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.123 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 t80 -62.34 -48.53 79.41 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.6 -42.19 93.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.989 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.21 -40.27 74.64 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.86 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -48.46 -29.81 4.49 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.605 -179.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 73.3 p -64.86 -30.87 71.89 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.621 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.5 mp -69.87 -51.74 37.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.26 -31.73 27.79 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.7 t-160 -60.4 -28.28 68.12 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.549 0.214 . . . . 0.0 111.276 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.306 -1.312 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.487 -177.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.494 1.509 0 CA-C-O 120.986 0.327 . . . . 0.0 111.594 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -70.39 -43.83 69.25 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.043 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.6 p -70.89 -42.62 77.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.487 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.507 ' N ' HG13 ' A' ' 27' ' ' VAL . 66.1 t -68.41 -43.64 83.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.815 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.81 -34.45 53.74 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -30.54 67.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.5 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -60.36 -44.83 95.22 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.621 -179.051 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.2 mp -50.29 -29.08 5.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-O 120.825 0.345 . . . . 0.0 110.71 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.95 -29.32 39.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.809 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.54 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -68.61 -50.18 38.7 Favored Glycine 0 C--N 1.305 -1.172 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.324 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.569 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -65.98 -29.56 47.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.999 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.22 -46.02 88.96 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.705 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.7 OUTLIER -57.7 -28.35 63.74 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.625 -178.787 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 30.9 t80 -55.5 -45.76 77.02 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 3.4 tp -57.36 -44.56 84.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.299 -178.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.453 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.9 -35.4 72.28 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 120.824 0.345 . . . . 0.0 110.827 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.3 t-105 -48.95 -32.02 8.36 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.353 -178.724 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 61.2 p -57.56 -30.23 65.07 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.198 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 67.1 mt -64.2 -46.29 93.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.086 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.89 -27.56 3.4 Favored Glycine 0 C--N 1.297 -1.608 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.592 -178.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 t-80 . . . . . 0 C--N 1.304 -1.402 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -179.07 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 25' ' ' PRO . . . . . 0.434 ' O ' ' HB2' ' B' ' 29' ' ' ALA . 46.8 Cg_exo . . . . . 0 N--CA 1.496 1.641 0 CA-C-O 121.151 0.396 . . . . 0.0 111.91 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 tp -70.66 -49.15 50.36 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.417 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.444 HG13 ' N ' ' B' ' 28' ' ' VAL . 11.6 p -70.3 -38.95 76.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.573 -179.134 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.444 ' N ' HG13 ' B' ' 27' ' ' VAL . 8.2 t -70.56 -45.24 75.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 120.602 -0.439 . . . . 0.0 109.891 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.434 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -48.63 -33.41 9.86 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.242 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.28 69.96 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.482 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.2 t -49.69 -41.82 44.1 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.032 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -50.97 -29.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-O 120.904 0.383 . . . . 0.0 110.456 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.16 -29.55 36.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.204 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.91 -47.08 89.38 Favored Glycine 0 C--N 1.307 -1.067 0 C-N-CA 121.308 -0.472 . . . . 0.0 112.06 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.1 pt -62.12 -44.87 99.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.861 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 55.4 tp -59.97 -45.9 91.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.997 0.427 . . . . 0.0 109.905 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 33.8 t-80 -50.39 -47.56 56.33 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.142 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -66.95 -38.81 86.82 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.516 -179.443 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.08 -42.16 93.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.762 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.86 -39.74 76.17 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.964 0.412 . . . . 0.0 110.627 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -49.05 -29.32 4.9 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.956 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 77.8 p -54.67 -37.46 65.77 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 35.6 mm -61.16 -49.07 86.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.729 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.88 -29.91 8.66 Favored Glycine 0 C--N 1.305 -1.152 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.743 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -53.96 -27.48 31.49 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -46.43 -32.11 3.07 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -61.41 -50.31 73.38 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 120.705 -0.398 . . . . 0.0 112.039 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.416 ' HG2' ' H ' ' B' ' 48' ' ' GLN . 12.1 mm100 -56.26 -53.95 51.1 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 7.8 tt . . . . . 0 C--N 1.296 -1.761 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.31 -179.36 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo . . . . . 0 N--CA 1.492 1.424 0 CA-C-O 120.78 0.242 . . . . 0.0 112.211 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -60.0 -50.67 72.83 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.035 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -70.98 -33.76 53.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 120.937 0.399 . . . . 0.0 111.178 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.7 t -70.3 -42.91 78.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.912 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.536 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.98 -39.35 40.61 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.51 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.19 -29.48 69.84 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 120.842 0.353 . . . . 0.0 111.292 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -53.05 -40.87 64.29 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.395 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.536 HG22 ' O ' ' C' ' 29' ' ' ALA . 3.4 tp -49.68 -31.53 6.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.751 0.31 . . . . 0.0 111.428 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -70.23 -29.84 41.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.94 -179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.526 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.26 -50.13 57.97 Favored Glycine 0 C--N 1.304 -1.218 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.908 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 36.8 pt -65.72 -29.65 47.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 120.776 0.322 . . . . 0.0 111.01 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 17.6 tp -61.29 -49.44 77.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.754 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.63 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.61 -29.69 62.42 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.767 -178.287 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.63 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 70.8 t80 -63.3 -44.37 95.21 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.258 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 72.5 mt -56.14 -48.21 79.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.155 -179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.86 -35.97 81.25 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -50.29 -36.34 31.24 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.346 -179.14 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.4 p -54.28 -47.13 72.69 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 120.741 0.305 . . . . 0.0 111.009 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.441 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -62.44 -49.82 82.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.76 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.75 -29.74 13.39 Favored Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.031 -179.16 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -56.68 -29.02 61.9 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.586 ' C ' HD12 ' C' ' 46' ' ' LEU . 3.8 pp . . . . . 0 C--N 1.305 -1.346 0 N-CA-C 111.625 0.231 . . . . 0.0 111.625 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 22.0 t70 . . . . . 0 CA--C 1.537 0.477 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -75.09 43.87 1.07 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.069 1.846 . . . . 0.0 112.166 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.47 -45.79 65.05 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.82 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.67 -41.08 77.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.912 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 28' ' ' VAL . . . . . 0.446 HG13 ' N ' ' D' ' 29' ' ' ALA . 8.1 p -70.73 -41.83 77.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.334 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.446 ' N ' HG13 ' D' ' 28' ' ' VAL . . . -49.8 -38.49 34.7 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.664 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.09 -31.54 72.8 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.258 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.5 t -56.22 -37.93 70.35 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.746 0.308 . . . . 0.0 110.793 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 mm -53.5 -29.59 17.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.387 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.4 mt -71.33 -29.24 34.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.465 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.33 -33.64 81.53 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 116.326 -0.397 . . . . 0.0 112.919 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -63.72 -38.48 82.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-N 117.402 0.601 . . . . 0.0 110.707 -179.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 43.6 tp -54.72 -43.09 72.28 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.8 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.705 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 19.3 m170 -51.13 -50.01 59.68 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.412 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -61.21 -42.45 98.61 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.557 -179.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.2 mt -60.28 -48.17 89.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.913 -179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.56 -34.73 72.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.82 0.343 . . . . 0.0 111.178 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.0 t-105 -49.0 -28.04 3.62 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.141 0.496 . . . . 0.0 110.017 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.7 p -57.92 -34.88 70.33 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.854 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.588 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -65.75 -50.92 67.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.759 0.314 . . . . 0.0 110.577 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.85 -29.67 62.08 Favored Glycine 0 C--N 1.302 -1.359 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.882 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -70.64 -32.91 70.39 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.306 -1.286 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.612 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo . . . . . 0 N--CA 1.495 1.581 0 CA-C-O 120.836 0.265 . . . . 0.0 111.755 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.4 tp -64.82 -44.89 88.4 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.202 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.5 p -70.29 -41.42 78.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.756 0.312 . . . . 0.0 111.307 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.489 ' N ' HG13 ' A' ' 27' ' ' VAL . 16.6 t -63.32 -39.89 86.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-O 120.94 0.4 . . . . 0.0 110.921 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.08 -44.12 82.8 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.551 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.59 -37.13 75.16 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.785 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -57.84 -43.48 85.86 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.137 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 69.4 mt -49.32 -37.82 11.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 120.814 0.34 . . . . 0.0 110.778 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -64.77 -29.67 48.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.406 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.537 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -63.27 -50.04 65.94 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.164 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -59.64 -29.62 43.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 122.686 -0.303 . . . . 0.0 111.34 -179.047 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tt -63.67 -50.83 67.71 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.672 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.5 OUTLIER -51.26 -29.44 14.6 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.272 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 63.8 t80 -58.35 -48.1 81.67 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.718 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.6 tp -49.67 -43.53 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.252 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.432 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -72.88 -30.03 63.64 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.76 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.507 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 10.9 t-105 -49.02 -32.38 9.25 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -177.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 42' ' ' THR . 0.2 OUTLIER -66.14 -33.01 74.79 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.463 -179.452 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.497 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -51.09 -43.86 27.51 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.03 0.443 . . . . 0.0 109.839 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.44 -28.71 4.93 Favored Glycine 0 C--N 1.299 -1.505 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.048 -178.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 . . . . . 0 C--N 1.307 -1.27 0 CA-C-N 117.251 0.526 . . . . 0.0 111.645 -179.485 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 N--CA 1.495 1.592 0 CA-C-O 121.15 0.396 . . . . 0.0 111.78 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 tp -70.13 -49.86 46.43 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.076 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -70.19 -33.02 52.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.943 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 87.7 t -69.68 -46.2 75.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.989 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.9 -33.02 9.93 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.639 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.26 -31.51 72.74 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.772 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 37.4 t -58.9 -40.93 85.96 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.623 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 mm -51.71 -29.23 10.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -70.41 -29.95 40.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.42 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.32 -48.4 69.72 Favored Glycine 0 C--N 1.307 -1.043 0 C-N-CA 121.185 -0.531 . . . . 0.0 111.948 -179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.8 pt -67.32 -29.79 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 120.871 0.367 . . . . 0.0 110.678 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.3 tp -59.45 -47.59 84.89 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.661 -179.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.636 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 7.2 m-70 -49.82 -49.78 47.65 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.648 -179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -50.92 -42.98 59.85 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.617 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 79.1 mt -61.12 -50.43 80.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.598 -178.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.32 -38.4 74.92 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.949 0.404 . . . . 0.0 111.076 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.6 t-105 -49.18 -28.73 4.72 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.035 -179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 44.1 p -59.9 -38.63 82.83 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.001 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 29.2 mm -65.77 -51.39 62.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 C-N-CA 120.836 -0.345 . . . . 0.0 111.379 -179.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.417 ' O ' ' OD1' ' B' ' 47' ' ' ASN . . . -50.21 -29.75 16.26 Favored Glycine 0 C--N 1.305 -1.193 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.558 ' O ' HG22 ' B' ' 49' ' ' ILE . 25.3 t60 -56.72 -27.66 59.59 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.446 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.5 pp -47.78 -35.9 10.75 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.672 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 25.0 p-10 -63.26 -49.62 73.38 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 -178.564 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.451 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 18.6 tm0? -68.89 -57.45 5.52 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.558 HG22 ' O ' ' B' ' 45' ' ' HIS . 13.0 tt . . . . . 0 C--N 1.298 -1.665 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo . . . . . 0 N--CA 1.493 1.452 0 CA-C-O 120.748 0.228 . . . . 0.0 111.999 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 59.7 tp -61.11 -42.21 98.1 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.739 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.2 t -70.13 -42.33 79.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.347 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 98.7 t -60.13 -43.48 93.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 120.955 0.407 . . . . 0.0 110.328 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.448 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.22 -48.25 79.27 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.638 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.28 -35.05 69.3 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.847 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.9 t -56.8 -43.66 81.18 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.724 0.297 . . . . 0.0 111.453 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.602 ' O ' HD13 ' C' ' 32' ' ' ILE . 0.3 OUTLIER -48.66 -34.6 5.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-O 120.884 0.373 . . . . 0.0 110.459 -178.892 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.8 mt -64.18 -29.69 48.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.702 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.548 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.9 -51.37 35.06 Favored Glycine 0 C--N 1.306 -1.129 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.579 -178.825 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 tt -63.1 -29.29 46.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 122.419 -0.46 . . . . 0.0 111.195 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 55.9 tp -62.22 -51.4 67.95 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.589 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.636 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 1.2 p80 -53.92 -29.5 42.39 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.815 -178.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 68.9 t80 -57.17 -49.52 75.7 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.564 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -49.88 -43.38 19.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.505 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.77 -31.98 70.23 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.144 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -54.3 -42.68 70.38 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 116.592 -0.276 . . . . 0.0 111.309 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 17.3 p -56.58 -40.36 75.1 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.987 0.422 . . . . 0.0 110.434 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.4 mm -59.06 -50.86 78.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.318 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.8 -28.16 6.93 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -50.41 -40.13 49.22 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.427 HD12 ' N ' ' C' ' 46' ' ' LEU . 0.1 OUTLIER . . . . . 0 C--N 1.308 -1.237 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 -177.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.9 m-20 . . . . . 0 CA--C 1.528 0.111 0 CA-C-O 120.699 0.285 . . . . 0.0 110.983 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.11 12.6 0.98 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.85 2.366 . . . . 0.0 111.447 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' D' ' 24' ' ' ASP . 39.3 tp -70.74 -44.75 66.17 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.607 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.4 p -70.54 -35.06 59.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.39 -50.04 49.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.528 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.66 -33.46 15.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.87 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.46 -34.77 74.87 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.865 0.364 . . . . 0.0 111.132 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 36.7 t -51.85 -38.47 56.08 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.161 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 mm -61.3 -29.64 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.89 0.376 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.405 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 5.1 mt -71.33 -39.17 71.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.418 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.38 -42.2 96.12 Favored Glycine 0 C--N 1.307 -1.068 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.198 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 9.9 tt -70.27 -39.27 76.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.301 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 44.3 tp -49.48 -36.36 22.62 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.437 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.672 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 45.6 m170 -49.93 -43.11 49.65 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.164 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -57.6 -38.29 74.66 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.442 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mm -61.67 -50.81 78.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.157 -179.205 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.507 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.68 -35.62 72.91 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.956 -179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.57 -28.65 3.56 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.109 0.48 . . . . 0.0 110.403 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.4 p -51.05 -36.66 41.05 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.057 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 32.2 mm -68.23 -51.13 51.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.127 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.95 -29.48 55.39 Favored Glycine 0 C--N 1.305 -1.184 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -57.23 -27.57 62.14 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.298 -1.636 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.819 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 N--CA 1.492 1.41 0 CA-C-O 120.849 0.271 . . . . 0.0 112.123 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -66.52 -44.32 82.82 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.63 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.07 -35.14 62.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.311 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.9 t -69.63 -43.91 79.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.938 0.399 . . . . 0.0 110.762 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.67 -39.13 35.34 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.115 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.59 -34.38 76.86 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.726 0.298 . . . . 0.0 111.165 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.4 ' O ' ' CD1' ' A' ' 35' ' ' ILE . 33.5 t -59.88 -41.79 92.35 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.797 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mm -52.55 -32.21 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.152 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.6 mt -70.25 -29.78 40.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.702 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.62 -45.1 93.92 Favored Glycine 0 C--N 1.304 -1.23 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.253 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.905 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.82 -29.13 45.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 122.589 -0.359 . . . . 0.0 111.189 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.603 ' O ' HG22 ' A' ' 39' ' ' ILE . 35.9 tp -62.92 -46.96 85.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -178.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.69 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.4 p80 -58.96 -28.42 66.29 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 120.201 -0.6 . . . . 0.0 111.423 -178.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.619 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 33.7 t80 -56.74 -48.66 77.29 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.4 tt -59.4 -41.17 83.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.171 -178.466 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -35.94 73.88 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.47 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.425 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 5.2 t-105 -49.67 -34.19 17.77 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.412 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.2 p -62.19 -29.98 70.75 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.036 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.403 HG21 ' NE2' ' B' ' 48' ' ' GLN . 58.4 mt -61.33 -47.1 95.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.385 -179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.71 -28.36 5.19 Favored Glycine 0 C--N 1.307 -1.051 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.167 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 4.9 t-160 . . . . . 0 C--N 1.302 -1.496 0 CA-C-N 116.762 0.281 . . . . 0.0 111.271 -179.619 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.495 1.599 0 CA-C-O 120.903 0.293 . . . . 0.0 111.774 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -68.06 -47.96 66.89 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.695 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -70.52 -34.0 55.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -70.0 -45.88 75.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.265 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.04 -35.37 15.46 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.629 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.21 -29.81 70.64 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.679 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 7.0 t -57.88 -41.36 82.34 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.766 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 mm -50.44 -30.61 7.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.584 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.63 -29.34 37.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.4 -49.93 58.3 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 121.047 -0.596 . . . . 0.0 111.787 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.408 HG12 ' H ' ' B' ' 35' ' ' ILE . 10.5 pt -63.42 -42.84 97.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.691 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 58.1 tp -60.26 -45.18 94.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.279 0.561 . . . . 0.0 109.615 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -61.08 -41.17 96.16 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.347 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 88.9 t80 -70.67 -46.58 62.94 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.474 ' O ' ' OG1' ' B' ' 42' ' ' THR . 18.0 tt -68.07 -29.97 46.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.317 -178.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -39.98 72.02 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.213 0.53 . . . . 0.0 110.139 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -54.35 -37.45 64.94 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.432 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 31.6 p -55.16 -36.58 65.97 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.603 -0.439 . . . . 0.0 110.934 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -65.04 -50.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.015 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.542 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.51 -30.36 12.8 Favored Glycine 0 C--N 1.305 -1.185 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 48.6 t60 -59.81 -27.04 66.26 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.7 0.286 . . . . 0.0 111.562 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.89 -31.65 12.69 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.774 -0.371 . . . . 0.0 111.943 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 6.9 p30 -68.95 -50.06 52.56 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -177.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.546 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 7.5 pt20 -69.28 -48.51 61.5 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.12 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 16.4 tt . . . . . 0 C--N 1.296 -1.744 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.214 -179.154 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo . . . . . 0 N--CA 1.494 1.516 0 CA-C-O 120.861 0.275 . . . . 0.0 111.885 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.3 tp -64.11 -48.44 76.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 59.5 t -70.42 -37.02 69.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 85.8 t -70.12 -43.71 78.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.742 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.56 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.48 -38.47 74.6 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.549 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.08 -30.38 71.45 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 120.906 0.384 . . . . 0.0 110.903 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -50.74 -36.47 36.61 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.178 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.56 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.8 tt -55.27 -29.76 23.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.603 -179.174 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.41 -36.92 76.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.429 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.61 -46.41 84.49 Favored Glycine 0 C--N 1.303 -1.261 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.16 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 11.0 tt -70.28 -29.06 37.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.778 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 31.8 tp -61.94 -47.23 85.83 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.99 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -56.7 -29.94 62.95 Favored 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 120.421 -0.512 . . . . 0.0 111.876 -178.474 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 77.4 t80 -62.33 -40.63 96.99 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.393 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -57.43 -46.93 85.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.54 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.18 -34.62 73.19 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 120.81 0.338 . . . . 0.0 110.812 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.2 -30.68 7.31 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.354 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 42.2 p -53.97 -44.02 70.41 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.923 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.479 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -63.66 -48.86 84.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.617 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.23 -33.56 15.67 Favored Glycine 0 C--N 1.304 -1.217 0 C-N-CA 121.259 -0.496 . . . . 0.0 111.881 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -50.58 -28.57 8.95 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 116.814 0.307 . . . . 0.0 111.628 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.448 ' C ' HD12 ' C' ' 46' ' ' LEU . 2.2 pp . . . . . 0 C--N 1.308 -1.197 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.931 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' D' ' 24' ' ' ASP . 4.2 p30 . . . . . 0 CA--C 1.533 0.296 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.72 45.56 0.9 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.322 2.015 . . . . 0.0 111.753 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 53.9 tp -69.97 -44.02 70.31 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.282 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.52 -38.62 74.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.979 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 95.6 t -67.08 -47.71 81.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.696 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.78 -34.37 19.18 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.015 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.31 -29.73 67.65 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.138 -179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.2 t -57.17 -42.79 81.8 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.127 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mm -51.46 -33.34 14.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 120.881 0.372 . . . . 0.0 110.481 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 4.6 mt -71.51 -29.04 33.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.282 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.36 -47.47 79.08 Favored Glycine 0 C--N 1.309 -0.937 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.118 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -61.15 -42.07 91.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.786 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.5 tp -49.13 -32.24 9.63 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.69 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 29.5 m170 -65.35 -42.88 92.39 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.554 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.69 -50.07 66.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.3 pp -62.83 -39.04 83.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.847 -0.741 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.425 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -69.08 -40.75 78.24 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.335 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.1 t-105 -49.78 -30.2 9.18 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.73 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.2 m -69.59 -35.78 75.64 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 115.604 -0.726 . . . . 0.0 111.116 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.519 ' O ' HD12 ' D' ' 46' ' ' LEU . 60.7 mt -70.6 -51.54 36.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.012 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.97 -27.8 65.19 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -55.99 -26.56 48.97 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.519 HD12 ' O ' ' D' ' 43' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -177.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo . . . . . 0 N--CA 1.494 1.523 0 CA-C-O 120.796 0.248 . . . . 0.0 111.991 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -67.75 -45.11 75.89 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.2 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.0 p -70.1 -37.2 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.655 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.429 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.6 t -68.91 -43.7 82.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 120.982 0.42 . . . . 0.0 110.989 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.82 -38.3 21.79 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.629 -179.255 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.08 -35.86 81.67 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.32 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 35' ' ' ILE . 44.8 t -60.4 -44.75 95.41 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.333 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.0 mm -50.01 -29.72 5.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.042 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.9 mt -70.5 -30.96 44.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.813 -179.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.53 -48.49 72.82 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.379 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.698 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.4 mp -68.07 -29.5 44.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.74 0.305 . . . . 0.0 111.057 -179.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 39' ' ' ILE . 45.2 tp -61.8 -47.43 85.17 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.464 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.1 -28.59 69.2 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.243 -0.583 . . . . 0.0 111.41 -178.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 51.4 t80 -60.18 -48.74 80.47 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.509 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -60.73 -39.96 83.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.083 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -39.47 72.44 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 120.926 0.393 . . . . 0.0 110.968 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.497 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.0 t-105 -48.94 -30.83 6.42 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.856 -178.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -57.83 -37.54 73.99 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.8 mm -61.04 -48.88 87.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.804 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.27 -28.12 6.01 Favored Glycine 0 C--N 1.305 -1.163 0 N-CA-C 111.709 -0.557 . . . . 0.0 111.709 -179.093 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 . . . . . 0 C--N 1.301 -1.507 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.515 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo . . . . . 0 N--CA 1.497 1.689 0 CA-C-O 121.034 0.348 . . . . 0.0 111.567 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 18.1 tp -70.27 -45.07 67.12 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.013 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 95.5 t -70.64 -38.12 72.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.545 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.44 -42.47 78.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.739 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.17 -29.74 14.76 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.595 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.74 -31.55 69.59 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.702 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.5 t -52.17 -40.25 61.2 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.749 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.415 ' O ' HD13 ' B' ' 35' ' ' ILE . 20.3 mm -51.37 -32.79 13.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-O 121.224 0.535 . . . . 0.0 110.368 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -72.35 -29.17 30.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.377 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.36 -52.01 24.12 Favored Glycine 0 CA--C 1.528 0.899 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.731 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.415 HD13 ' O ' ' B' ' 32' ' ' ILE . 0.2 OUTLIER -70.95 -29.48 37.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 117.971 0.886 . . . . 0.0 110.267 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 57.4 tp -64.7 -44.97 88.56 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.167 0.508 . . . . 0.0 110.113 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -52.91 -43.24 66.07 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.547 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -69.8 -36.7 75.9 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.406 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.33 -42.94 98.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.978 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.41 -36.04 78.53 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.85 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -53.44 -33.48 54.2 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.087 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.0 p -54.91 -40.12 69.51 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.775 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.52 -47.64 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.614 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.12 -29.35 9.04 Favored Glycine 0 C--N 1.305 -1.161 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -49.46 -27.06 3.82 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.551 0.215 . . . . 0.0 111.484 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -47.43 -38.2 13.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.45 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -48.42 -51.06 28.51 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.315 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.479 ' O ' HG22 ' B' ' 49' ' ' ILE . 16.4 tt0 -82.08 -143.99 0.06 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.052 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.479 HG22 ' O ' ' B' ' 48' ' ' GLN . 12.4 tt . . . . . 0 C--N 1.308 -1.2 0 N-CA-C 113.085 0.772 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo . . . . . 0 N--CA 1.494 1.53 0 CA-C-O 120.788 0.245 . . . . 0.0 111.988 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 30.8 tp -70.0 -44.71 68.83 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.721 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.8 t -70.68 -39.33 75.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.348 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 13.6 t -69.7 -44.56 79.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.499 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -60.92 -39.15 88.29 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.265 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.85 -29.92 71.11 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.975 0.417 . . . . 0.0 110.786 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -50.51 -34.23 24.45 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.949 -0.568 . . . . 0.0 111.255 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.499 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.9 tp -53.18 -30.23 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.449 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.53 -32.03 51.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.013 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.58 -47.46 62.07 Favored Glycine 0 C--N 1.304 -1.233 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.312 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 13.1 tt -69.4 -29.82 43.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.026 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 28.5 tp -62.62 -48.95 77.13 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -53.42 -29.44 35.14 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.59 -178.7 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 58.0 t80 -61.57 -41.42 97.37 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 92.4 mt -57.61 -48.86 82.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.535 -178.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.45 -32.83 72.02 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.967 0.413 . . . . 0.0 110.316 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.8 -35.03 21.28 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.145 -179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -58.77 -32.31 69.17 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.372 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.1 -48.66 80.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.309 -179.318 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.93 -36.56 27.28 Favored Glycine 0 C--N 1.305 -1.141 0 CA-C-N 116.387 -0.37 . . . . 0.0 112.721 -178.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -51.47 -27.84 11.58 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 117.296 0.548 . . . . 0.0 111.283 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.574 ' C ' HD12 ' C' ' 46' ' ' LEU . 1.7 pp . . . . . 0 C--N 1.303 -1.432 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.187 -177.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.487 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.0 m-20 . . . . . 0 CA--C 1.532 0.271 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.83 22.0 0.21 Allowed 'Trans proline' 0 N--CA 1.495 1.573 0 C-N-CA 122.1 1.867 . . . . 0.0 111.972 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.487 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.5 tp -71.87 -39.93 69.31 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.923 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.7 t -70.03 -45.24 77.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -178.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 28' ' ' VAL . . . . . 0.437 HG23 ' N ' ' D' ' 29' ' ' ALA . 17.1 m -67.91 -35.87 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.059 0.457 . . . . 0.0 110.439 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.437 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.66 -36.36 56.77 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.302 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.67 -39.46 73.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.316 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -61.86 -48.59 79.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.744 ' O ' HD12 ' D' ' 35' ' ' ILE . 12.5 pt -50.35 -28.21 5.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.751 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.77 -28.69 34.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.301 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -44.55 84.49 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 116.337 -0.392 . . . . 0.0 113.632 -178.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 35' ' ' ILE . . . . . 0.999 HD13 ' N ' ' D' ' 36' ' ' LEU . 0.0 OUTLIER -56.36 -28.43 26.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-N 117.411 0.605 . . . . 0.0 110.516 -178.954 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 36' ' ' LEU . . . . . 0.999 ' N ' HD13 ' D' ' 35' ' ' ILE . 4.1 tp -60.47 -43.1 97.3 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 120.892 0.377 . . . . 0.0 110.565 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.627 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 7.0 m170 -55.14 -49.16 72.52 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.526 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -56.46 -50.08 72.75 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -178.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.6 pt -61.29 -44.93 99.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.919 -0.712 . . . . 0.0 111.045 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.497 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.3 -37.51 74.79 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.187 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.7 t-105 -48.63 -30.13 5.09 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.843 0.354 . . . . 0.0 110.653 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.4 p -60.09 -36.75 78.11 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.842 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.64 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -69.23 -51.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.231 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.44 -28.74 37.11 Favored Glycine 0 C--N 1.304 -1.228 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.6 t-80 -65.29 -33.33 75.72 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -177.762 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 CA-C-O 120.752 0.23 . . . . 0.0 112.031 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.3 tp -66.12 -46.61 76.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.956 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.411 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.0 p -70.34 -36.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.649 -179.231 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.411 ' N ' HG13 ' A' ' 27' ' ' VAL . 74.3 t -69.55 -42.27 80.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 120.918 0.389 . . . . 0.0 110.855 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.55 -38.12 29.8 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.828 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.42 75.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.303 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -59.93 -42.74 94.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.112 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.6 mm -49.69 -31.49 6.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.876 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -70.48 -29.59 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.547 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -65.57 -49.83 58.07 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.461 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.866 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -65.64 -29.73 47.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 122.576 -0.367 . . . . 0.0 111.089 -179.187 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 39' ' ' ILE . 56.5 tp -61.41 -46.11 91.5 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.643 -179.024 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.0 OUTLIER -61.34 -28.99 69.61 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 120.195 -0.602 . . . . 0.0 111.358 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 91.6 t80 -62.78 -50.16 72.12 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.465 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -57.79 -40.38 75.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 C-N-CA 120.089 -0.644 . . . . 0.0 110.521 -178.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -36.15 72.37 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.629 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.9 t-105 -48.83 -34.08 11.76 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.744 -179.106 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 38.1 p -58.9 -33.67 70.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.814 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.605 ' CG2' ' NE2' ' B' ' 48' ' ' GLN . 96.6 mt -65.36 -44.24 94.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.201 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.0 -26.13 1.15 Allowed Glycine 0 C--N 1.306 -1.124 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 . . . . . 0 C--N 1.299 -1.625 0 O-C-N 123.016 -0.108 . . . . 0.0 111.104 179.846 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 N--CA 1.499 1.84 0 CA-C-O 121.147 0.395 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 20.6 tp -71.47 -50.88 27.28 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.504 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 t -70.69 -35.5 61.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-O 121.127 0.489 . . . . 0.0 111.514 -179.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 99.3 t -70.39 -44.18 77.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.274 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -29.52 5.71 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.813 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.53 -29.71 69.18 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.939 0.4 . . . . 0.0 110.524 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.0 t -49.98 -37.13 31.08 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.828 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -54.7 -29.51 21.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 120.978 0.418 . . . . 0.0 110.443 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -71.02 -29.84 38.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.323 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.45 -46.6 76.31 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.17 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 12.3 pt -66.01 -42.35 91.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.164 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.4 tp -62.32 -46.54 88.28 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.143 0.497 . . . . 0.0 109.818 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.4 t-80 -51.6 -42.03 61.65 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.444 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.13 -36.03 74.5 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.539 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -41.85 93.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.129 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.41 -40.42 77.32 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.01 0.434 . . . . 0.0 110.817 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.26 -32.05 10.0 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.067 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.8 p -51.38 -33.91 32.02 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.264 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 34.3 mm -65.74 -50.46 70.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.61 -30.11 26.6 Favored Glycine 0 C--N 1.306 -1.089 0 C-N-CA 121.232 -0.509 . . . . 0.0 111.928 -179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.443 ' O ' ' OE1' ' B' ' 48' ' ' GLN . 0.1 OUTLIER -63.78 -27.73 69.39 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 122.574 0.349 . . . . 0.0 111.342 -179.286 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.596 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.0 OUTLIER -48.75 -29.03 4.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.498 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -58.18 -51.7 68.66 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -177.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.618 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -75.38 -47.82 25.78 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.25 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--N 1.295 -1.771 0 C-N-CA 120.301 -0.56 . . . . 0.0 110.474 -179.36 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo . . . . . 0 N--CA 1.494 1.54 0 CA-C-O 120.787 0.244 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -69.35 -47.97 62.73 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.49 -36.61 66.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.058 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 64.2 t -70.33 -46.74 70.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.84 -36.61 27.38 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.18 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.5 -29.64 67.32 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.787 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -51.7 -41.94 61.85 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.278 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' C' ' 29' ' ' ALA . 7.4 tt -53.93 -27.13 15.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.018 0.437 . . . . 0.0 111.031 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 1.6 mm -59.89 -37.72 73.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.754 -178.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.446 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.4 -46.66 76.3 Favored Glycine 0 C--N 1.304 -1.212 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.991 -178.142 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -70.16 -29.13 38.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.533 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 34.4 tp -61.64 -50.62 71.79 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.667 -179.174 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -57.62 -29.0 64.17 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.652 -178.741 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.2 t80 -59.94 -42.64 94.44 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.638 0.256 . . . . 0.0 111.294 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' C' ' 42' ' ' THR . 19.6 mm -58.14 -45.71 88.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.071 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.01 -30.28 65.06 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.225 0.536 . . . . 0.0 111.056 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -52.6 -38.02 59.28 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -57.77 -29.99 65.27 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.48 -178.262 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.607 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.6 mp -61.24 -48.97 86.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.165 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.42 -29.74 11.32 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -50.84 -28.09 8.73 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.69 0.281 . . . . 0.0 111.207 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.624 ' C ' HD12 ' C' ' 46' ' ' LEU . 3.3 pp . . . . . 0 C--N 1.305 -1.35 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.892 -177.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 . . . . . 0 CA--C 1.534 0.34 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.54 42.23 0.56 Allowed 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.201 1.934 . . . . 0.0 111.743 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.4 tp -70.15 -47.08 63.2 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.574 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.3 t -70.68 -34.42 56.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.093 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 91.8 t -69.96 -47.67 67.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.648 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -31.45 10.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.839 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.01 -33.76 74.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -58.06 -41.21 82.85 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 68.3 mt -58.36 -30.15 39.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-O 120.976 0.417 . . . . 0.0 110.816 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.441 ' O ' ' NE2' ' D' ' 37' ' ' HIS . 6.0 mt -71.43 -31.96 44.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.515 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.6 -39.61 90.68 Favored Glycine 0 C--N 1.307 -1.07 0 C-N-CA 121.429 -0.415 . . . . 0.0 112.579 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 19.9 pt -69.99 -35.76 65.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.601 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 27.6 tp -49.34 -36.09 20.39 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.484 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 8.7 m170 -58.99 -34.73 72.18 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -62.05 -45.96 91.25 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.5 pp -67.22 -40.23 84.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.522 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.87 -41.28 71.59 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.211 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -48.96 -28.72 4.07 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.1 p -60.3 -32.5 71.26 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 84.8 mt -66.01 -51.57 58.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.174 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.84 -29.5 42.35 Favored Glycine 0 C--N 1.304 -1.215 0 N-CA-C 111.685 -0.566 . . . . 0.0 111.685 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 9.0 t-80 -55.77 -28.21 54.91 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.253 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.522 -177.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo . . . . . 0 N--CA 1.493 1.497 0 CA-C-O 120.847 0.27 . . . . 0.0 112.024 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.3 tp -66.48 -48.52 69.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.03 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.34 -35.56 63.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.586 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.0 t -70.36 -43.63 78.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 120.868 0.366 . . . . 0.0 110.684 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -35.82 18.13 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.997 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.14 -35.26 79.69 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 120.734 0.302 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -61.07 -41.78 97.27 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.124 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -55.92 -29.76 26.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.114 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.3 mt -70.39 -32.47 50.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.397 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -61.21 -40.24 98.3 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.375 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 mt -69.98 -29.6 40.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.937 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HD23 ' A' ' 36' ' ' LEU . 1.7 tt -60.6 -47.83 84.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.314 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.5 p80 -61.61 -28.76 69.59 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.45 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 56.1 t80 -60.97 -48.24 82.76 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 10.2 pt -62.64 -40.53 88.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.074 -0.65 . . . . 0.0 111.098 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -39.58 75.31 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.69 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.6 t-105 -49.09 -30.96 7.1 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.016 -179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 70.4 p -63.78 -30.9 71.94 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 76.7 mt -59.69 -49.57 83.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.815 0.341 . . . . 0.0 111.016 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.26 -28.99 9.45 Favored Glycine 0 C--N 1.305 -1.175 0 N-CA-C 111.618 -0.593 . . . . 0.0 111.618 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 . . . . . 0 C--N 1.304 -1.398 0 CA-C-O 120.764 0.316 . . . . 0.0 110.897 -179.764 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo . . . . . 0 N--CA 1.495 1.583 0 CA-C-O 120.97 0.321 . . . . 0.0 111.753 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 tp -70.44 -46.14 64.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.039 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 91.9 t -70.28 -38.69 75.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.323 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -70.35 -45.95 73.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.56 -35.38 20.35 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.656 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -36.8 77.99 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.5 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -51.57 -37.48 49.89 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.311 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.6 -36.12 47.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.847 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -70.63 -33.12 51.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.481 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.86 -44.72 78.5 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.284 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 16.6 pt -70.04 -37.41 72.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.553 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.525 ' O ' HD13 ' B' ' 36' ' ' LEU . 0.2 OUTLIER -49.15 -42.63 40.26 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.035 -179.75 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 0.5 OUTLIER -53.2 -45.79 68.74 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.783 -179.761 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -57.85 -45.07 86.8 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.537 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.6 mp -61.28 -45.72 98.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.838 -179.12 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.33 -39.92 74.44 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.181 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.58 -28.64 5.91 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.435 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 43.4 p -62.01 -38.62 89.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.43 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.653 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.45 -50.17 80.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.607 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.74 -29.65 58.6 Favored Glycine 0 C--N 1.304 -1.218 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -56.0 -28.41 57.12 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.65 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.9 pp -47.61 -29.44 2.91 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.738 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -62.92 -45.58 91.83 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 10.2 tt0 -61.29 -53.11 60.96 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.011 0.434 . . . . 0.0 111.86 -179.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 1.5 tp . . . . . 0 C--N 1.295 -1.778 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.566 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo . . . . . 0 N--CA 1.49 1.273 0 CA-C-O 120.744 0.227 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.493 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -55.24 -50.31 69.79 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.762 -179.312 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 80.0 t -69.87 -39.91 78.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.829 0.347 . . . . 0.0 111.198 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 66.9 t -62.3 -44.21 98.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.618 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.541 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -64.03 -50.19 69.43 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.609 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.43 -29.34 67.7 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.488 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -54.71 -42.6 71.69 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.448 -179.227 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.541 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.7 tp -50.75 -30.58 8.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.97 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -70.45 -34.26 57.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.342 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.49 -49.25 57.53 Favored Glycine 0 C--N 1.303 -1.291 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.128 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 35' ' ' ILE . . . . . 0.412 ' O ' HD12 ' C' ' 39' ' ' ILE . 14.4 tt -64.81 -37.45 80.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 122.52 -0.4 . . . . 0.0 110.713 -179.519 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 36' ' ' LEU . . . . . 0.695 ' C ' HD12 ' C' ' 36' ' ' LEU . 0.1 OUTLIER -53.29 -47.11 69.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.151 -178.807 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.625 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 0.8 OUTLIER -61.0 -28.58 69.14 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.555 -178.258 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.621 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.2 t80 -58.88 -48.01 82.9 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.615 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.597 ' H ' HD12 ' C' ' 39' ' ' ILE . 4.3 mp -60.73 -45.58 97.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.484 -0.487 . . . . 0.0 111.078 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -29.88 65.92 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.472 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 41' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' C' ' 41' ' ' TRP . 10.7 t-105 -48.93 -50.36 35.71 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.769 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.523 HG22 ' O ' ' C' ' 39' ' ' ILE . 12.2 t -47.79 -28.05 2.34 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.055 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.515 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tp -49.83 -49.32 20.83 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 120.299 -0.56 . . . . 0.0 110.358 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.515 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -54.18 -28.44 42.1 Favored Glycine 0 C--N 1.302 -1.321 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.93 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.66 -33.39 15.48 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.818 0.309 . . . . 0.0 111.415 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.592 ' C ' HD12 ' C' ' 46' ' ' LEU . 2.0 pp . . . . . 0 C--N 1.306 -1.311 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 t70 . . . . . 0 CA--C 1.538 0.484 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -74.55 45.36 1.24 Allowed 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.979 1.786 . . . . 0.0 111.935 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 41.6 tp -70.52 -44.39 67.65 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.0 t -70.7 -41.96 77.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.164 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.75 -38.39 72.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.329 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -35.13 21.41 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.69 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.17 -29.41 70.76 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.022 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.0 t -52.71 -42.54 64.93 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.199 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.664 HD12 ' N ' ' D' ' 32' ' ' ILE . 1.9 mp -54.97 -37.35 41.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.733 0.301 . . . . 0.0 110.5 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.412 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 6.0 mt -71.45 -29.71 36.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.401 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.5 -48.92 47.97 Favored Glycine 0 C--N 1.306 -1.108 0 C-N-CA 121.361 -0.447 . . . . 0.0 113.025 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 pp -66.34 -32.47 58.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 117.194 0.497 . . . . 0.0 110.579 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 tp -51.06 -37.68 46.98 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.198 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.624 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 20.3 m170 -58.63 -40.44 83.37 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.858 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.02 -48.27 82.56 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 39' ' ' ILE . . . . . 0.408 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.6 pt -61.53 -41.88 91.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.175 -0.61 . . . . 0.0 111.422 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.6 -38.34 73.99 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.083 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.4 -30.77 8.39 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 42' ' ' THR . . . . . 0.408 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 77.7 p -64.65 -34.11 77.52 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.252 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.643 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -70.49 -52.08 32.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.688 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.52 -29.35 24.01 Favored Glycine 0 C--N 1.306 -1.105 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -56.4 -27.03 55.21 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 111.528 0.195 . . . . 0.0 111.528 -179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.273 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.429 -177.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.493 1.458 0 CA-C-O 121.075 0.365 . . . . 0.0 111.599 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.9 tp -70.52 -42.85 70.71 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.21 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.15 -40.92 78.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.589 -179.163 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.7 t -68.16 -46.21 81.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.822 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -38.43 34.96 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.879 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.47 79.01 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.428 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.29 -39.92 80.59 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.949 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -51.26 -29.67 9.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.263 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.9 mt -69.75 -29.82 42.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.623 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.26 -48.17 66.27 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 121.182 -0.532 . . . . 0.0 112.287 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.859 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.1 mp -67.14 -29.68 46.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 120.681 -0.407 . . . . 0.0 111.126 -179.223 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.73 -46.3 90.94 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.574 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.695 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.1 p80 -61.78 -28.79 69.7 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.385 -178.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 64.1 t80 -60.62 -50.14 74.72 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.8 -39.17 69.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.007 -178.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.42 -36.04 73.77 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.891 0.377 . . . . 0.0 110.944 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.8 t-105 -49.68 -38.05 31.22 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.103 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.1 p -52.47 -39.76 61.52 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.91 -49.32 84.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.834 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.36 -28.6 9.49 Favored Glycine 0 C--N 1.304 -1.205 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 . . . . . 0 C--N 1.303 -1.427 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -179.307 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo . . . . . 0 N--CA 1.496 1.651 0 CA-C-O 121.065 0.361 . . . . 0.0 111.681 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -70.42 -46.62 63.56 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.067 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 48.7 t -70.42 -37.55 70.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.582 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.17 -44.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.598 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -33.22 12.04 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.356 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.92 -33.67 76.59 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.766 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -57.56 -41.03 80.23 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.782 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -56.71 -35.94 47.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.279 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.57 -33.74 50.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.441 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.17 73.38 Favored Glycine 0 C--N 1.305 -1.183 0 C-N-CA 121.249 -0.5 . . . . 0.0 111.898 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.418 HG23 ' N ' ' B' ' 36' ' ' LEU . 3.7 tp -68.47 -43.99 83.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.745 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.418 ' N ' HG23 ' B' ' 35' ' ' ILE . 53.9 tp -49.97 -38.12 35.42 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.136 0.493 . . . . 0.0 110.078 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -49.64 -41.9 43.73 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.012 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -67.41 -38.71 85.04 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.726 -179.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.56 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.5 mp -62.01 -43.91 98.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.65 -179.321 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.56 74.96 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.152 0.501 . . . . 0.0 110.788 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.49 -29.56 6.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.819 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.3 p -61.62 -36.14 79.89 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.464 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -63.67 -50.79 76.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.093 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.21 -29.48 29.48 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.493 ' O ' HG22 ' B' ' 49' ' ' ILE . 44.7 t60 -61.46 -28.92 69.62 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 120.616 0.246 . . . . 0.0 111.327 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.533 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.8 OUTLIER -49.4 -34.66 16.83 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.397 -178.877 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -64.45 -50.43 67.53 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.463 ' OE1' ' CE1' ' B' ' 45' ' ' HIS . 9.5 pt20 -69.66 -50.05 47.8 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.254 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.493 HG22 ' O ' ' B' ' 45' ' ' HIS . 15.9 tt . . . . . 0 C--N 1.297 -1.705 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.93 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.494 1.529 0 CA-C-O 120.847 0.27 . . . . 0.0 112.116 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.8 tp -66.6 -45.07 80.4 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.994 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.22 -34.34 58.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.301 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.57 -47.3 80.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -37.38 26.42 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.788 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.4 -29.8 70.85 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.47 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.4 t -57.26 -42.85 82.34 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.693 0.283 . . . . 0.0 111.321 -179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.674 ' N ' HD12 ' C' ' 32' ' ' ILE . 2.2 mp -54.77 -30.28 22.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.397 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 mt -68.14 -36.38 75.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.525 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.61 -45.29 94.96 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.396 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 tp -69.96 -29.6 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 116.964 0.382 . . . . 0.0 110.824 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 33.0 tp -61.75 -49.26 77.13 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.916 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -55.66 -28.83 57.62 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 120.566 -0.454 . . . . 0.0 111.552 -178.61 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 51.4 t80 -61.07 -42.44 98.5 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.696 -0.229 . . . . 0.0 111.509 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 57.2 mt -58.1 -45.36 88.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.348 -178.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.26 -35.4 76.05 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.854 0.359 . . . . 0.0 110.743 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -49.47 -35.26 19.13 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 29.1 p -55.42 -39.07 69.79 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.031 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 85.1 mt -62.1 -48.49 88.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.901 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.17 -27.79 5.58 Favored Glycine 0 C--N 1.305 -1.189 0 N-CA-C 111.613 -0.595 . . . . 0.0 111.613 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -47.71 -28.1 2.28 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 122.744 -0.268 . . . . 0.0 111.511 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 pp . . . . . 0 C--N 1.305 -1.368 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.323 -178.044 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.483 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.2 m-20 . . . . . 0 CA--C 1.533 0.293 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.8 34.59 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 122.081 1.854 . . . . 0.0 111.841 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.483 ' H ' ' C ' ' D' ' 24' ' ' ASP . 48.4 tp -71.99 -38.25 69.7 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.801 179.05 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.73 -40.7 77.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 28' ' ' VAL . . . . . 0.413 HG23 ' N ' ' D' ' 29' ' ' ALA . 31.0 m -70.11 -40.23 78.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 CA-C-O 120.687 0.28 . . . . 0.0 110.836 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.413 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.45 -30.93 32.19 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.48 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.19 -34.61 68.53 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.237 179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.4 t -63.68 -44.85 92.49 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 pt -56.71 -28.17 27.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 120.852 0.358 . . . . 0.0 110.696 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.97 -29.02 35.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.315 179.437 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.07 -38.5 95.45 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 116.36 -0.382 . . . . 0.0 113.263 -178.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -68.96 -29.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 117.49 0.645 . . . . 0.0 110.366 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 36' ' ' LEU . . . . . 0.544 ' O ' HD23 ' D' ' 36' ' ' LEU . 0.9 OUTLIER -57.31 -29.49 63.97 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.382 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.695 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 8.7 m170 -69.75 -35.6 75.09 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.539 -179.187 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -66.18 -46.68 76.51 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -178.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 pp -66.33 -39.14 83.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.416 -178.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -38.92 74.6 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.054 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -52.96 -30.74 36.58 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.952 0.406 . . . . 0.0 111.0 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 67.6 p -63.95 -32.08 73.49 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.023 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 18.1 mm -70.66 -51.63 35.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.461 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.42 -29.74 31.68 Favored Glycine 0 C--N 1.307 -1.082 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 t-80 -54.62 -27.19 37.65 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 120.715 0.293 . . . . 0.0 111.137 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.303 -1.44 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.668 -178.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo . . . . . 0 N--CA 1.494 1.51 0 CA-C-O 120.821 0.259 . . . . 0.0 111.912 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.4 tt -65.32 -49.54 69.06 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 -179.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' N ' ' A' ' 28' ' ' VAL . 11.9 p -70.6 -39.43 75.97 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.005 179.749 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.468 ' N ' HG13 ' A' ' 27' ' ' VAL . 69.0 t -62.95 -29.95 48.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.754 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.87 69.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.522 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.34 -36.0 80.53 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.596 -179.375 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.2 t -56.52 -46.19 80.72 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.565 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.696 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.35 -39.85 22.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.935 0.398 . . . . 0.0 110.166 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -70.46 -28.61 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.289 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.96 -50.68 56.81 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.199 -0.524 . . . . 0.0 112.796 -178.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' N ' ' A' ' 36' ' ' LEU . 2.8 pp -66.04 -29.15 45.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.065 0.432 . . . . 0.0 111.413 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 35' ' ' ILE . 7.2 tt -62.74 -41.13 99.05 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.451 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.632 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -65.56 -28.74 69.37 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.659 -178.976 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 60.3 t80 -64.49 -50.44 67.42 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -178.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.4 pt -51.56 -40.46 25.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.149 -179.024 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.32 -33.25 65.05 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 120.97 0.414 . . . . 0.0 111.272 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.453 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 11.8 t-105 -49.23 -31.06 7.99 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -177.548 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -69.39 -29.6 67.4 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.331 -179.443 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.5 mp -56.17 -44.98 80.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.847 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.15 -28.43 4.25 Favored Glycine 0 C--N 1.304 -1.236 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -178.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 . . . . . 0 C--N 1.301 -1.511 0 CA-C-O 120.806 0.336 . . . . 0.0 110.398 179.799 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo . . . . . 0 N--CA 1.493 1.482 0 CA-C-O 120.879 0.283 . . . . 0.0 111.618 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 52.2 tp -70.23 -43.21 71.08 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.503 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 96.3 t -70.16 -41.77 78.99 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.738 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 50.2 t -70.21 -41.11 78.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.176 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.8 -37.31 18.82 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.349 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.9 -29.52 65.14 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.72 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.6 t -58.64 -41.73 86.66 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 23.9 mm -50.66 -36.65 14.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.684 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -69.99 -29.76 41.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.15 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.68 -50.16 63.61 Favored Glycine 0 C--N 1.306 -1.131 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.622 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.0 pt -62.5 -43.65 98.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.998 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.5 tp -62.28 -49.16 76.76 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.019 0.438 . . . . 0.0 109.828 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -49.79 -39.45 38.21 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.95 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 74.8 t80 -69.99 -39.74 75.71 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.48 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.37 -43.67 94.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.968 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.05 -40.76 91.23 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.995 0.426 . . . . 0.0 110.594 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.81 -32.74 14.74 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.285 -179.502 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 58.0 p -60.98 -38.16 84.99 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.993 -179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.594 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.6 mp -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.503 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.19 -29.81 16.24 Favored Glycine 0 C--N 1.304 -1.224 0 C-N-CA 121.335 -0.46 . . . . 0.0 112.089 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -58.07 -28.5 64.62 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -47.03 -32.22 3.83 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.321 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 -62.29 -44.99 95.26 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.414 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -61.74 -53.33 57.43 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 120.916 0.389 . . . . 0.0 112.027 -178.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 1.9 tp . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.135 -179.142 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo . . . . . 0 N--CA 1.495 1.602 0 CA-C-O 120.911 0.296 . . . . 0.0 111.729 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.42 HD21 HG13 ' D' ' 28' ' ' VAL . 41.4 tp -70.07 -43.68 70.68 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.754 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.36 -40.92 78.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.923 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.2 -47.76 80.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.73 -37.18 28.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.976 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.97 -29.55 70.49 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-O 120.83 0.347 . . . . 0.0 111.07 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -52.49 -43.72 65.19 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -50.1 -29.1 5.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-O 120.75 0.31 . . . . 0.0 111.324 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.1 -31.83 48.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.116 -179.065 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.62 -50.16 38.78 Favored Glycine 0 C--N 1.303 -1.267 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.753 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 tp -69.54 -29.49 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 120.852 0.358 . . . . 0.0 110.281 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.11 -48.86 79.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.79 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -55.59 -29.14 58.55 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 120.646 -0.422 . . . . 0.0 111.935 -178.491 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -59.04 -42.61 90.67 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.375 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.439 ' H ' HD12 ' C' ' 39' ' ' ILE . 3.8 mp -58.38 -47.57 87.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.577 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.93 78.63 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.889 -0.325 . . . . 0.0 110.847 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -49.13 -29.99 6.06 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 67.7 p -57.13 -37.39 71.94 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.248 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 75.9 mt -63.22 -50.23 79.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.912 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.15 -28.83 6.3 Favored Glycine 0 C--N 1.305 -1.182 0 N-CA-C 112.059 -0.416 . . . . 0.0 112.059 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -49.12 -27.96 3.89 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.856 0.328 . . . . 0.0 111.341 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 C--N 1.306 -1.3 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.917 -177.943 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' D' ' 26' ' ' LEU . 4.1 m-20 . . . . . 0 CA--C 1.533 0.307 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -72.21 27.08 0.26 Allowed 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 122.218 1.945 . . . . 0.0 111.829 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.7 tp -70.17 -44.86 67.91 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.582 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -70.17 -36.97 70.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.998 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 28' ' ' VAL . . . . . 0.42 HG13 HD21 ' C' ' 26' ' ' LEU . 87.9 t -67.97 -46.76 81.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.412 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.67 -34.35 11.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.46 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.96 -29.65 69.56 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 34.6 t -58.82 -43.72 90.69 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.218 -179.408 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.674 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -53.98 -29.9 19.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 120.835 0.35 . . . . 0.0 110.351 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.36 -29.91 37.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.265 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.93 -43.94 95.26 Favored Glycine 0 C--N 1.308 -1.024 0 C-N-CA 121.34 -0.457 . . . . 0.0 112.188 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -67.19 -37.64 79.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.499 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.1 tt -49.81 -43.31 48.55 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 26.4 m170 -57.8 -44.19 86.14 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.923 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -61.56 -47.26 86.34 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -178.229 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 39' ' ' ILE . . . . . 0.415 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.6 pt -63.79 -41.76 93.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.301 -0.56 . . . . 0.0 111.425 -178.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.432 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.16 -40.76 74.53 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.804 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.53 -29.32 6.65 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.042 0.449 . . . . 0.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 42' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.2 p -62.25 -33.21 74.18 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.345 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.602 ' O ' HD12 ' D' ' 46' ' ' LEU . 90.7 mt -65.56 -50.72 70.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.03 -28.15 47.84 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -56.85 -28.06 61.17 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 112.628 0.603 . . . . 0.0 112.628 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.602 HD12 ' O ' ' D' ' 43' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -178.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo . . . . . 0 N--CA 1.493 1.46 0 CA-C-O 120.931 0.305 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.2 tp -70.14 -42.89 71.98 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.084 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.3 p -70.69 -39.19 75.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.65 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.471 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.0 t -66.77 -42.57 89.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.85 0.357 . . . . 0.0 110.971 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -34.54 18.85 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.683 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.61 82.54 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.739 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -59.31 -44.03 92.6 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.392 -179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -49.81 -34.68 9.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 120.95 0.405 . . . . 0.0 110.759 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.0 mt -69.8 -29.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.555 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.13 -50.27 52.6 Favored Glycine 0 C--N 1.306 -1.109 0 C-N-CA 121.105 -0.569 . . . . 0.0 112.363 -179.198 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 40.5 mt -61.04 -29.63 46.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 122.509 -0.407 . . . . 0.0 110.918 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.469 ' O ' HG22 ' A' ' 39' ' ' ILE . 46.3 tp -61.88 -44.43 96.83 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.361 -179.216 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -61.56 -28.83 69.62 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.501 -178.855 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 40.4 t80 -63.19 -50.63 69.54 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.253 0.464 . . . . 0.0 112.253 -178.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 42' ' ' THR . 5.8 tt -57.07 -38.83 62.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.23 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -30.62 64.77 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 120.936 0.398 . . . . 0.0 111.448 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -55.09 -36.49 65.7 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 -177.365 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.52 ' O ' ' ND1' ' A' ' 45' ' ' HIS . 0.1 OUTLIER -59.06 -34.01 71.45 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.995 -178.946 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 mp -60.68 -38.21 77.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.114 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.87 -25.81 1.75 Allowed Glycine 0 C--N 1.306 -1.111 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.397 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.52 ' ND1' ' O ' ' A' ' 42' ' ' THR . 39.1 m170 . . . . . 0 C--N 1.3 -1.55 0 C-N-CA 122.77 0.428 . . . . 0.0 111.173 179.365 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 CA-C-O 121.027 0.345 . . . . 0.0 111.549 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 tt -63.35 -49.62 73.18 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.69 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.08 -33.77 56.52 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.375 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.6 t -69.93 -44.5 78.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.516 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.86 -39.37 39.01 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.672 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.25 -33.47 74.67 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.846 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 6.8 t -57.8 -41.82 82.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.849 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mm -51.79 -34.33 16.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.727 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.88 -29.76 38.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.224 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.15 -48.74 62.54 Favored Glycine 0 C--N 1.305 -1.159 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 11.3 mm -61.54 -46.22 97.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.64 -179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.3 tp -52.39 -42.49 64.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.019 0.438 . . . . 0.0 109.933 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -49.92 -44.67 50.38 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.835 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -66.65 -41.6 87.98 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.555 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 93.3 mt -60.85 -45.16 98.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.899 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.416 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -67.81 -36.88 81.18 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.467 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.66 -34.85 19.57 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.534 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 25.0 p -52.43 -41.05 62.92 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.349 -179.37 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.66 -50.3 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.929 -0.308 . . . . 0.0 111.121 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.16 -29.72 15.88 Favored Glycine 0 C--N 1.305 -1.167 0 C-N-CA 121.187 -0.53 . . . . 0.0 111.964 -179.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -60.69 -28.1 68.37 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -46.81 -31.08 2.79 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.863 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -60.0 -48.96 79.54 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -63.14 -54.48 37.09 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -178.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 2.6 tt . . . . . 0 C--N 1.297 -1.684 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.07 -179.22 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.495 1.6 0 CA-C-O 120.715 0.215 . . . . 0.0 112.156 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 40.5 tp -64.21 -48.33 76.28 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.097 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 23.4 t -70.22 -40.21 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.222 -179.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.4 t -69.47 -44.18 80.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.806 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.535 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -51.25 -43.1 61.43 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.957 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.44 69.37 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.093 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 5.8 t -51.22 -43.42 61.43 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.493 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.535 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -49.5 -29.61 4.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.344 -179.105 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.5 mt -69.03 -30.55 47.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.912 -179.088 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.546 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.64 -49.71 58.38 Favored Glycine 0 C--N 1.303 -1.292 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.312 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -66.41 -29.34 46.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.841 -179.444 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 10.4 tp -62.02 -50.71 70.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.528 -0.306 . . . . 0.0 111.823 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -52.51 -29.24 24.11 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.665 -178.401 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.7 t80 -58.06 -44.5 87.5 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 120.578 0.228 . . . . 0.0 111.481 -179.488 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.0 mt -54.55 -48.99 69.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.587 -178.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.53 -30.49 67.25 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.994 0.426 . . . . 0.0 110.761 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' B' ' 40' ' ' ALA . 2.7 t-105 -49.28 -36.67 21.3 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.058 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 33.6 p -59.23 -36.94 76.34 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.088 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -63.16 -50.98 77.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.283 -179.483 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.55 -29.8 25.4 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.916 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -51.76 -29.73 19.92 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp . . . . . 0 C--N 1.306 -1.303 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.472 -177.543 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.12 42.52 0.64 Allowed 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.164 1.909 . . . . 0.0 111.745 179.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 51.7 tp -70.22 -47.92 59.32 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.649 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 10.5 t -70.87 -35.97 62.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.145 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -70.14 -46.29 72.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.659 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -29.8 7.71 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.005 -179.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.72 66.86 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.22 -40.38 81.52 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.22 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -55.22 -29.77 23.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.899 0.38 . . . . 0.0 110.836 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.23 -29.67 37.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.49 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.74 -44.43 80.87 Favored Glycine 0 C--N 1.307 -1.04 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.444 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.0 pt -67.03 -36.15 76.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.64 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -49.91 -36.68 28.37 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.457 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -59.17 -47.04 86.79 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.85 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -57.54 -46.14 84.24 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.9 pt -66.39 -43.14 91.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.436 -178.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -39.78 72.87 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.367 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 t-105 -49.39 -28.86 5.53 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 120.974 0.416 . . . . 0.0 110.673 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -62.0 -29.92 70.59 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.755 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 82.1 mt -70.21 -52.25 31.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-O 121.025 0.44 . . . . 0.0 111.053 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.09 -28.21 32.79 Favored Glycine 0 C--N 1.302 -1.321 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -68.22 -29.34 68.14 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.527 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.42 HD12 ' C ' ' D' ' 46' ' ' LEU . 2.4 pp . . . . . 0 C--N 1.309 -1.171 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.478 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo . . . . . 0 N--CA 1.493 1.477 0 CA-C-O 120.841 0.267 . . . . 0.0 112.003 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 57.7 tp -63.69 -45.73 88.72 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.83 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.2 p -70.37 -37.61 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.453 -179.439 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.418 ' N ' HG13 ' A' ' 27' ' ' VAL . 62.6 t -70.08 -35.99 66.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 CA-C-O 120.982 0.42 . . . . 0.0 110.784 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -38.16 31.66 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.62 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.57 -34.0 76.16 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.341 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.2 t -63.01 -50.34 71.11 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -178.608 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 11.2 pt -51.99 -29.49 11.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.636 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -67.25 -29.58 46.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -59.76 -46.24 94.38 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.4 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' D' ' 33' ' ' ILE . 10.0 mm -61.24 -35.75 68.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 CA-C-O 120.77 0.319 . . . . 0.0 111.145 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.65 -49.75 76.4 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.954 -178.549 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -57.72 -28.86 64.25 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.812 -178.768 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 71.2 t80 -59.63 -50.11 75.16 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.711 ' O ' HG22 ' A' ' 42' ' ' THR . 1.5 pp -59.22 -41.67 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.768 -178.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.92 -34.03 68.76 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.106 0.479 . . . . 0.0 111.002 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.474 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 10.1 t-105 -48.23 -35.3 11.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.517 -178.066 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.711 HG22 ' O ' ' A' ' 39' ' ' ILE . 14.9 t -56.86 -29.34 62.81 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.508 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 80.0 mt -55.28 -46.08 77.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.04 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.5 -28.63 2.42 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 120.762 -0.733 . . . . 0.0 111.534 -177.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 116.928 0.364 . . . . 0.0 110.79 179.299 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo . . . . . 0 N--CA 1.495 1.595 0 CA-C-O 121.071 0.363 . . . . 0.0 111.63 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 37.4 tp -69.35 -45.93 68.24 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.535 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 79.9 t -70.43 -41.1 78.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 57.3 t -68.65 -46.85 79.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.321 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.76 -38.37 33.72 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.663 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.89 -31.53 72.18 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.31 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 31.9 t -56.04 -42.11 76.05 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.991 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.6 mm -49.67 -29.86 4.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.649 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.9 mt -71.92 -29.82 34.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.51 -50.61 42.34 Favored Glycine 0 C--N 1.307 -1.076 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.324 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -64.53 -47.1 90.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.831 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -51.51 -41.26 60.87 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.059 0.457 . . . . 0.0 110.074 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -49.58 -39.79 36.38 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.813 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.46 -40.03 92.71 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.688 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.566 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.7 mp -57.48 -42.84 81.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.51 -179.26 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.98 -37.18 69.93 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.228 0.537 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.8 t-105 -54.91 -39.65 69.02 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.471 HG22 ' H ' ' B' ' 42' ' ' THR . 0.0 OUTLIER -57.69 -34.14 69.11 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.243 -178.903 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.586 ' O ' HD12 ' B' ' 46' ' ' LEU . 28.8 mm -62.14 -47.72 91.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.603 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.09 -28.67 8.2 Favored Glycine 0 C--N 1.306 -1.089 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -61.23 -27.05 68.17 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.978 HD13 ' H ' ' B' ' 47' ' ' ASN . 0.0 OUTLIER -47.71 -30.63 3.98 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.676 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.978 ' H ' HD13 ' B' ' 46' ' ' LEU . 29.4 p-10 -61.5 -50.5 72.47 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.372 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -59.27 -53.07 62.47 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 120.978 0.418 . . . . 0.0 112.112 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 2.5 tp . . . . . 0 C--N 1.295 -1.763 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.162 -179.192 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo . . . . . 0 N--CA 1.493 1.452 0 CA-C-O 120.995 0.331 . . . . 0.0 111.738 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 44.5 tp -70.13 -42.64 72.33 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.091 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 92.8 t -70.12 -44.22 78.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.192 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.09 -46.64 84.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.545 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.55 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -54.87 -44.37 73.99 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.941 -179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.54 -29.63 70.71 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 120.777 0.322 . . . . 0.0 110.925 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 7.1 t -50.56 -41.86 54.68 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.181 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.55 HG22 ' O ' ' C' ' 29' ' ' ALA . 16.2 tt -49.8 -29.06 4.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-O 120.851 0.357 . . . . 0.0 111.295 -179.376 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.9 mt -65.81 -33.45 63.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.144 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.57 -50.33 37.93 Favored Glycine 0 C--N 1.303 -1.256 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.202 -178.714 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.05 -29.48 44.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-O 120.868 0.366 . . . . 0.0 110.529 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -61.28 -50.62 72.26 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.782 -179.033 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -55.08 -28.65 54.06 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.742 -178.577 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 43.9 t80 -57.9 -44.38 86.72 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 121.031 -0.268 . . . . 0.0 111.456 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -56.34 -48.37 79.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.943 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.05 -34.28 73.02 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.855 0.359 . . . . 0.0 110.755 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 -48.4 -30.25 4.83 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.565 -179.287 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.7 p -56.38 -38.74 71.89 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.634 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.632 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.7 mp -64.05 -49.93 79.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.013 -179.557 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.82 -28.28 5.34 Favored Glycine 0 C--N 1.304 -1.198 0 C-N-CA 121.301 -0.476 . . . . 0.0 112.024 -178.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -49.07 -27.84 3.64 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 pp . . . . . 0 C--N 1.307 -1.253 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.399 -177.543 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 CA--C 1.532 0.273 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.69 33.6 0.37 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.189 1.926 . . . . 0.0 111.756 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' D' ' 24' ' ' ASP . 2.1 tt -63.9 -50.54 68.32 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.613 -179.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 t -70.49 -33.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.113 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 92.5 t -69.95 -45.1 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.692 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.58 -32.71 8.51 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.718 -178.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.31 -32.17 73.69 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 120.769 0.319 . . . . 0.0 110.912 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 43.0 t -60.4 -42.93 96.95 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.217 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 mm -58.05 -35.21 51.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 121.148 0.499 . . . . 0.0 110.346 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' A' ' 35' ' ' ILE . 8.8 mt -71.67 -29.98 36.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.303 179.243 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.36 91.73 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.589 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 12.8 pt -68.51 -38.13 78.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.782 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tp -49.69 -38.63 33.76 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 120.946 0.403 . . . . 0.0 110.455 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.533 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 16.4 m170 -57.53 -39.78 77.36 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.371 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -58.23 -46.55 85.72 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.24 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.6 pt -66.63 -42.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.125 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -41.96 77.18 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.723 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -48.74 -29.46 4.5 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.745 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.5 m -66.8 -29.85 69.89 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.515 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 30.0 mm -65.48 -50.8 70.22 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.988 -0.285 . . . . 0.0 111.181 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.48 -34.17 63.34 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.7 t-80 -55.98 -28.05 55.44 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 120.653 0.263 . . . . 0.0 111.522 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.438 HD23 ' O ' ' D' ' 43' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.303 -1.434 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.17 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo . . . . . 0 N--CA 1.493 1.47 0 CA-C-O 120.843 0.268 . . . . 0.0 112.04 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' N ' HD12 ' A' ' 26' ' ' LEU . 10.3 mp -69.5 -40.91 76.71 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.711 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.544 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.4 p -70.76 -44.15 76.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.475 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.544 ' N ' HG13 ' A' ' 27' ' ' VAL . 88.5 t -63.63 -41.75 93.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.737 -179.46 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -37.38 29.53 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.476 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.76 -36.8 84.24 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.471 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -53.81 -47.14 71.13 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.994 -0.283 . . . . 0.0 111.233 -179.258 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.692 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.56 -40.17 24.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.462 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.87 -29.5 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.1 -50.66 44.37 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.907 -179.373 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 57.3 mt -64.74 -29.71 48.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 122.652 -0.322 . . . . 0.0 111.047 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.474 ' O ' HG22 ' A' ' 39' ' ' ILE . 33.4 tp -61.47 -45.18 95.33 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.331 -179.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.632 ' CE1' ' NE2' ' D' ' 37' ' ' HIS . 0.6 OUTLIER -61.66 -28.79 69.64 Favored 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 120.151 -0.62 . . . . 0.0 111.497 -178.839 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.2 t80 -63.47 -50.82 68.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.772 ' O ' HG22 ' A' ' 42' ' ' THR . 5.4 tt -54.91 -39.67 49.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.135 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -35.3 69.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.922 0.392 . . . . 0.0 111.215 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.462 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 11.3 t-105 -49.78 -35.07 21.2 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.244 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 39' ' ' ILE . 9.8 t -65.4 -29.4 70.1 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -179.275 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 36.5 mm -60.87 -45.15 98.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.777 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.16 -27.03 2.44 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.037 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 . . . . . 0 C--N 1.304 -1.38 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.562 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.493 1.464 0 CA-C-O 121.055 0.356 . . . . 0.0 111.574 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.01 -48.74 67.49 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.552 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.59 -30.35 42.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.48 HG22 HD23 ' A' ' 26' ' ' LEU . 58.0 t -70.14 -46.7 71.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.392 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.11 -31.5 8.2 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.613 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.69 -29.64 70.22 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.538 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.6 t -54.44 -38.08 65.89 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.796 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 25.8 mm -55.6 -36.94 44.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-O 120.923 0.392 . . . . 0.0 110.456 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.24 -29.98 38.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.337 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.96 -48.41 54.47 Favored Glycine 0 C--N 1.306 -1.11 0 N-CA-C 111.659 -0.576 . . . . 0.0 111.659 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -63.93 -42.44 95.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.611 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -60.61 -44.26 96.51 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 24.2 t-80 -49.86 -44.36 49.68 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.696 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -70.12 -37.55 75.34 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.272 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' B' ' 42' ' ' THR . 91.8 mt -63.41 -42.64 97.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.856 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.412 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.66 -37.47 70.78 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.009 0.433 . . . . 0.0 111.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -49.55 -44.84 46.94 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.81 -27.83 5.55 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.655 -178.528 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 9.3 tp -56.17 -48.57 79.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.252 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.517 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -57.65 -29.73 61.58 Favored Glycine 0 C--N 1.304 -1.229 0 C-N-CA 121.32 -0.466 . . . . 0.0 111.963 -179.213 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -53.17 -29.53 32.11 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.653 ' C ' HD12 ' B' ' 46' ' ' LEU . 2.7 pp -50.58 -34.0 24.13 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.836 -0.346 . . . . 0.0 111.519 -178.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.573 ' N ' HD12 ' B' ' 46' ' ' LEU . 5.3 m120 -63.19 -50.38 70.55 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.096 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -67.41 -55.89 11.88 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.142 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 7.7 tp . . . . . 0 C--N 1.297 -1.714 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -178.599 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 N--CA 1.494 1.526 0 CA-C-O 120.861 0.275 . . . . 0.0 111.97 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.552 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -67.1 -42.71 84.13 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.637 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 27' ' ' VAL . . . . . 0.508 HG13 ' N ' ' C' ' 28' ' ' VAL . 12.9 p -70.28 -40.9 78.46 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.206 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 28' ' ' VAL . . . . . 0.508 ' N ' HG13 ' C' ' 27' ' ' VAL . 92.2 t -64.47 -46.63 92.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.746 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -55.96 -40.69 73.6 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.92 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.56 -29.65 70.67 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.746 0.308 . . . . 0.0 111.138 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 15.1 t -52.56 -44.27 65.76 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.617 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 12.3 tt -49.68 -29.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.269 -179.101 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.4 mt -69.02 -31.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.037 -179.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.15 -50.43 39.79 Favored Glycine 0 C--N 1.306 -1.085 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.016 -179.214 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 35' ' ' ILE . . . . . 0.439 HG22 ' H ' ' C' ' 35' ' ' ILE . 0.0 OUTLIER -66.72 -29.48 46.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.722 -179.76 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.4 tp -60.72 -48.77 80.31 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.687 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.79 -29.99 63.24 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.863 -178.367 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.2 t80 -62.18 -44.26 96.99 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.098 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -55.65 -45.61 79.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.723 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.15 -33.79 72.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.015 0.436 . . . . 0.0 110.779 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.29 -34.68 16.0 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.173 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 18.5 p -57.3 -45.05 84.53 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.376 -179.428 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.486 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.2 mp -66.45 -51.09 61.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.603 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.47 -29.52 17.42 Favored Glycine 0 C--N 1.303 -1.267 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -59.77 -28.96 67.85 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.116 0.414 . . . . 0.0 112.116 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.301 -1.527 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.446 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 . . . . . 0 CA--C 1.535 0.378 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.34 41.0 0.64 Allowed 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.1 1.867 . . . . 0.0 111.872 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.3 tp -63.85 -48.97 74.63 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.617 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 47.3 t -70.42 -34.21 57.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 57.6 t -70.05 -44.14 78.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.584 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -35.08 19.7 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.722 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.23 -29.63 70.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.2 t -55.54 -41.5 73.28 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.035 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.666 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -54.87 -35.62 34.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.491 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.76 -30.05 40.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.352 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.25 -46.02 88.88 Favored Glycine 0 C--N 1.306 -1.096 0 C-N-CA 121.249 -0.501 . . . . 0.0 112.07 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.1 pt -66.68 -29.79 47.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-O 120.815 0.341 . . . . 0.0 110.753 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tp -56.29 -42.39 77.46 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.708 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 15.3 m170 -56.62 -43.52 80.28 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.133 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -59.52 -47.09 86.88 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.4 pt -64.03 -43.8 97.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.491 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.12 -39.37 75.5 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.058 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -48.81 -29.4 4.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.859 0.361 . . . . 0.0 110.502 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 64.8 p -61.99 -31.51 71.88 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.769 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 33.7 mm -67.38 -51.33 53.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.76 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.99 -29.95 21.66 Favored Glycine 0 C--N 1.304 -1.245 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -59.02 -29.61 67.39 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 120.648 0.261 . . . . 0.0 111.274 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.595 HD12 ' C ' ' D' ' 46' ' ' LEU . 2.6 pp . . . . . 0 C--N 1.305 -1.357 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.395 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.1 m . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -172.0 61.04 0.3 Allowed Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.949 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -79.96 8.68 3.92 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.819 2.346 . . . . 0.0 111.973 179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.1 tp -63.52 -44.61 93.77 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.779 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.9 p -70.23 -37.76 72.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.436 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.427 ' N ' HG13 ' A' ' 27' ' ' VAL . 97.3 t -67.08 -42.12 87.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.947 0.403 . . . . 0.0 110.663 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -43.85 46.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.007 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.3 -35.08 71.31 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.407 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.0 t -60.64 -43.24 97.77 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.027 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.7 mt -53.42 -37.85 30.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.079 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.91 -29.84 41.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.104 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.573 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -61.93 -47.66 88.65 Favored Glycine 0 C--N 1.302 -1.31 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.053 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.47 -29.37 38.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 122.382 -0.481 . . . . 0.0 110.775 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.518 ' O ' HD23 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -61.24 -49.33 77.54 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.709 -178.978 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.606 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.2 p80 -56.7 -28.95 61.87 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.968 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.606 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.1 t80 -63.78 -50.36 69.31 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.517 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.5 tt -57.85 -38.51 66.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.814 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -38.85 74.15 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.472 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -48.65 -32.44 8.29 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 120.847 0.356 . . . . 0.0 110.155 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -53.24 -42.47 66.44 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.319 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.4 mp -60.95 -47.94 91.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.032 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.56 -29.34 5.56 Favored Glycine 0 C--N 1.303 -1.296 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.74 -27.92 5.49 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 122.779 -0.248 . . . . 0.0 111.377 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.8 pp -44.99 -41.96 7.82 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.511 -176.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.458 ' OD1' ' N ' ' A' ' 48' ' ' GLN . 27.8 p-10 -50.19 -45.46 53.58 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.458 ' N ' ' OD1' ' A' ' 47' ' ' ASN . 0.6 OUTLIER -73.34 -57.88 3.7 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.217 0.532 . . . . 0.0 111.255 -179.38 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.477 HD13 ' O ' ' A' ' 49' ' ' ILE . 0.4 OUTLIER -48.68 -14.52 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.079 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 33.5 ttpt -109.48 -59.46 1.9 Allowed 'General case' 0 C--N 1.32 -0.712 0 O-C-N 122.092 -0.38 . . . . 0.0 110.739 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -84.04 104.9 14.49 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.823 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.108 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 179.783 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 11.1 m . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' B' ' 26' ' ' LEU . 12.4 m-20 52.62 58.0 14.9 Favored Pre-proline 0 C--N 1.304 -1.376 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.481 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.45 24.89 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.644 2.229 . . . . 0.0 111.938 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' B' ' 24' ' ' ASP . 49.8 tp -68.0 -43.96 77.68 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.666 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.05 -35.81 65.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.086 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 89.4 t -67.33 -44.02 87.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.53 -37.63 27.64 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.656 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.36 -34.02 75.86 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.948 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -60.05 -42.74 95.11 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.741 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.7 mm -49.96 -31.78 7.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.555 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -69.61 -29.61 42.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.333 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.17 -50.6 44.41 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 121.026 -0.607 . . . . 0.0 111.889 -179.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.0 pt -62.71 -29.8 47.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.88 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -61.16 -46.93 88.51 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.576 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' C' ' 37' ' ' HIS . 7.8 m-70 -51.53 -50.54 59.82 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -54.2 -44.67 71.82 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.615 ' O ' HG22 ' B' ' 42' ' ' THR . 81.9 mt -59.02 -50.24 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.507 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.401 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -72.14 -36.85 69.48 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 121.086 0.47 . . . . 0.0 111.424 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.408 ' O ' ' CD1' ' B' ' 41' ' ' TRP . 9.8 t-105 -49.35 -34.6 16.31 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 113.294 0.849 . . . . 0.0 113.294 -177.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.615 HG22 ' O ' ' B' ' 39' ' ' ILE . 1.7 t -69.29 -29.31 67.14 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.048 -0.661 . . . . 0.0 110.709 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -61.99 -51.4 72.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.924 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.62 -29.83 19.01 Favored Glycine 0 C--N 1.306 -1.09 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -54.37 -27.47 36.61 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 120.88 0.371 . . . . 0.0 111.176 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -45.72 -29.83 1.4 Allowed 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.986 -176.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' B' ' 50' ' ' LYS . 29.3 m120 -58.29 -51.71 68.62 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.584 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -79.19 -58.91 2.99 Favored 'General case' 0 C--N 1.314 -0.959 0 O-C-N 121.871 -0.518 . . . . 0.0 111.741 -178.183 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 4.7 tt -49.62 -2.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -179.195 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.545 ' H ' ' C ' ' B' ' 48' ' ' GLN . 22.2 ttpp -176.38 147.9 0.72 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 62.4 ttm-85 -155.54 99.18 2.01 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 120.866 0.365 . . . . 0.0 110.64 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -173.23 58.97 0.23 Allowed Pre-proline 0 C--N 1.306 -1.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.716 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.82 8.2 3.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.837 2.358 . . . . 0.0 111.818 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 37.2 tp -65.81 -47.27 75.66 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -69.38 -40.88 80.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.918 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.4 t -67.39 -47.57 80.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.496 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.526 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -50.44 -42.98 54.85 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.105 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.858 0.361 . . . . 0.0 111.009 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 8.9 t -50.48 -43.88 55.62 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.4 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.526 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.3 tp -49.69 -29.35 4.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-O 120.804 0.335 . . . . 0.0 111.279 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.96 -31.69 48.81 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -178.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.544 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.39 -50.28 45.48 Favored Glycine 0 C--N 1.303 -1.266 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.564 -178.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.85 -29.51 43.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-O 120.987 0.422 . . . . 0.0 110.452 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.3 tp -62.04 -50.78 70.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.066 -0.515 . . . . 0.0 112.13 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' B' ' 37' ' ' HIS . 1.8 p80 -57.79 -28.96 64.49 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.642 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 87.4 t80 -56.99 -44.24 82.52 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.228 -179.308 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.401 ' O ' ' OG1' ' C' ' 42' ' ' THR . 68.1 mt -55.1 -42.68 66.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.152 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.28 -38.16 75.01 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 120.967 0.413 . . . . 0.0 110.722 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 41' ' ' TRP . . . . . 0.424 ' CZ3' ' ND1' ' B' ' 37' ' ' HIS . 5.7 t-105 -49.59 -32.85 13.64 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.199 -179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.2 p -65.58 -38.26 89.03 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.829 0.347 . . . . 0.0 110.961 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 29.5 mm -60.64 -50.43 80.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.021 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.21 -29.47 15.74 Favored Glycine 0 C--N 1.307 -1.066 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -50.19 -28.2 7.12 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -45.94 -32.61 2.8 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.934 -177.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 20.7 p-10 -60.85 -42.74 98.42 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.544 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -87.14 72.15 10.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.655 HG23 ' H ' ' C' ' 50' ' ' LYS . 1.7 tt 178.83 -79.4 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 O-C-N 122.346 -0.221 . . . . 0.0 110.467 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.655 ' H ' HG23 ' C' ' 49' ' ' ILE . 15.0 ptpt -60.2 134.64 57.25 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 31.3 ttm180 63.24 -4.91 0.25 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.919 0.39 . . . . 0.0 110.481 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 52' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.108 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 55.7 m . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.17 149.89 70.33 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.283 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.03 41.48 0.66 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.087 1.858 . . . . 0.0 111.938 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -65.54 -48.69 71.62 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.672 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.32 -34.44 58.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.203 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 96.2 t -69.83 -45.62 76.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.524 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.44 -34.87 17.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.032 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.71 -29.74 69.8 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.062 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.4 t -55.04 -42.1 72.25 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.034 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -53.93 -31.84 21.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.73 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -70.98 -29.71 38.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.079 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.93 -45.0 90.7 Favored Glycine 0 C--N 1.306 -1.103 0 C-N-CA 121.26 -0.495 . . . . 0.0 112.392 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 16.5 pt -65.8 -38.42 82.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.038 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 47.5 tp -49.52 -40.34 37.43 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.551 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.422 ' ND1' ' N ' ' D' ' 37' ' ' HIS . 2.1 m-70 -59.82 -39.16 84.12 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.687 -0.405 . . . . 0.0 111.739 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 79.7 t80 -61.24 -48.57 80.84 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -178.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.3 pp -66.02 -39.07 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.534 -178.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.45 -41.31 72.97 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.803 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.02 -29.54 5.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.429 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 53.1 p -65.29 -30.3 71.15 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -70.15 -51.48 38.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.397 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' D' ' 47' ' ' ASN . . . -55.83 -29.99 55.92 Favored Glycine 0 C--N 1.305 -1.158 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.481 ' O ' HG22 ' D' ' 49' ' ' ILE . 27.0 t-80 -56.3 -28.32 58.4 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 122.866 -0.196 . . . . 0.0 111.515 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.43 HD12 ' C ' ' D' ' 46' ' ' LEU . 0.9 OUTLIER -48.4 -36.62 15.09 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.979 -178.523 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' D' ' 48' ' ' GLN . 6.6 p30 -67.23 -44.18 80.1 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.93 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.538 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 37.8 mt-30 -63.87 -55.18 24.72 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-O 121.109 0.48 . . . . 0.0 111.635 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.878 HG23 ' H ' ' D' ' 50' ' ' LYS . 4.8 tp -59.07 -68.63 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.11 -179.334 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.878 ' H ' HG23 ' D' ' 49' ' ' ILE . 9.2 ptmm? -166.73 122.01 1.14 Allowed 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.007 0.432 . . . . 0.0 110.473 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -80.35 4.9 16.41 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.683 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.897 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.6 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -162.35 58.84 0.87 Allowed Pre-proline 0 C--N 1.308 -1.222 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -77.73 -3.15 13.28 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.785 2.323 . . . . 0.0 112.085 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 12.4 tp -62.15 -48.88 78.15 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.186 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.0 p -70.33 -32.39 50.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.532 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.4 t -70.29 -43.33 78.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 120.78 0.324 . . . . 0.0 110.929 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.46 -40.06 58.7 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.158 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -31.23 69.74 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.362 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -62.38 -37.8 87.12 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.008 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -57.37 -35.04 47.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.075 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.7 mt -67.99 -32.42 56.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.539 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.498 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.48 -44.72 82.69 Favored Glycine 0 C--N 1.302 -1.329 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.425 -178.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 70.4 mt -70.14 -29.74 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.888 0.375 . . . . 0.0 111.202 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.438 ' O ' HG22 ' A' ' 39' ' ' ILE . 54.5 tp -62.72 -47.66 82.62 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.704 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -58.27 -28.69 65.18 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.468 -179.054 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.9 t80 -54.13 -44.06 71.03 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 36' ' ' LEU . 8.9 tp -58.02 -43.12 84.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.378 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.426 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.5 -35.12 73.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.984 0.421 . . . . 0.0 110.976 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.484 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 3.2 t-105 -49.21 -37.85 24.23 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.151 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.37 -29.53 68.99 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.287 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mm -60.42 -48.86 86.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.104 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.87 -32.28 11.28 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 121.294 -0.479 . . . . 0.0 112.015 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.7 t60 -49.39 -28.37 5.02 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.865 0.333 . . . . 0.0 111.369 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.581 HD12 ' N ' ' A' ' 47' ' ' ASN . 3.0 pp -46.03 -40.84 11.17 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -177.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.584 ' ND2' HD21 ' D' ' 46' ' ' LEU . 0.3 OUTLIER -56.09 -43.71 78.29 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 120.399 -0.52 . . . . 0.0 111.493 -179.513 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -64.78 -59.12 4.59 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 120.896 0.379 . . . . 0.0 111.098 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.51 ' CG1' ' N ' ' A' ' 50' ' ' LYS . 1.1 pt -58.14 -51.73 67.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.51 ' N ' ' CG1' ' A' ' 49' ' ' ILE . 54.2 tttp -49.13 -74.95 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 120.721 0.296 . . . . 0.0 110.768 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -72.42 139.69 47.92 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.654 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.223 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.809 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 23' ' ' SER . . . . . 0.465 ' OG ' ' N ' ' B' ' 24' ' ' ASP . 46.5 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' B' ' 26' ' ' LEU . 3.8 m-20 41.08 71.43 1.29 Allowed Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.528 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -66.69 30.07 0.11 Allowed 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.779 2.319 . . . . 0.0 111.647 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.539 ' H ' ' C ' ' B' ' 24' ' ' ASP . 22.7 tp -70.7 -42.98 69.94 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -70.35 -44.85 77.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.519 -179.077 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 39.8 t -68.82 -43.83 82.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.74 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.483 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -49.89 -40.9 44.44 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.151 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -54.6 -28.57 47.36 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -48.77 -40.39 28.68 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.483 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.0 tp -49.2 -36.64 9.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.447 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.401 ' N ' HG23 ' B' ' 32' ' ' ILE . 8.3 mt -70.18 -29.54 40.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.532 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.54 -51.02 55.86 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.022 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 29.7 pt -65.46 -37.99 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.132 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.508 ' O ' HD23 ' B' ' 36' ' ' LEU . 1.7 tt -59.68 -48.68 80.73 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 121.307 0.575 . . . . 0.0 109.547 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -48.98 -46.72 44.12 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.249 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -68.64 -39.17 80.83 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.946 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 80.1 mt -61.42 -46.33 96.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.04 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.12 -40.89 95.13 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.843 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 -48.42 -33.1 8.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.407 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -52.26 -49.51 63.92 Favored 'General case' 0 C--N 1.3 -1.575 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.266 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.16 -51.45 71.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 C-N-CA 121.004 -0.279 . . . . 0.0 111.416 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.12 -29.4 36.12 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 3.9 t-160 -60.72 -30.0 69.7 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 120.89 0.376 . . . . 0.0 110.996 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.525 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.6 OUTLIER -48.67 -33.22 9.62 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.58 -178.49 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.467 ' OD1' ' ND2' ' C' ' 47' ' ' ASN . 73.3 m-20 -64.37 -49.62 70.93 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -178.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.4 OUTLIER -59.79 -51.59 69.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-O 120.828 0.347 . . . . 0.0 111.928 -178.552 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.734 HG23 ' H ' ' B' ' 50' ' ' LYS . 5.6 tt -56.09 -67.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.529 -179.705 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.734 ' H ' HG23 ' B' ' 49' ' ' ILE . 20.0 pttp -136.75 172.21 13.36 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 120.874 0.368 . . . . 0.0 110.426 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 60.7 ttm-85 -152.22 147.73 26.74 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.367 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.22 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.927 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.9 m . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -172.6 60.23 0.27 Allowed Pre-proline 0 C--N 1.306 -1.285 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.689 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -77.52 15.46 1.23 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.836 2.357 . . . . 0.0 112.039 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.509 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -70.11 -40.59 74.8 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.835 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.16 -45.59 75.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.384 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.8 t -66.66 -45.41 88.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.902 0.382 . . . . 0.0 110.758 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -58.09 -44.24 87.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.57 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.84 -29.43 70.62 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.315 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 22.7 t -53.54 -41.3 66.29 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.328 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.3 tt -49.91 -29.15 4.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-O 120.94 0.4 . . . . 0.0 111.175 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 16.1 mt -64.55 -37.43 80.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.12 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.55 -47.8 83.69 Favored Glycine 0 C--N 1.302 -1.321 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.408 -178.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -69.58 -30.02 43.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.72 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -62.2 -50.62 71.08 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -178.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -52.92 -29.17 27.07 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.642 -178.523 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.636 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.7 t80 -61.16 -42.28 98.27 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.572 -0.285 . . . . 0.0 111.522 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 76.9 mt -58.25 -49.72 80.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.824 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.59 -34.65 74.44 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.036 0.446 . . . . 0.0 110.649 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.1 -32.71 10.31 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.233 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -60.51 -36.08 77.51 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.258 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.39 -50.41 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.469 -179.201 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.89 -30.05 35.89 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 121.206 -0.521 . . . . 0.0 111.979 -179.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -50.87 -29.55 12.19 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 120.661 0.267 . . . . 0.0 111.627 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -47.46 -34.95 7.9 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.739 -177.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.559 ' C ' HD21 ' C' ' 47' ' ' ASN . 0.2 OUTLIER -50.24 -50.17 50.75 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.552 -179.647 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 13.7 tp60 -56.47 -47.38 79.32 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.459 HG23 ' O ' ' C' ' 49' ' ' ILE . 9.5 tt -102.2 96.21 4.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.432 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -158.5 -74.9 0.08 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.349 179.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -62.02 -41.81 98.48 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.028 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.103 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 179.863 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.1 p . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -70.51 138.79 86.29 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.363 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.33 55.97 3.73 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.015 1.81 . . . . 0.0 112.002 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.58 -45.51 68.49 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.597 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 t -70.48 -38.21 72.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.425 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 85.1 t -68.57 -43.22 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.848 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -31.9 12.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.021 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.09 69.5 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.959 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.2 t -54.22 -42.15 69.48 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.025 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 mm -50.7 -34.47 12.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.68 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -71.43 -29.27 34.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.358 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.59 -50.99 51.52 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.645 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 35' ' ' ILE . . . . . 0.833 HD12 ' N ' ' D' ' 36' ' ' LEU . 2.8 pp -62.87 -28.97 46.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.07 0.435 . . . . 0.0 110.628 -179.442 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 36' ' ' LEU . . . . . 0.833 ' N ' HD12 ' D' ' 35' ' ' ILE . 4.5 tp -60.88 -41.61 96.32 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.305 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 25.2 m170 -56.07 -41.3 74.89 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.613 -179.276 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -61.43 -47.86 83.81 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -178.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 12.3 pt -63.46 -43.73 98.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.163 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.484 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -63.33 -42.87 98.99 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.967 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -49.67 -33.83 16.8 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.521 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 54.5 p -59.21 -42.18 90.34 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.785 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.542 ' O ' HD12 ' D' ' 46' ' ' LEU . 4.7 mp -71.56 -53.1 21.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.4 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.39 -29.07 10.26 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -58.72 -28.18 65.59 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.964 HD13 ' H ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -48.26 -32.31 7.08 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 112.654 0.613 . . . . 0.0 112.654 -177.543 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.964 ' H ' HD13 ' D' ' 46' ' ' LEU . 4.7 t-20 -62.32 -50.79 70.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 48' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -59.53 -50.35 74.23 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.534 ' O ' HG23 ' D' ' 49' ' ' ILE . 12.6 tt -70.78 89.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 CA-C-O 121.588 0.708 . . . . 0.0 110.408 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 26.4 ttmt 45.62 -139.3 0.46 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.474 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 ptt-85 -174.11 -15.92 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 120.846 0.355 . . . . 0.0 110.6 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.916 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.0 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -168.9 62.16 0.48 Allowed Pre-proline 0 C--N 1.306 -1.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.5 7.16 4.65 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.817 2.345 . . . . 0.0 112.069 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.3 tp -66.84 -46.49 74.95 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.686 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.5 p -70.47 -38.46 73.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.373 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.457 ' N ' HG13 ' A' ' 27' ' ' VAL . 89.0 t -70.03 -43.28 79.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.948 0.404 . . . . 0.0 110.674 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -36.47 25.73 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.096 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.43 -29.25 69.92 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -56.39 -43.83 79.65 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.4 pt -50.59 -29.51 6.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-O 120.746 0.308 . . . . 0.0 111.204 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -67.94 -29.95 46.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.592 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.99 -49.85 51.05 Favored Glycine 0 C--N 1.303 -1.275 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.181 -179.205 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.778 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.4 -29.53 46.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-O 120.696 0.284 . . . . 0.0 111.063 -179.364 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 34.0 tp -62.02 -49.25 76.78 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.634 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.3 p80 -57.91 -29.21 64.92 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.937 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.634 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.1 t80 -59.31 -44.29 92.58 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.742 -0.383 . . . . 0.0 111.031 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 77.9 mt -57.34 -48.89 81.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.89 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.6 -35.49 77.41 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 120.911 0.386 . . . . 0.0 110.747 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.67 -33.31 9.77 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.788 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 54.1 p -62.42 -33.2 74.31 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.003 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.535 ' O ' HD23 ' A' ' 46' ' ' LEU . 16.1 mm -70.12 -46.65 71.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.886 -0.325 . . . . 0.0 110.583 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.23 -24.28 0.56 Allowed Glycine 0 C--N 1.301 -1.379 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.423 ' N ' ' O ' ' A' ' 43' ' ' ILE . 5.7 t-80 -46.3 -26.54 0.83 Allowed 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.535 HD23 ' O ' ' A' ' 43' ' ' ILE . 4.2 mm? -44.15 -49.8 8.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 118.73 0.695 . . . . 0.0 110.602 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -50.21 -33.86 20.86 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.173 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.69 -58.57 3.22 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.868 0.366 . . . . 0.0 111.734 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.451 HD11 HD13 ' A' ' 46' ' ' LEU . 1.7 pt -58.42 -26.37 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.0 tttp -87.37 -69.56 0.68 Allowed 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.869 0.366 . . . . 0.0 110.232 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -85.27 147.25 26.65 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.448 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.215 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.982 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' B' ' 26' ' ' LEU . 1.4 m-20 -88.05 150.98 48.69 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.115 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -71.92 37.43 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 122.281 1.987 . . . . 0.0 111.676 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.429 ' H ' ' C ' ' B' ' 24' ' ' ASP . 40.1 tp -69.55 -47.46 63.62 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.861 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -70.43 -35.14 60.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.03 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 45.5 t -70.15 -47.09 69.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.358 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -37.85 30.87 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.162 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.08 -31.61 69.04 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.667 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 5.7 t -57.09 -36.02 70.11 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.57 -35.11 37.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.5 mt -71.29 -29.69 36.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.471 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.68 -44.7 88.97 Favored Glycine 0 C--N 1.307 -1.058 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.017 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -64.46 -43.42 96.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.825 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.2 tp -57.45 -42.7 83.03 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.21 -47.64 46.05 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.101 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -70.06 -37.25 75.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.421 ' O ' ' OG1' ' B' ' 42' ' ' THR . 96.1 mt -63.39 -43.59 98.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.587 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.63 -37.82 80.02 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 120.927 0.394 . . . . 0.0 110.681 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.63 -31.15 10.18 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.283 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 41.0 p -50.96 -36.06 36.87 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.158 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.5 mp -64.48 -50.29 76.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.66 -0.246 . . . . 0.0 111.078 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.3 -29.3 10.05 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.735 -0.546 . . . . 0.0 111.735 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.582 ' O ' HG22 ' B' ' 49' ' ' ILE . 7.7 t-160 -53.56 -27.01 23.87 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' B' ' 50' ' ' LYS . 2.1 pp -48.92 -37.54 20.16 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.287 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -64.36 -51.15 64.75 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.586 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -68.45 -53.99 19.91 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -178.246 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.932 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -50.04 -71.93 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 C-N-CA 120.684 -0.407 . . . . 0.0 111.391 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.932 ' H ' HG23 ' B' ' 49' ' ' ILE . 81.2 tttt -139.73 154.69 47.5 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 120.899 0.381 . . . . 0.0 110.905 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 8.6 tpp85 -152.22 83.11 1.26 Allowed 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.292 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.201 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' C' ' 26' ' ' LEU . 23.1 t70 -172.23 57.27 0.23 Allowed Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.933 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.59 20.24 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.576 2.184 . . . . 0.0 111.765 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.503 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -63.95 -47.16 81.54 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.368 -179.718 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -69.67 -43.14 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.148 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -64.36 -43.32 97.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.575 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.579 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -62.13 -44.63 96.21 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.011 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.38 -29.49 70.56 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.789 0.328 . . . . 0.0 111.349 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -55.82 -43.02 76.54 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.432 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.579 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.4 tp -49.71 -28.9 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 120.804 0.335 . . . . 0.0 111.341 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.0 -31.03 46.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.104 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.99 -50.28 41.78 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.271 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 5.8 tp -68.41 -29.48 44.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.849 0.357 . . . . 0.0 110.482 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.16 -48.77 80.32 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.777 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -58.78 -29.24 66.65 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.561 -0.456 . . . . 0.0 111.886 -178.538 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 66.7 t80 -60.33 -45.49 93.27 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.939 -0.305 . . . . 0.0 111.361 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.414 ' O ' ' OG1' ' C' ' 42' ' ' THR . 73.7 mt -54.98 -46.4 76.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.562 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -34.56 72.77 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.411 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -48.55 -29.69 4.49 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.879 -178.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.5 p -63.06 -33.21 74.95 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.743 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.615 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.5 mp -65.28 -47.84 85.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.859 0.361 . . . . 0.0 110.598 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.78 -29.12 5.83 Favored Glycine 0 C--N 1.3 -1.466 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.504 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -53.41 -29.33 34.46 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.874 0.337 . . . . 0.0 111.732 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.601 HD13 ' O ' ' C' ' 43' ' ' ILE . 7.5 mp -46.33 -45.39 17.51 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 120.415 0.15 . . . . 0.0 111.05 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 71.6 m-20 -52.02 -50.25 61.78 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 120.511 -0.476 . . . . 0.0 111.615 -179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 43.7 tt0 -96.84 59.26 1.69 Allowed 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -178.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.704 HG23 ' O ' ' C' ' 49' ' ' ILE . 0.1 OUTLIER -171.71 91.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 CA-C-O 121.889 0.852 . . . . 0.0 110.079 178.355 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.6 pttt -179.92 -43.65 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.671 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 82.6 mtt85 -70.08 173.46 6.53 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.861 0.362 . . . . 0.0 110.751 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.177 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.825 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -75.64 151.19 84.78 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.204 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -72.33 40.18 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.221 1.947 . . . . 0.0 111.968 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.74 -43.59 68.54 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.68 -40.67 77.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.061 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 28' ' ' VAL . . . . . 0.469 HG13 ' N ' ' D' ' 29' ' ' ALA . 14.3 p -70.46 -42.25 78.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.599 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.489 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -56.51 -40.02 74.32 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.791 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.86 -29.37 70.14 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.649 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -49.32 -36.41 21.03 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.489 HG22 ' O ' ' D' ' 29' ' ' ALA . 3.7 tp -53.75 -33.84 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 121.059 0.457 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.6 mt -71.16 -29.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.429 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.51 -43.92 91.27 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 121.358 -0.449 . . . . 0.0 112.503 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 28.3 pt -68.39 -32.68 56.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.653 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -53.24 -41.44 65.42 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 18.7 m170 -54.48 -42.92 71.27 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.704 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -56.96 -47.19 81.3 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -178.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.7 pt -65.01 -46.04 92.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.932 -0.707 . . . . 0.0 111.503 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.43 -37.92 77.62 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.63 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.472 ' O ' ' CD1' ' D' ' 41' ' ' TRP . 13.1 t-105 -49.07 -28.46 4.15 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.35 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 4.0 m -59.61 -30.95 69.05 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 96.1 mt -62.46 -50.55 79.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.487 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.22 -29.48 9.77 Favored Glycine 0 C--N 1.303 -1.281 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -62.89 -29.13 70.53 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.76 0.281 . . . . 0.0 111.76 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -47.99 -34.27 9.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -177.426 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -58.87 -52.29 66.36 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.166 -178.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -92.04 66.93 5.04 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 122.237 -0.289 . . . . 0.0 111.647 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.442 ' O ' ' N ' ' D' ' 51' ' ' ARG . 1.6 tp -175.66 103.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 121.187 0.517 . . . . 0.0 110.409 179.051 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' D' ' 51' ' ' ARG . 19.1 tptp 61.88 -76.38 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.258 179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' D' ' 49' ' ' ILE . 17.3 ptt180 38.45 -162.32 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.325 -179.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.893 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.458 ' C ' ' H ' ' A' ' 26' ' ' LEU . 5.8 p-10 -173.39 56.53 0.2 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.23 18.55 0.32 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.813 2.342 . . . . 0.0 111.573 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 24' ' ' ASP . 50.8 tp -70.16 -44.53 68.62 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.754 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.7 -36.27 64.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.122 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.07 -44.7 78.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.976 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.49 -31.05 9.25 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.582 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.5 -30.11 66.8 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 35' ' ' ILE . 41.2 t -60.7 -44.45 96.54 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.592 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.682 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -52.12 -29.79 12.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.804 0.335 . . . . 0.0 110.353 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.4 mt -70.6 -29.62 39.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.211 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.501 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -64.04 -45.93 92.62 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.555 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -69.9 -29.56 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.053 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 39' ' ' ILE . 8.0 tt -61.84 -42.48 99.09 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.54 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -68.03 -28.59 67.53 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 120.239 -0.584 . . . . 0.0 111.456 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 76.7 t80 -66.49 -47.86 71.66 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.434 HG22 ' O ' ' A' ' 36' ' ' LEU . 7.2 tt -57.61 -35.9 52.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.24 -0.584 . . . . 0.0 110.442 -179.149 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.64 -36.11 73.25 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.659 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -52.95 -35.5 58.77 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.809 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.0 p -59.49 -37.12 77.43 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.669 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.604 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -69.25 -50.9 48.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.673 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.68 -28.32 6.87 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 111.991 -0.444 . . . . 0.0 111.991 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.446 ' O ' ' OE1' ' A' ' 48' ' ' GLN . 41.2 t60 -49.54 -27.31 4.26 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -179.382 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.422 HD23 ' O ' ' A' ' 43' ' ' ILE . 1.2 pt? -47.99 -33.93 8.57 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -176.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.412 ' N ' ' HG ' ' A' ' 46' ' ' LEU . 7.8 t-20 -48.56 -52.87 20.63 Favored 'General case' 0 C--N 1.311 -1.084 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.403 -178.116 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.604 ' C ' ' H ' ' A' ' 50' ' ' LYS . 4.6 mp0 -67.52 -140.8 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 178.355 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.479 HG23 ' C ' ' A' ' 48' ' ' GLN . 0.1 OUTLIER 54.14 -8.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 179.878 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.604 ' H ' ' C ' ' A' ' 48' ' ' GLN . 61.4 pttt -171.89 -163.94 0.28 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 118.217 0.462 . . . . 0.0 110.648 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.655 HH21 ' NH2' ' C' ' 51' ' ' ARG . 25.4 tpt85 47.79 96.56 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.256 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.879 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 23' ' ' SER . . . . . 0.433 ' O ' ' CB ' ' B' ' 24' ' ' ASP . 34.1 t . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.512 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.9 m-20 81.1 52.04 0.08 OUTLIER Pre-proline 0 C--N 1.31 -1.145 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.06 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.472 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 17.9 Cg_endo -58.26 68.79 0.05 OUTLIER 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.85 2.367 . . . . 0.0 112.113 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' B' ' 24' ' ' ASP . 51.6 tp -70.85 -48.84 51.72 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.793 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 93.9 t -70.19 -39.43 76.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.095 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 53.1 t -70.17 -45.45 75.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.959 179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -49.07 -30.39 6.3 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.438 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.05 -29.54 69.79 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.057 0.456 . . . . 0.0 110.313 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -54.26 -37.23 64.46 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.649 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 70.4 mt -55.28 -33.9 32.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.1 mt -70.9 -31.5 45.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.223 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.71 -45.42 92.84 Favored Glycine 0 C--N 1.306 -1.127 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.045 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -65.59 -41.95 91.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.205 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -59.42 -46.39 88.86 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -49.87 -42.88 48.7 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.856 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -68.15 -39.07 82.75 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.364 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.71 -40.97 86.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.919 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.06 -40.85 74.81 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.023 0.44 . . . . 0.0 110.402 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.52 -31.09 9.5 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.858 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 62.7 p -60.77 -35.68 77.05 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.41 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.2 mm -67.38 -51.16 55.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.837 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.8 -39.38 31.88 Favored Glycine 0 C--N 1.305 -1.144 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.575 ' O ' HG22 ' B' ' 49' ' ' ILE . 40.2 t60 -49.05 -26.55 2.7 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 120.741 0.305 . . . . 0.0 111.563 -179.648 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.413 HD22 ' OE1' ' C' ' 48' ' ' GLN . 1.0 OUTLIER -48.1 -32.55 6.98 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.778 -178.485 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' B' ' 44' ' ' GLY . 11.1 p30 -70.37 -50.32 40.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -177.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.522 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 4.1 pt20 -69.54 -52.43 26.33 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -177.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.906 HG23 ' H ' ' B' ' 50' ' ' LYS . 10.6 tt -45.47 -71.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 C-N-CA 120.661 -0.416 . . . . 0.0 110.638 -179.377 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.906 ' H ' HG23 ' B' ' 49' ' ' ILE . 18.0 pttp -148.7 149.27 31.15 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 120.803 0.335 . . . . 0.0 110.316 179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.477 ' CZ ' ' O ' ' C' ' 51' ' ' ARG . 0.0 OUTLIER -163.55 106.26 0.98 Allowed 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.996 -179.951 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.907 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.1 t . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -133.41 65.79 73.02 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.349 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -78.9 46.21 2.12 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.834 2.356 . . . . 0.0 111.919 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 45.8 tp -66.46 -47.72 72.23 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.471 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.5 t -69.98 -32.17 50.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.991 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.94 -49.5 56.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.588 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.25 -35.32 17.29 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.293 -179.007 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.22 -29.79 71.06 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 120.915 0.388 . . . . 0.0 110.904 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 34.7 t -50.0 -38.91 39.43 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.157 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.1 tp -53.69 -29.47 17.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.187 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.24 -36.93 69.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.014 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' NE2' ' C' ' 37' ' ' HIS . . . -63.72 -49.4 68.98 Favored Glycine 0 C--N 1.305 -1.156 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.687 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 tp -70.05 -29.86 41.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 CA-C-O 121.032 0.444 . . . . 0.0 110.105 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 27.2 tp -59.81 -49.41 77.83 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.64 -179.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.3 p80 -59.62 -29.03 67.72 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.68 -178.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 65.0 t80 -61.16 -43.36 99.0 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.031 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 66.2 mt -58.8 -45.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.087 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -38.96 75.55 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.585 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.6 -29.89 7.86 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.807 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 64.6 p -60.9 -37.7 83.16 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.748 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.5 mm -63.05 -50.54 79.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.31 -179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.434 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -50.12 -31.3 18.58 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 111.899 -0.48 . . . . 0.0 111.899 -179.061 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -49.86 -28.09 6.03 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.438 ' O ' ' O ' ' C' ' 49' ' ' ILE . 2.0 pp -48.58 -38.88 21.84 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.696 -0.401 . . . . 0.0 111.451 -178.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.453 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 9.7 p30 -51.94 -49.26 63.51 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.594 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.453 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 4.1 tp-100 -46.92 -38.57 10.75 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.042 0.449 . . . . 0.0 110.956 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.519 ' O ' ' CB ' ' C' ' 50' ' ' LYS . 12.8 tt -112.52 112.49 40.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.727 -179.253 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.55 ' O ' ' N ' ' C' ' 52' ' ' GLY . 0.8 OUTLIER 94.32 119.34 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.497 -1.228 . . . . 0.0 110.713 179.591 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 51' ' ' ARG . . . . . 0.655 ' NH2' HH21 ' A' ' 51' ' ' ARG . 62.4 ttt180 38.78 -86.89 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.553 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 52' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.307 -1.053 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 36.0 m . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' D' ' 26' ' ' LEU . 10.5 m-20 -161.82 151.06 13.32 Favored Pre-proline 0 C--N 1.306 -1.297 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.144 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.56 21.02 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.244 1.963 . . . . 0.0 111.752 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.462 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.9 tp -67.95 -47.15 69.44 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.532 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.97 -37.8 73.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 84.5 t -69.93 -43.57 79.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.525 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.39 -32.16 11.01 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.651 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.81 -29.68 69.68 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.964 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.0 t -56.27 -42.17 77.03 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.053 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.678 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -55.32 -35.63 37.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.448 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -71.06 -32.58 48.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.412 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.74 -44.29 98.1 Favored Glycine 0 C--N 1.305 -1.141 0 C-N-CA 121.336 -0.459 . . . . 0.0 112.123 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.6 pt -68.44 -29.35 43.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.841 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.6 tp -57.35 -43.04 83.13 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.037 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 4.1 m170 -60.76 -35.02 75.35 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.123 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 t80 -62.34 -48.53 79.41 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.6 -42.19 93.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.989 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.21 -40.27 74.64 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.86 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -48.46 -29.81 4.49 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.605 -179.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 73.3 p -64.86 -30.87 71.89 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.621 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.5 mp -69.87 -51.74 37.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.26 -31.73 27.79 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.55 ' O ' HG22 ' D' ' 49' ' ' ILE . 16.8 t60 -60.4 -28.28 68.12 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.549 0.214 . . . . 0.0 111.276 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -46.61 -31.23 2.71 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.487 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -61.03 -50.7 72.26 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.095 0.406 . . . . 0.0 112.095 -178.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.534 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -74.04 -68.39 0.52 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.187 0.517 . . . . 0.0 111.427 -178.718 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.713 ' O ' HG23 ' D' ' 49' ' ' ILE . 20.6 tt -54.24 88.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.643 -179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' D' ' 48' ' ' GLN . 7.1 tppt? 58.12 116.72 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.734 179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.03 129.38 34.45 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.32 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.772 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -170.34 58.73 0.3 Allowed Pre-proline 0 C--N 1.306 -1.307 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.951 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -78.22 25.51 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.818 2.345 . . . . 0.0 111.594 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -70.39 -43.83 69.25 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.043 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.6 p -70.89 -42.62 77.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.487 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.507 ' N ' HG13 ' A' ' 27' ' ' VAL . 66.1 t -68.41 -43.64 83.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.815 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.81 -34.45 53.74 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -30.54 67.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.5 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -60.36 -44.83 95.22 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.621 -179.051 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.2 mp -50.29 -29.08 5.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-O 120.825 0.345 . . . . 0.0 110.71 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.95 -29.32 39.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.809 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.54 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -68.61 -50.18 38.7 Favored Glycine 0 C--N 1.305 -1.172 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.324 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.569 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -65.98 -29.56 47.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.999 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.22 -46.02 88.96 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.705 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.7 OUTLIER -57.7 -28.35 63.74 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.625 -178.787 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 30.9 t80 -55.5 -45.76 77.02 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 3.4 tp -57.36 -44.56 84.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.299 -178.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.453 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.9 -35.4 72.28 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 120.824 0.345 . . . . 0.0 110.827 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.3 t-105 -48.95 -32.02 8.36 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.353 -178.724 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 61.2 p -57.56 -30.23 65.07 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.198 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 67.1 mt -64.2 -46.29 93.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.086 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.89 -27.56 3.4 Favored Glycine 0 C--N 1.297 -1.608 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.592 -178.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.596 ' NE2' ' NE2' ' A' ' 48' ' ' GLN . 13.4 t-80 -49.76 -32.91 14.8 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.427 HD22 ' OE1' ' B' ' 48' ' ' GLN . 6.4 mp -46.02 -40.15 10.14 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.938 -0.476 . . . . 0.0 111.633 -177.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -47.47 -52.68 16.41 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.455 -177.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.596 ' NE2' ' NE2' ' A' ' 45' ' ' HIS . 6.8 pt20 -72.41 -130.11 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.477 ' CG1' ' O ' ' A' ' 48' ' ' GLN . 3.8 pt 56.93 -13.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -179.129 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.569 ' H ' ' C ' ' A' ' 48' ' ' GLN . 42.6 pttt -170.12 19.94 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.012 0.434 . . . . 0.0 110.05 179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.493 HH21 ' CB ' ' D' ' 51' ' ' ARG . 64.9 ttt180 -150.22 80.36 1.36 Allowed 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.236 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.151 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.864 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 73.39 73.18 0.23 Allowed Pre-proline 0 C--N 1.307 -1.271 0 CA-C-O 121.059 0.457 . . . . 0.0 110.389 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.434 ' O ' ' HB2' ' B' ' 29' ' ' ALA . 46.8 Cg_exo -53.35 89.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.641 0 C-N-CA 122.72 2.28 . . . . 0.0 111.91 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 tp -70.66 -49.15 50.36 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.417 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.444 HG13 ' N ' ' B' ' 28' ' ' VAL . 11.6 p -70.3 -38.95 76.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.573 -179.134 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.444 ' N ' HG13 ' B' ' 27' ' ' VAL . 8.2 t -70.56 -45.24 75.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 120.602 -0.439 . . . . 0.0 109.891 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.434 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -48.63 -33.41 9.86 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.242 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.28 69.96 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.482 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.2 t -49.69 -41.82 44.1 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.032 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -50.97 -29.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-O 120.904 0.383 . . . . 0.0 110.456 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.16 -29.55 36.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.204 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.91 -47.08 89.38 Favored Glycine 0 C--N 1.307 -1.067 0 C-N-CA 121.308 -0.472 . . . . 0.0 112.06 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.1 pt -62.12 -44.87 99.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.861 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 55.4 tp -59.97 -45.9 91.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.997 0.427 . . . . 0.0 109.905 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 33.8 t-80 -50.39 -47.56 56.33 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.142 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -66.95 -38.81 86.82 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.516 -179.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.08 -42.16 93.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.762 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.86 -39.74 76.17 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.964 0.412 . . . . 0.0 110.627 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -49.05 -29.32 4.9 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.956 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 77.8 p -54.67 -37.46 65.77 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 35.6 mm -61.16 -49.07 86.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.729 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.88 -29.91 8.66 Favored Glycine 0 C--N 1.305 -1.152 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.743 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -53.96 -27.48 31.49 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.525 HD21 ' ND2' ' C' ' 47' ' ' ASN . 1.5 pp -46.43 -32.11 3.07 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -177.027 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -61.41 -50.31 73.38 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 120.705 -0.398 . . . . 0.0 112.039 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.427 ' OE1' HD22 ' A' ' 46' ' ' LEU . 47.5 mm-40 -56.26 -53.95 51.1 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.732 HG23 ' H ' ' B' ' 50' ' ' LYS . 7.8 tt -60.59 -66.6 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.761 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.31 -179.36 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.732 ' H ' HG23 ' B' ' 49' ' ' ILE . 15.9 ttpp -117.85 134.51 54.86 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.815 0.34 . . . . 0.0 110.585 -179.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 11.5 tpp180 -158.78 117.76 3.03 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.124 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.189 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 179.972 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -172.91 61.04 0.27 Allowed Pre-proline 0 C--N 1.306 -1.286 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.512 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -78.78 4.02 6.82 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.822 2.348 . . . . 0.0 112.211 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -60.0 -50.67 72.83 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.035 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -70.98 -33.76 53.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 120.937 0.399 . . . . 0.0 111.178 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.7 t -70.3 -42.91 78.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.912 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.536 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.98 -39.35 40.61 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.51 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.19 -29.48 69.84 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 120.842 0.353 . . . . 0.0 111.292 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -53.05 -40.87 64.29 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.395 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.536 HG22 ' O ' ' C' ' 29' ' ' ALA . 3.4 tp -49.68 -31.53 6.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.751 0.31 . . . . 0.0 111.428 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -70.23 -29.84 41.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.94 -179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.526 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.26 -50.13 57.97 Favored Glycine 0 C--N 1.304 -1.218 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.908 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 36.8 pt -65.72 -29.65 47.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 120.776 0.322 . . . . 0.0 111.01 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 17.6 tp -61.29 -49.44 77.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.754 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.63 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.61 -29.69 62.42 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.767 -178.287 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.63 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 70.8 t80 -63.3 -44.37 95.21 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.258 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 72.5 mt -56.14 -48.21 79.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.155 -179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.86 -35.97 81.25 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -50.29 -36.34 31.24 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.346 -179.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.4 p -54.28 -47.13 72.69 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 120.741 0.305 . . . . 0.0 111.009 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.441 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -62.44 -49.82 82.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.76 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.75 -29.74 13.39 Favored Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.031 -179.16 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -56.68 -29.02 61.9 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.929 ' O ' HG22 ' C' ' 49' ' ' ILE . 3.8 pp -47.12 -35.91 7.72 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.625 0.231 . . . . 0.0 111.625 -177.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.66 ' N ' HD12 ' C' ' 46' ' ' LEU . 25.6 p-10 -48.51 -40.59 27.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.599 -0.841 . . . . 0.0 110.365 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -90.53 67.1 6.45 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.845 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.929 HG22 ' O ' ' C' ' 46' ' ' LEU . 17.7 tt -160.7 86.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 121.401 0.619 . . . . 0.0 111.285 179.289 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -175.06 160.91 2.83 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.786 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 65.8 mtp85 47.97 -121.54 1.37 Allowed 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.433 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.153 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.976 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 69.4 p . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -76.32 136.76 68.37 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -75.09 43.87 1.07 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.069 1.846 . . . . 0.0 112.166 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.47 -45.79 65.05 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.82 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.67 -41.08 77.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.912 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 28' ' ' VAL . . . . . 0.446 HG13 ' N ' ' D' ' 29' ' ' ALA . 8.1 p -70.73 -41.83 77.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.334 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.446 ' N ' HG13 ' D' ' 28' ' ' VAL . . . -49.8 -38.49 34.7 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.664 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.09 -31.54 72.8 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.258 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.5 t -56.22 -37.93 70.35 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.746 0.308 . . . . 0.0 110.793 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 mm -53.5 -29.59 17.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.387 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.4 mt -71.33 -29.24 34.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.465 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.33 -33.64 81.53 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 116.326 -0.397 . . . . 0.0 112.919 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -63.72 -38.48 82.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-N 117.402 0.601 . . . . 0.0 110.707 -179.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 43.6 tp -54.72 -43.09 72.28 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.8 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.705 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 19.3 m170 -51.13 -50.01 59.68 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.412 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -61.21 -42.45 98.61 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.557 -179.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.2 mt -60.28 -48.17 89.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.913 -179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.56 -34.73 72.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.82 0.343 . . . . 0.0 111.178 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.0 t-105 -49.0 -28.04 3.62 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.141 0.496 . . . . 0.0 110.017 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.7 p -57.92 -34.88 70.33 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.854 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.588 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -65.75 -50.92 67.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.759 0.314 . . . . 0.0 110.577 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.85 -29.67 62.08 Favored Glycine 0 C--N 1.302 -1.359 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.882 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.483 ' O ' HG22 ' D' ' 49' ' ' ILE . 11.6 t-160 -70.64 -32.91 70.39 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' D' ' 50' ' ' LYS . 0.7 OUTLIER -53.29 -30.18 37.38 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.612 -178.542 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -63.38 -50.26 70.6 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -178.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.532 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -67.1 -61.13 2.08 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.293 0.568 . . . . 0.0 111.632 -178.561 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.834 HG23 ' H ' ' D' ' 50' ' ' LYS . 7.2 tp -52.88 -67.17 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.975 -178.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.834 ' H ' HG23 ' D' ' 49' ' ' ILE . 34.7 ttpt -106.9 154.91 20.36 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 120.809 0.338 . . . . 0.0 110.545 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.493 ' CB ' HH21 ' A' ' 51' ' ' ARG . 0.0 OUTLIER -162.13 9.49 0.07 Allowed 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.782 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.202 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 179.935 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.409 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 16.6 p-10 -173.3 57.75 0.22 Allowed Pre-proline 0 C--N 1.306 -1.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.081 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -77.38 25.74 0.47 Allowed 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.763 2.309 . . . . 0.0 111.755 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.4 tp -64.82 -44.89 88.4 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.202 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.5 p -70.29 -41.42 78.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.756 0.312 . . . . 0.0 111.307 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.489 ' N ' HG13 ' A' ' 27' ' ' VAL . 16.6 t -63.32 -39.89 86.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-O 120.94 0.4 . . . . 0.0 110.921 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.08 -44.12 82.8 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.551 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.59 -37.13 75.16 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.785 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -57.84 -43.48 85.86 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.137 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 69.4 mt -49.32 -37.82 11.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 120.814 0.34 . . . . 0.0 110.778 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -64.77 -29.67 48.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.406 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.537 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -63.27 -50.04 65.94 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.164 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -59.64 -29.62 43.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 122.686 -0.303 . . . . 0.0 111.34 -179.047 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tt -63.67 -50.83 67.71 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.672 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.5 OUTLIER -51.26 -29.44 14.6 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.272 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 63.8 t80 -58.35 -48.1 81.67 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.718 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.6 tp -49.67 -43.53 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.252 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -72.88 -30.03 63.64 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.76 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.507 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 10.9 t-105 -49.02 -32.38 9.25 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -177.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 42' ' ' THR . 0.2 OUTLIER -66.14 -33.01 74.79 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.463 -179.452 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.497 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -51.09 -43.86 27.51 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.03 0.443 . . . . 0.0 109.839 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.44 -28.71 4.93 Favored Glycine 0 C--N 1.299 -1.505 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.048 -178.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -51.7 -33.78 35.69 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 117.251 0.526 . . . . 0.0 111.645 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.491 HD13 ' O ' ' A' ' 43' ' ' ILE . 6.5 mp -45.69 -45.21 14.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 119.551 -0.262 . . . . 0.0 111.531 -177.433 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -46.65 -49.86 18.55 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.201 -178.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.42 ' HB3' ' H ' ' A' ' 49' ' ' ILE . 12.8 mm100 -67.28 -130.11 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.42 ' H ' ' HB3' ' A' ' 48' ' ' GLN . 4.9 tt 35.78 56.28 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-O 121.373 0.606 . . . . 0.0 111.867 179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.405 ' H ' ' H ' ' A' ' 51' ' ' ARG . 19.3 pttp -169.27 4.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.799 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.405 ' H ' ' H ' ' A' ' 50' ' ' LYS . 91.8 mtt180 -145.47 152.27 39.52 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.854 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.174 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 54.2 m . . . . . 0 N--CA 1.488 1.465 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.403 ' O ' ' OD2' ' B' ' 24' ' ' ASP . 5.6 p-10 -140.21 60.69 15.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.484 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.32 56.95 1.69 Allowed 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.602 2.201 . . . . 0.0 111.78 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 tp -70.13 -49.86 46.43 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.076 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -70.19 -33.02 52.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.943 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 87.7 t -69.68 -46.2 75.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.989 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.9 -33.02 9.93 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.639 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.26 -31.51 72.74 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.772 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 37.4 t -58.9 -40.93 85.96 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.623 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 mm -51.71 -29.23 10.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -70.41 -29.95 40.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.42 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.32 -48.4 69.72 Favored Glycine 0 C--N 1.307 -1.043 0 C-N-CA 121.185 -0.531 . . . . 0.0 111.948 -179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.8 pt -67.32 -29.79 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 120.871 0.367 . . . . 0.0 110.678 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.3 tp -59.45 -47.59 84.89 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.661 -179.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.636 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 7.2 m-70 -49.82 -49.78 47.65 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.648 -179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -50.92 -42.98 59.85 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.617 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 79.1 mt -61.12 -50.43 80.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.598 -178.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.32 -38.4 74.92 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.949 0.404 . . . . 0.0 111.076 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.6 t-105 -49.18 -28.73 4.72 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.035 -179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 44.1 p -59.9 -38.63 82.83 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.001 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 29.2 mm -65.77 -51.39 62.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 C-N-CA 120.836 -0.345 . . . . 0.0 111.379 -179.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.417 ' O ' ' OD1' ' B' ' 47' ' ' ASN . . . -50.21 -29.75 16.26 Favored Glycine 0 C--N 1.305 -1.193 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.558 ' O ' HG22 ' B' ' 49' ' ' ILE . 25.3 t60 -56.72 -27.66 59.59 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.446 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.5 pp -47.78 -35.9 10.75 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.672 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 25.0 p-10 -63.26 -49.62 73.38 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 -178.564 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.451 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 18.6 tm0? -68.89 -57.45 5.52 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.929 HG23 ' H ' ' B' ' 50' ' ' LYS . 13.0 tt -51.13 -71.35 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -178.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.929 ' H ' HG23 ' B' ' 49' ' ' ILE . 33.5 ttpt -111.78 147.3 35.96 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-O 120.827 0.346 . . . . 0.0 110.63 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 63.3 ttm-85 -146.49 143.33 28.88 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.387 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.92 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.18 61.83 1.93 Allowed Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.444 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -78.32 0.34 10.0 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.894 2.396 . . . . 0.0 111.999 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 59.7 tp -61.11 -42.21 98.1 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.739 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.2 t -70.13 -42.33 79.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.347 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 98.7 t -60.13 -43.48 93.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 120.955 0.407 . . . . 0.0 110.328 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.448 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.22 -48.25 79.27 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.638 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.28 -35.05 69.3 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.847 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.9 t -56.8 -43.66 81.18 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.724 0.297 . . . . 0.0 111.453 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.602 ' O ' HD13 ' C' ' 32' ' ' ILE . 0.3 OUTLIER -48.66 -34.6 5.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-O 120.884 0.373 . . . . 0.0 110.459 -178.892 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.8 mt -64.18 -29.69 48.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.702 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.548 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.9 -51.37 35.06 Favored Glycine 0 C--N 1.306 -1.129 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.579 -178.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 tt -63.1 -29.29 46.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 122.419 -0.46 . . . . 0.0 111.195 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 55.9 tp -62.22 -51.4 67.95 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.589 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.636 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 1.2 p80 -53.92 -29.5 42.39 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.815 -178.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 68.9 t80 -57.17 -49.52 75.7 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.564 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -49.88 -43.38 19.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.505 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.77 -31.98 70.23 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.144 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -54.3 -42.68 70.38 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 116.592 -0.276 . . . . 0.0 111.309 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 17.3 p -56.58 -40.36 75.1 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.987 0.422 . . . . 0.0 110.434 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.4 mm -59.06 -50.86 78.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.318 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.8 -28.16 6.93 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 45' ' ' HIS . . . . . 0.786 ' NE2' HD13 ' C' ' 49' ' ' ILE . 6.5 t-160 -50.41 -40.13 49.22 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.477 ' CD1' ' N ' ' C' ' 47' ' ' ASN . 0.1 OUTLIER -56.27 -28.05 57.31 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 -177.77 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.477 ' N ' ' CD1' ' C' ' 46' ' ' LEU . 25.0 p-10 -45.81 -51.5 12.71 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -174.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.427 ' CD ' HD11 ' B' ' 46' ' ' LEU . 6.5 tt0 -141.27 49.83 1.63 Allowed 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 119.205 0.911 . . . . 0.0 112.392 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.786 HD13 ' NE2' ' C' ' 45' ' ' HIS . 11.2 tp -96.68 41.12 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.56 0.695 . . . . 0.0 109.207 178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.63 25.58 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.942 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 11.1 tpt180 -155.38 126.14 6.96 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.855 0.36 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.7 m . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.9 m-20 47.7 57.73 17.69 Favored Pre-proline 0 C--N 1.304 -1.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.983 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.11 12.6 0.98 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.85 2.366 . . . . 0.0 111.447 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' D' ' 24' ' ' ASP . 39.3 tp -70.74 -44.75 66.17 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.607 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.4 p -70.54 -35.06 59.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.39 -50.04 49.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.528 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.66 -33.46 15.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.87 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.46 -34.77 74.87 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.865 0.364 . . . . 0.0 111.132 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 36.7 t -51.85 -38.47 56.08 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.161 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 mm -61.3 -29.64 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.89 0.376 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.405 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 5.1 mt -71.33 -39.17 71.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.418 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.38 -42.2 96.12 Favored Glycine 0 C--N 1.307 -1.068 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.198 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 9.9 tt -70.27 -39.27 76.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.301 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 44.3 tp -49.48 -36.36 22.62 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.437 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.672 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 45.6 m170 -49.93 -43.11 49.65 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.164 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -57.6 -38.29 74.66 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.442 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mm -61.67 -50.81 78.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.157 -179.205 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.507 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.68 -35.62 72.91 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.956 -179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.57 -28.65 3.56 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.109 0.48 . . . . 0.0 110.403 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.4 p -51.05 -36.66 41.05 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.057 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 32.2 mm -68.23 -51.13 51.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.127 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.95 -29.48 55.39 Favored Glycine 0 C--N 1.305 -1.184 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -57.23 -27.57 62.14 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -47.3 -28.94 2.18 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.819 -178.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -50.74 -52.57 39.27 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 120.36 -0.536 . . . . 0.0 112.302 -178.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.574 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -84.32 -64.22 1.2 Allowed 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 120.68 0.276 . . . . 0.0 111.64 -179.001 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 15.4 tt -62.77 14.54 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.492 ' H ' ' C ' ' D' ' 48' ' ' GLN . 12.2 ttmm -169.62 121.55 0.71 Allowed 'General case' 0 C--N 1.308 -1.22 0 O-C-N 121.844 -0.535 . . . . 0.0 110.524 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 20.9 tpt85 -162.95 80.62 0.48 Allowed 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.546 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.969 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.95 60.93 0.24 Allowed Pre-proline 0 C--N 1.305 -1.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.709 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -79.11 10.04 3.11 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.821 2.347 . . . . 0.0 112.123 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -66.52 -44.32 82.82 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.63 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.07 -35.14 62.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.311 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.9 t -69.63 -43.91 79.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.938 0.399 . . . . 0.0 110.762 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.67 -39.13 35.34 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.115 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.59 -34.38 76.86 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.726 0.298 . . . . 0.0 111.165 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.4 ' O ' ' CD1' ' A' ' 35' ' ' ILE . 33.5 t -59.88 -41.79 92.35 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.797 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mm -52.55 -32.21 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.152 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.6 mt -70.25 -29.78 40.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.702 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.62 -45.1 93.92 Favored Glycine 0 C--N 1.304 -1.23 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.253 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.905 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.82 -29.13 45.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 122.589 -0.359 . . . . 0.0 111.189 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.603 ' O ' HG22 ' A' ' 39' ' ' ILE . 35.9 tp -62.92 -46.96 85.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -178.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.69 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.4 p80 -58.96 -28.42 66.29 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 120.201 -0.6 . . . . 0.0 111.423 -178.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.619 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 33.7 t80 -56.74 -48.66 77.29 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.4 tt -59.4 -41.17 83.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.171 -178.466 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -35.94 73.88 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.47 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.425 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 5.2 t-105 -49.67 -34.19 17.77 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.412 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.2 p -62.19 -29.98 70.75 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.036 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.403 HG21 ' NE2' ' B' ' 48' ' ' GLN . 58.4 mt -61.33 -47.1 95.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.385 -179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.71 -28.36 5.19 Favored Glycine 0 C--N 1.307 -1.051 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.167 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.448 ' O ' ' O ' ' A' ' 48' ' ' GLN . 4.9 t-160 -48.88 -27.71 3.26 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 116.762 0.281 . . . . 0.0 111.271 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 pp -45.47 -41.89 9.98 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.54 -0.3 . . . . 0.0 111.745 -177.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.709 ' CG ' HD22 ' D' ' 47' ' ' ASN . 5.8 m120 -48.22 -50.22 30.21 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.615 ' O ' HG22 ' A' ' 49' ' ' ILE . 5.2 tt0 -93.65 175.39 6.76 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.016 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.615 HG22 ' O ' ' A' ' 48' ' ' GLN . 0.4 OUTLIER 75.7 -30.58 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 CA-C-N 118.154 0.433 . . . . 0.0 111.434 179.805 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' A' ' 48' ' ' GLN . 36.1 ttpt -92.09 -62.75 1.35 Allowed 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 120.558 0.218 . . . . 0.0 111.1 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -67.24 -38.33 85.02 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.507 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.266 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.835 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' B' ' 24' ' ' ASP . 1.5 p30 -85.83 151.95 55.88 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.079 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -71.33 38.6 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.365 2.043 . . . . 0.0 111.774 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.415 ' H ' ' C ' ' B' ' 24' ' ' ASP . 43.9 tp -68.06 -47.96 66.89 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.695 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -70.52 -34.0 55.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -70.0 -45.88 75.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.265 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.04 -35.37 15.46 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.629 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.21 -29.81 70.64 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.679 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 7.0 t -57.88 -41.36 82.34 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.766 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 mm -50.44 -30.61 7.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.584 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.63 -29.34 37.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.4 -49.93 58.3 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 121.047 -0.596 . . . . 0.0 111.787 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.408 HG12 ' H ' ' B' ' 35' ' ' ILE . 10.5 pt -63.42 -42.84 97.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.691 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 58.1 tp -60.26 -45.18 94.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.279 0.561 . . . . 0.0 109.615 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -61.08 -41.17 96.16 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.347 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 88.9 t80 -70.67 -46.58 62.94 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.474 ' O ' ' OG1' ' B' ' 42' ' ' THR . 18.0 tt -68.07 -29.97 46.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.317 -178.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -39.98 72.02 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.213 0.53 . . . . 0.0 110.139 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -54.35 -37.45 64.94 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.432 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 31.6 p -55.16 -36.58 65.97 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.603 -0.439 . . . . 0.0 110.934 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -65.04 -50.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.015 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.542 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.51 -30.36 12.8 Favored Glycine 0 C--N 1.305 -1.185 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 48.6 t60 -59.81 -27.04 66.26 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.7 0.286 . . . . 0.0 111.562 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.89 -31.65 12.69 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.774 -0.371 . . . . 0.0 111.943 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 6.9 p30 -68.95 -50.06 52.56 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -177.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.546 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 7.5 pt20 -69.28 -48.51 61.5 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.12 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.821 HG23 ' H ' ' B' ' 50' ' ' LYS . 16.4 tt -53.95 -67.18 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.214 -179.154 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.821 ' H ' HG23 ' B' ' 49' ' ' ILE . 1.5 pptp? -131.07 164.06 26.26 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 120.853 0.359 . . . . 0.0 110.762 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 60.1 ttm-85 -153.52 -48.33 0.09 Allowed 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.543 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.164 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 -179.96 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 91.0 p . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -173.08 60.13 0.25 Allowed Pre-proline 0 C--N 1.305 -1.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.788 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -77.31 6.34 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.767 2.311 . . . . 0.0 111.885 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.3 tp -64.11 -48.44 76.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 59.5 t -70.42 -37.02 69.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 85.8 t -70.12 -43.71 78.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.742 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.56 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.48 -38.47 74.6 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.549 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.08 -30.38 71.45 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 120.906 0.384 . . . . 0.0 110.903 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -50.74 -36.47 36.61 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.178 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.56 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.8 tt -55.27 -29.76 23.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.603 -179.174 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.41 -36.92 76.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.429 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.61 -46.41 84.49 Favored Glycine 0 C--N 1.303 -1.261 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.16 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 11.0 tt -70.28 -29.06 37.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.778 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 31.8 tp -61.94 -47.23 85.83 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.99 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -56.7 -29.94 62.95 Favored 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 120.421 -0.512 . . . . 0.0 111.876 -178.474 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 77.4 t80 -62.33 -40.63 96.99 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.393 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -57.43 -46.93 85.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.54 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.18 -34.62 73.19 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 120.81 0.338 . . . . 0.0 110.812 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.2 -30.68 7.31 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.354 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 42.2 p -53.97 -44.02 70.41 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.923 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.479 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -63.66 -48.86 84.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.617 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.23 -33.56 15.67 Favored Glycine 0 C--N 1.304 -1.217 0 C-N-CA 121.259 -0.496 . . . . 0.0 111.881 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -50.58 -28.57 8.95 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 116.814 0.307 . . . . 0.0 111.628 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.448 ' C ' HD12 ' C' ' 46' ' ' LEU . 2.2 pp -46.82 -39.55 12.11 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.931 -177.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 32.1 p30 -49.95 -35.03 22.63 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.191 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.524 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 0.9 OUTLIER -73.91 -53.4 10.23 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 112.473 0.545 . . . . 0.0 112.473 -178.483 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.602 HG23 ' N ' ' C' ' 50' ' ' LYS . 13.2 tt -62.7 -56.74 15.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.602 ' N ' HG23 ' C' ' 49' ' ' ILE . 52.5 pttt -37.51 147.46 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 117.934 0.333 . . . . 0.0 111.287 -179.31 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 51' ' ' ARG . . . . . 0.466 ' N ' ' CD ' ' C' ' 51' ' ' ARG . 10.5 mpt_? 45.79 -90.72 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.593 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 52' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.163 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 14.9 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' D' ' 24' ' ' ASP . 4.2 p30 -71.65 151.81 93.57 Favored Pre-proline 0 C--N 1.305 -1.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.223 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.72 45.56 0.9 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.322 2.015 . . . . 0.0 111.753 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 53.9 tp -69.97 -44.02 70.31 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.282 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.52 -38.62 74.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.979 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 95.6 t -67.08 -47.71 81.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.696 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.78 -34.37 19.18 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.015 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.31 -29.73 67.65 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.138 -179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.2 t -57.17 -42.79 81.8 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.127 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mm -51.46 -33.34 14.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 120.881 0.372 . . . . 0.0 110.481 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 4.6 mt -71.51 -29.04 33.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.282 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.36 -47.47 79.08 Favored Glycine 0 C--N 1.309 -0.937 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.118 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -61.15 -42.07 91.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.786 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.5 tp -49.13 -32.24 9.63 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.69 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 29.5 m170 -65.35 -42.88 92.39 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.554 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.69 -50.07 66.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.3 pp -62.83 -39.04 83.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.847 -0.741 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.425 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -69.08 -40.75 78.24 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.335 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.1 t-105 -49.78 -30.2 9.18 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.73 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.2 m -69.59 -35.78 75.64 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 115.604 -0.726 . . . . 0.0 111.116 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.519 ' O ' HD12 ' D' ' 46' ' ' LEU . 60.7 mt -70.6 -51.54 36.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.012 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.97 -27.8 65.19 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -55.99 -26.56 48.97 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.758 HD13 ' N ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -47.07 -25.11 0.77 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -177.642 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.758 ' N ' HD13 ' D' ' 46' ' ' LEU . 44.9 m-80 -49.23 -51.51 32.81 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.066 -0.654 . . . . 0.0 111.402 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.526 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -85.07 -69.32 0.66 Allowed 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.997 0.427 . . . . 0.0 111.098 -179.443 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.629 ' O ' HG23 ' D' ' 49' ' ' ILE . 7.3 tp -57.94 92.45 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 CA-C-O 121.546 0.689 . . . . 0.0 110.603 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' D' ' 46' ' ' LEU . 17.2 ttpp 59.13 145.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.928 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 25.1 ptt-85 -152.5 -22.69 0.17 Allowed 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.429 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.261 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.981 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.5 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -174.37 57.58 0.2 Allowed Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.38 9.74 2.41 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.828 2.352 . . . . 0.0 111.991 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -67.75 -45.11 75.89 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.2 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.0 p -70.1 -37.2 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.655 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.429 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.6 t -68.91 -43.7 82.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 120.982 0.42 . . . . 0.0 110.989 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.82 -38.3 21.79 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.629 -179.255 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.08 -35.86 81.67 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.32 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 35' ' ' ILE . 44.8 t -60.4 -44.75 95.41 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.333 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.0 mm -50.01 -29.72 5.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.042 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.9 mt -70.5 -30.96 44.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.813 -179.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.53 -48.49 72.82 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.379 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.698 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.4 mp -68.07 -29.5 44.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.74 0.305 . . . . 0.0 111.057 -179.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 39' ' ' ILE . 45.2 tp -61.8 -47.43 85.17 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.464 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.1 -28.59 69.2 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.243 -0.583 . . . . 0.0 111.41 -178.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 51.4 t80 -60.18 -48.74 80.47 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.509 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -60.73 -39.96 83.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.083 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -39.47 72.44 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 120.926 0.393 . . . . 0.0 110.968 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.497 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.0 t-105 -48.94 -30.83 6.42 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.856 -178.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -57.83 -37.54 73.99 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.8 mm -61.04 -48.88 87.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.804 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.27 -28.12 6.01 Favored Glycine 0 C--N 1.305 -1.163 0 N-CA-C 111.709 -0.557 . . . . 0.0 111.709 -179.093 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 -48.2 -27.87 2.68 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.614 ' O ' HG23 ' A' ' 49' ' ' ILE . 2.6 pp -45.8 -37.46 6.1 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.732 -0.387 . . . . 0.0 111.656 -177.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -55.77 -50.24 70.97 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.431 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -86.52 68.44 10.18 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 111.612 0.227 . . . . 0.0 111.612 -179.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.614 HG23 ' O ' ' A' ' 46' ' ' LEU . 18.3 pt -110.22 -122.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.619 0.247 . . . . 0.0 111.083 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -63.54 -36.66 84.53 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 120.837 0.351 . . . . 0.0 110.693 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -69.41 -21.54 63.75 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.95 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.216 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.988 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 27.2 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.425 ' C ' ' H ' ' B' ' 26' ' ' LEU . 21.4 m-20 50.01 56.13 17.38 Favored Pre-proline 0 C--N 1.304 -1.409 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.974 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 60.7 Cg_endo -71.53 38.68 0.35 Allowed 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.731 2.288 . . . . 0.0 111.567 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.425 ' H ' ' C ' ' B' ' 24' ' ' ASP . 18.1 tp -70.27 -45.07 67.12 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.013 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 95.5 t -70.64 -38.12 72.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.545 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.44 -42.47 78.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.739 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.17 -29.74 14.76 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.595 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.74 -31.55 69.59 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.702 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.5 t -52.17 -40.25 61.2 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.749 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.415 ' O ' HD13 ' B' ' 35' ' ' ILE . 20.3 mm -51.37 -32.79 13.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-O 121.224 0.535 . . . . 0.0 110.368 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -72.35 -29.17 30.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.36 -52.01 24.12 Favored Glycine 0 CA--C 1.528 0.899 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.731 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.415 HD13 ' O ' ' B' ' 32' ' ' ILE . 0.2 OUTLIER -70.95 -29.48 37.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 117.971 0.886 . . . . 0.0 110.267 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 57.4 tp -64.7 -44.97 88.56 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.167 0.508 . . . . 0.0 110.113 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -52.91 -43.24 66.07 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.547 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -69.8 -36.7 75.9 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.406 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.33 -42.94 98.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.978 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.41 -36.04 78.53 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.85 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -53.44 -33.48 54.2 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.087 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.0 p -54.91 -40.12 69.51 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.775 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.52 -47.64 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.614 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.12 -29.35 9.04 Favored Glycine 0 C--N 1.305 -1.161 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -49.46 -27.06 3.82 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.551 0.215 . . . . 0.0 111.484 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -47.43 -38.2 13.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.45 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -48.42 -51.06 28.51 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.315 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.572 ' C ' ' H ' ' B' ' 50' ' ' LYS . 16.4 tt0 -82.08 -143.99 0.06 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.052 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.479 HG22 ' O ' ' B' ' 48' ' ' GLN . 12.4 tt 46.57 1.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 N-CA-C 113.085 0.772 . . . . 0.0 113.085 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.572 ' H ' ' C ' ' B' ' 48' ' ' GLN . 20.7 pttp -175.18 132.1 0.3 Allowed 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 56.6 ttm-85 -164.95 123.73 1.75 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.848 0.356 . . . . 0.0 110.969 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.081 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.781 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 26.3 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -162.09 58.8 0.9 Allowed Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.491 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -76.17 8.02 3.05 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.841 2.361 . . . . 0.0 111.988 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 30.8 tp -70.0 -44.71 68.83 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.721 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.8 t -70.68 -39.33 75.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.348 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 13.6 t -69.7 -44.56 79.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.499 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -60.92 -39.15 88.29 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.265 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.85 -29.92 71.11 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.975 0.417 . . . . 0.0 110.786 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -50.51 -34.23 24.45 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.949 -0.568 . . . . 0.0 111.255 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.499 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.9 tp -53.18 -30.23 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.449 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.53 -32.03 51.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.013 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.58 -47.46 62.07 Favored Glycine 0 C--N 1.304 -1.233 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.312 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 13.1 tt -69.4 -29.82 43.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.026 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 28.5 tp -62.62 -48.95 77.13 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -53.42 -29.44 35.14 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.59 -178.7 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 58.0 t80 -61.57 -41.42 97.37 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 92.4 mt -57.61 -48.86 82.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.535 -178.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.45 -32.83 72.02 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.967 0.413 . . . . 0.0 110.316 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.8 -35.03 21.28 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.145 -179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -58.77 -32.31 69.17 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.372 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.1 -48.66 80.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.309 -179.318 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.603 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -49.93 -36.56 27.28 Favored Glycine 0 C--N 1.305 -1.141 0 CA-C-N 116.387 -0.37 . . . . 0.0 112.721 -178.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -51.47 -27.84 11.58 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 117.296 0.548 . . . . 0.0 111.283 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.597 HD21 ' CB ' ' D' ' 48' ' ' GLN . 1.7 pp -45.95 -41.22 11.35 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.187 -177.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.603 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 23.3 p30 -54.14 -39.0 66.1 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.017 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.5 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 5.3 tp-100 -63.73 -51.59 64.26 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.007 0.432 . . . . 0.0 111.408 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.659 HG23 ' N ' ' C' ' 50' ' ' LYS . 0.6 OUTLIER -96.54 -144.62 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.935 -179.344 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.659 ' N ' HG23 ' C' ' 49' ' ' ILE . 46.9 tttp 53.57 161.03 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.754 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 50.38 69.46 0.62 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.442 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.17 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.946 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.487 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.0 m-20 -153.84 150.64 23.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.139 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.83 22.0 0.21 Allowed 'Trans proline' 0 N--CA 1.495 1.573 0 C-N-CA 122.1 1.867 . . . . 0.0 111.972 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.487 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.5 tp -71.87 -39.93 69.31 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.923 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.7 t -70.03 -45.24 77.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -178.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 28' ' ' VAL . . . . . 0.437 HG23 ' N ' ' D' ' 29' ' ' ALA . 17.1 m -67.91 -35.87 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.059 0.457 . . . . 0.0 110.439 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.437 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.66 -36.36 56.77 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.302 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.67 -39.46 73.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.316 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -61.86 -48.59 79.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.744 ' O ' HD12 ' D' ' 35' ' ' ILE . 12.5 pt -50.35 -28.21 5.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.751 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.77 -28.69 34.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.301 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -44.55 84.49 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 116.337 -0.392 . . . . 0.0 113.632 -178.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 35' ' ' ILE . . . . . 0.999 HD13 ' N ' ' D' ' 36' ' ' LEU . 0.0 OUTLIER -56.36 -28.43 26.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-N 117.411 0.605 . . . . 0.0 110.516 -178.954 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 36' ' ' LEU . . . . . 0.999 ' N ' HD13 ' D' ' 35' ' ' ILE . 4.1 tp -60.47 -43.1 97.3 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 120.892 0.377 . . . . 0.0 110.565 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.627 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 7.0 m170 -55.14 -49.16 72.52 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.526 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -56.46 -50.08 72.75 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -178.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.6 pt -61.29 -44.93 99.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.919 -0.712 . . . . 0.0 111.045 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.497 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.3 -37.51 74.79 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.187 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.7 t-105 -48.63 -30.13 5.09 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.843 0.354 . . . . 0.0 110.653 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.4 p -60.09 -36.75 78.11 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.842 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.64 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -69.23 -51.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.231 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' D' ' 47' ' ' ASN . . . -53.44 -28.74 37.11 Favored Glycine 0 C--N 1.304 -1.228 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.495 ' O ' HG22 ' D' ' 49' ' ' ILE . 10.6 t-80 -65.29 -33.33 75.72 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -59.41 -41.33 89.23 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.446 ' OD1' ' O ' ' D' ' 44' ' ' GLY . 0.7 OUTLIER -64.43 -50.33 67.97 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.948 -178.771 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.597 ' CB ' HD21 ' C' ' 46' ' ' LEU . 0.2 OUTLIER -63.63 -61.56 2.24 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.955 0.407 . . . . 0.0 111.233 -179.251 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.653 HG23 ' N ' ' D' ' 50' ' ' LYS . 4.2 tp -47.42 -60.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.126 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.653 ' N ' HG23 ' D' ' 49' ' ' ILE . 46.4 mtpt -125.86 153.53 44.01 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.91 21.63 1.12 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.838 0.351 . . . . 0.0 110.403 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.898 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.4 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 43.2 m . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-20 -161.62 64.0 1.73 Allowed Pre-proline 0 C--N 1.307 -1.246 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.638 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -79.55 0.48 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 122.876 2.384 . . . . 0.0 112.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.3 tp -66.12 -46.61 76.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.956 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.411 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.0 p -70.34 -36.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.649 -179.231 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.411 ' N ' HG13 ' A' ' 27' ' ' VAL . 74.3 t -69.55 -42.27 80.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 120.918 0.389 . . . . 0.0 110.855 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.55 -38.12 29.8 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.828 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.42 75.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.303 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -59.93 -42.74 94.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.112 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.6 mm -49.69 -31.49 6.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.876 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -70.48 -29.59 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.547 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -65.57 -49.83 58.07 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.461 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.866 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -65.64 -29.73 47.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 122.576 -0.367 . . . . 0.0 111.089 -179.187 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 39' ' ' ILE . 56.5 tp -61.41 -46.11 91.5 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.643 -179.024 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.0 OUTLIER -61.34 -28.99 69.61 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 120.195 -0.602 . . . . 0.0 111.358 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 91.6 t80 -62.78 -50.16 72.12 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.465 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -57.79 -40.38 75.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 C-N-CA 120.089 -0.644 . . . . 0.0 110.521 -178.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -36.15 72.37 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.629 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.9 t-105 -48.83 -34.08 11.76 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.744 -179.106 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 38.1 p -58.9 -33.67 70.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.814 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.455 ' CG2' ' OE1' ' B' ' 48' ' ' GLN . 96.6 mt -65.36 -44.24 94.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.201 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.0 -26.13 1.15 Allowed Glycine 0 C--N 1.306 -1.124 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -46.94 -25.02 0.7 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 123.016 -0.108 . . . . 0.0 111.104 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.419 ' CD1' ' OE1' ' B' ' 48' ' ' GLN . 1.1 mt -44.34 -50.58 9.02 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.208 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -56.94 -42.28 79.78 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.564 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.413 ' O ' ' OE1' ' A' ' 48' ' ' GLN . 0.1 OUTLIER -66.47 -57.67 6.86 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 120.897 0.38 . . . . 0.0 111.62 -179.054 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.743 HG23 ' H ' ' A' ' 50' ' ' LYS . 7.3 tp -59.91 -64.03 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.221 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.743 ' H ' HG23 ' A' ' 49' ' ' ILE . 34.4 ttmt -47.02 146.5 1.69 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 49.7 ptt85 37.74 -154.66 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.983 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.729 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 23' ' ' SER . . . . . 0.49 ' O ' ' CB ' ' B' ' 24' ' ' ASP . 14.9 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' B' ' 26' ' ' LEU . 4.0 t70 84.79 52.58 0.04 OUTLIER Pre-proline 0 C--N 1.312 -1.044 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.38 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.466 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 13.5 Cg_endo -56.06 70.46 0.03 OUTLIER 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 122.985 2.457 . . . . 0.0 112.29 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' B' ' 24' ' ' ASP . 20.6 tp -71.47 -50.88 27.28 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.504 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 t -70.69 -35.5 61.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-O 121.127 0.489 . . . . 0.0 111.514 -179.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 99.3 t -70.39 -44.18 77.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.274 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -29.52 5.71 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.813 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.53 -29.71 69.18 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.939 0.4 . . . . 0.0 110.524 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.0 t -49.98 -37.13 31.08 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.828 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -54.7 -29.51 21.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 120.978 0.418 . . . . 0.0 110.443 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -71.02 -29.84 38.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.323 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.45 -46.6 76.31 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.17 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 12.3 pt -66.01 -42.35 91.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.164 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.4 tp -62.32 -46.54 88.28 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.143 0.497 . . . . 0.0 109.818 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.4 t-80 -51.6 -42.03 61.65 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.444 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.13 -36.03 74.5 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.539 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -41.85 93.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.129 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.41 -40.42 77.32 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.01 0.434 . . . . 0.0 110.817 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.26 -32.05 10.0 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.067 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.8 p -51.38 -33.91 32.02 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.264 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 34.3 mm -65.74 -50.46 70.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.61 -30.11 26.6 Favored Glycine 0 C--N 1.306 -1.089 0 C-N-CA 121.232 -0.509 . . . . 0.0 111.928 -179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.587 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 0.1 OUTLIER -63.78 -27.73 69.39 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 122.574 0.349 . . . . 0.0 111.342 -179.286 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.596 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.0 OUTLIER -48.75 -29.03 4.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.498 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.403 ' ND2' HH21 ' B' ' 51' ' ' ARG . 17.7 t-20 -58.18 -51.7 68.66 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -177.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.904 ' NE2' ' H ' ' B' ' 48' ' ' GLN . 0.2 OUTLIER -75.38 -47.82 25.78 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.25 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.909 HG23 ' H ' ' B' ' 50' ' ' LYS . 8.6 tt -55.05 -73.41 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 C-N-CA 120.301 -0.56 . . . . 0.0 110.474 -179.36 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.909 ' H ' HG23 ' B' ' 49' ' ' ILE . 0.0 OUTLIER -147.84 149.41 32.25 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.015 0.436 . . . . 0.0 110.939 179.672 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.403 HH21 ' ND2' ' B' ' 47' ' ' ASN . 57.8 ttm-85 -141.47 -53.45 0.45 Allowed 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.086 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.931 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 16.8 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -175.34 57.99 0.18 Allowed Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.39 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -75.68 7.58 3.06 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.881 2.387 . . . . 0.0 112.061 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -69.35 -47.97 62.73 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.49 -36.61 66.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.058 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 64.2 t -70.33 -46.74 70.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.84 -36.61 27.38 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.18 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.5 -29.64 67.32 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.787 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -51.7 -41.94 61.85 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.278 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' C' ' 29' ' ' ALA . 7.4 tt -53.93 -27.13 15.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.018 0.437 . . . . 0.0 111.031 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 1.6 mm -59.89 -37.72 73.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.754 -178.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.446 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.4 -46.66 76.3 Favored Glycine 0 C--N 1.304 -1.212 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.991 -178.142 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -70.16 -29.13 38.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.533 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 34.4 tp -61.64 -50.62 71.79 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.667 -179.174 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -57.62 -29.0 64.17 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.652 -178.741 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.2 t80 -59.94 -42.64 94.44 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.638 0.256 . . . . 0.0 111.294 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' C' ' 42' ' ' THR . 19.6 mm -58.14 -45.71 88.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.071 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.01 -30.28 65.06 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.225 0.536 . . . . 0.0 111.056 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -52.6 -38.02 59.28 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -57.77 -29.99 65.27 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.48 -178.262 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.607 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.6 mp -61.24 -48.97 86.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.165 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.42 -29.74 11.32 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -50.84 -28.09 8.73 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.69 0.281 . . . . 0.0 111.207 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.624 ' C ' HD12 ' C' ' 46' ' ' LEU . 3.3 pp -45.85 -33.6 3.28 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.892 -177.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.591 ' N ' HD12 ' C' ' 46' ' ' LEU . 71.1 m-20 -62.36 -49.03 77.18 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.732 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -82.04 71.03 9.08 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-O 120.604 0.24 . . . . 0.0 111.58 -178.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.768 HG23 ' H ' ' C' ' 50' ' ' LYS . 1.5 tp -179.51 -78.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 O-C-N 122.088 -0.382 . . . . 0.0 110.687 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.768 ' H ' HG23 ' C' ' 49' ' ' ILE . 51.5 pttt -50.86 -27.12 6.76 Favored 'General case' 0 C--N 1.309 -1.191 0 O-C-N 122.067 -0.395 . . . . 0.0 110.457 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -156.69 145.3 19.91 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.205 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.218 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 60.3 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -81.6 150.02 65.7 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.316 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.54 42.23 0.56 Allowed 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.201 1.934 . . . . 0.0 111.743 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.4 tp -70.15 -47.08 63.2 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.574 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.3 t -70.68 -34.42 56.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.093 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 91.8 t -69.96 -47.67 67.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.648 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -31.45 10.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.839 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.01 -33.76 74.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -58.06 -41.21 82.85 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 68.3 mt -58.36 -30.15 39.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-O 120.976 0.417 . . . . 0.0 110.816 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.441 ' O ' ' NE2' ' D' ' 37' ' ' HIS . 6.0 mt -71.43 -31.96 44.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.515 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.6 -39.61 90.68 Favored Glycine 0 C--N 1.307 -1.07 0 C-N-CA 121.429 -0.415 . . . . 0.0 112.579 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 19.9 pt -69.99 -35.76 65.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.601 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 27.6 tp -49.34 -36.09 20.39 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.484 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 8.7 m170 -58.99 -34.73 72.18 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -62.05 -45.96 91.25 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.5 pp -67.22 -40.23 84.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.522 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.87 -41.28 71.59 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.211 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -48.96 -28.72 4.07 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.1 p -60.3 -32.5 71.26 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 84.8 mt -66.01 -51.57 58.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.174 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.84 -29.5 42.35 Favored Glycine 0 C--N 1.304 -1.215 0 N-CA-C 111.685 -0.566 . . . . 0.0 111.685 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 9.0 t-80 -55.77 -28.21 54.91 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.436 ' O ' ' O ' ' D' ' 50' ' ' LYS . 1.0 OUTLIER -47.02 -31.81 3.52 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.522 -177.618 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 19.5 p-10 -54.07 -48.25 70.82 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.107 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 48' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -65.02 -53.33 47.64 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-O 120.936 0.398 . . . . 0.0 111.006 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.455 ' O ' HG23 ' D' ' 49' ' ' ILE . 3.6 tp -87.35 95.59 5.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-O 121.797 0.808 . . . . 0.0 110.389 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' D' ' 46' ' ' LEU . 5.7 ttpm? 64.32 161.42 0.11 Allowed 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.645 -1.161 . . . . 0.0 111.234 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.12 3.11 0.44 Allowed 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.771 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.413 ' H ' ' HG2' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.303 -1.28 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 79.2 p . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -177.73 60.28 0.15 Allowed Pre-proline 0 C--N 1.307 -1.244 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.847 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -78.62 4.1 6.68 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.891 2.394 . . . . 0.0 112.024 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.3 tp -66.48 -48.52 69.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.03 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.34 -35.56 63.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.586 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.0 t -70.36 -43.63 78.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 120.868 0.366 . . . . 0.0 110.684 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -35.82 18.13 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.997 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.14 -35.26 79.69 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 120.734 0.302 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -61.07 -41.78 97.27 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.124 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -55.92 -29.76 26.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.114 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.3 mt -70.39 -32.47 50.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.397 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -61.21 -40.24 98.3 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.375 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 mt -69.98 -29.6 40.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.937 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HD23 ' A' ' 36' ' ' LEU . 1.7 tt -60.6 -47.83 84.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.314 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.5 p80 -61.61 -28.76 69.59 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.45 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 56.1 t80 -60.97 -48.24 82.76 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 10.2 pt -62.64 -40.53 88.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.074 -0.65 . . . . 0.0 111.098 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -39.58 75.31 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.69 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.6 t-105 -49.09 -30.96 7.1 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.016 -179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 70.4 p -63.78 -30.9 71.94 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 76.7 mt -59.69 -49.57 83.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.815 0.341 . . . . 0.0 111.016 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.26 -28.99 9.45 Favored Glycine 0 C--N 1.305 -1.175 0 N-CA-C 111.618 -0.593 . . . . 0.0 111.618 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.76 -27.63 5.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 120.764 0.316 . . . . 0.0 110.897 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.505 ' O ' ' CD1' ' A' ' 49' ' ' ILE . 2.5 pp -44.63 -36.96 3.33 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 52' ' ' GLY . 52.3 m-80 -70.5 -36.19 73.67 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.573 ' C ' ' H ' ' A' ' 50' ' ' LYS . 32.8 tt0 -67.55 -57.92 5.62 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.505 ' CD1' ' O ' ' A' ' 46' ' ' LEU . 0.0 OUTLIER -60.63 15.39 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -177.658 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.581 ' CG ' ' H ' ' A' ' 51' ' ' ARG . 0.4 OUTLIER -164.2 -80.45 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 178.686 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.581 ' H ' ' CG ' ' A' ' 50' ' ' LYS . 60.8 ttt180 -57.18 -9.09 0.83 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.975 0.417 . . . . 0.0 110.166 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 47' ' ' ASN . . . . . . . . 0 C--N 1.308 -0.996 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 32.9 t . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.426 ' C ' ' H ' ' B' ' 26' ' ' LEU . 6.1 p-10 42.09 57.56 10.27 Favored Pre-proline 0 C--N 1.306 -1.309 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.963 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.27 12.1 0.52 Allowed 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.744 2.296 . . . . 0.0 111.753 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.426 ' H ' ' C ' ' B' ' 24' ' ' ASP . 36.0 tp -70.44 -46.14 64.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.039 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 91.9 t -70.28 -38.69 75.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.323 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -70.35 -45.95 73.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.56 -35.38 20.35 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.656 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -36.8 77.99 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.5 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -51.57 -37.48 49.89 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.311 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.6 -36.12 47.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.847 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -70.63 -33.12 51.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.481 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.86 -44.72 78.5 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.284 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 16.6 pt -70.04 -37.41 72.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.553 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.525 ' O ' HD13 ' B' ' 36' ' ' LEU . 0.2 OUTLIER -49.15 -42.63 40.26 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.035 -179.75 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 0.5 OUTLIER -53.2 -45.79 68.74 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.783 -179.761 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -57.85 -45.07 86.8 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.537 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.6 mp -61.28 -45.72 98.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.838 -179.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.33 -39.92 74.44 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.181 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.58 -28.64 5.91 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.435 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 43.4 p -62.01 -38.62 89.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.43 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.653 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.45 -50.17 80.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.607 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.74 -29.65 58.6 Favored Glycine 0 C--N 1.304 -1.218 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -56.0 -28.41 57.12 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.916 HD21 HE21 ' C' ' 48' ' ' GLN . 1.9 pp -47.61 -29.44 2.91 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.738 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.491 ' OD1' ' NH2' ' B' ' 51' ' ' ARG . 83.5 m-20 -62.92 -45.58 91.83 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 10.2 tt0 -61.29 -53.11 60.96 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.011 0.434 . . . . 0.0 111.86 -179.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.673 HG23 ' H ' ' B' ' 50' ' ' LYS . 1.5 tp -55.85 -66.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.673 ' H ' HG23 ' B' ' 49' ' ' ILE . 18.0 pttp -150.89 172.23 15.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.995 0.426 . . . . 0.0 110.71 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.491 ' NH2' ' OD1' ' B' ' 47' ' ' ASN . 32.9 ttm-85 -152.23 135.21 15.65 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.233 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.227 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.932 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 41.6 t . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -106.08 100.05 26.48 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.372 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -83.12 10.51 3.62 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 122.145 1.897 . . . . 0.0 112.37 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.493 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -55.24 -50.31 69.79 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.762 -179.312 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 80.0 t -69.87 -39.91 78.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.829 0.347 . . . . 0.0 111.198 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 66.9 t -62.3 -44.21 98.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.618 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.541 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -64.03 -50.19 69.43 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.609 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.43 -29.34 67.7 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.488 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -54.71 -42.6 71.69 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.448 -179.227 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.541 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.7 tp -50.75 -30.58 8.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.97 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -70.45 -34.26 57.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.342 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.49 -49.25 57.53 Favored Glycine 0 C--N 1.303 -1.291 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.128 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 35' ' ' ILE . . . . . 0.412 ' O ' HD12 ' C' ' 39' ' ' ILE . 14.4 tt -64.81 -37.45 80.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 122.52 -0.4 . . . . 0.0 110.713 -179.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 36' ' ' LEU . . . . . 0.695 ' C ' HD12 ' C' ' 36' ' ' LEU . 0.1 OUTLIER -53.29 -47.11 69.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.151 -178.807 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.625 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 0.8 OUTLIER -61.0 -28.58 69.14 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.555 -178.258 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.621 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.2 t80 -58.88 -48.01 82.9 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.615 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.597 ' H ' HD12 ' C' ' 39' ' ' ILE . 4.3 mp -60.73 -45.58 97.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.484 -0.487 . . . . 0.0 111.078 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -29.88 65.92 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.472 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 41' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' C' ' 41' ' ' TRP . 10.7 t-105 -48.93 -50.36 35.71 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.769 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.523 HG22 ' O ' ' C' ' 39' ' ' ILE . 12.2 t -47.79 -28.05 2.34 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.055 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.515 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tp -49.83 -49.32 20.83 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 120.299 -0.56 . . . . 0.0 110.358 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.586 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -54.18 -28.44 42.1 Favored Glycine 0 C--N 1.302 -1.321 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.93 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.66 -33.39 15.48 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.818 0.309 . . . . 0.0 111.415 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.609 HD12 ' N ' ' C' ' 47' ' ' ASN . 2.0 pp -60.7 -44.56 96.42 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.609 ' N ' HD12 ' C' ' 46' ' ' LEU . 6.4 p30 -61.57 -49.69 75.63 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 120.188 -0.605 . . . . 0.0 111.143 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.916 HE21 HD21 ' B' ' 46' ' ' LEU . 1.9 mm100 -44.64 -15.63 0.02 OUTLIER 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.834 0.35 . . . . 0.0 111.096 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.812 HG23 ' H ' ' C' ' 50' ' ' LYS . 2.0 tt -136.43 -98.37 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -179.493 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.812 ' H ' HG23 ' C' ' 49' ' ' ILE . 58.7 pttt 42.7 32.89 0.42 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.764 0.316 . . . . 0.0 111.005 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -141.99 87.43 2.04 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.408 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.987 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 12.6 p . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -63.85 137.1 97.0 Favored Pre-proline 0 C--N 1.305 -1.365 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.213 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -74.55 45.36 1.24 Allowed 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.979 1.786 . . . . 0.0 111.935 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 41.6 tp -70.52 -44.39 67.65 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.0 t -70.7 -41.96 77.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.164 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.75 -38.39 72.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.329 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -35.13 21.41 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.69 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.17 -29.41 70.76 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.022 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.0 t -52.71 -42.54 64.93 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.199 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.664 HD12 ' N ' ' D' ' 32' ' ' ILE . 1.9 mp -54.97 -37.35 41.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.733 0.301 . . . . 0.0 110.5 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.412 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 6.0 mt -71.45 -29.71 36.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.401 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.5 -48.92 47.97 Favored Glycine 0 C--N 1.306 -1.108 0 C-N-CA 121.361 -0.447 . . . . 0.0 113.025 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 pp -66.34 -32.47 58.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 117.194 0.497 . . . . 0.0 110.579 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 tp -51.06 -37.68 46.98 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.198 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.624 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 20.3 m170 -58.63 -40.44 83.37 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.858 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.02 -48.27 82.56 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 39' ' ' ILE . . . . . 0.408 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.6 pt -61.53 -41.88 91.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.175 -0.61 . . . . 0.0 111.422 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.6 -38.34 73.99 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.083 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.4 -30.77 8.39 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 42' ' ' THR . . . . . 0.408 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 77.7 p -64.65 -34.11 77.52 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.252 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.643 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -70.49 -52.08 32.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.688 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.52 -29.35 24.01 Favored Glycine 0 C--N 1.306 -1.105 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.44 ' O ' HG22 ' D' ' 49' ' ' ILE . 5.6 t-80 -56.4 -27.03 55.21 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 111.528 0.195 . . . . 0.0 111.528 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -46.3 -31.9 2.82 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.429 -177.542 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 30.5 t-20 -59.49 -50.86 72.29 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.767 -0.373 . . . . 0.0 111.558 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.551 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -73.31 -66.22 0.71 Allowed 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.159 0.504 . . . . 0.0 111.417 -178.789 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.721 ' O ' HG23 ' D' ' 49' ' ' ILE . 17.9 tt -63.63 93.6 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 CA-C-O 121.717 0.77 . . . . 0.0 110.046 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 33.5 ttpt 60.6 106.67 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.62 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -76.51 -169.17 1.15 Allowed 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.496 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.989 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.6 m . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -129.45 65.4 74.44 Favored Pre-proline 0 C--N 1.312 -1.032 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.153 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -78.65 48.41 2.75 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.767 2.311 . . . . 0.0 111.599 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.9 tp -70.52 -42.85 70.71 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.21 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.15 -40.92 78.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.589 -179.163 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.7 t -68.16 -46.21 81.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.822 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -38.43 34.96 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.879 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.47 79.01 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.428 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.29 -39.92 80.59 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.949 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -51.26 -29.67 9.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.263 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.9 mt -69.75 -29.82 42.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.623 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.26 -48.17 66.27 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 121.182 -0.532 . . . . 0.0 112.287 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.859 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.1 mp -67.14 -29.68 46.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 120.681 -0.407 . . . . 0.0 111.126 -179.223 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.73 -46.3 90.94 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.574 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.695 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.1 p80 -61.78 -28.79 69.7 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.385 -178.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 64.1 t80 -60.62 -50.14 74.72 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.8 -39.17 69.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.007 -178.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.42 -36.04 73.77 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.891 0.377 . . . . 0.0 110.944 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.8 t-105 -49.68 -38.05 31.22 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.103 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.1 p -52.47 -39.76 61.52 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.91 -49.32 84.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.834 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.36 -28.6 9.49 Favored Glycine 0 C--N 1.304 -1.205 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 -48.85 -28.22 3.59 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.478 ' O ' HG22 ' A' ' 49' ' ' ILE . 2.4 pp -46.15 -33.77 3.8 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.292 -177.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 11.2 m-20 -46.12 -28.03 1.12 Allowed 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.597 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.539 ' O ' ' N ' ' A' ' 50' ' ' LYS . 12.1 tt0 -92.26 -45.62 8.13 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 120.66 0.267 . . . . 0.0 111.25 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.478 HG22 ' O ' ' A' ' 46' ' ' LEU . 1.8 tp -42.62 -15.19 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -178.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.539 ' N ' ' O ' ' A' ' 48' ' ' GLN . 0.0 OUTLIER -94.65 -74.76 0.53 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 120.86 0.362 . . . . 0.0 110.034 179.336 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -52.31 -71.03 0.07 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.707 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.074 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -179.866 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 34.3 p . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.475 ' C ' ' H ' ' B' ' 26' ' ' LEU . 0.9 OUTLIER -77.86 152.17 79.88 Favored Pre-proline 0 C--N 1.304 -1.377 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.147 179.853 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 35.43 0.24 Allowed 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.14 1.893 . . . . 0.0 111.681 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.475 ' H ' ' C ' ' B' ' 24' ' ' ASP . 48.4 tp -70.42 -46.62 63.56 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.067 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 48.7 t -70.42 -37.55 70.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.582 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.17 -44.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.598 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -33.22 12.04 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.356 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.92 -33.67 76.59 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.766 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -57.56 -41.03 80.23 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.782 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -56.71 -35.94 47.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.279 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.57 -33.74 50.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.441 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.17 73.38 Favored Glycine 0 C--N 1.305 -1.183 0 C-N-CA 121.249 -0.5 . . . . 0.0 111.898 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.418 HG23 ' N ' ' B' ' 36' ' ' LEU . 3.7 tp -68.47 -43.99 83.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.745 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.418 ' N ' HG23 ' B' ' 35' ' ' ILE . 53.9 tp -49.97 -38.12 35.42 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.136 0.493 . . . . 0.0 110.078 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -49.64 -41.9 43.73 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.012 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -67.41 -38.71 85.04 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.726 -179.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.56 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.5 mp -62.01 -43.91 98.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.65 -179.321 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.56 74.96 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.152 0.501 . . . . 0.0 110.788 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.49 -29.56 6.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.819 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.3 p -61.62 -36.14 79.89 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.464 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -63.67 -50.79 76.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.093 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.21 -29.48 29.48 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.493 ' O ' HG22 ' B' ' 49' ' ' ILE . 44.7 t60 -61.46 -28.92 69.62 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 120.616 0.246 . . . . 0.0 111.327 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.533 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.8 OUTLIER -49.4 -34.66 16.83 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.397 -178.877 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -64.45 -50.43 67.53 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.463 ' OE1' ' CE1' ' B' ' 45' ' ' HIS . 9.5 pt20 -69.66 -50.05 47.8 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.254 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.864 HG23 ' H ' ' B' ' 50' ' ' LYS . 15.9 tt -58.43 -68.88 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.93 -179.272 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.864 ' H ' HG23 ' B' ' 49' ' ' ILE . 17.8 ptmt -114.84 155.39 26.88 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.671 0.272 . . . . 0.0 110.442 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 61.5 ttm-85 -147.54 -61.42 0.27 Allowed 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.362 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.135 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 93.3 p . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 m-20 -162.32 57.32 0.72 Allowed Pre-proline 0 C--N 1.307 -1.262 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -76.21 0.78 9.01 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.723 2.282 . . . . 0.0 112.116 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.8 tp -66.6 -45.07 80.4 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.994 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.22 -34.34 58.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.301 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.57 -47.3 80.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -37.38 26.42 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.788 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.4 -29.8 70.85 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.47 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.4 t -57.26 -42.85 82.34 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.693 0.283 . . . . 0.0 111.321 -179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.674 ' N ' HD12 ' C' ' 32' ' ' ILE . 2.2 mp -54.77 -30.28 22.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.397 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 mt -68.14 -36.38 75.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.525 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.61 -45.29 94.96 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.396 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 tp -69.96 -29.6 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 116.964 0.382 . . . . 0.0 110.824 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 33.0 tp -61.75 -49.26 77.13 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.916 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -55.66 -28.83 57.62 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 120.566 -0.454 . . . . 0.0 111.552 -178.61 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 51.4 t80 -61.07 -42.44 98.5 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.696 -0.229 . . . . 0.0 111.509 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 57.2 mt -58.1 -45.36 88.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.348 -178.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.26 -35.4 76.05 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.854 0.359 . . . . 0.0 110.743 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -49.47 -35.26 19.13 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 29.1 p -55.42 -39.07 69.79 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.031 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 85.1 mt -62.1 -48.49 88.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.901 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.17 -27.79 5.58 Favored Glycine 0 C--N 1.305 -1.189 0 N-CA-C 111.613 -0.595 . . . . 0.0 111.613 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -47.71 -28.1 2.28 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 122.744 -0.268 . . . . 0.0 111.511 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.418 HD12 ' N ' ' C' ' 47' ' ' ASN . 3.2 pp -46.15 -43.73 15.29 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.323 -178.044 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.418 ' N ' HD12 ' C' ' 46' ' ' LEU . 35.6 p-10 -50.14 -37.93 36.72 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.24 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.407 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 44.9 tt0 -63.19 -49.1 75.58 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.921 0.391 . . . . 0.0 111.445 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.703 HG23 ' N ' ' C' ' 50' ' ' LYS . 0.5 OUTLIER -94.56 -142.7 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.474 -179.499 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.703 ' N ' HG23 ' C' ' 49' ' ' ILE . 8.4 mtpm? 39.72 26.55 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.727 -179.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 51' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' C' ' 49' ' ' ILE . 11.3 tpt180 -157.31 112.22 2.75 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.177 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.086 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 95.8 p . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.483 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.2 m-20 -53.11 150.94 9.84 Favored Pre-proline 0 C--N 1.306 -1.314 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.058 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.8 34.59 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 122.081 1.854 . . . . 0.0 111.841 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.483 ' H ' ' C ' ' D' ' 24' ' ' ASP . 48.4 tp -71.99 -38.25 69.7 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.801 179.05 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.73 -40.7 77.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 28' ' ' VAL . . . . . 0.413 HG23 ' N ' ' D' ' 29' ' ' ALA . 31.0 m -70.11 -40.23 78.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 CA-C-O 120.687 0.28 . . . . 0.0 110.836 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.413 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.45 -30.93 32.19 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.48 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.19 -34.61 68.53 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.237 179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.4 t -63.68 -44.85 92.49 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 pt -56.71 -28.17 27.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 120.852 0.358 . . . . 0.0 110.696 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.97 -29.02 35.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.315 179.437 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.07 -38.5 95.45 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 116.36 -0.382 . . . . 0.0 113.263 -178.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -68.96 -29.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 117.49 0.645 . . . . 0.0 110.366 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 36' ' ' LEU . . . . . 0.544 ' O ' HD23 ' D' ' 36' ' ' LEU . 0.9 OUTLIER -57.31 -29.49 63.97 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.382 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.695 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 8.7 m170 -69.75 -35.6 75.09 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.539 -179.187 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -66.18 -46.68 76.51 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -178.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 pp -66.33 -39.14 83.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.416 -178.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -38.92 74.6 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.054 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -52.96 -30.74 36.58 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.952 0.406 . . . . 0.0 111.0 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 67.6 p -63.95 -32.08 73.49 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.023 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 18.1 mm -70.66 -51.63 35.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.461 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.42 -29.74 31.68 Favored Glycine 0 C--N 1.307 -1.082 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.435 ' O ' ' OE1' ' D' ' 48' ' ' GLN . 22.3 t60 -54.62 -27.19 37.65 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 120.715 0.293 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.83 -33.38 10.43 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.668 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 51.0 t-20 -48.72 -51.82 26.75 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.733 -178.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.447 ' H ' ' CD ' ' D' ' 48' ' ' GLN . 3.0 pm0 -88.46 -132.53 0.08 Allowed 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.693 ' O ' HG23 ' D' ' 49' ' ' ILE . 0.2 OUTLIER 29.78 89.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.959 0.885 . . . . 0.0 112.203 179.139 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt 42.83 77.68 0.06 Allowed 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.835 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 33.7 ptt-85 -49.29 -38.7 28.23 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.153 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.84 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.4 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 26' ' ' LEU . 49.5 m-20 -160.85 58.25 0.98 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.761 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.89 20.33 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.761 2.307 . . . . 0.0 111.912 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' A' ' 24' ' ' ASP . 1.4 tt -65.32 -49.54 69.06 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 -179.569 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' N ' ' A' ' 28' ' ' VAL . 11.9 p -70.6 -39.43 75.97 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.005 179.749 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.468 ' N ' HG13 ' A' ' 27' ' ' VAL . 69.0 t -62.95 -29.95 48.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.754 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.87 69.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.522 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.34 -36.0 80.53 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.596 -179.375 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.2 t -56.52 -46.19 80.72 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.565 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.696 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.35 -39.85 22.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.935 0.398 . . . . 0.0 110.166 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -70.46 -28.61 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.289 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.96 -50.68 56.81 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.199 -0.524 . . . . 0.0 112.796 -178.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' N ' ' A' ' 36' ' ' LEU . 2.8 pp -66.04 -29.15 45.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.065 0.432 . . . . 0.0 111.413 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 35' ' ' ILE . 7.2 tt -62.74 -41.13 99.05 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.451 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.632 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -65.56 -28.74 69.37 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.659 -178.976 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 60.3 t80 -64.49 -50.44 67.42 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -178.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.4 pt -51.56 -40.46 25.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.149 -179.024 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.32 -33.25 65.05 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 120.97 0.414 . . . . 0.0 111.272 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.453 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 11.8 t-105 -49.23 -31.06 7.99 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -177.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -69.39 -29.6 67.4 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.331 -179.443 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.5 mp -56.17 -44.98 80.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.847 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.15 -28.43 4.25 Favored Glycine 0 C--N 1.304 -1.236 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -178.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 -48.88 -28.48 3.81 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 120.806 0.336 . . . . 0.0 110.398 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.844 ' O ' HG23 ' A' ' 49' ' ' ILE . 2.8 pp -45.44 -44.22 12.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.905 -177.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.438 ' HB3' HD21 ' D' ' 47' ' ' ASN . 55.8 m-20 -49.98 -51.76 39.05 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.689 -0.632 . . . . 0.0 111.102 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.408 ' OE1' ' CG2' ' D' ' 43' ' ' ILE . 1.7 pt20 -96.94 59.46 1.68 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -178.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.844 HG23 ' O ' ' A' ' 46' ' ' LEU . 0.1 OUTLIER -64.1 -55.2 23.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.585 179.299 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.4 ' N ' HG12 ' A' ' 49' ' ' ILE . 0.0 OUTLIER -138.2 -12.87 1.4 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 120.854 0.359 . . . . 0.0 110.073 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -67.73 -22.54 65.24 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.561 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.095 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 80.5 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.436 ' C ' ' H ' ' B' ' 26' ' ' LEU . 48.7 m-20 54.02 57.54 12.88 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.818 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.49 24.55 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.702 2.268 . . . . 0.0 111.618 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.436 ' H ' ' C ' ' B' ' 24' ' ' ASP . 52.2 tp -70.23 -43.21 71.08 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.503 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 96.3 t -70.16 -41.77 78.99 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.738 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 50.2 t -70.21 -41.11 78.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.176 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.8 -37.31 18.82 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.349 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.9 -29.52 65.14 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.72 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.6 t -58.64 -41.73 86.66 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 23.9 mm -50.66 -36.65 14.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.684 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -69.99 -29.76 41.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.15 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.68 -50.16 63.61 Favored Glycine 0 C--N 1.306 -1.131 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.622 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.0 pt -62.5 -43.65 98.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.998 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.5 tp -62.28 -49.16 76.76 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.019 0.438 . . . . 0.0 109.828 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -49.79 -39.45 38.21 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.95 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 74.8 t80 -69.99 -39.74 75.71 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.48 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.37 -43.67 94.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.968 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.05 -40.76 91.23 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.995 0.426 . . . . 0.0 110.594 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.81 -32.74 14.74 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.285 -179.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 58.0 p -60.98 -38.16 84.99 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.993 -179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.594 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.6 mp -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.503 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.19 -29.81 16.24 Favored Glycine 0 C--N 1.304 -1.224 0 C-N-CA 121.335 -0.46 . . . . 0.0 112.089 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -58.07 -28.5 64.62 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.565 ' CD1' HH21 ' B' ' 51' ' ' ARG . 1.0 OUTLIER -47.03 -32.22 3.83 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.321 -177.605 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.574 HD21 ' CD ' ' B' ' 51' ' ' ARG . 18.3 m120 -62.29 -44.99 95.26 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 7.8 mm100 -61.74 -53.33 57.43 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 120.916 0.389 . . . . 0.0 112.027 -178.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.736 HG23 ' H ' ' B' ' 50' ' ' LYS . 1.9 tp -58.75 -67.53 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.135 -179.142 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.736 ' H ' HG23 ' B' ' 49' ' ' ILE . 24.0 pttm -136.15 149.3 48.57 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.959 0.409 . . . . 0.0 110.709 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.574 ' CD ' HD21 ' B' ' 47' ' ' ASN . 3.3 tpm_? -153.93 -43.93 0.09 Allowed 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.314 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.223 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -172.0 56.18 0.22 Allowed Pre-proline 0 C--N 1.306 -1.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.956 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -76.21 11.57 1.76 Allowed 'Trans proline' 0 N--CA 1.495 1.602 0 C-N-CA 122.747 2.298 . . . . 0.0 111.729 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.42 HD21 HG13 ' D' ' 28' ' ' VAL . 41.4 tp -70.07 -43.68 70.68 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.754 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.36 -40.92 78.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.923 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.2 -47.76 80.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.73 -37.18 28.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.976 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.97 -29.55 70.49 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-O 120.83 0.347 . . . . 0.0 111.07 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -52.49 -43.72 65.19 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -50.1 -29.1 5.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-O 120.75 0.31 . . . . 0.0 111.324 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.1 -31.83 48.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.116 -179.065 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.62 -50.16 38.78 Favored Glycine 0 C--N 1.303 -1.267 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.753 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 tp -69.54 -29.49 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 120.852 0.358 . . . . 0.0 110.281 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.11 -48.86 79.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.79 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -55.59 -29.14 58.55 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 120.646 -0.422 . . . . 0.0 111.935 -178.491 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -59.04 -42.61 90.67 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.375 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.439 ' H ' HD12 ' C' ' 39' ' ' ILE . 3.8 mp -58.38 -47.57 87.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.577 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.93 78.63 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.889 -0.325 . . . . 0.0 110.847 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -49.13 -29.99 6.06 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 67.7 p -57.13 -37.39 71.94 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.248 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 75.9 mt -63.22 -50.23 79.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.912 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.41 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -48.15 -28.83 6.3 Favored Glycine 0 C--N 1.305 -1.182 0 N-CA-C 112.059 -0.416 . . . . 0.0 112.059 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -49.12 -27.96 3.89 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.856 0.328 . . . . 0.0 111.341 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.496 HD12 ' N ' ' C' ' 47' ' ' ASN . 3.4 pp -46.04 -44.39 15.26 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.917 -177.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.496 ' N ' HD12 ' C' ' 46' ' ' LEU . 28.4 p-10 -52.05 -46.54 65.13 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.046 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.459 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 1.4 tm0? -53.84 -48.14 70.24 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.645 -179.045 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.677 ' CG1' ' H ' ' C' ' 50' ' ' LYS . 0.9 OUTLIER -94.43 -143.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.637 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.677 ' H ' ' CG1' ' C' ' 49' ' ' ILE . 50.1 mttm 43.0 -167.19 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 120.663 0.268 . . . . 0.0 110.31 -179.222 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -43.09 133.28 3.89 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.839 0.352 . . . . 0.0 110.878 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 52' ' ' GLY . . . . . 0.468 ' C ' ' NH1' ' B' ' 51' ' ' ARG . . . . . . . . 0 C--N 1.305 -1.163 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' D' ' 26' ' ' LEU . 4.1 m-20 -67.92 151.13 97.43 Favored Pre-proline 0 C--N 1.306 -1.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.124 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -72.21 27.08 0.26 Allowed 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 122.218 1.945 . . . . 0.0 111.829 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.7 tp -70.17 -44.86 67.91 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.582 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -70.17 -36.97 70.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.998 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 28' ' ' VAL . . . . . 0.42 HG13 HD21 ' C' ' 26' ' ' LEU . 87.9 t -67.97 -46.76 81.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.412 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.67 -34.35 11.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.46 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.96 -29.65 69.56 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 34.6 t -58.82 -43.72 90.69 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.218 -179.408 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.674 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -53.98 -29.9 19.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 120.835 0.35 . . . . 0.0 110.351 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.36 -29.91 37.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.265 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.93 -43.94 95.26 Favored Glycine 0 C--N 1.308 -1.024 0 C-N-CA 121.34 -0.457 . . . . 0.0 112.188 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -67.19 -37.64 79.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.499 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.1 tt -49.81 -43.31 48.55 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 26.4 m170 -57.8 -44.19 86.14 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.923 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -61.56 -47.26 86.34 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -178.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 39' ' ' ILE . . . . . 0.415 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.6 pt -63.79 -41.76 93.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.301 -0.56 . . . . 0.0 111.425 -178.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.432 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.16 -40.76 74.53 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.804 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.53 -29.32 6.65 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.042 0.449 . . . . 0.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 42' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.2 p -62.25 -33.21 74.18 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.345 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.602 ' O ' HD12 ' D' ' 46' ' ' LEU . 90.7 mt -65.56 -50.72 70.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.03 -28.15 47.84 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -56.85 -28.06 61.17 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 112.628 0.603 . . . . 0.0 112.628 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.898 HD13 ' N ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -49.21 -28.08 4.23 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -178.342 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.898 ' N ' HD13 ' D' ' 46' ' ' LEU . 16.0 m120 -65.09 -50.61 65.47 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.471 HE22 HD21 ' C' ' 46' ' ' LEU . 0.0 OUTLIER -64.21 -53.79 43.64 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -177.904 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.87 HG23 ' H ' ' D' ' 50' ' ' LYS . 14.7 tt -55.6 -68.63 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.237 -179.017 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.87 ' H ' HG23 ' D' ' 49' ' ' ILE . 14.7 tptm -121.79 156.03 34.05 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 120.814 0.34 . . . . 0.0 110.497 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 37.8 ptt-85 -151.02 16.94 0.76 Allowed 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.406 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.165 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.978 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 68.7 m . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -173.58 60.55 0.25 Allowed Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.41 24.7 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.716 2.277 . . . . 0.0 111.851 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.2 tp -70.14 -42.89 71.98 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.084 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.3 p -70.69 -39.19 75.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.65 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.471 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.0 t -66.77 -42.57 89.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.85 0.357 . . . . 0.0 110.971 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -34.54 18.85 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.683 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.61 82.54 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.739 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -59.31 -44.03 92.6 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.392 -179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -49.81 -34.68 9.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 120.95 0.405 . . . . 0.0 110.759 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.0 mt -69.8 -29.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.555 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.13 -50.27 52.6 Favored Glycine 0 C--N 1.306 -1.109 0 C-N-CA 121.105 -0.569 . . . . 0.0 112.363 -179.198 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 40.5 mt -61.04 -29.63 46.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 122.509 -0.407 . . . . 0.0 110.918 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.469 ' O ' HG22 ' A' ' 39' ' ' ILE . 46.3 tp -61.88 -44.43 96.83 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.361 -179.216 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -61.56 -28.83 69.62 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.501 -178.855 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 40.4 t80 -63.19 -50.63 69.54 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.253 0.464 . . . . 0.0 112.253 -178.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 42' ' ' THR . 5.8 tt -57.07 -38.83 62.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.23 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -30.62 64.77 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 120.936 0.398 . . . . 0.0 111.448 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -55.09 -36.49 65.7 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 -177.365 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.52 ' O ' ' ND1' ' A' ' 45' ' ' HIS . 0.1 OUTLIER -59.06 -34.01 71.45 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.995 -178.946 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 mp -60.68 -38.21 77.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.114 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.87 -25.81 1.75 Allowed Glycine 0 C--N 1.306 -1.111 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.397 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.52 ' ND1' ' O ' ' A' ' 42' ' ' THR . 39.1 m170 -46.96 -23.65 0.49 Allowed 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 122.77 0.428 . . . . 0.0 111.173 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mt -42.21 -47.32 4.67 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.984 -0.287 . . . . 0.0 110.504 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -53.59 -51.1 64.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -178.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' HG3' ' H ' ' A' ' 49' ' ' ILE . 8.0 pt20 -69.74 -55.16 10.68 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -178.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.414 ' H ' ' HG3' ' A' ' 48' ' ' GLN . 4.5 pt -54.23 -38.31 38.88 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.998 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -76.03 -72.61 0.31 Allowed 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.834 0.35 . . . . 0.0 110.527 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.514 HH22 ' HZ1' ' C' ' 50' ' ' LYS . 98.8 mtt180 -83.26 139.53 33.04 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.431 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.125 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.974 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 71.9 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.407 ' C ' ' H ' ' B' ' 26' ' ' LEU . 51.8 m-20 -77.74 149.6 77.78 Favored Pre-proline 0 C--N 1.305 -1.359 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.203 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -72.7 39.55 0.44 Allowed 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.104 1.87 . . . . 0.0 111.549 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.407 ' H ' ' C ' ' B' ' 24' ' ' ASP . 1.6 tt -63.35 -49.62 73.18 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.69 -179.569 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.08 -33.77 56.52 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.375 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.6 t -69.93 -44.5 78.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.516 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.86 -39.37 39.01 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.672 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.25 -33.47 74.67 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.846 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 6.8 t -57.8 -41.82 82.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.849 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mm -51.79 -34.33 16.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.727 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.88 -29.76 38.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.224 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.15 -48.74 62.54 Favored Glycine 0 C--N 1.305 -1.159 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 11.3 mm -61.54 -46.22 97.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.64 -179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.3 tp -52.39 -42.49 64.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.019 0.438 . . . . 0.0 109.933 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -49.92 -44.67 50.38 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.835 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -66.65 -41.6 87.98 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.555 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 93.3 mt -60.85 -45.16 98.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.899 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.416 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -67.81 -36.88 81.18 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.467 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.66 -34.85 19.57 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.534 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 25.0 p -52.43 -41.05 62.92 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.349 -179.37 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.66 -50.3 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.929 -0.308 . . . . 0.0 111.121 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.16 -29.72 15.88 Favored Glycine 0 C--N 1.305 -1.167 0 C-N-CA 121.187 -0.53 . . . . 0.0 111.964 -179.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -60.69 -28.1 68.37 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.5 ' CD1' HH21 ' B' ' 51' ' ' ARG . 1.0 OUTLIER -46.81 -31.08 2.79 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.863 -177.364 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -60.0 -48.96 79.54 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -63.14 -54.48 37.09 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -178.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.601 HG23 ' H ' ' B' ' 50' ' ' LYS . 2.6 tt -58.42 -68.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.07 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.601 ' H ' HG23 ' B' ' 49' ' ' ILE . 60.7 pttt -121.85 161.77 22.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.846 0.355 . . . . 0.0 110.668 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.5 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.6 tpm_? -167.92 -57.61 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.611 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.173 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.953 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 40.9 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -174.92 56.42 0.17 Allowed Pre-proline 0 C--N 1.307 -1.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.708 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.07 11.49 1.45 Allowed 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 122.692 2.261 . . . . 0.0 112.156 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 40.5 tp -64.21 -48.33 76.28 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.097 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 23.4 t -70.22 -40.21 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.222 -179.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.4 t -69.47 -44.18 80.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.806 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.535 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -51.25 -43.1 61.43 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.957 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.44 69.37 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.093 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 5.8 t -51.22 -43.42 61.43 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.493 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.535 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -49.5 -29.61 4.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.344 -179.105 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.5 mt -69.03 -30.55 47.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.912 -179.088 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.546 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.64 -49.71 58.38 Favored Glycine 0 C--N 1.303 -1.292 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.312 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -66.41 -29.34 46.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.841 -179.444 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 10.4 tp -62.02 -50.71 70.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.528 -0.306 . . . . 0.0 111.823 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -52.51 -29.24 24.11 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.665 -178.401 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.7 t80 -58.06 -44.5 87.5 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 120.578 0.228 . . . . 0.0 111.481 -179.488 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.0 mt -54.55 -48.99 69.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.587 -178.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.53 -30.49 67.25 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.994 0.426 . . . . 0.0 110.761 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' B' ' 40' ' ' ALA . 2.7 t-105 -49.28 -36.67 21.3 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.058 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 33.6 p -59.23 -36.94 76.34 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.088 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -63.16 -50.98 77.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.283 -179.483 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.55 -29.8 25.4 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.916 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -51.76 -29.73 19.92 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.4 ' HG ' ' N ' ' C' ' 47' ' ' ASN . 1.5 pp -46.54 -35.8 6.13 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.472 -177.543 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.443 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 7.5 p30 -48.96 -44.86 41.17 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.371 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.443 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 11.7 tp60 -63.15 -48.71 77.28 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.695 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.465 HG23 ' O ' ' C' ' 49' ' ' ILE . 3.0 tp -111.58 101.13 12.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 121.452 0.644 . . . . 0.0 110.252 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.514 ' HZ1' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER -170.1 -39.76 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.682 179.605 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -74.81 -43.93 52.06 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.496 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.209 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.903 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 46.9 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -82.22 149.92 63.2 Favored Pre-proline 0 C--N 1.307 -1.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.347 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.12 42.52 0.64 Allowed 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.164 1.909 . . . . 0.0 111.745 179.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 51.7 tp -70.22 -47.92 59.32 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.649 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 10.5 t -70.87 -35.97 62.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.145 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -70.14 -46.29 72.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.659 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -29.8 7.71 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.005 -179.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.72 66.86 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.22 -40.38 81.52 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.22 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -55.22 -29.77 23.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.899 0.38 . . . . 0.0 110.836 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.23 -29.67 37.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.49 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.74 -44.43 80.87 Favored Glycine 0 C--N 1.307 -1.04 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.444 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.0 pt -67.03 -36.15 76.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.64 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -49.91 -36.68 28.37 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.457 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -59.17 -47.04 86.79 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.85 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -57.54 -46.14 84.24 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.9 pt -66.39 -43.14 91.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.436 -178.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -39.78 72.87 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.367 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 t-105 -49.39 -28.86 5.53 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 120.974 0.416 . . . . 0.0 110.673 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -62.0 -29.92 70.59 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.755 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 82.1 mt -70.21 -52.25 31.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-O 121.025 0.44 . . . . 0.0 111.053 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.576 ' O ' ' ND2' ' D' ' 47' ' ' ASN . . . -53.09 -28.21 32.79 Favored Glycine 0 C--N 1.302 -1.321 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.457 ' O ' HG23 ' D' ' 49' ' ' ILE . 0.0 OUTLIER -68.22 -29.34 68.14 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.527 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.467 HD12 ' N ' ' D' ' 47' ' ' ASN . 2.4 pp -52.76 -46.67 67.61 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.478 -179.021 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.591 HD21 ' CD ' ' D' ' 48' ' ' GLN . 0.7 OUTLIER -60.8 -45.63 93.67 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.609 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.591 ' CD ' HD21 ' D' ' 47' ' ' ASN . 2.1 mm100 -67.42 -110.57 0.0 OUTLIER 'General case' 0 N--CA 1.429 -1.517 0 C-N-CA 122.287 0.235 . . . . 0.0 111.214 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.457 HG23 ' O ' ' D' ' 45' ' ' HIS . 32.1 pt 32.69 50.59 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.379 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' D' ' 49' ' ' ILE . 50.5 mtpt 47.99 -178.11 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.422 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 ppt_? -158.51 -3.29 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.761 0.315 . . . . 0.0 110.51 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.252 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 179.956 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 49.9 m . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -161.64 59.17 1.0 Allowed Pre-proline 0 C--N 1.306 -1.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.735 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -77.55 -3.38 13.55 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.754 2.303 . . . . 0.0 112.003 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 57.7 tp -63.69 -45.73 88.72 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.83 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.2 p -70.37 -37.61 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.453 -179.439 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.418 ' N ' HG13 ' A' ' 27' ' ' VAL . 62.6 t -70.08 -35.99 66.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 CA-C-O 120.982 0.42 . . . . 0.0 110.784 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -38.16 31.66 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.62 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.57 -34.0 76.16 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.341 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.2 t -63.01 -50.34 71.11 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -178.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 11.2 pt -51.99 -29.49 11.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.636 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -67.25 -29.58 46.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -59.76 -46.24 94.38 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.4 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' D' ' 33' ' ' ILE . 10.0 mm -61.24 -35.75 68.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 CA-C-O 120.77 0.319 . . . . 0.0 111.145 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.65 -49.75 76.4 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.954 -178.549 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -57.72 -28.86 64.25 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.812 -178.768 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 71.2 t80 -59.63 -50.11 75.16 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.711 ' O ' HG22 ' A' ' 42' ' ' THR . 1.5 pp -59.22 -41.67 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.768 -178.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.92 -34.03 68.76 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.106 0.479 . . . . 0.0 111.002 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.474 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 10.1 t-105 -48.23 -35.3 11.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.517 -178.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.711 HG22 ' O ' ' A' ' 39' ' ' ILE . 14.9 t -56.86 -29.34 62.81 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.508 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 80.0 mt -55.28 -46.08 77.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.04 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' O ' ' OD1' ' A' ' 47' ' ' ASN . . . -45.5 -28.63 2.42 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 120.762 -0.733 . . . . 0.0 111.534 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 -48.59 -25.98 2.0 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.928 0.364 . . . . 0.0 110.79 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.664 ' O ' HG23 ' A' ' 49' ' ' ILE . 0.3 OUTLIER -45.2 -50.21 11.69 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.399 -178.175 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.542 ' OD1' ' NE2' ' A' ' 48' ' ' GLN . 0.1 OUTLIER -59.41 -44.02 92.92 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.507 -179.024 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.673 ' OE1' HD21 ' D' ' 46' ' ' LEU . 9.0 mm-40 -85.0 68.18 10.47 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.442 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.887 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.0 OUTLIER -115.93 -137.63 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 CA-C-O 120.873 0.368 . . . . 0.0 111.972 -179.699 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.418 ' N ' HG12 ' A' ' 49' ' ' ILE . 22.4 pttp -102.94 12.31 36.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.156 -179.227 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.8 ttt-85 -63.51 -41.04 98.54 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.23 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.146 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 179.651 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 41.2 m . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' B' ' 26' ' ' LEU . 0.8 OUTLIER -79.77 152.22 74.66 Favored Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.167 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 40.72 0.32 Allowed 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.226 1.951 . . . . 0.0 111.63 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.432 ' H ' ' C ' ' B' ' 24' ' ' ASP . 37.4 tp -69.35 -45.93 68.24 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.535 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 79.9 t -70.43 -41.1 78.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 57.3 t -68.65 -46.85 79.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.321 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.76 -38.37 33.72 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.663 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.89 -31.53 72.18 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.31 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 31.9 t -56.04 -42.11 76.05 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.991 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.6 mm -49.67 -29.86 4.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.649 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.9 mt -71.92 -29.82 34.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.51 -50.61 42.34 Favored Glycine 0 C--N 1.307 -1.076 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.324 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -64.53 -47.1 90.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.831 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -51.51 -41.26 60.87 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.059 0.457 . . . . 0.0 110.074 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -49.58 -39.79 36.38 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.813 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.46 -40.03 92.71 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.688 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.566 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.7 mp -57.48 -42.84 81.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.51 -179.26 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.98 -37.18 69.93 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.228 0.537 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.8 t-105 -54.91 -39.65 69.02 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.471 HG22 ' H ' ' B' ' 42' ' ' THR . 0.0 OUTLIER -57.69 -34.14 69.11 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.243 -178.903 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.586 ' O ' HD12 ' B' ' 46' ' ' LEU . 28.8 mm -62.14 -47.72 91.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.603 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.09 -28.67 8.2 Favored Glycine 0 C--N 1.306 -1.089 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -61.23 -27.05 68.17 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.978 HD13 ' H ' ' B' ' 47' ' ' ASN . 0.0 OUTLIER -47.71 -30.63 3.98 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.676 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.978 ' H ' HD13 ' B' ' 46' ' ' LEU . 29.4 p-10 -61.5 -50.5 72.47 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.372 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -59.27 -53.07 62.47 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 120.978 0.418 . . . . 0.0 112.112 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.798 HG23 ' H ' ' B' ' 50' ' ' LYS . 2.5 tp -60.67 -67.2 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.162 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.798 ' H ' HG23 ' B' ' 49' ' ' ILE . 57.4 mttp -71.57 116.21 11.65 Favored 'General case' 0 C--N 1.309 -1.175 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.149 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -166.3 129.61 2.02 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.474 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.16 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.938 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -162.02 56.37 0.66 Allowed Pre-proline 0 C--N 1.306 -1.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -77.82 8.57 3.36 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.692 2.261 . . . . 0.0 111.738 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 44.5 tp -70.13 -42.64 72.33 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.091 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 92.8 t -70.12 -44.22 78.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.192 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.09 -46.64 84.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.545 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.55 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -54.87 -44.37 73.99 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.941 -179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.54 -29.63 70.71 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 120.777 0.322 . . . . 0.0 110.925 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 7.1 t -50.56 -41.86 54.68 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.181 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.55 HG22 ' O ' ' C' ' 29' ' ' ALA . 16.2 tt -49.8 -29.06 4.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-O 120.851 0.357 . . . . 0.0 111.295 -179.376 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.9 mt -65.81 -33.45 63.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.144 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.57 -50.33 37.93 Favored Glycine 0 C--N 1.303 -1.256 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.202 -178.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.05 -29.48 44.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-O 120.868 0.366 . . . . 0.0 110.529 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -61.28 -50.62 72.26 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.782 -179.033 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -55.08 -28.65 54.06 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.742 -178.577 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 43.9 t80 -57.9 -44.38 86.72 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 121.031 -0.268 . . . . 0.0 111.456 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -56.34 -48.37 79.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.943 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.05 -34.28 73.02 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.855 0.359 . . . . 0.0 110.755 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 -48.4 -30.25 4.83 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.565 -179.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.7 p -56.38 -38.74 71.89 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.634 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.632 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.7 mp -64.05 -49.93 79.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.013 -179.557 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -47.82 -28.28 5.34 Favored Glycine 0 C--N 1.304 -1.198 0 C-N-CA 121.301 -0.476 . . . . 0.0 112.024 -178.453 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -49.07 -27.84 3.64 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.4 ' O ' ' O ' ' C' ' 49' ' ' ILE . 3.0 pp -46.04 -41.41 12.02 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.399 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.451 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 20.8 p-10 -49.13 -50.24 38.32 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.174 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -58.09 -49.14 77.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.162 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.607 HG23 ' O ' ' C' ' 49' ' ' ILE . 0.1 OUTLIER -120.8 110.39 28.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.909 -179.565 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.523 ' N ' HD13 ' C' ' 49' ' ' ILE . 3.4 ttmp? -131.78 -76.74 0.51 Allowed 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.12 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 84.3 mtt85 -89.24 9.55 25.4 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.485 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.963 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 74.1 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.4 m-20 -88.5 150.89 47.42 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.232 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.69 33.6 0.37 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.189 1.926 . . . . 0.0 111.756 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' D' ' 24' ' ' ASP . 2.1 tt -63.9 -50.54 68.32 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.613 -179.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 t -70.49 -33.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.113 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 92.5 t -69.95 -45.1 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.692 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.58 -32.71 8.51 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.718 -178.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.31 -32.17 73.69 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 120.769 0.319 . . . . 0.0 110.912 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 43.0 t -60.4 -42.93 96.95 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.217 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 mm -58.05 -35.21 51.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 121.148 0.499 . . . . 0.0 110.346 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' A' ' 35' ' ' ILE . 8.8 mt -71.67 -29.98 36.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.303 179.243 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.36 91.73 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.589 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 12.8 pt -68.51 -38.13 78.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.782 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tp -49.69 -38.63 33.76 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 120.946 0.403 . . . . 0.0 110.455 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.533 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 16.4 m170 -57.53 -39.78 77.36 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.371 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -58.23 -46.55 85.72 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.24 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.6 pt -66.63 -42.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.125 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -41.96 77.18 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.723 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -48.74 -29.46 4.5 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.745 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.5 m -66.8 -29.85 69.89 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.515 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 30.0 mm -65.48 -50.8 70.22 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.988 -0.285 . . . . 0.0 111.181 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.48 -34.17 63.34 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.451 ' O ' ' OE1' ' D' ' 48' ' ' GLN . 10.7 t-80 -55.98 -28.05 55.44 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 120.653 0.263 . . . . 0.0 111.522 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.673 HD21 ' OE1' ' A' ' 48' ' ' GLN . 0.4 OUTLIER -53.58 -29.82 39.26 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.17 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.685 ' ND2' ' N ' ' D' ' 48' ' ' GLN . 0.2 OUTLIER -59.75 -49.88 76.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.405 -0.518 . . . . 0.0 112.313 -178.0 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.685 ' N ' ' ND2' ' D' ' 47' ' ' ASN . 0.1 OUTLIER -83.31 53.02 2.35 Favored 'General case' 0 C--N 1.309 -1.184 0 O-C-N 122.208 -0.307 . . . . 0.0 111.616 -179.056 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.418 ' O ' ' O ' ' D' ' 50' ' ' LYS . 0.0 OUTLIER -177.2 127.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.119 0 CA-C-O 121.18 0.515 . . . . 0.0 110.229 179.085 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' D' ' 49' ' ' ILE . 54.1 tttp 60.18 131.01 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.833 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -161.46 136.57 7.47 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.467 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.173 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.919 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -171.23 60.11 0.31 Allowed Pre-proline 0 C--N 1.305 -1.329 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.827 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.68 28.68 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.788 2.325 . . . . 0.0 112.04 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' N ' HD12 ' A' ' 26' ' ' LEU . 10.3 mp -69.5 -40.91 76.71 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.711 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.544 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.4 p -70.76 -44.15 76.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.475 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.544 ' N ' HG13 ' A' ' 27' ' ' VAL . 88.5 t -63.63 -41.75 93.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.737 -179.46 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -37.38 29.53 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.476 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.76 -36.8 84.24 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.471 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -53.81 -47.14 71.13 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.994 -0.283 . . . . 0.0 111.233 -179.258 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.692 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.56 -40.17 24.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.462 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.87 -29.5 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.1 -50.66 44.37 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.907 -179.373 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 57.3 mt -64.74 -29.71 48.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 122.652 -0.322 . . . . 0.0 111.047 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.474 ' O ' HG22 ' A' ' 39' ' ' ILE . 33.4 tp -61.47 -45.18 95.33 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.331 -179.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.632 ' CE1' ' NE2' ' D' ' 37' ' ' HIS . 0.6 OUTLIER -61.66 -28.79 69.64 Favored 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 120.151 -0.62 . . . . 0.0 111.497 -178.839 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.2 t80 -63.47 -50.82 68.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.772 ' O ' HG22 ' A' ' 42' ' ' THR . 5.4 tt -54.91 -39.67 49.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.135 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -35.3 69.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.922 0.392 . . . . 0.0 111.215 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.462 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 11.3 t-105 -49.78 -35.07 21.2 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.244 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 39' ' ' ILE . 9.8 t -65.4 -29.4 70.1 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -179.275 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 36.5 mm -60.87 -45.15 98.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.777 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.16 -27.03 2.44 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.037 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -49.41 -29.62 6.69 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 mp -46.06 -43.17 14.33 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 121.181 -0.208 . . . . 0.0 111.036 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.402 ' HB2' ' NE2' ' A' ' 48' ' ' GLN . 18.9 m120 -58.02 -51.92 67.65 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.905 -0.718 . . . . 0.0 112.122 -178.166 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.72 ' OE1' HD11 ' D' ' 46' ' ' LEU . 3.5 mm-40 -61.89 -53.22 58.72 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -177.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 40.1 pt -48.64 -3.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -177.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 48' ' ' GLN . 17.9 pttp -143.78 -44.85 0.27 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 118.301 0.5 . . . . 0.0 111.077 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -76.69 -143.27 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.797 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.133 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.765 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 24' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -133.72 62.63 59.73 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.498 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -76.1 45.32 1.51 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.75 2.3 . . . . 0.0 111.574 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.01 -48.74 67.49 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.552 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.59 -30.35 42.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.48 HG22 HD23 ' A' ' 26' ' ' LEU . 58.0 t -70.14 -46.7 71.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.392 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.11 -31.5 8.2 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.613 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.69 -29.64 70.22 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.538 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.6 t -54.44 -38.08 65.89 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.796 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 25.8 mm -55.6 -36.94 44.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-O 120.923 0.392 . . . . 0.0 110.456 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.24 -29.98 38.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.337 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.96 -48.41 54.47 Favored Glycine 0 C--N 1.306 -1.11 0 N-CA-C 111.659 -0.576 . . . . 0.0 111.659 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -63.93 -42.44 95.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.611 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -60.61 -44.26 96.51 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 24.2 t-80 -49.86 -44.36 49.68 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.696 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -70.12 -37.55 75.34 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.272 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' B' ' 42' ' ' THR . 91.8 mt -63.41 -42.64 97.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.856 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.412 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.66 -37.47 70.78 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.009 0.433 . . . . 0.0 111.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -49.55 -44.84 46.94 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.81 -27.83 5.55 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.655 -178.528 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 9.3 tp -56.17 -48.57 79.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.252 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.517 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -57.65 -29.73 61.58 Favored Glycine 0 C--N 1.304 -1.229 0 C-N-CA 121.32 -0.466 . . . . 0.0 111.963 -179.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -53.17 -29.53 32.11 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.653 ' C ' HD12 ' B' ' 46' ' ' LEU . 2.7 pp -50.58 -34.0 24.13 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.836 -0.346 . . . . 0.0 111.519 -178.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.723 HD21 ' H ' ' B' ' 47' ' ' ASN . 1.1 m-80 -63.19 -50.38 70.55 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.096 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -67.41 -55.89 11.88 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.142 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.815 HG23 ' H ' ' B' ' 50' ' ' LYS . 7.7 tp -50.51 -67.71 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.815 ' H ' HG23 ' B' ' 49' ' ' ILE . 23.0 ttpp -139.82 146.49 39.48 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.997 0.427 . . . . 0.0 111.114 -179.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.526 HH21 ' CG ' ' B' ' 47' ' ' ASN . 48.2 ttm-85 -162.53 115.06 1.66 Allowed 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.383 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.978 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -175.74 59.68 0.19 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.778 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.95 19.74 0.57 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.862 2.375 . . . . 0.0 111.97 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.552 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -67.1 -42.71 84.13 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.637 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 27' ' ' VAL . . . . . 0.508 HG13 ' N ' ' C' ' 28' ' ' VAL . 12.9 p -70.28 -40.9 78.46 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.206 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 28' ' ' VAL . . . . . 0.508 ' N ' HG13 ' C' ' 27' ' ' VAL . 92.2 t -64.47 -46.63 92.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.746 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -55.96 -40.69 73.6 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.92 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.56 -29.65 70.67 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.746 0.308 . . . . 0.0 111.138 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 15.1 t -52.56 -44.27 65.76 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.617 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 12.3 tt -49.68 -29.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.269 -179.101 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.4 mt -69.02 -31.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.037 -179.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.15 -50.43 39.79 Favored Glycine 0 C--N 1.306 -1.085 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.016 -179.214 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 35' ' ' ILE . . . . . 0.439 HG22 ' H ' ' C' ' 35' ' ' ILE . 0.0 OUTLIER -66.72 -29.48 46.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.722 -179.76 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.4 tp -60.72 -48.77 80.31 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.687 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.79 -29.99 63.24 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.863 -178.367 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.2 t80 -62.18 -44.26 96.99 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.098 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -55.65 -45.61 79.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.723 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.15 -33.79 72.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.015 0.436 . . . . 0.0 110.779 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.29 -34.68 16.0 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.173 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 18.5 p -57.3 -45.05 84.53 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.376 -179.428 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.486 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.2 mp -66.45 -51.09 61.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.603 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.47 -29.52 17.42 Favored Glycine 0 C--N 1.303 -1.267 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 45' ' ' HIS . . . . . 0.509 ' CG ' HE21 ' C' ' 48' ' ' GLN . 41.4 t60 -59.77 -28.96 67.85 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.116 0.414 . . . . 0.0 112.116 -179.051 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.584 ' CD2' ' NE2' ' D' ' 48' ' ' GLN . 0.9 OUTLIER -46.1 -28.27 1.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.446 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -47.43 -51.48 19.95 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.383 -178.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.571 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 3.4 pm0 -73.24 -45.74 54.24 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.269 -179.622 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 1.1 tp -47.93 -5.73 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.515 ' N ' ' O ' ' C' ' 48' ' ' GLN . 49.8 mttm -92.08 153.65 19.25 Favored 'General case' 0 C--N 1.317 -0.833 0 O-C-N 122.046 -0.408 . . . . 0.0 110.234 179.425 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 51' ' ' ARG . . . . . 0.428 ' O ' ' O ' ' C' ' 50' ' ' LYS . 2.1 mpt_? 48.28 -176.96 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.162 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 47.2 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -76.82 148.35 79.05 Favored Pre-proline 0 C--N 1.305 -1.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.113 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.34 41.0 0.64 Allowed 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.1 1.867 . . . . 0.0 111.872 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.3 tp -63.85 -48.97 74.63 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.617 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 47.3 t -70.42 -34.21 57.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 57.6 t -70.05 -44.14 78.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.584 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -35.08 19.7 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.722 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.23 -29.63 70.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.2 t -55.54 -41.5 73.28 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.035 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.666 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -54.87 -35.62 34.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.491 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.76 -30.05 40.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.352 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.25 -46.02 88.88 Favored Glycine 0 C--N 1.306 -1.096 0 C-N-CA 121.249 -0.501 . . . . 0.0 112.07 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.1 pt -66.68 -29.79 47.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-O 120.815 0.341 . . . . 0.0 110.753 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tp -56.29 -42.39 77.46 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.708 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 15.3 m170 -56.62 -43.52 80.28 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.133 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -59.52 -47.09 86.88 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.4 pt -64.03 -43.8 97.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.491 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.12 -39.37 75.5 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.058 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -48.81 -29.4 4.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.859 0.361 . . . . 0.0 110.502 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 64.8 p -61.99 -31.51 71.88 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.769 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 33.7 mm -67.38 -51.33 53.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.76 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.99 -29.95 21.66 Favored Glycine 0 C--N 1.304 -1.245 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -59.02 -29.61 67.39 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 120.648 0.261 . . . . 0.0 111.274 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.72 HD11 ' OE1' ' A' ' 48' ' ' GLN . 2.6 pp -49.52 -43.49 45.68 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.395 -178.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.656 ' N ' HD12 ' D' ' 46' ' ' LEU . 0.9 OUTLIER -62.32 -49.42 75.68 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 -179.055 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.584 ' NE2' ' CD2' ' C' ' 46' ' ' LEU . 3.5 mm100 -54.22 -40.27 67.5 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-O 120.943 0.402 . . . . 0.0 111.603 -179.401 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.601 ' O ' HG23 ' D' ' 49' ' ' ILE . 20.4 tt -102.55 113.24 38.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-O 121.531 0.681 . . . . 0.0 109.973 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt 62.76 144.98 0.02 OUTLIER 'General case' 0 C--N 1.292 -1.914 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.805 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.95 18.96 1.44 Allowed 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.315 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.16 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.999 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo . . . . . 0 N--CA 1.492 1.423 0 CA-C-O 120.788 0.245 . . . . 0.0 111.973 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.1 tp -63.52 -44.61 93.77 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.779 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.9 p -70.23 -37.76 72.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.436 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.427 ' N ' HG13 ' A' ' 27' ' ' VAL . 97.3 t -67.08 -42.12 87.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.947 0.403 . . . . 0.0 110.663 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -43.85 46.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.007 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.3 -35.08 71.31 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.407 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.0 t -60.64 -43.24 97.77 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.027 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.7 mt -53.42 -37.85 30.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.079 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.91 -29.84 41.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.104 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.573 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -61.93 -47.66 88.65 Favored Glycine 0 C--N 1.302 -1.31 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.053 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.47 -29.37 38.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 122.382 -0.481 . . . . 0.0 110.775 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.518 ' O ' HD23 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -61.24 -49.33 77.54 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.709 -178.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.606 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.2 p80 -56.7 -28.95 61.87 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.968 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.606 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.1 t80 -63.78 -50.36 69.31 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.517 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.5 tt -57.85 -38.51 66.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.814 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -38.85 74.15 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.472 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -48.65 -32.44 8.29 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 120.847 0.356 . . . . 0.0 110.155 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -53.24 -42.47 66.44 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.319 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.4 mp -60.95 -47.94 91.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.032 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.56 -29.34 5.56 Favored Glycine 0 C--N 1.303 -1.296 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 . . . . . 0 C--N 1.303 -1.45 0 O-C-N 122.779 -0.248 . . . . 0.0 111.377 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 CA-C-O 120.872 0.28 . . . . 0.0 111.938 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.8 tp -68.0 -43.96 77.68 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.666 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.05 -35.81 65.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.086 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 89.4 t -67.33 -44.02 87.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.53 -37.63 27.64 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.656 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.36 -34.02 75.86 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.948 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -60.05 -42.74 95.11 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.741 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.7 mm -49.96 -31.78 7.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.555 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -69.61 -29.61 42.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.333 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.17 -50.6 44.41 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 121.026 -0.607 . . . . 0.0 111.889 -179.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.0 pt -62.71 -29.8 47.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.88 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -61.16 -46.93 88.51 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.576 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' C' ' 37' ' ' HIS . 7.8 m-70 -51.53 -50.54 59.82 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -54.2 -44.67 71.82 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.615 ' O ' HG22 ' B' ' 42' ' ' THR . 81.9 mt -59.02 -50.24 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.507 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.401 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -72.14 -36.85 69.48 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 121.086 0.47 . . . . 0.0 111.424 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.408 ' O ' ' CD1' ' B' ' 41' ' ' TRP . 9.8 t-105 -49.35 -34.6 16.31 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 113.294 0.849 . . . . 0.0 113.294 -177.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.615 HG22 ' O ' ' B' ' 39' ' ' ILE . 1.7 t -69.29 -29.31 67.14 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.048 -0.661 . . . . 0.0 110.709 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -61.99 -51.4 72.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.924 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.62 -29.83 19.01 Favored Glycine 0 C--N 1.306 -1.09 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -54.37 -27.47 36.61 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 120.88 0.371 . . . . 0.0 111.176 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -45.72 -29.83 1.4 Allowed 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.986 -176.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -58.29 -51.71 68.62 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.584 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -79.19 -58.91 2.99 Favored 'General case' 0 C--N 1.314 -0.959 0 O-C-N 121.871 -0.518 . . . . 0.0 111.741 -178.183 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 4.7 tt . . . . . 0 C--N 1.294 -1.837 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -179.195 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo . . . . . 0 N--CA 1.494 1.513 0 CA-C-O 120.748 0.228 . . . . 0.0 111.818 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 37.2 tp -65.81 -47.27 75.66 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -69.38 -40.88 80.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.918 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.4 t -67.39 -47.57 80.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.496 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.526 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -50.44 -42.98 54.85 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.105 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.858 0.361 . . . . 0.0 111.009 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 8.9 t -50.48 -43.88 55.62 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.4 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.526 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.3 tp -49.69 -29.35 4.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-O 120.804 0.335 . . . . 0.0 111.279 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.96 -31.69 48.81 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -178.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.544 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.39 -50.28 45.48 Favored Glycine 0 C--N 1.303 -1.266 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.564 -178.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.85 -29.51 43.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-O 120.987 0.422 . . . . 0.0 110.452 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.3 tp -62.04 -50.78 70.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.066 -0.515 . . . . 0.0 112.13 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' B' ' 37' ' ' HIS . 1.8 p80 -57.79 -28.96 64.49 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.642 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 87.4 t80 -56.99 -44.24 82.52 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.228 -179.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.401 ' O ' ' OG1' ' C' ' 42' ' ' THR . 68.1 mt -55.1 -42.68 66.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.152 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.28 -38.16 75.01 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 120.967 0.413 . . . . 0.0 110.722 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . 0.424 ' CZ3' ' ND1' ' B' ' 37' ' ' HIS . 5.7 t-105 -49.59 -32.85 13.64 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.199 -179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.2 p -65.58 -38.26 89.03 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.829 0.347 . . . . 0.0 110.961 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 29.5 mm -60.64 -50.43 80.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.021 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.21 -29.47 15.74 Favored Glycine 0 C--N 1.307 -1.066 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -50.19 -28.2 7.12 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp . . . . . 0 C--N 1.306 -1.322 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.934 -177.678 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 CA--C 1.533 0.307 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.03 41.48 0.66 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.087 1.858 . . . . 0.0 111.938 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -65.54 -48.69 71.62 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.672 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.32 -34.44 58.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.203 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 96.2 t -69.83 -45.62 76.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.524 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.44 -34.87 17.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.032 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.71 -29.74 69.8 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.062 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.4 t -55.04 -42.1 72.25 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.034 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -53.93 -31.84 21.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.73 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -70.98 -29.71 38.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.079 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.93 -45.0 90.7 Favored Glycine 0 C--N 1.306 -1.103 0 C-N-CA 121.26 -0.495 . . . . 0.0 112.392 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 16.5 pt -65.8 -38.42 82.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.038 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 47.5 tp -49.52 -40.34 37.43 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.551 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.422 ' ND1' ' N ' ' D' ' 37' ' ' HIS . 2.1 m-70 -59.82 -39.16 84.12 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.687 -0.405 . . . . 0.0 111.739 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 79.7 t80 -61.24 -48.57 80.84 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -178.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.3 pp -66.02 -39.07 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.534 -178.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.45 -41.31 72.97 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.803 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.02 -29.54 5.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.429 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 53.1 p -65.29 -30.3 71.15 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -70.15 -51.48 38.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.397 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.83 -29.99 55.92 Favored Glycine 0 C--N 1.305 -1.158 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 27.0 t-80 -56.3 -28.32 58.4 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 122.866 -0.196 . . . . 0.0 111.515 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.43 HD12 ' C ' ' D' ' 46' ' ' LEU . 0.9 OUTLIER . . . . . 0 C--N 1.308 -1.204 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.979 -178.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo . . . . . 0 N--CA 1.493 1.488 0 CA-C-O 120.882 0.284 . . . . 0.0 112.085 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 12.4 tp -62.15 -48.88 78.15 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.186 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.0 p -70.33 -32.39 50.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.532 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.4 t -70.29 -43.33 78.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 120.78 0.324 . . . . 0.0 110.929 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.46 -40.06 58.7 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.158 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -31.23 69.74 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.362 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -62.38 -37.8 87.12 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.008 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -57.37 -35.04 47.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.075 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.7 mt -67.99 -32.42 56.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.539 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.498 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.48 -44.72 82.69 Favored Glycine 0 C--N 1.302 -1.329 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.425 -178.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 70.4 mt -70.14 -29.74 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.888 0.375 . . . . 0.0 111.202 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.438 ' O ' HG22 ' A' ' 39' ' ' ILE . 54.5 tp -62.72 -47.66 82.62 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.704 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -58.27 -28.69 65.18 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.468 -179.054 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.9 t80 -54.13 -44.06 71.03 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 36' ' ' LEU . 8.9 tp -58.02 -43.12 84.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.378 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.426 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.5 -35.12 73.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.984 0.421 . . . . 0.0 110.976 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.484 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 3.2 t-105 -49.21 -37.85 24.23 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.151 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.37 -29.53 68.99 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.287 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mm -60.42 -48.86 86.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.104 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.87 -32.28 11.28 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 121.294 -0.479 . . . . 0.0 112.015 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-160 . . . . . 0 C--N 1.304 -1.404 0 CA-C-N 116.865 0.333 . . . . 0.0 111.369 -179.549 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo . . . . . 0 N--CA 1.496 1.632 0 CA-C-O 120.743 0.226 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 tp -70.7 -42.98 69.94 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -70.35 -44.85 77.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.519 -179.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 39.8 t -68.82 -43.83 82.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.74 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.483 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -49.89 -40.9 44.44 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.151 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -54.6 -28.57 47.36 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -48.77 -40.39 28.68 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.483 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.0 tp -49.2 -36.64 9.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.447 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.401 ' N ' HG23 ' B' ' 32' ' ' ILE . 8.3 mt -70.18 -29.54 40.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.532 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.54 -51.02 55.86 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.022 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 29.7 pt -65.46 -37.99 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.132 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.508 ' O ' HD23 ' B' ' 36' ' ' LEU . 1.7 tt -59.68 -48.68 80.73 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 121.307 0.575 . . . . 0.0 109.547 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -48.98 -46.72 44.12 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.249 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -68.64 -39.17 80.83 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.946 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 80.1 mt -61.42 -46.33 96.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.04 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.12 -40.89 95.13 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.843 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 -48.42 -33.1 8.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.407 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -52.26 -49.51 63.92 Favored 'General case' 0 C--N 1.3 -1.575 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.266 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.16 -51.45 71.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 C-N-CA 121.004 -0.279 . . . . 0.0 111.416 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.12 -29.4 36.12 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 3.9 t-160 -60.72 -30.0 69.7 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 120.89 0.376 . . . . 0.0 110.996 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.525 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.6 OUTLIER -48.67 -33.22 9.62 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.58 -178.49 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -64.37 -49.62 70.93 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.4 OUTLIER -59.79 -51.59 69.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-O 120.828 0.347 . . . . 0.0 111.928 -178.552 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 5.6 tt . . . . . 0 C--N 1.299 -1.618 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.529 -179.705 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo . . . . . 0 N--CA 1.493 1.443 0 CA-C-O 120.86 0.275 . . . . 0.0 112.039 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.509 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -70.11 -40.59 74.8 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.835 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.16 -45.59 75.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.384 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.8 t -66.66 -45.41 88.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.902 0.382 . . . . 0.0 110.758 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -58.09 -44.24 87.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.84 -29.43 70.62 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.315 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 22.7 t -53.54 -41.3 66.29 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.328 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.3 tt -49.91 -29.15 4.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-O 120.94 0.4 . . . . 0.0 111.175 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 16.1 mt -64.55 -37.43 80.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.12 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.55 -47.8 83.69 Favored Glycine 0 C--N 1.302 -1.321 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.408 -178.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -69.58 -30.02 43.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.72 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -62.2 -50.62 71.08 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -178.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -52.92 -29.17 27.07 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.642 -178.523 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.636 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.7 t80 -61.16 -42.28 98.27 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.572 -0.285 . . . . 0.0 111.522 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 76.9 mt -58.25 -49.72 80.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.824 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.59 -34.65 74.44 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.036 0.446 . . . . 0.0 110.649 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.1 -32.71 10.31 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.233 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -60.51 -36.08 77.51 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.258 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.39 -50.41 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.469 -179.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.89 -30.05 35.89 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 121.206 -0.521 . . . . 0.0 111.979 -179.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -50.87 -29.55 12.19 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 120.661 0.267 . . . . 0.0 111.627 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp . . . . . 0 C--N 1.304 -1.413 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.739 -177.666 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 t70 . . . . . 0 CA--C 1.538 0.489 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.33 55.97 3.73 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.015 1.81 . . . . 0.0 112.002 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.58 -45.51 68.49 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.597 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 t -70.48 -38.21 72.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.425 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 85.1 t -68.57 -43.22 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.848 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -31.9 12.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.021 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.09 69.5 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.959 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.2 t -54.22 -42.15 69.48 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.025 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 mm -50.7 -34.47 12.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.68 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -71.43 -29.27 34.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.358 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.59 -50.99 51.52 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.645 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . 0.833 HD12 ' N ' ' D' ' 36' ' ' LEU . 2.8 pp -62.87 -28.97 46.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.07 0.435 . . . . 0.0 110.628 -179.442 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . 0.833 ' N ' HD12 ' D' ' 35' ' ' ILE . 4.5 tp -60.88 -41.61 96.32 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.305 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 25.2 m170 -56.07 -41.3 74.89 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.613 -179.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -61.43 -47.86 83.81 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -178.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 12.3 pt -63.46 -43.73 98.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.163 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.484 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -63.33 -42.87 98.99 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.967 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -49.67 -33.83 16.8 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.521 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 54.5 p -59.21 -42.18 90.34 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.785 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.542 ' O ' HD12 ' D' ' 46' ' ' LEU . 4.7 mp -71.56 -53.1 21.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.4 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.39 -29.07 10.26 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -58.72 -28.18 65.59 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.593 HD22 ' C ' ' D' ' 46' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.244 0 N-CA-C 112.654 0.613 . . . . 0.0 112.654 -177.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo . . . . . 0 N--CA 1.492 1.424 0 CA-C-O 120.765 0.235 . . . . 0.0 112.069 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.3 tp -66.84 -46.49 74.95 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.686 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.5 p -70.47 -38.46 73.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.373 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.457 ' N ' HG13 ' A' ' 27' ' ' VAL . 89.0 t -70.03 -43.28 79.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.948 0.404 . . . . 0.0 110.674 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -36.47 25.73 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.096 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.43 -29.25 69.92 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -56.39 -43.83 79.65 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.4 pt -50.59 -29.51 6.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-O 120.746 0.308 . . . . 0.0 111.204 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -67.94 -29.95 46.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.592 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.99 -49.85 51.05 Favored Glycine 0 C--N 1.303 -1.275 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.181 -179.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.778 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.4 -29.53 46.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-O 120.696 0.284 . . . . 0.0 111.063 -179.364 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 34.0 tp -62.02 -49.25 76.78 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.634 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.3 p80 -57.91 -29.21 64.92 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.937 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.634 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.1 t80 -59.31 -44.29 92.58 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.742 -0.383 . . . . 0.0 111.031 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 77.9 mt -57.34 -48.89 81.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.89 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.6 -35.49 77.41 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 120.911 0.386 . . . . 0.0 110.747 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.67 -33.31 9.77 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.788 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 54.1 p -62.42 -33.2 74.31 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.003 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' A' ' 45' ' ' HIS . 16.1 mm -70.12 -46.65 71.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.886 -0.325 . . . . 0.0 110.583 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.23 -24.28 0.56 Allowed Glycine 0 C--N 1.301 -1.379 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.423 ' N ' ' O ' ' A' ' 43' ' ' ILE . 5.7 t-80 . . . . . 0 C--N 1.299 -1.597 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo . . . . . 0 N--CA 1.495 1.584 0 CA-C-O 120.935 0.306 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 40.1 tp -69.55 -47.46 63.62 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.861 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -70.43 -35.14 60.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.03 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 45.5 t -70.15 -47.09 69.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.358 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -37.85 30.87 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.162 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.08 -31.61 69.04 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.667 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 5.7 t -57.09 -36.02 70.11 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.57 -35.11 37.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.5 mt -71.29 -29.69 36.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.471 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.68 -44.7 88.97 Favored Glycine 0 C--N 1.307 -1.058 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.017 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -64.46 -43.42 96.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.825 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.2 tp -57.45 -42.7 83.03 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.21 -47.64 46.05 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.101 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -70.06 -37.25 75.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.421 ' O ' ' OG1' ' B' ' 42' ' ' THR . 96.1 mt -63.39 -43.59 98.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.587 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.63 -37.82 80.02 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 120.927 0.394 . . . . 0.0 110.681 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.63 -31.15 10.18 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.283 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 41.0 p -50.96 -36.06 36.87 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.158 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.5 mp -64.48 -50.29 76.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.66 -0.246 . . . . 0.0 111.078 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.3 -29.3 10.05 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.735 -0.546 . . . . 0.0 111.735 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.582 ' O ' HG22 ' B' ' 49' ' ' ILE . 7.7 t-160 -53.56 -27.01 23.87 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 2.1 pp -48.92 -37.54 20.16 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -64.36 -51.15 64.75 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.586 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -68.45 -53.99 19.91 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -178.246 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.582 HG22 ' O ' ' B' ' 45' ' ' HIS . 14.4 tt . . . . . 0 C--N 1.297 -1.691 0 C-N-CA 120.684 -0.407 . . . . 0.0 111.391 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo . . . . . 0 N--CA 1.494 1.515 0 CA-C-O 120.961 0.317 . . . . 0.0 111.765 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.503 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -63.95 -47.16 81.54 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.368 -179.718 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -69.67 -43.14 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.148 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -64.36 -43.32 97.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.575 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.579 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -62.13 -44.63 96.21 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.011 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.38 -29.49 70.56 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.789 0.328 . . . . 0.0 111.349 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -55.82 -43.02 76.54 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.432 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.579 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.4 tp -49.71 -28.9 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 120.804 0.335 . . . . 0.0 111.341 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.0 -31.03 46.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.104 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.99 -50.28 41.78 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.271 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 5.8 tp -68.41 -29.48 44.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.849 0.357 . . . . 0.0 110.482 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.16 -48.77 80.32 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.777 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -58.78 -29.24 66.65 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.561 -0.456 . . . . 0.0 111.886 -178.538 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 66.7 t80 -60.33 -45.49 93.27 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.939 -0.305 . . . . 0.0 111.361 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.414 ' O ' ' OG1' ' C' ' 42' ' ' THR . 73.7 mt -54.98 -46.4 76.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.562 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -34.56 72.77 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.411 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -48.55 -29.69 4.49 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.879 -178.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.5 p -63.06 -33.21 74.95 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.743 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.615 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.5 mp -65.28 -47.84 85.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.859 0.361 . . . . 0.0 110.598 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.78 -29.12 5.83 Favored Glycine 0 C--N 1.3 -1.466 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.504 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -53.41 -29.33 34.46 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.874 0.337 . . . . 0.0 111.732 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.601 HD13 ' O ' ' C' ' 43' ' ' ILE . 7.5 mp . . . . . 0 C--N 1.308 -1.205 0 CA-C-O 120.415 0.15 . . . . 0.0 111.05 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 . . . . . 0 CA--C 1.533 0.29 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -72.33 40.18 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.221 1.947 . . . . 0.0 111.968 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.74 -43.59 68.54 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.68 -40.67 77.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.061 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . 0.469 HG13 ' N ' ' D' ' 29' ' ' ALA . 14.3 p -70.46 -42.25 78.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.599 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.489 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -56.51 -40.02 74.32 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.791 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.86 -29.37 70.14 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.649 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -49.32 -36.41 21.03 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.489 HG22 ' O ' ' D' ' 29' ' ' ALA . 3.7 tp -53.75 -33.84 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 121.059 0.457 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.6 mt -71.16 -29.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.429 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.51 -43.92 91.27 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 121.358 -0.449 . . . . 0.0 112.503 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 28.3 pt -68.39 -32.68 56.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.653 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -53.24 -41.44 65.42 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 18.7 m170 -54.48 -42.92 71.27 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.704 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -56.96 -47.19 81.3 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -178.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.7 pt -65.01 -46.04 92.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.932 -0.707 . . . . 0.0 111.503 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.43 -37.92 77.62 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.63 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.472 ' O ' ' CD1' ' D' ' 41' ' ' TRP . 13.1 t-105 -49.07 -28.46 4.15 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.35 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 4.0 m -59.61 -30.95 69.05 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 96.1 mt -62.46 -50.55 79.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.487 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.22 -29.48 9.77 Favored Glycine 0 C--N 1.303 -1.281 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -62.89 -29.13 70.53 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.76 0.281 . . . . 0.0 111.76 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.304 -1.396 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo . . . . . 0 N--CA 1.495 1.588 0 CA-C-O 120.9 0.292 . . . . 0.0 111.573 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.8 tp -70.16 -44.53 68.62 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.754 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.7 -36.27 64.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.122 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.07 -44.7 78.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.976 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.49 -31.05 9.25 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.582 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.5 -30.11 66.8 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 35' ' ' ILE . 41.2 t -60.7 -44.45 96.54 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.592 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.682 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -52.12 -29.79 12.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.804 0.335 . . . . 0.0 110.353 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.4 mt -70.6 -29.62 39.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.211 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.501 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -64.04 -45.93 92.62 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.555 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -69.9 -29.56 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.053 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 39' ' ' ILE . 8.0 tt -61.84 -42.48 99.09 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.54 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -68.03 -28.59 67.53 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 120.239 -0.584 . . . . 0.0 111.456 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 76.7 t80 -66.49 -47.86 71.66 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.434 HG22 ' O ' ' A' ' 36' ' ' LEU . 7.2 tt -57.61 -35.9 52.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.24 -0.584 . . . . 0.0 110.442 -179.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.64 -36.11 73.25 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.659 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -52.95 -35.5 58.77 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.809 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.0 p -59.49 -37.12 77.43 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.669 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.604 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -69.25 -50.9 48.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.673 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.68 -28.32 6.87 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 111.991 -0.444 . . . . 0.0 111.991 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 33.7 t-80 . . . . . 0 C--N 1.293 -1.859 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -179.382 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . 0.432 ' O ' ' HB2' ' B' ' 29' ' ' ALA . 17.9 Cg_endo . . . . . 0 N--CA 1.498 1.756 0 CA-C-O 121.213 0.422 . . . . 0.0 112.113 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -70.85 -48.84 51.72 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.793 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 93.9 t -70.19 -39.43 76.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.095 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 53.1 t -70.17 -45.45 75.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.959 179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -49.07 -30.39 6.3 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.438 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.05 -29.54 69.79 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.057 0.456 . . . . 0.0 110.313 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -54.26 -37.23 64.46 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.649 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 70.4 mt -55.28 -33.9 32.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.1 mt -70.9 -31.5 45.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.223 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.71 -45.42 92.84 Favored Glycine 0 C--N 1.306 -1.127 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.045 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -65.59 -41.95 91.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.205 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -59.42 -46.39 88.86 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -49.87 -42.88 48.7 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.856 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -68.15 -39.07 82.75 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.364 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.71 -40.97 86.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.919 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.06 -40.85 74.81 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.023 0.44 . . . . 0.0 110.402 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.52 -31.09 9.5 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.858 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 62.7 p -60.77 -35.68 77.05 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.41 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.2 mm -67.38 -51.16 55.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.837 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.8 -39.38 31.88 Favored Glycine 0 C--N 1.305 -1.144 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.575 ' O ' HG22 ' B' ' 49' ' ' ILE . 23.3 t-80 -49.05 -26.55 2.7 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 120.741 0.305 . . . . 0.0 111.563 -179.648 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.1 -32.55 6.98 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.778 -178.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' B' ' 44' ' ' GLY . 11.1 p30 -70.37 -50.32 40.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -177.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.522 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 4.1 pt20 -69.54 -52.43 26.33 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -177.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.575 HG22 ' O ' ' B' ' 45' ' ' HIS . 10.6 tt . . . . . 0 C--N 1.296 -1.725 0 C-N-CA 120.661 -0.416 . . . . 0.0 110.638 -179.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo . . . . . 0 N--CA 1.493 1.448 0 CA-C-O 121.062 0.359 . . . . 0.0 111.919 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 45.8 tp -66.46 -47.72 72.23 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.471 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.5 t -69.98 -32.17 50.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.991 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.94 -49.5 56.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.588 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.25 -35.32 17.29 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.293 -179.007 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.22 -29.79 71.06 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 120.915 0.388 . . . . 0.0 110.904 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 34.7 t -50.0 -38.91 39.43 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.157 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.1 tp -53.69 -29.47 17.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.187 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.24 -36.93 69.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.014 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' NE2' ' C' ' 37' ' ' HIS . . . -63.72 -49.4 68.98 Favored Glycine 0 C--N 1.305 -1.156 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.687 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 tp -70.05 -29.86 41.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 CA-C-O 121.032 0.444 . . . . 0.0 110.105 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 27.2 tp -59.81 -49.41 77.83 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.64 -179.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.3 p80 -59.62 -29.03 67.72 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.68 -178.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 65.0 t80 -61.16 -43.36 99.0 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.031 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 66.2 mt -58.8 -45.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.087 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -38.96 75.55 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.585 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.6 -29.89 7.86 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.807 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 64.6 p -60.9 -37.7 83.16 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.748 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.5 mm -63.05 -50.54 79.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.31 -179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.12 -31.3 18.58 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 111.899 -0.48 . . . . 0.0 111.899 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -49.86 -28.09 6.03 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.0 pp . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 120.696 -0.401 . . . . 0.0 111.451 -178.458 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' D' ' 26' ' ' LEU . 10.5 m-20 . . . . . 0 CA--C 1.534 0.34 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.56 21.02 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.244 1.963 . . . . 0.0 111.752 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.462 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.9 tp -67.95 -47.15 69.44 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.532 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.97 -37.8 73.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 84.5 t -69.93 -43.57 79.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.525 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.39 -32.16 11.01 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.651 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.81 -29.68 69.68 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.964 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.0 t -56.27 -42.17 77.03 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.053 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.678 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -55.32 -35.63 37.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.448 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -71.06 -32.58 48.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.412 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.74 -44.29 98.1 Favored Glycine 0 C--N 1.305 -1.141 0 C-N-CA 121.336 -0.459 . . . . 0.0 112.123 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.6 pt -68.44 -29.35 43.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.841 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.6 tp -57.35 -43.04 83.13 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.037 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 4.1 m170 -60.76 -35.02 75.35 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.123 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 t80 -62.34 -48.53 79.41 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.6 -42.19 93.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.989 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.21 -40.27 74.64 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.86 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -48.46 -29.81 4.49 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.605 -179.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 73.3 p -64.86 -30.87 71.89 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.621 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.5 mp -69.87 -51.74 37.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.26 -31.73 27.79 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.7 t-160 -60.4 -28.28 68.12 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.549 0.214 . . . . 0.0 111.276 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.306 -1.312 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.487 -177.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.494 1.509 0 CA-C-O 120.986 0.327 . . . . 0.0 111.594 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -70.39 -43.83 69.25 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.043 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.6 p -70.89 -42.62 77.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.487 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.507 ' N ' HG13 ' A' ' 27' ' ' VAL . 66.1 t -68.41 -43.64 83.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.815 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.81 -34.45 53.74 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -30.54 67.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.5 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -60.36 -44.83 95.22 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.621 -179.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.2 mp -50.29 -29.08 5.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-O 120.825 0.345 . . . . 0.0 110.71 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.95 -29.32 39.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.809 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.54 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -68.61 -50.18 38.7 Favored Glycine 0 C--N 1.305 -1.172 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.324 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.569 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -65.98 -29.56 47.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.999 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.22 -46.02 88.96 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.705 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.7 OUTLIER -57.7 -28.35 63.74 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.625 -178.787 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 30.9 t80 -55.5 -45.76 77.02 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 3.4 tp -57.36 -44.56 84.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.299 -178.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.453 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.9 -35.4 72.28 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 120.824 0.345 . . . . 0.0 110.827 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.3 t-105 -48.95 -32.02 8.36 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.353 -178.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 61.2 p -57.56 -30.23 65.07 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.198 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 67.1 mt -64.2 -46.29 93.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.086 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.89 -27.56 3.4 Favored Glycine 0 C--N 1.297 -1.608 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.592 -178.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 t-80 . . . . . 0 C--N 1.304 -1.402 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -179.07 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . 0.434 ' O ' ' HB2' ' B' ' 29' ' ' ALA . 46.8 Cg_exo . . . . . 0 N--CA 1.496 1.641 0 CA-C-O 121.151 0.396 . . . . 0.0 111.91 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 tp -70.66 -49.15 50.36 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.417 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.444 HG13 ' N ' ' B' ' 28' ' ' VAL . 11.6 p -70.3 -38.95 76.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.573 -179.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.444 ' N ' HG13 ' B' ' 27' ' ' VAL . 8.2 t -70.56 -45.24 75.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 120.602 -0.439 . . . . 0.0 109.891 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.434 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -48.63 -33.41 9.86 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.242 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.28 69.96 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.482 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.2 t -49.69 -41.82 44.1 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.032 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -50.97 -29.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-O 120.904 0.383 . . . . 0.0 110.456 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.16 -29.55 36.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.204 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.91 -47.08 89.38 Favored Glycine 0 C--N 1.307 -1.067 0 C-N-CA 121.308 -0.472 . . . . 0.0 112.06 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.1 pt -62.12 -44.87 99.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.861 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 55.4 tp -59.97 -45.9 91.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.997 0.427 . . . . 0.0 109.905 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 33.8 t-80 -50.39 -47.56 56.33 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.142 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -66.95 -38.81 86.82 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.516 -179.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.08 -42.16 93.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.762 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.86 -39.74 76.17 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.964 0.412 . . . . 0.0 110.627 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -49.05 -29.32 4.9 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.956 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 77.8 p -54.67 -37.46 65.77 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 35.6 mm -61.16 -49.07 86.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.729 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.88 -29.91 8.66 Favored Glycine 0 C--N 1.305 -1.152 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.743 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -53.96 -27.48 31.49 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -46.43 -32.11 3.07 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -61.41 -50.31 73.38 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 120.705 -0.398 . . . . 0.0 112.039 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.416 ' HG2' ' H ' ' B' ' 48' ' ' GLN . 47.5 mm-40 -56.26 -53.95 51.1 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 7.8 tt . . . . . 0 C--N 1.296 -1.761 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.31 -179.36 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo . . . . . 0 N--CA 1.492 1.424 0 CA-C-O 120.78 0.242 . . . . 0.0 112.211 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -60.0 -50.67 72.83 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.035 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -70.98 -33.76 53.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 120.937 0.399 . . . . 0.0 111.178 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.7 t -70.3 -42.91 78.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.912 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.536 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.98 -39.35 40.61 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.51 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.19 -29.48 69.84 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 120.842 0.353 . . . . 0.0 111.292 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -53.05 -40.87 64.29 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.395 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.536 HG22 ' O ' ' C' ' 29' ' ' ALA . 3.4 tp -49.68 -31.53 6.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.751 0.31 . . . . 0.0 111.428 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -70.23 -29.84 41.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.94 -179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.526 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.26 -50.13 57.97 Favored Glycine 0 C--N 1.304 -1.218 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.908 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 36.8 pt -65.72 -29.65 47.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 120.776 0.322 . . . . 0.0 111.01 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 17.6 tp -61.29 -49.44 77.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.754 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.63 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.61 -29.69 62.42 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.767 -178.287 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.63 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 70.8 t80 -63.3 -44.37 95.21 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.258 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 72.5 mt -56.14 -48.21 79.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.155 -179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.86 -35.97 81.25 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -50.29 -36.34 31.24 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.346 -179.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.4 p -54.28 -47.13 72.69 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 120.741 0.305 . . . . 0.0 111.009 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.441 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -62.44 -49.82 82.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.76 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.75 -29.74 13.39 Favored Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.031 -179.16 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -56.68 -29.02 61.9 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.586 ' C ' HD12 ' C' ' 46' ' ' LEU . 3.8 pp . . . . . 0 C--N 1.305 -1.346 0 N-CA-C 111.625 0.231 . . . . 0.0 111.625 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 22.0 t70 . . . . . 0 CA--C 1.537 0.477 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -75.09 43.87 1.07 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.069 1.846 . . . . 0.0 112.166 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.47 -45.79 65.05 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.82 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.67 -41.08 77.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.912 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . 0.446 HG13 ' N ' ' D' ' 29' ' ' ALA . 8.1 p -70.73 -41.83 77.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.334 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.446 ' N ' HG13 ' D' ' 28' ' ' VAL . . . -49.8 -38.49 34.7 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.664 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.09 -31.54 72.8 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.258 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.5 t -56.22 -37.93 70.35 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.746 0.308 . . . . 0.0 110.793 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 mm -53.5 -29.59 17.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.387 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.4 mt -71.33 -29.24 34.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.465 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.33 -33.64 81.53 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 116.326 -0.397 . . . . 0.0 112.919 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -63.72 -38.48 82.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-N 117.402 0.601 . . . . 0.0 110.707 -179.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 43.6 tp -54.72 -43.09 72.28 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.8 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.705 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 19.3 m170 -51.13 -50.01 59.68 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.412 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -61.21 -42.45 98.61 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.557 -179.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.2 mt -60.28 -48.17 89.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.913 -179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.56 -34.73 72.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.82 0.343 . . . . 0.0 111.178 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.0 t-105 -49.0 -28.04 3.62 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.141 0.496 . . . . 0.0 110.017 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.7 p -57.92 -34.88 70.33 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.854 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.588 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -65.75 -50.92 67.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.759 0.314 . . . . 0.0 110.577 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.85 -29.67 62.08 Favored Glycine 0 C--N 1.302 -1.359 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.882 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -70.64 -32.91 70.39 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.306 -1.286 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.612 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo . . . . . 0 N--CA 1.495 1.581 0 CA-C-O 120.836 0.265 . . . . 0.0 111.755 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.4 tp -64.82 -44.89 88.4 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.202 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.5 p -70.29 -41.42 78.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.756 0.312 . . . . 0.0 111.307 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.489 ' N ' HG13 ' A' ' 27' ' ' VAL . 16.6 t -63.32 -39.89 86.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-O 120.94 0.4 . . . . 0.0 110.921 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.08 -44.12 82.8 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.551 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.59 -37.13 75.16 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.785 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -57.84 -43.48 85.86 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.137 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 69.4 mt -49.32 -37.82 11.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 120.814 0.34 . . . . 0.0 110.778 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -64.77 -29.67 48.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.406 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.537 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -63.27 -50.04 65.94 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.164 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -59.64 -29.62 43.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 122.686 -0.303 . . . . 0.0 111.34 -179.047 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tt -63.67 -50.83 67.71 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.672 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.5 OUTLIER -51.26 -29.44 14.6 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.272 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 63.8 t80 -58.35 -48.1 81.67 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.718 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.6 tp -49.67 -43.53 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.252 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.432 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -72.88 -30.03 63.64 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.76 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.507 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 10.9 t-105 -49.02 -32.38 9.25 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -177.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 42' ' ' THR . 0.2 OUTLIER -66.14 -33.01 74.79 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.463 -179.452 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.497 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -51.09 -43.86 27.51 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.03 0.443 . . . . 0.0 109.839 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.44 -28.71 4.93 Favored Glycine 0 C--N 1.299 -1.505 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.048 -178.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 . . . . . 0 C--N 1.307 -1.27 0 CA-C-N 117.251 0.526 . . . . 0.0 111.645 -179.485 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 N--CA 1.495 1.592 0 CA-C-O 121.15 0.396 . . . . 0.0 111.78 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 tp -70.13 -49.86 46.43 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.076 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -70.19 -33.02 52.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.943 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 87.7 t -69.68 -46.2 75.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.989 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.9 -33.02 9.93 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.639 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.26 -31.51 72.74 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.772 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 37.4 t -58.9 -40.93 85.96 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.623 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 mm -51.71 -29.23 10.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -70.41 -29.95 40.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.42 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.32 -48.4 69.72 Favored Glycine 0 C--N 1.307 -1.043 0 C-N-CA 121.185 -0.531 . . . . 0.0 111.948 -179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.8 pt -67.32 -29.79 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 120.871 0.367 . . . . 0.0 110.678 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.3 tp -59.45 -47.59 84.89 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.661 -179.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.636 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 7.2 m-70 -49.82 -49.78 47.65 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.648 -179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -50.92 -42.98 59.85 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.617 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 79.1 mt -61.12 -50.43 80.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.598 -178.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.32 -38.4 74.92 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.949 0.404 . . . . 0.0 111.076 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.6 t-105 -49.18 -28.73 4.72 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.035 -179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 44.1 p -59.9 -38.63 82.83 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.001 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 29.2 mm -65.77 -51.39 62.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 C-N-CA 120.836 -0.345 . . . . 0.0 111.379 -179.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.417 ' O ' ' OD1' ' B' ' 47' ' ' ASN . . . -50.21 -29.75 16.26 Favored Glycine 0 C--N 1.305 -1.193 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.558 ' O ' HG22 ' B' ' 49' ' ' ILE . 8.6 t-160 -56.72 -27.66 59.59 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.446 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.5 pp -47.78 -35.9 10.75 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.672 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 25.0 p-10 -63.26 -49.62 73.38 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 -178.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.451 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 1.4 tm0? -68.89 -57.45 5.52 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.558 HG22 ' O ' ' B' ' 45' ' ' HIS . 13.0 tt . . . . . 0 C--N 1.298 -1.665 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo . . . . . 0 N--CA 1.493 1.452 0 CA-C-O 120.748 0.228 . . . . 0.0 111.999 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 59.7 tp -61.11 -42.21 98.1 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.739 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.2 t -70.13 -42.33 79.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.347 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 98.7 t -60.13 -43.48 93.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 120.955 0.407 . . . . 0.0 110.328 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.448 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.22 -48.25 79.27 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.638 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.28 -35.05 69.3 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.847 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.9 t -56.8 -43.66 81.18 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.724 0.297 . . . . 0.0 111.453 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.602 ' O ' HD13 ' C' ' 32' ' ' ILE . 0.3 OUTLIER -48.66 -34.6 5.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-O 120.884 0.373 . . . . 0.0 110.459 -178.892 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.8 mt -64.18 -29.69 48.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.702 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.548 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.9 -51.37 35.06 Favored Glycine 0 C--N 1.306 -1.129 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.579 -178.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 tt -63.1 -29.29 46.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 122.419 -0.46 . . . . 0.0 111.195 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 55.9 tp -62.22 -51.4 67.95 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.589 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.636 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 1.2 p80 -53.92 -29.5 42.39 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.815 -178.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 68.9 t80 -57.17 -49.52 75.7 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.564 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -49.88 -43.38 19.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.505 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.77 -31.98 70.23 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.144 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -54.3 -42.68 70.38 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 116.592 -0.276 . . . . 0.0 111.309 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 17.3 p -56.58 -40.36 75.1 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.987 0.422 . . . . 0.0 110.434 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.4 mm -59.06 -50.86 78.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.318 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.8 -28.16 6.93 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -50.41 -40.13 49.22 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.427 HD12 ' N ' ' C' ' 46' ' ' LEU . 0.1 OUTLIER . . . . . 0 C--N 1.308 -1.237 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 -177.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.9 m-20 . . . . . 0 CA--C 1.528 0.111 0 CA-C-O 120.699 0.285 . . . . 0.0 110.983 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.11 12.6 0.98 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.85 2.366 . . . . 0.0 111.447 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' D' ' 24' ' ' ASP . 39.3 tp -70.74 -44.75 66.17 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.607 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.4 p -70.54 -35.06 59.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.39 -50.04 49.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.528 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.66 -33.46 15.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.87 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.46 -34.77 74.87 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.865 0.364 . . . . 0.0 111.132 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 36.7 t -51.85 -38.47 56.08 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.161 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 mm -61.3 -29.64 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.89 0.376 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.405 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 5.1 mt -71.33 -39.17 71.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.418 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.38 -42.2 96.12 Favored Glycine 0 C--N 1.307 -1.068 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.198 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 9.9 tt -70.27 -39.27 76.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.301 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 44.3 tp -49.48 -36.36 22.62 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.437 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.672 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 45.6 m170 -49.93 -43.11 49.65 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.164 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -57.6 -38.29 74.66 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.442 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mm -61.67 -50.81 78.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.157 -179.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.507 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.68 -35.62 72.91 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.956 -179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.57 -28.65 3.56 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.109 0.48 . . . . 0.0 110.403 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.4 p -51.05 -36.66 41.05 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.057 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 32.2 mm -68.23 -51.13 51.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.127 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.95 -29.48 55.39 Favored Glycine 0 C--N 1.305 -1.184 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -57.23 -27.57 62.14 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.298 -1.636 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.819 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 N--CA 1.492 1.41 0 CA-C-O 120.849 0.271 . . . . 0.0 112.123 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -66.52 -44.32 82.82 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.63 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.07 -35.14 62.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.311 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.9 t -69.63 -43.91 79.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.938 0.399 . . . . 0.0 110.762 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.67 -39.13 35.34 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.115 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.59 -34.38 76.86 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.726 0.298 . . . . 0.0 111.165 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.4 ' O ' ' CD1' ' A' ' 35' ' ' ILE . 33.5 t -59.88 -41.79 92.35 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.797 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mm -52.55 -32.21 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.152 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.6 mt -70.25 -29.78 40.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.702 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.62 -45.1 93.92 Favored Glycine 0 C--N 1.304 -1.23 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.253 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.905 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.82 -29.13 45.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 122.589 -0.359 . . . . 0.0 111.189 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.603 ' O ' HG22 ' A' ' 39' ' ' ILE . 35.9 tp -62.92 -46.96 85.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -178.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.69 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.4 p80 -58.96 -28.42 66.29 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 120.201 -0.6 . . . . 0.0 111.423 -178.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.619 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 33.7 t80 -56.74 -48.66 77.29 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.4 tt -59.4 -41.17 83.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.171 -178.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -35.94 73.88 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.47 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.425 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 5.2 t-105 -49.67 -34.19 17.77 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.412 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.2 p -62.19 -29.98 70.75 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.036 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.403 HG21 ' NE2' ' B' ' 48' ' ' GLN . 58.4 mt -61.33 -47.1 95.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.385 -179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.71 -28.36 5.19 Favored Glycine 0 C--N 1.307 -1.051 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.167 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 4.9 t-160 . . . . . 0 C--N 1.302 -1.496 0 CA-C-N 116.762 0.281 . . . . 0.0 111.271 -179.619 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.495 1.599 0 CA-C-O 120.903 0.293 . . . . 0.0 111.774 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -68.06 -47.96 66.89 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.695 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -70.52 -34.0 55.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -70.0 -45.88 75.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.265 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.04 -35.37 15.46 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.629 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.21 -29.81 70.64 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.679 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 7.0 t -57.88 -41.36 82.34 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.766 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 mm -50.44 -30.61 7.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.584 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.63 -29.34 37.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.4 -49.93 58.3 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 121.047 -0.596 . . . . 0.0 111.787 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.408 HG12 ' H ' ' B' ' 35' ' ' ILE . 10.5 pt -63.42 -42.84 97.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.691 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 58.1 tp -60.26 -45.18 94.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.279 0.561 . . . . 0.0 109.615 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -61.08 -41.17 96.16 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.347 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 88.9 t80 -70.67 -46.58 62.94 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.474 ' O ' ' OG1' ' B' ' 42' ' ' THR . 18.0 tt -68.07 -29.97 46.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.317 -178.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -39.98 72.02 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.213 0.53 . . . . 0.0 110.139 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -54.35 -37.45 64.94 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.432 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 31.6 p -55.16 -36.58 65.97 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.603 -0.439 . . . . 0.0 110.934 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -65.04 -50.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.015 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.542 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.51 -30.36 12.8 Favored Glycine 0 C--N 1.305 -1.185 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.43 ' CD2' ' CD ' ' B' ' 48' ' ' GLN . 31.7 t-80 -59.81 -27.04 66.26 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.7 0.286 . . . . 0.0 111.562 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.89 -31.65 12.69 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.774 -0.371 . . . . 0.0 111.943 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 6.9 p30 -68.95 -50.06 52.56 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -177.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.546 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 7.5 pt20 -69.28 -48.51 61.5 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 16.4 tt . . . . . 0 C--N 1.296 -1.744 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.214 -179.154 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo . . . . . 0 N--CA 1.494 1.516 0 CA-C-O 120.861 0.275 . . . . 0.0 111.885 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.3 tp -64.11 -48.44 76.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 59.5 t -70.42 -37.02 69.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 85.8 t -70.12 -43.71 78.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.742 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.56 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.48 -38.47 74.6 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.549 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.08 -30.38 71.45 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 120.906 0.384 . . . . 0.0 110.903 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -50.74 -36.47 36.61 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.178 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.56 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.8 tt -55.27 -29.76 23.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.603 -179.174 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.41 -36.92 76.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.429 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.61 -46.41 84.49 Favored Glycine 0 C--N 1.303 -1.261 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.16 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 11.0 tt -70.28 -29.06 37.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.778 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 31.8 tp -61.94 -47.23 85.83 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.99 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -56.7 -29.94 62.95 Favored 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 120.421 -0.512 . . . . 0.0 111.876 -178.474 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 77.4 t80 -62.33 -40.63 96.99 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.393 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -57.43 -46.93 85.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.54 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.18 -34.62 73.19 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 120.81 0.338 . . . . 0.0 110.812 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.2 -30.68 7.31 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.354 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 42.2 p -53.97 -44.02 70.41 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.923 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.479 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -63.66 -48.86 84.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.617 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.23 -33.56 15.67 Favored Glycine 0 C--N 1.304 -1.217 0 C-N-CA 121.259 -0.496 . . . . 0.0 111.881 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -50.58 -28.57 8.95 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 116.814 0.307 . . . . 0.0 111.628 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.448 ' C ' HD12 ' C' ' 46' ' ' LEU . 2.2 pp . . . . . 0 C--N 1.308 -1.197 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.931 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' D' ' 24' ' ' ASP . 4.2 p30 . . . . . 0 CA--C 1.533 0.296 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.72 45.56 0.9 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.322 2.015 . . . . 0.0 111.753 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 53.9 tp -69.97 -44.02 70.31 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.282 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.52 -38.62 74.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.979 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 95.6 t -67.08 -47.71 81.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.696 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.78 -34.37 19.18 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.015 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.31 -29.73 67.65 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.138 -179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.2 t -57.17 -42.79 81.8 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.127 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mm -51.46 -33.34 14.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 120.881 0.372 . . . . 0.0 110.481 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 4.6 mt -71.51 -29.04 33.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.282 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.36 -47.47 79.08 Favored Glycine 0 C--N 1.309 -0.937 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.118 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -61.15 -42.07 91.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.786 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.5 tp -49.13 -32.24 9.63 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.69 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 29.5 m170 -65.35 -42.88 92.39 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.554 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.69 -50.07 66.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.3 pp -62.83 -39.04 83.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.847 -0.741 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.425 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -69.08 -40.75 78.24 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.335 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.1 t-105 -49.78 -30.2 9.18 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.73 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.2 m -69.59 -35.78 75.64 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 115.604 -0.726 . . . . 0.0 111.116 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.519 ' O ' HD12 ' D' ' 46' ' ' LEU . 60.7 mt -70.6 -51.54 36.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.012 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.97 -27.8 65.19 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -55.99 -26.56 48.97 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.519 HD12 ' O ' ' D' ' 43' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -177.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo . . . . . 0 N--CA 1.494 1.523 0 CA-C-O 120.796 0.248 . . . . 0.0 111.991 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -67.75 -45.11 75.89 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.2 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.0 p -70.1 -37.2 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.655 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.429 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.6 t -68.91 -43.7 82.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 120.982 0.42 . . . . 0.0 110.989 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.82 -38.3 21.79 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.629 -179.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.08 -35.86 81.67 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.32 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 35' ' ' ILE . 44.8 t -60.4 -44.75 95.41 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.333 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.0 mm -50.01 -29.72 5.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.042 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.9 mt -70.5 -30.96 44.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.813 -179.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.53 -48.49 72.82 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.379 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.698 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.4 mp -68.07 -29.5 44.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.74 0.305 . . . . 0.0 111.057 -179.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 39' ' ' ILE . 45.2 tp -61.8 -47.43 85.17 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.464 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.1 -28.59 69.2 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.243 -0.583 . . . . 0.0 111.41 -178.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 51.4 t80 -60.18 -48.74 80.47 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.509 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -60.73 -39.96 83.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.083 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -39.47 72.44 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 120.926 0.393 . . . . 0.0 110.968 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.497 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.0 t-105 -48.94 -30.83 6.42 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.856 -178.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -57.83 -37.54 73.99 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.8 mm -61.04 -48.88 87.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.804 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.27 -28.12 6.01 Favored Glycine 0 C--N 1.305 -1.163 0 N-CA-C 111.709 -0.557 . . . . 0.0 111.709 -179.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 . . . . . 0 C--N 1.301 -1.507 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.515 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo . . . . . 0 N--CA 1.497 1.689 0 CA-C-O 121.034 0.348 . . . . 0.0 111.567 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 18.1 tp -70.27 -45.07 67.12 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.013 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 95.5 t -70.64 -38.12 72.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.545 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.44 -42.47 78.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.739 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.17 -29.74 14.76 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.595 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.74 -31.55 69.59 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.702 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.5 t -52.17 -40.25 61.2 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.749 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.415 ' O ' HD13 ' B' ' 35' ' ' ILE . 20.3 mm -51.37 -32.79 13.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-O 121.224 0.535 . . . . 0.0 110.368 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -72.35 -29.17 30.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.36 -52.01 24.12 Favored Glycine 0 CA--C 1.528 0.899 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.731 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.415 HD13 ' O ' ' B' ' 32' ' ' ILE . 0.2 OUTLIER -70.95 -29.48 37.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 117.971 0.886 . . . . 0.0 110.267 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 57.4 tp -64.7 -44.97 88.56 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.167 0.508 . . . . 0.0 110.113 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -52.91 -43.24 66.07 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.547 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -69.8 -36.7 75.9 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.406 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.33 -42.94 98.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.978 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.41 -36.04 78.53 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.85 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -53.44 -33.48 54.2 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.087 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.0 p -54.91 -40.12 69.51 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.775 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.52 -47.64 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.614 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.12 -29.35 9.04 Favored Glycine 0 C--N 1.305 -1.161 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -49.46 -27.06 3.82 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.551 0.215 . . . . 0.0 111.484 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -47.43 -38.2 13.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.45 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -48.42 -51.06 28.51 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.315 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.479 ' O ' HG22 ' B' ' 49' ' ' ILE . 16.4 tt0 -82.08 -143.99 0.06 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.052 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.479 HG22 ' O ' ' B' ' 48' ' ' GLN . 12.4 tt . . . . . 0 C--N 1.308 -1.2 0 N-CA-C 113.085 0.772 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo . . . . . 0 N--CA 1.494 1.53 0 CA-C-O 120.788 0.245 . . . . 0.0 111.988 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 30.8 tp -70.0 -44.71 68.83 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.721 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.8 t -70.68 -39.33 75.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.348 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 13.6 t -69.7 -44.56 79.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.499 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -60.92 -39.15 88.29 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.265 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.85 -29.92 71.11 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.975 0.417 . . . . 0.0 110.786 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -50.51 -34.23 24.45 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.949 -0.568 . . . . 0.0 111.255 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.499 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.9 tp -53.18 -30.23 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.449 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.53 -32.03 51.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.013 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.58 -47.46 62.07 Favored Glycine 0 C--N 1.304 -1.233 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.312 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 13.1 tt -69.4 -29.82 43.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.026 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 28.5 tp -62.62 -48.95 77.13 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -53.42 -29.44 35.14 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.59 -178.7 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 58.0 t80 -61.57 -41.42 97.37 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 92.4 mt -57.61 -48.86 82.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.535 -178.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.45 -32.83 72.02 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.967 0.413 . . . . 0.0 110.316 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.8 -35.03 21.28 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.145 -179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -58.77 -32.31 69.17 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.372 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.1 -48.66 80.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.309 -179.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.93 -36.56 27.28 Favored Glycine 0 C--N 1.305 -1.141 0 CA-C-N 116.387 -0.37 . . . . 0.0 112.721 -178.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -51.47 -27.84 11.58 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 117.296 0.548 . . . . 0.0 111.283 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.574 ' C ' HD12 ' C' ' 46' ' ' LEU . 1.7 pp . . . . . 0 C--N 1.303 -1.432 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.187 -177.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.487 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.0 m-20 . . . . . 0 CA--C 1.532 0.271 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.83 22.0 0.21 Allowed 'Trans proline' 0 N--CA 1.495 1.573 0 C-N-CA 122.1 1.867 . . . . 0.0 111.972 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.487 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.5 tp -71.87 -39.93 69.31 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.923 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.7 t -70.03 -45.24 77.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -178.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . 0.437 HG23 ' N ' ' D' ' 29' ' ' ALA . 17.1 m -67.91 -35.87 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.059 0.457 . . . . 0.0 110.439 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.437 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.66 -36.36 56.77 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.302 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.67 -39.46 73.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.316 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -61.86 -48.59 79.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.744 ' O ' HD12 ' D' ' 35' ' ' ILE . 12.5 pt -50.35 -28.21 5.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.751 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.77 -28.69 34.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.301 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -44.55 84.49 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 116.337 -0.392 . . . . 0.0 113.632 -178.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . 0.999 HD13 ' N ' ' D' ' 36' ' ' LEU . 0.0 OUTLIER -56.36 -28.43 26.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-N 117.411 0.605 . . . . 0.0 110.516 -178.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . 0.999 ' N ' HD13 ' D' ' 35' ' ' ILE . 4.1 tp -60.47 -43.1 97.3 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 120.892 0.377 . . . . 0.0 110.565 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.627 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 7.0 m170 -55.14 -49.16 72.52 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.526 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -56.46 -50.08 72.75 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -178.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.6 pt -61.29 -44.93 99.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.919 -0.712 . . . . 0.0 111.045 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.497 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.3 -37.51 74.79 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.187 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.7 t-105 -48.63 -30.13 5.09 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.843 0.354 . . . . 0.0 110.653 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.4 p -60.09 -36.75 78.11 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.842 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.64 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -69.23 -51.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.231 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.44 -28.74 37.11 Favored Glycine 0 C--N 1.304 -1.228 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.6 t-80 -65.29 -33.33 75.72 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -177.762 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 CA-C-O 120.752 0.23 . . . . 0.0 112.031 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.3 tp -66.12 -46.61 76.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.956 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.411 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.0 p -70.34 -36.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.649 -179.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.411 ' N ' HG13 ' A' ' 27' ' ' VAL . 74.3 t -69.55 -42.27 80.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 120.918 0.389 . . . . 0.0 110.855 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.55 -38.12 29.8 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.828 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.42 75.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.303 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -59.93 -42.74 94.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.112 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.6 mm -49.69 -31.49 6.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.876 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -70.48 -29.59 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.547 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -65.57 -49.83 58.07 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.461 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.866 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -65.64 -29.73 47.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 122.576 -0.367 . . . . 0.0 111.089 -179.187 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 39' ' ' ILE . 56.5 tp -61.41 -46.11 91.5 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.643 -179.024 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.0 OUTLIER -61.34 -28.99 69.61 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 120.195 -0.602 . . . . 0.0 111.358 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 91.6 t80 -62.78 -50.16 72.12 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.465 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -57.79 -40.38 75.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 C-N-CA 120.089 -0.644 . . . . 0.0 110.521 -178.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -36.15 72.37 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.629 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.9 t-105 -48.83 -34.08 11.76 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.744 -179.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 38.1 p -58.9 -33.67 70.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.814 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.605 ' CG2' ' NE2' ' B' ' 48' ' ' GLN . 96.6 mt -65.36 -44.24 94.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.201 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.0 -26.13 1.15 Allowed Glycine 0 C--N 1.306 -1.124 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 . . . . . 0 C--N 1.299 -1.625 0 O-C-N 123.016 -0.108 . . . . 0.0 111.104 179.846 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 N--CA 1.499 1.84 0 CA-C-O 121.147 0.395 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 20.6 tp -71.47 -50.88 27.28 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.504 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 t -70.69 -35.5 61.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-O 121.127 0.489 . . . . 0.0 111.514 -179.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 99.3 t -70.39 -44.18 77.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.274 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -29.52 5.71 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.813 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.53 -29.71 69.18 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.939 0.4 . . . . 0.0 110.524 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.0 t -49.98 -37.13 31.08 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.828 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -54.7 -29.51 21.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 120.978 0.418 . . . . 0.0 110.443 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -71.02 -29.84 38.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.323 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.45 -46.6 76.31 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.17 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 12.3 pt -66.01 -42.35 91.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.164 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.4 tp -62.32 -46.54 88.28 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.143 0.497 . . . . 0.0 109.818 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.4 t-80 -51.6 -42.03 61.65 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.444 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.13 -36.03 74.5 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.539 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -41.85 93.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.129 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.41 -40.42 77.32 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.01 0.434 . . . . 0.0 110.817 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.26 -32.05 10.0 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.067 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.8 p -51.38 -33.91 32.02 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.264 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 34.3 mm -65.74 -50.46 70.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.61 -30.11 26.6 Favored Glycine 0 C--N 1.306 -1.089 0 C-N-CA 121.232 -0.509 . . . . 0.0 111.928 -179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.443 ' O ' ' OE1' ' B' ' 48' ' ' GLN . 0.1 OUTLIER -63.78 -27.73 69.39 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 122.574 0.349 . . . . 0.0 111.342 -179.286 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.596 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.0 OUTLIER -48.75 -29.03 4.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.498 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -58.18 -51.7 68.66 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -177.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.618 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -75.38 -47.82 25.78 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.25 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--N 1.295 -1.771 0 C-N-CA 120.301 -0.56 . . . . 0.0 110.474 -179.36 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo . . . . . 0 N--CA 1.494 1.54 0 CA-C-O 120.787 0.244 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -69.35 -47.97 62.73 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.49 -36.61 66.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.058 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 64.2 t -70.33 -46.74 70.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.84 -36.61 27.38 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.18 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.5 -29.64 67.32 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.787 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -51.7 -41.94 61.85 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.278 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' C' ' 29' ' ' ALA . 7.4 tt -53.93 -27.13 15.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.018 0.437 . . . . 0.0 111.031 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 1.6 mm -59.89 -37.72 73.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.754 -178.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.446 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.4 -46.66 76.3 Favored Glycine 0 C--N 1.304 -1.212 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.991 -178.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -70.16 -29.13 38.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.533 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 34.4 tp -61.64 -50.62 71.79 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.667 -179.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -57.62 -29.0 64.17 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.652 -178.741 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.2 t80 -59.94 -42.64 94.44 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.638 0.256 . . . . 0.0 111.294 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' C' ' 42' ' ' THR . 19.6 mm -58.14 -45.71 88.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.071 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.01 -30.28 65.06 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.225 0.536 . . . . 0.0 111.056 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -52.6 -38.02 59.28 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -57.77 -29.99 65.27 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.48 -178.262 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.607 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.6 mp -61.24 -48.97 86.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.165 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.42 -29.74 11.32 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -50.84 -28.09 8.73 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.69 0.281 . . . . 0.0 111.207 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.624 ' C ' HD12 ' C' ' 46' ' ' LEU . 3.3 pp . . . . . 0 C--N 1.305 -1.35 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.892 -177.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 . . . . . 0 CA--C 1.534 0.34 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.54 42.23 0.56 Allowed 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.201 1.934 . . . . 0.0 111.743 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.4 tp -70.15 -47.08 63.2 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.574 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.3 t -70.68 -34.42 56.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.093 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 91.8 t -69.96 -47.67 67.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.648 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -31.45 10.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.839 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.01 -33.76 74.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -58.06 -41.21 82.85 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 68.3 mt -58.36 -30.15 39.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-O 120.976 0.417 . . . . 0.0 110.816 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.441 ' O ' ' NE2' ' D' ' 37' ' ' HIS . 6.0 mt -71.43 -31.96 44.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.515 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.6 -39.61 90.68 Favored Glycine 0 C--N 1.307 -1.07 0 C-N-CA 121.429 -0.415 . . . . 0.0 112.579 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 19.9 pt -69.99 -35.76 65.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.601 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 27.6 tp -49.34 -36.09 20.39 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.484 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 8.7 m170 -58.99 -34.73 72.18 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -62.05 -45.96 91.25 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.5 pp -67.22 -40.23 84.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.522 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.87 -41.28 71.59 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.211 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -48.96 -28.72 4.07 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.1 p -60.3 -32.5 71.26 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 84.8 mt -66.01 -51.57 58.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.174 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.84 -29.5 42.35 Favored Glycine 0 C--N 1.304 -1.215 0 N-CA-C 111.685 -0.566 . . . . 0.0 111.685 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 9.0 t-80 -55.77 -28.21 54.91 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.253 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.522 -177.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo . . . . . 0 N--CA 1.493 1.497 0 CA-C-O 120.847 0.27 . . . . 0.0 112.024 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.3 tp -66.48 -48.52 69.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.03 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.34 -35.56 63.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.586 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.0 t -70.36 -43.63 78.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 120.868 0.366 . . . . 0.0 110.684 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -35.82 18.13 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.997 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.14 -35.26 79.69 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 120.734 0.302 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -61.07 -41.78 97.27 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.124 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -55.92 -29.76 26.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.114 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.3 mt -70.39 -32.47 50.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.397 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -61.21 -40.24 98.3 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.375 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 mt -69.98 -29.6 40.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.937 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HD23 ' A' ' 36' ' ' LEU . 1.7 tt -60.6 -47.83 84.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.314 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.5 p80 -61.61 -28.76 69.59 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.45 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 56.1 t80 -60.97 -48.24 82.76 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 10.2 pt -62.64 -40.53 88.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.074 -0.65 . . . . 0.0 111.098 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -39.58 75.31 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.69 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.6 t-105 -49.09 -30.96 7.1 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.016 -179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 70.4 p -63.78 -30.9 71.94 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 76.7 mt -59.69 -49.57 83.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.815 0.341 . . . . 0.0 111.016 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.26 -28.99 9.45 Favored Glycine 0 C--N 1.305 -1.175 0 N-CA-C 111.618 -0.593 . . . . 0.0 111.618 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 . . . . . 0 C--N 1.304 -1.398 0 CA-C-O 120.764 0.316 . . . . 0.0 110.897 -179.764 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo . . . . . 0 N--CA 1.495 1.583 0 CA-C-O 120.97 0.321 . . . . 0.0 111.753 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 tp -70.44 -46.14 64.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.039 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 91.9 t -70.28 -38.69 75.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.323 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -70.35 -45.95 73.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.56 -35.38 20.35 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.656 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -36.8 77.99 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.5 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -51.57 -37.48 49.89 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.311 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.6 -36.12 47.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.847 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -70.63 -33.12 51.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.481 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.86 -44.72 78.5 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.284 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 16.6 pt -70.04 -37.41 72.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.553 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.525 ' O ' HD13 ' B' ' 36' ' ' LEU . 0.2 OUTLIER -49.15 -42.63 40.26 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.035 -179.75 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 0.5 OUTLIER -53.2 -45.79 68.74 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.783 -179.761 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -57.85 -45.07 86.8 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.537 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.6 mp -61.28 -45.72 98.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.838 -179.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.33 -39.92 74.44 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.181 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.58 -28.64 5.91 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.435 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 43.4 p -62.01 -38.62 89.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.43 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.653 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.45 -50.17 80.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.607 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.74 -29.65 58.6 Favored Glycine 0 C--N 1.304 -1.218 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -56.0 -28.41 57.12 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.65 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.9 pp -47.61 -29.44 2.91 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.738 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -62.92 -45.58 91.83 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -61.29 -53.11 60.96 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.011 0.434 . . . . 0.0 111.86 -179.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 1.5 tp . . . . . 0 C--N 1.295 -1.778 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.566 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo . . . . . 0 N--CA 1.49 1.273 0 CA-C-O 120.744 0.227 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.493 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -55.24 -50.31 69.79 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.762 -179.312 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 80.0 t -69.87 -39.91 78.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.829 0.347 . . . . 0.0 111.198 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 66.9 t -62.3 -44.21 98.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.618 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.541 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -64.03 -50.19 69.43 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.609 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.43 -29.34 67.7 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.488 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -54.71 -42.6 71.69 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.448 -179.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.541 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.7 tp -50.75 -30.58 8.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.97 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -70.45 -34.26 57.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.342 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.49 -49.25 57.53 Favored Glycine 0 C--N 1.303 -1.291 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.128 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . 0.412 ' O ' HD12 ' C' ' 39' ' ' ILE . 14.4 tt -64.81 -37.45 80.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 122.52 -0.4 . . . . 0.0 110.713 -179.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . 0.695 ' C ' HD12 ' C' ' 36' ' ' LEU . 0.1 OUTLIER -53.29 -47.11 69.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.151 -178.807 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.625 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 0.8 OUTLIER -61.0 -28.58 69.14 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.555 -178.258 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.621 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.2 t80 -58.88 -48.01 82.9 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.615 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.597 ' H ' HD12 ' C' ' 39' ' ' ILE . 4.3 mp -60.73 -45.58 97.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.484 -0.487 . . . . 0.0 111.078 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -29.88 65.92 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.472 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' C' ' 41' ' ' TRP . 10.7 t-105 -48.93 -50.36 35.71 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.769 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.523 HG22 ' O ' ' C' ' 39' ' ' ILE . 12.2 t -47.79 -28.05 2.34 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.515 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tp -49.83 -49.32 20.83 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 120.299 -0.56 . . . . 0.0 110.358 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.515 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -54.18 -28.44 42.1 Favored Glycine 0 C--N 1.302 -1.321 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.93 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.66 -33.39 15.48 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.818 0.309 . . . . 0.0 111.415 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.592 ' C ' HD12 ' C' ' 46' ' ' LEU . 2.0 pp . . . . . 0 C--N 1.306 -1.311 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 t70 . . . . . 0 CA--C 1.538 0.484 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -74.55 45.36 1.24 Allowed 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.979 1.786 . . . . 0.0 111.935 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 41.6 tp -70.52 -44.39 67.65 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.0 t -70.7 -41.96 77.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.164 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.75 -38.39 72.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.329 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -35.13 21.41 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.69 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.17 -29.41 70.76 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.022 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.0 t -52.71 -42.54 64.93 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.199 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.664 HD12 ' N ' ' D' ' 32' ' ' ILE . 1.9 mp -54.97 -37.35 41.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.733 0.301 . . . . 0.0 110.5 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.412 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 6.0 mt -71.45 -29.71 36.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.401 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.5 -48.92 47.97 Favored Glycine 0 C--N 1.306 -1.108 0 C-N-CA 121.361 -0.447 . . . . 0.0 113.025 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 pp -66.34 -32.47 58.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 117.194 0.497 . . . . 0.0 110.579 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 tp -51.06 -37.68 46.98 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.198 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.624 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 20.3 m170 -58.63 -40.44 83.37 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.858 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.02 -48.27 82.56 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . 0.408 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.6 pt -61.53 -41.88 91.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.175 -0.61 . . . . 0.0 111.422 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.6 -38.34 73.99 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.083 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.4 -30.77 8.39 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . 0.408 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 77.7 p -64.65 -34.11 77.52 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.252 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.643 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -70.49 -52.08 32.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.688 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.52 -29.35 24.01 Favored Glycine 0 C--N 1.306 -1.105 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -56.4 -27.03 55.21 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 111.528 0.195 . . . . 0.0 111.528 -179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.273 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.429 -177.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.493 1.458 0 CA-C-O 121.075 0.365 . . . . 0.0 111.599 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.9 tp -70.52 -42.85 70.71 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.21 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.15 -40.92 78.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.589 -179.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.7 t -68.16 -46.21 81.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.822 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -38.43 34.96 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.879 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.47 79.01 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.428 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.29 -39.92 80.59 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.949 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -51.26 -29.67 9.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.263 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.9 mt -69.75 -29.82 42.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.623 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.26 -48.17 66.27 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 121.182 -0.532 . . . . 0.0 112.287 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.859 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.1 mp -67.14 -29.68 46.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 120.681 -0.407 . . . . 0.0 111.126 -179.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.73 -46.3 90.94 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.574 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.695 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.1 p80 -61.78 -28.79 69.7 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.385 -178.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 64.1 t80 -60.62 -50.14 74.72 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.8 -39.17 69.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.007 -178.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.42 -36.04 73.77 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.891 0.377 . . . . 0.0 110.944 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.8 t-105 -49.68 -38.05 31.22 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.103 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.1 p -52.47 -39.76 61.52 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.91 -49.32 84.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.834 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.36 -28.6 9.49 Favored Glycine 0 C--N 1.304 -1.205 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 . . . . . 0 C--N 1.303 -1.427 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -179.307 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo . . . . . 0 N--CA 1.496 1.651 0 CA-C-O 121.065 0.361 . . . . 0.0 111.681 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -70.42 -46.62 63.56 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.067 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 48.7 t -70.42 -37.55 70.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.582 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.17 -44.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.598 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -33.22 12.04 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.356 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.92 -33.67 76.59 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.766 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -57.56 -41.03 80.23 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.782 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -56.71 -35.94 47.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.279 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.57 -33.74 50.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.441 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.17 73.38 Favored Glycine 0 C--N 1.305 -1.183 0 C-N-CA 121.249 -0.5 . . . . 0.0 111.898 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.418 HG23 ' N ' ' B' ' 36' ' ' LEU . 3.7 tp -68.47 -43.99 83.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.745 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.418 ' N ' HG23 ' B' ' 35' ' ' ILE . 53.9 tp -49.97 -38.12 35.42 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.136 0.493 . . . . 0.0 110.078 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -49.64 -41.9 43.73 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.012 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -67.41 -38.71 85.04 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.726 -179.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.56 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.5 mp -62.01 -43.91 98.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.65 -179.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.56 74.96 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.152 0.501 . . . . 0.0 110.788 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.49 -29.56 6.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.819 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.3 p -61.62 -36.14 79.89 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.464 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -63.67 -50.79 76.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.093 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.21 -29.48 29.48 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.493 ' O ' HG22 ' B' ' 49' ' ' ILE . 29.2 t-80 -61.46 -28.92 69.62 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 120.616 0.246 . . . . 0.0 111.327 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.533 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.8 OUTLIER -49.4 -34.66 16.83 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.397 -178.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -64.45 -50.43 67.53 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.478 ' CD ' ' CD2' ' B' ' 45' ' ' HIS . 9.5 pt20 -69.66 -50.05 47.8 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.493 HG22 ' O ' ' B' ' 45' ' ' HIS . 15.9 tt . . . . . 0 C--N 1.297 -1.705 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.93 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.494 1.529 0 CA-C-O 120.847 0.27 . . . . 0.0 112.116 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.8 tp -66.6 -45.07 80.4 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.994 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.22 -34.34 58.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.301 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.57 -47.3 80.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -37.38 26.42 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.788 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.4 -29.8 70.85 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.47 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.4 t -57.26 -42.85 82.34 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.693 0.283 . . . . 0.0 111.321 -179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.674 ' N ' HD12 ' C' ' 32' ' ' ILE . 2.2 mp -54.77 -30.28 22.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 mt -68.14 -36.38 75.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.525 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.61 -45.29 94.96 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.396 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 tp -69.96 -29.6 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 116.964 0.382 . . . . 0.0 110.824 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 33.0 tp -61.75 -49.26 77.13 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.916 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -55.66 -28.83 57.62 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 120.566 -0.454 . . . . 0.0 111.552 -178.61 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 51.4 t80 -61.07 -42.44 98.5 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.696 -0.229 . . . . 0.0 111.509 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 57.2 mt -58.1 -45.36 88.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.348 -178.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.26 -35.4 76.05 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.854 0.359 . . . . 0.0 110.743 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -49.47 -35.26 19.13 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 29.1 p -55.42 -39.07 69.79 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.031 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 85.1 mt -62.1 -48.49 88.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.901 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.17 -27.79 5.58 Favored Glycine 0 C--N 1.305 -1.189 0 N-CA-C 111.613 -0.595 . . . . 0.0 111.613 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -47.71 -28.1 2.28 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 122.744 -0.268 . . . . 0.0 111.511 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 pp . . . . . 0 C--N 1.305 -1.368 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.323 -178.044 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.483 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.2 m-20 . . . . . 0 CA--C 1.533 0.293 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.8 34.59 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 122.081 1.854 . . . . 0.0 111.841 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.483 ' H ' ' C ' ' D' ' 24' ' ' ASP . 48.4 tp -71.99 -38.25 69.7 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.801 179.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.73 -40.7 77.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . 0.413 HG23 ' N ' ' D' ' 29' ' ' ALA . 31.0 m -70.11 -40.23 78.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 CA-C-O 120.687 0.28 . . . . 0.0 110.836 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.413 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.45 -30.93 32.19 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.48 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.19 -34.61 68.53 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.237 179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.4 t -63.68 -44.85 92.49 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 pt -56.71 -28.17 27.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 120.852 0.358 . . . . 0.0 110.696 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.97 -29.02 35.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.315 179.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.07 -38.5 95.45 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 116.36 -0.382 . . . . 0.0 113.263 -178.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -68.96 -29.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 117.49 0.645 . . . . 0.0 110.366 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . 0.544 ' O ' HD23 ' D' ' 36' ' ' LEU . 0.9 OUTLIER -57.31 -29.49 63.97 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.382 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.695 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 8.7 m170 -69.75 -35.6 75.09 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.539 -179.187 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -66.18 -46.68 76.51 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -178.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 pp -66.33 -39.14 83.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.416 -178.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -38.92 74.6 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.054 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -52.96 -30.74 36.58 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.952 0.406 . . . . 0.0 111.0 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 67.6 p -63.95 -32.08 73.49 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.023 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 18.1 mm -70.66 -51.63 35.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.461 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.42 -29.74 31.68 Favored Glycine 0 C--N 1.307 -1.082 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 t-80 -54.62 -27.19 37.65 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 120.715 0.293 . . . . 0.0 111.137 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.303 -1.44 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.668 -178.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo . . . . . 0 N--CA 1.494 1.51 0 CA-C-O 120.821 0.259 . . . . 0.0 111.912 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.4 tt -65.32 -49.54 69.06 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 -179.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' N ' ' A' ' 28' ' ' VAL . 11.9 p -70.6 -39.43 75.97 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.005 179.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.468 ' N ' HG13 ' A' ' 27' ' ' VAL . 69.0 t -62.95 -29.95 48.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.754 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.87 69.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.522 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.34 -36.0 80.53 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.596 -179.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.2 t -56.52 -46.19 80.72 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.565 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.696 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.35 -39.85 22.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.935 0.398 . . . . 0.0 110.166 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -70.46 -28.61 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.289 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.96 -50.68 56.81 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.199 -0.524 . . . . 0.0 112.796 -178.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' N ' ' A' ' 36' ' ' LEU . 2.8 pp -66.04 -29.15 45.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.065 0.432 . . . . 0.0 111.413 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 35' ' ' ILE . 7.2 tt -62.74 -41.13 99.05 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.451 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.632 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -65.56 -28.74 69.37 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.659 -178.976 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 60.3 t80 -64.49 -50.44 67.42 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -178.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.4 pt -51.56 -40.46 25.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.149 -179.024 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.32 -33.25 65.05 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 120.97 0.414 . . . . 0.0 111.272 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.453 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 11.8 t-105 -49.23 -31.06 7.99 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -177.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -69.39 -29.6 67.4 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.331 -179.443 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.5 mp -56.17 -44.98 80.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.847 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.15 -28.43 4.25 Favored Glycine 0 C--N 1.304 -1.236 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -178.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 . . . . . 0 C--N 1.301 -1.511 0 CA-C-O 120.806 0.336 . . . . 0.0 110.398 179.799 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo . . . . . 0 N--CA 1.493 1.482 0 CA-C-O 120.879 0.283 . . . . 0.0 111.618 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 52.2 tp -70.23 -43.21 71.08 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.503 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 96.3 t -70.16 -41.77 78.99 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.738 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 50.2 t -70.21 -41.11 78.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.176 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.8 -37.31 18.82 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.349 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.9 -29.52 65.14 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.72 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.6 t -58.64 -41.73 86.66 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 23.9 mm -50.66 -36.65 14.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.684 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -69.99 -29.76 41.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.15 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.68 -50.16 63.61 Favored Glycine 0 C--N 1.306 -1.131 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.622 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.0 pt -62.5 -43.65 98.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.998 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.5 tp -62.28 -49.16 76.76 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.019 0.438 . . . . 0.0 109.828 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -49.79 -39.45 38.21 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.95 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 74.8 t80 -69.99 -39.74 75.71 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.48 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.37 -43.67 94.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.968 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.05 -40.76 91.23 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.995 0.426 . . . . 0.0 110.594 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.81 -32.74 14.74 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.285 -179.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 58.0 p -60.98 -38.16 84.99 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.993 -179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.594 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.6 mp -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.503 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.19 -29.81 16.24 Favored Glycine 0 C--N 1.304 -1.224 0 C-N-CA 121.335 -0.46 . . . . 0.0 112.089 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -58.07 -28.5 64.62 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -47.03 -32.22 3.83 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.321 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 -62.29 -44.99 95.26 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -61.74 -53.33 57.43 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 120.916 0.389 . . . . 0.0 112.027 -178.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 1.9 tp . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.135 -179.142 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo . . . . . 0 N--CA 1.495 1.602 0 CA-C-O 120.911 0.296 . . . . 0.0 111.729 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.42 HD21 HG13 ' D' ' 28' ' ' VAL . 41.4 tp -70.07 -43.68 70.68 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.754 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.36 -40.92 78.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.923 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.2 -47.76 80.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.73 -37.18 28.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.976 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.97 -29.55 70.49 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-O 120.83 0.347 . . . . 0.0 111.07 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -52.49 -43.72 65.19 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -50.1 -29.1 5.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-O 120.75 0.31 . . . . 0.0 111.324 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.1 -31.83 48.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.116 -179.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.62 -50.16 38.78 Favored Glycine 0 C--N 1.303 -1.267 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.753 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 tp -69.54 -29.49 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 120.852 0.358 . . . . 0.0 110.281 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.11 -48.86 79.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.79 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -55.59 -29.14 58.55 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 120.646 -0.422 . . . . 0.0 111.935 -178.491 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -59.04 -42.61 90.67 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.375 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.439 ' H ' HD12 ' C' ' 39' ' ' ILE . 3.8 mp -58.38 -47.57 87.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.577 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.93 78.63 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.889 -0.325 . . . . 0.0 110.847 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -49.13 -29.99 6.06 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 67.7 p -57.13 -37.39 71.94 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.248 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 75.9 mt -63.22 -50.23 79.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.912 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.15 -28.83 6.3 Favored Glycine 0 C--N 1.305 -1.182 0 N-CA-C 112.059 -0.416 . . . . 0.0 112.059 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -49.12 -27.96 3.89 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.856 0.328 . . . . 0.0 111.341 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 C--N 1.306 -1.3 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.917 -177.943 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' D' ' 26' ' ' LEU . 4.1 m-20 . . . . . 0 CA--C 1.533 0.307 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -72.21 27.08 0.26 Allowed 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 122.218 1.945 . . . . 0.0 111.829 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.7 tp -70.17 -44.86 67.91 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.582 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -70.17 -36.97 70.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.998 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . 0.42 HG13 HD21 ' C' ' 26' ' ' LEU . 87.9 t -67.97 -46.76 81.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.412 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.67 -34.35 11.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.46 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.96 -29.65 69.56 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 34.6 t -58.82 -43.72 90.69 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.218 -179.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.674 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -53.98 -29.9 19.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 120.835 0.35 . . . . 0.0 110.351 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.36 -29.91 37.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.265 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.93 -43.94 95.26 Favored Glycine 0 C--N 1.308 -1.024 0 C-N-CA 121.34 -0.457 . . . . 0.0 112.188 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -67.19 -37.64 79.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.499 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.1 tt -49.81 -43.31 48.55 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 26.4 m170 -57.8 -44.19 86.14 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.923 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -61.56 -47.26 86.34 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -178.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . 0.415 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.6 pt -63.79 -41.76 93.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.301 -0.56 . . . . 0.0 111.425 -178.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.432 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.16 -40.76 74.53 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.804 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.53 -29.32 6.65 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.042 0.449 . . . . 0.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.2 p -62.25 -33.21 74.18 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.345 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.602 ' O ' HD12 ' D' ' 46' ' ' LEU . 90.7 mt -65.56 -50.72 70.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.03 -28.15 47.84 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -56.85 -28.06 61.17 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 112.628 0.603 . . . . 0.0 112.628 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.602 HD12 ' O ' ' D' ' 43' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -178.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo . . . . . 0 N--CA 1.493 1.46 0 CA-C-O 120.931 0.305 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.2 tp -70.14 -42.89 71.98 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.084 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.3 p -70.69 -39.19 75.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.65 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.471 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.0 t -66.77 -42.57 89.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.85 0.357 . . . . 0.0 110.971 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -34.54 18.85 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.683 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.61 82.54 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.739 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -59.31 -44.03 92.6 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.392 -179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -49.81 -34.68 9.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 120.95 0.405 . . . . 0.0 110.759 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.0 mt -69.8 -29.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.555 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.13 -50.27 52.6 Favored Glycine 0 C--N 1.306 -1.109 0 C-N-CA 121.105 -0.569 . . . . 0.0 112.363 -179.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 40.5 mt -61.04 -29.63 46.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 122.509 -0.407 . . . . 0.0 110.918 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.469 ' O ' HG22 ' A' ' 39' ' ' ILE . 46.3 tp -61.88 -44.43 96.83 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.361 -179.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -61.56 -28.83 69.62 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.501 -178.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 40.4 t80 -63.19 -50.63 69.54 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.253 0.464 . . . . 0.0 112.253 -178.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 42' ' ' THR . 5.8 tt -57.07 -38.83 62.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.23 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -30.62 64.77 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 120.936 0.398 . . . . 0.0 111.448 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -55.09 -36.49 65.7 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 -177.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.52 ' O ' ' ND1' ' A' ' 45' ' ' HIS . 0.1 OUTLIER -59.06 -34.01 71.45 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.995 -178.946 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 mp -60.68 -38.21 77.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.114 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.87 -25.81 1.75 Allowed Glycine 0 C--N 1.306 -1.111 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.52 ' ND1' ' O ' ' A' ' 42' ' ' THR . 39.1 m170 . . . . . 0 C--N 1.3 -1.55 0 C-N-CA 122.77 0.428 . . . . 0.0 111.173 179.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 CA-C-O 121.027 0.345 . . . . 0.0 111.549 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 tt -63.35 -49.62 73.18 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.69 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.08 -33.77 56.52 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.375 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.6 t -69.93 -44.5 78.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.516 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.86 -39.37 39.01 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.672 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.25 -33.47 74.67 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.846 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 6.8 t -57.8 -41.82 82.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.849 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mm -51.79 -34.33 16.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.727 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.88 -29.76 38.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.224 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.15 -48.74 62.54 Favored Glycine 0 C--N 1.305 -1.159 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 11.3 mm -61.54 -46.22 97.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.64 -179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.3 tp -52.39 -42.49 64.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.019 0.438 . . . . 0.0 109.933 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -49.92 -44.67 50.38 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.835 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -66.65 -41.6 87.98 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.555 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 93.3 mt -60.85 -45.16 98.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.899 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.416 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -67.81 -36.88 81.18 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.467 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.66 -34.85 19.57 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.534 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 25.0 p -52.43 -41.05 62.92 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.349 -179.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.66 -50.3 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.929 -0.308 . . . . 0.0 111.121 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.16 -29.72 15.88 Favored Glycine 0 C--N 1.305 -1.167 0 C-N-CA 121.187 -0.53 . . . . 0.0 111.964 -179.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -60.69 -28.1 68.37 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -46.81 -31.08 2.79 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.863 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -60.0 -48.96 79.54 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -63.14 -54.48 37.09 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -178.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 2.6 tt . . . . . 0 C--N 1.297 -1.684 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.07 -179.22 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.495 1.6 0 CA-C-O 120.715 0.215 . . . . 0.0 112.156 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 40.5 tp -64.21 -48.33 76.28 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.097 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 23.4 t -70.22 -40.21 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.222 -179.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.4 t -69.47 -44.18 80.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.806 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.535 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -51.25 -43.1 61.43 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.957 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.44 69.37 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.093 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 5.8 t -51.22 -43.42 61.43 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.493 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.535 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -49.5 -29.61 4.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.344 -179.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.5 mt -69.03 -30.55 47.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.912 -179.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.546 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.64 -49.71 58.38 Favored Glycine 0 C--N 1.303 -1.292 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.312 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -66.41 -29.34 46.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.841 -179.444 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 10.4 tp -62.02 -50.71 70.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.528 -0.306 . . . . 0.0 111.823 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -52.51 -29.24 24.11 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.665 -178.401 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.7 t80 -58.06 -44.5 87.5 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 120.578 0.228 . . . . 0.0 111.481 -179.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.0 mt -54.55 -48.99 69.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.587 -178.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.53 -30.49 67.25 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.994 0.426 . . . . 0.0 110.761 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' B' ' 40' ' ' ALA . 2.7 t-105 -49.28 -36.67 21.3 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.058 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 33.6 p -59.23 -36.94 76.34 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.088 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -63.16 -50.98 77.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.283 -179.483 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.55 -29.8 25.4 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.916 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -51.76 -29.73 19.92 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp . . . . . 0 C--N 1.306 -1.303 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.472 -177.543 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.12 42.52 0.64 Allowed 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.164 1.909 . . . . 0.0 111.745 179.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 51.7 tp -70.22 -47.92 59.32 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.649 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 10.5 t -70.87 -35.97 62.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.145 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -70.14 -46.29 72.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.659 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -29.8 7.71 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.005 -179.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.72 66.86 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.22 -40.38 81.52 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.22 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -55.22 -29.77 23.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.899 0.38 . . . . 0.0 110.836 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.23 -29.67 37.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.49 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.74 -44.43 80.87 Favored Glycine 0 C--N 1.307 -1.04 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.444 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.0 pt -67.03 -36.15 76.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.64 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -49.91 -36.68 28.37 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.457 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -59.17 -47.04 86.79 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.85 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -57.54 -46.14 84.24 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.9 pt -66.39 -43.14 91.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.436 -178.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -39.78 72.87 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.367 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 t-105 -49.39 -28.86 5.53 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 120.974 0.416 . . . . 0.0 110.673 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -62.0 -29.92 70.59 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.755 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 82.1 mt -70.21 -52.25 31.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-O 121.025 0.44 . . . . 0.0 111.053 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.09 -28.21 32.79 Favored Glycine 0 C--N 1.302 -1.321 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -68.22 -29.34 68.14 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.42 HD12 ' C ' ' D' ' 46' ' ' LEU . 2.4 pp . . . . . 0 C--N 1.309 -1.171 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.478 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo . . . . . 0 N--CA 1.493 1.477 0 CA-C-O 120.841 0.267 . . . . 0.0 112.003 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 57.7 tp -63.69 -45.73 88.72 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.83 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.2 p -70.37 -37.61 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.453 -179.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.418 ' N ' HG13 ' A' ' 27' ' ' VAL . 62.6 t -70.08 -35.99 66.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 CA-C-O 120.982 0.42 . . . . 0.0 110.784 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -38.16 31.66 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.62 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.57 -34.0 76.16 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.341 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.2 t -63.01 -50.34 71.11 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -178.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 11.2 pt -51.99 -29.49 11.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.636 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -67.25 -29.58 46.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -59.76 -46.24 94.38 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.4 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' D' ' 33' ' ' ILE . 10.0 mm -61.24 -35.75 68.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 CA-C-O 120.77 0.319 . . . . 0.0 111.145 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.65 -49.75 76.4 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.954 -178.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -57.72 -28.86 64.25 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.812 -178.768 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 71.2 t80 -59.63 -50.11 75.16 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.711 ' O ' HG22 ' A' ' 42' ' ' THR . 1.5 pp -59.22 -41.67 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.768 -178.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.92 -34.03 68.76 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.106 0.479 . . . . 0.0 111.002 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.474 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 10.1 t-105 -48.23 -35.3 11.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.517 -178.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.711 HG22 ' O ' ' A' ' 39' ' ' ILE . 14.9 t -56.86 -29.34 62.81 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.508 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 80.0 mt -55.28 -46.08 77.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.04 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.5 -28.63 2.42 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 120.762 -0.733 . . . . 0.0 111.534 -177.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 116.928 0.364 . . . . 0.0 110.79 179.299 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo . . . . . 0 N--CA 1.495 1.595 0 CA-C-O 121.071 0.363 . . . . 0.0 111.63 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 37.4 tp -69.35 -45.93 68.24 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.535 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 79.9 t -70.43 -41.1 78.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 57.3 t -68.65 -46.85 79.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.321 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.76 -38.37 33.72 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.663 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.89 -31.53 72.18 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.31 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 31.9 t -56.04 -42.11 76.05 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.991 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.6 mm -49.67 -29.86 4.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.649 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.9 mt -71.92 -29.82 34.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.51 -50.61 42.34 Favored Glycine 0 C--N 1.307 -1.076 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.324 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -64.53 -47.1 90.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.831 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -51.51 -41.26 60.87 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.059 0.457 . . . . 0.0 110.074 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -49.58 -39.79 36.38 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.813 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.46 -40.03 92.71 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.688 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.566 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.7 mp -57.48 -42.84 81.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.51 -179.26 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.98 -37.18 69.93 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.228 0.537 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.8 t-105 -54.91 -39.65 69.02 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.471 HG22 ' H ' ' B' ' 42' ' ' THR . 0.0 OUTLIER -57.69 -34.14 69.11 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.243 -178.903 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.586 ' O ' HD12 ' B' ' 46' ' ' LEU . 28.8 mm -62.14 -47.72 91.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.603 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.09 -28.67 8.2 Favored Glycine 0 C--N 1.306 -1.089 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -61.23 -27.05 68.17 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.978 HD13 ' H ' ' B' ' 47' ' ' ASN . 0.0 OUTLIER -47.71 -30.63 3.98 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.676 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.978 ' H ' HD13 ' B' ' 46' ' ' LEU . 29.4 p-10 -61.5 -50.5 72.47 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -59.27 -53.07 62.47 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 120.978 0.418 . . . . 0.0 112.112 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 2.5 tp . . . . . 0 C--N 1.295 -1.763 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.162 -179.192 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo . . . . . 0 N--CA 1.493 1.452 0 CA-C-O 120.995 0.331 . . . . 0.0 111.738 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 44.5 tp -70.13 -42.64 72.33 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.091 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 92.8 t -70.12 -44.22 78.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.192 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.09 -46.64 84.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.545 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.55 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -54.87 -44.37 73.99 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.941 -179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.54 -29.63 70.71 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 120.777 0.322 . . . . 0.0 110.925 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 7.1 t -50.56 -41.86 54.68 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.181 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.55 HG22 ' O ' ' C' ' 29' ' ' ALA . 16.2 tt -49.8 -29.06 4.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-O 120.851 0.357 . . . . 0.0 111.295 -179.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.9 mt -65.81 -33.45 63.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.144 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.57 -50.33 37.93 Favored Glycine 0 C--N 1.303 -1.256 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.202 -178.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.05 -29.48 44.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-O 120.868 0.366 . . . . 0.0 110.529 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -61.28 -50.62 72.26 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.782 -179.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -55.08 -28.65 54.06 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.742 -178.577 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 43.9 t80 -57.9 -44.38 86.72 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 121.031 -0.268 . . . . 0.0 111.456 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -56.34 -48.37 79.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.943 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.05 -34.28 73.02 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.855 0.359 . . . . 0.0 110.755 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 -48.4 -30.25 4.83 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.565 -179.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.7 p -56.38 -38.74 71.89 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.634 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.632 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.7 mp -64.05 -49.93 79.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.013 -179.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.82 -28.28 5.34 Favored Glycine 0 C--N 1.304 -1.198 0 C-N-CA 121.301 -0.476 . . . . 0.0 112.024 -178.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -49.07 -27.84 3.64 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 pp . . . . . 0 C--N 1.307 -1.253 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.399 -177.543 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 CA--C 1.532 0.273 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.69 33.6 0.37 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.189 1.926 . . . . 0.0 111.756 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' D' ' 24' ' ' ASP . 2.1 tt -63.9 -50.54 68.32 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.613 -179.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 t -70.49 -33.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.113 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 92.5 t -69.95 -45.1 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.692 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.58 -32.71 8.51 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.718 -178.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.31 -32.17 73.69 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 120.769 0.319 . . . . 0.0 110.912 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 43.0 t -60.4 -42.93 96.95 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.217 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 mm -58.05 -35.21 51.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 121.148 0.499 . . . . 0.0 110.346 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' A' ' 35' ' ' ILE . 8.8 mt -71.67 -29.98 36.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.303 179.243 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.36 91.73 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.589 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 12.8 pt -68.51 -38.13 78.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.782 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tp -49.69 -38.63 33.76 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 120.946 0.403 . . . . 0.0 110.455 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.533 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 16.4 m170 -57.53 -39.78 77.36 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.371 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -58.23 -46.55 85.72 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.6 pt -66.63 -42.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.125 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -41.96 77.18 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.723 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -48.74 -29.46 4.5 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.745 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.5 m -66.8 -29.85 69.89 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.515 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 30.0 mm -65.48 -50.8 70.22 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.988 -0.285 . . . . 0.0 111.181 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.48 -34.17 63.34 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 10.7 t-80 -55.98 -28.05 55.44 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 120.653 0.263 . . . . 0.0 111.522 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.438 HD23 ' O ' ' D' ' 43' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.303 -1.434 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo . . . . . 0 N--CA 1.493 1.47 0 CA-C-O 120.843 0.268 . . . . 0.0 112.04 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' N ' HD12 ' A' ' 26' ' ' LEU . 10.3 mp -69.5 -40.91 76.71 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.711 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.544 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.4 p -70.76 -44.15 76.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.475 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.544 ' N ' HG13 ' A' ' 27' ' ' VAL . 88.5 t -63.63 -41.75 93.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.737 -179.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -37.38 29.53 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.476 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.76 -36.8 84.24 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.471 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -53.81 -47.14 71.13 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.994 -0.283 . . . . 0.0 111.233 -179.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.692 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.56 -40.17 24.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.462 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.87 -29.5 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.1 -50.66 44.37 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.907 -179.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 57.3 mt -64.74 -29.71 48.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 122.652 -0.322 . . . . 0.0 111.047 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.474 ' O ' HG22 ' A' ' 39' ' ' ILE . 33.4 tp -61.47 -45.18 95.33 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.331 -179.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.632 ' CE1' ' NE2' ' D' ' 37' ' ' HIS . 0.6 OUTLIER -61.66 -28.79 69.64 Favored 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 120.151 -0.62 . . . . 0.0 111.497 -178.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.2 t80 -63.47 -50.82 68.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.772 ' O ' HG22 ' A' ' 42' ' ' THR . 5.4 tt -54.91 -39.67 49.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.135 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -35.3 69.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.922 0.392 . . . . 0.0 111.215 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.462 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 11.3 t-105 -49.78 -35.07 21.2 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.244 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 39' ' ' ILE . 9.8 t -65.4 -29.4 70.1 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -179.275 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 36.5 mm -60.87 -45.15 98.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.777 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.16 -27.03 2.44 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.037 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 . . . . . 0 C--N 1.304 -1.38 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.562 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.493 1.464 0 CA-C-O 121.055 0.356 . . . . 0.0 111.574 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.01 -48.74 67.49 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.552 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.59 -30.35 42.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.48 HG22 HD23 ' A' ' 26' ' ' LEU . 58.0 t -70.14 -46.7 71.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.392 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.11 -31.5 8.2 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.613 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.69 -29.64 70.22 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.538 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.6 t -54.44 -38.08 65.89 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.796 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 25.8 mm -55.6 -36.94 44.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-O 120.923 0.392 . . . . 0.0 110.456 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.24 -29.98 38.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.337 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.96 -48.41 54.47 Favored Glycine 0 C--N 1.306 -1.11 0 N-CA-C 111.659 -0.576 . . . . 0.0 111.659 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -63.93 -42.44 95.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.611 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -60.61 -44.26 96.51 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 24.2 t-80 -49.86 -44.36 49.68 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.696 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -70.12 -37.55 75.34 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.272 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' B' ' 42' ' ' THR . 91.8 mt -63.41 -42.64 97.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.856 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.412 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.66 -37.47 70.78 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.009 0.433 . . . . 0.0 111.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -49.55 -44.84 46.94 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.81 -27.83 5.55 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.655 -178.528 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 9.3 tp -56.17 -48.57 79.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.252 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.517 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -57.65 -29.73 61.58 Favored Glycine 0 C--N 1.304 -1.229 0 C-N-CA 121.32 -0.466 . . . . 0.0 111.963 -179.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -53.17 -29.53 32.11 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.653 ' C ' HD12 ' B' ' 46' ' ' LEU . 2.7 pp -50.58 -34.0 24.13 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.836 -0.346 . . . . 0.0 111.519 -178.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.573 ' N ' HD12 ' B' ' 46' ' ' LEU . 5.3 m120 -63.19 -50.38 70.55 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.096 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -67.41 -55.89 11.88 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.142 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 7.7 tp . . . . . 0 C--N 1.297 -1.714 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -178.599 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 N--CA 1.494 1.526 0 CA-C-O 120.861 0.275 . . . . 0.0 111.97 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.552 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -67.1 -42.71 84.13 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.637 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . 0.508 HG13 ' N ' ' C' ' 28' ' ' VAL . 12.9 p -70.28 -40.9 78.46 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.206 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . 0.508 ' N ' HG13 ' C' ' 27' ' ' VAL . 92.2 t -64.47 -46.63 92.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.746 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -55.96 -40.69 73.6 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.92 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.56 -29.65 70.67 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.746 0.308 . . . . 0.0 111.138 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 15.1 t -52.56 -44.27 65.76 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.617 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 12.3 tt -49.68 -29.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.269 -179.101 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.4 mt -69.02 -31.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.037 -179.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.15 -50.43 39.79 Favored Glycine 0 C--N 1.306 -1.085 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.016 -179.214 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . 0.439 HG22 ' H ' ' C' ' 35' ' ' ILE . 0.0 OUTLIER -66.72 -29.48 46.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.722 -179.76 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.4 tp -60.72 -48.77 80.31 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.687 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.79 -29.99 63.24 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.863 -178.367 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.2 t80 -62.18 -44.26 96.99 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.098 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -55.65 -45.61 79.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.723 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.15 -33.79 72.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.015 0.436 . . . . 0.0 110.779 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.29 -34.68 16.0 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.173 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 18.5 p -57.3 -45.05 84.53 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.376 -179.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.486 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.2 mp -66.45 -51.09 61.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.603 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.47 -29.52 17.42 Favored Glycine 0 C--N 1.303 -1.267 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -59.77 -28.96 67.85 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.116 0.414 . . . . 0.0 112.116 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.301 -1.527 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 . . . . . 0 CA--C 1.535 0.378 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.34 41.0 0.64 Allowed 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.1 1.867 . . . . 0.0 111.872 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.3 tp -63.85 -48.97 74.63 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.617 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 47.3 t -70.42 -34.21 57.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 57.6 t -70.05 -44.14 78.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.584 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -35.08 19.7 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.722 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.23 -29.63 70.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.2 t -55.54 -41.5 73.28 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.035 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.666 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -54.87 -35.62 34.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.491 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.76 -30.05 40.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.352 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.25 -46.02 88.88 Favored Glycine 0 C--N 1.306 -1.096 0 C-N-CA 121.249 -0.501 . . . . 0.0 112.07 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.1 pt -66.68 -29.79 47.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-O 120.815 0.341 . . . . 0.0 110.753 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tp -56.29 -42.39 77.46 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.708 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 15.3 m170 -56.62 -43.52 80.28 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -59.52 -47.09 86.88 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.4 pt -64.03 -43.8 97.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.491 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.12 -39.37 75.5 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.058 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -48.81 -29.4 4.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.859 0.361 . . . . 0.0 110.502 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 64.8 p -61.99 -31.51 71.88 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.769 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 33.7 mm -67.38 -51.33 53.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.76 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.99 -29.95 21.66 Favored Glycine 0 C--N 1.304 -1.245 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -59.02 -29.61 67.39 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 120.648 0.261 . . . . 0.0 111.274 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.595 HD12 ' C ' ' D' ' 46' ' ' LEU . 2.6 pp . . . . . 0 C--N 1.305 -1.357 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.395 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.1 m . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -172.0 61.04 0.3 Allowed Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.949 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -79.96 8.68 3.92 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.819 2.346 . . . . 0.0 111.973 179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.1 tp -63.52 -44.61 93.77 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.779 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.9 p -70.23 -37.76 72.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.436 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.427 ' N ' HG13 ' A' ' 27' ' ' VAL . 97.3 t -67.08 -42.12 87.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.947 0.403 . . . . 0.0 110.663 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -43.85 46.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.007 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.3 -35.08 71.31 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.407 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.0 t -60.64 -43.24 97.77 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.027 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.7 mt -53.42 -37.85 30.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.079 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.91 -29.84 41.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.104 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.573 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -61.93 -47.66 88.65 Favored Glycine 0 C--N 1.302 -1.31 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.053 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 mm -58.47 -29.37 38.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 122.382 -0.481 . . . . 0.0 110.775 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.518 ' O ' HD23 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -61.24 -49.33 77.54 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.709 -178.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.606 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.2 p80 -56.7 -28.95 61.87 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.968 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.606 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.1 t80 -63.78 -50.36 69.31 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.517 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.5 tt -57.85 -38.51 66.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.814 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -38.85 74.15 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.472 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -48.65 -32.44 8.29 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 120.847 0.356 . . . . 0.0 110.155 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -53.24 -42.47 66.44 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.319 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.4 mp -60.95 -47.94 91.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.032 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.56 -29.34 5.56 Favored Glycine 0 C--N 1.303 -1.296 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.74 -27.92 5.49 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 122.779 -0.248 . . . . 0.0 111.377 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.8 pp -44.99 -41.96 7.82 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.511 -176.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.458 ' OD1' ' N ' ' A' ' 48' ' ' GLN . 27.8 p-10 -50.19 -45.46 53.58 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.458 ' N ' ' OD1' ' A' ' 47' ' ' ASN . 0.6 OUTLIER -73.34 -57.88 3.7 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.217 0.532 . . . . 0.0 111.255 -179.38 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.477 HD13 ' O ' ' A' ' 49' ' ' ILE . 0.4 OUTLIER -48.68 -14.52 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.079 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 33.5 ttpt -109.48 -59.46 1.9 Allowed 'General case' 0 C--N 1.32 -0.712 0 O-C-N 122.092 -0.38 . . . . 0.0 110.739 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -84.04 104.9 14.49 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.823 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.108 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 179.783 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 11.1 m . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' B' ' 26' ' ' LEU . 12.4 m-20 52.62 58.0 14.9 Favored Pre-proline 0 C--N 1.304 -1.376 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.481 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.45 24.89 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.644 2.229 . . . . 0.0 111.938 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' B' ' 24' ' ' ASP . 49.8 tp -68.0 -43.96 77.68 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.666 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.3 p -70.05 -35.81 65.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.086 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 89.4 t -67.33 -44.02 87.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.53 -37.63 27.64 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.656 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.36 -34.02 75.86 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.948 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -60.05 -42.74 95.11 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.741 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.7 mm -49.96 -31.78 7.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.555 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -69.61 -29.61 42.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.333 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.17 -50.6 44.41 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 121.026 -0.607 . . . . 0.0 111.889 -179.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.0 pt -62.71 -29.8 47.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.88 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -61.16 -46.93 88.51 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.576 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' C' ' 37' ' ' HIS . 7.8 m-70 -51.53 -50.54 59.82 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -54.2 -44.67 71.82 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.615 ' O ' HG22 ' B' ' 42' ' ' THR . 81.9 mt -59.02 -50.24 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.507 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.401 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -72.14 -36.85 69.48 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 121.086 0.47 . . . . 0.0 111.424 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.408 ' O ' ' CD1' ' B' ' 41' ' ' TRP . 9.8 t-105 -49.35 -34.6 16.31 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 113.294 0.849 . . . . 0.0 113.294 -177.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.615 HG22 ' O ' ' B' ' 39' ' ' ILE . 1.7 t -69.29 -29.31 67.14 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.048 -0.661 . . . . 0.0 110.709 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -61.99 -51.4 72.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.924 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.62 -29.83 19.01 Favored Glycine 0 C--N 1.306 -1.09 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -54.37 -27.47 36.61 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 120.88 0.371 . . . . 0.0 111.176 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -45.72 -29.83 1.4 Allowed 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.986 -176.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' B' ' 50' ' ' LYS . 29.3 m120 -58.29 -51.71 68.62 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.584 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -79.19 -58.91 2.99 Favored 'General case' 0 C--N 1.314 -0.959 0 O-C-N 121.871 -0.518 . . . . 0.0 111.741 -178.183 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . . . . . . . . . 4.7 tt -49.62 -2.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -179.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.545 ' H ' ' C ' ' B' ' 48' ' ' GLN . 22.2 ttpp -176.38 147.9 0.72 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 62.4 ttm-85 -155.54 99.18 2.01 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 120.866 0.365 . . . . 0.0 110.64 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -173.23 58.97 0.23 Allowed Pre-proline 0 C--N 1.306 -1.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.716 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.82 8.2 3.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.837 2.358 . . . . 0.0 111.818 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 37.2 tp -65.81 -47.27 75.66 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -69.38 -40.88 80.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.918 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.4 t -67.39 -47.57 80.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.496 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.526 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -50.44 -42.98 54.85 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.105 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.858 0.361 . . . . 0.0 111.009 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 8.9 t -50.48 -43.88 55.62 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.4 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.526 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.3 tp -49.69 -29.35 4.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-O 120.804 0.335 . . . . 0.0 111.279 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -69.96 -31.69 48.81 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -178.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.544 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.39 -50.28 45.48 Favored Glycine 0 C--N 1.303 -1.266 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.564 -178.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.85 -29.51 43.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-O 120.987 0.422 . . . . 0.0 110.452 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.3 tp -62.04 -50.78 70.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.066 -0.515 . . . . 0.0 112.13 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.627 ' CE1' ' CE1' ' B' ' 37' ' ' HIS . 1.8 p80 -57.79 -28.96 64.49 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.642 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 87.4 t80 -56.99 -44.24 82.52 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.228 -179.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.401 ' O ' ' OG1' ' C' ' 42' ' ' THR . 68.1 mt -55.1 -42.68 66.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.152 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.28 -38.16 75.01 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 120.967 0.413 . . . . 0.0 110.722 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . 0.424 ' CZ3' ' ND1' ' B' ' 37' ' ' HIS . 5.7 t-105 -49.59 -32.85 13.64 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.199 -179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 40.2 p -65.58 -38.26 89.03 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.829 0.347 . . . . 0.0 110.961 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 29.5 mm -60.64 -50.43 80.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.021 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.467 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -50.21 -29.47 15.74 Favored Glycine 0 C--N 1.307 -1.066 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -50.19 -28.2 7.12 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -45.94 -32.61 2.8 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.934 -177.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.631 ' ND2' ' H ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -60.85 -42.74 98.42 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.544 179.986 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.631 ' H ' ' ND2' ' C' ' 47' ' ' ASN . 54.3 tt0 -87.14 72.15 10.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.655 HG23 ' H ' ' C' ' 50' ' ' LYS . 1.7 tt 178.83 -79.4 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 O-C-N 122.346 -0.221 . . . . 0.0 110.467 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.655 ' H ' HG23 ' C' ' 49' ' ' ILE . 15.0 ptpt -60.2 134.64 57.25 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 31.3 ttm180 63.24 -4.91 0.25 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.919 0.39 . . . . 0.0 110.481 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.108 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 55.7 m . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.17 149.89 70.33 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.283 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.03 41.48 0.66 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.087 1.858 . . . . 0.0 111.938 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -65.54 -48.69 71.62 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.672 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.32 -34.44 58.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.203 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 96.2 t -69.83 -45.62 76.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.524 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.44 -34.87 17.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.032 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.71 -29.74 69.8 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.062 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.4 t -55.04 -42.1 72.25 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.034 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -53.93 -31.84 21.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.73 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -70.98 -29.71 38.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.079 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.93 -45.0 90.7 Favored Glycine 0 C--N 1.306 -1.103 0 C-N-CA 121.26 -0.495 . . . . 0.0 112.392 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 16.5 pt -65.8 -38.42 82.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.038 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 47.5 tp -49.52 -40.34 37.43 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.551 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.422 ' ND1' ' N ' ' D' ' 37' ' ' HIS . 2.1 m-70 -59.82 -39.16 84.12 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.687 -0.405 . . . . 0.0 111.739 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 79.7 t80 -61.24 -48.57 80.84 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -178.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.3 pp -66.02 -39.07 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.534 -178.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.45 -41.31 72.97 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.803 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.02 -29.54 5.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.429 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 53.1 p -65.29 -30.3 71.15 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -70.15 -51.48 38.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.397 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' D' ' 47' ' ' ASN . . . -55.83 -29.99 55.92 Favored Glycine 0 C--N 1.305 -1.158 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.481 ' O ' HG22 ' D' ' 49' ' ' ILE . 27.0 t-80 -56.3 -28.32 58.4 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 122.866 -0.196 . . . . 0.0 111.515 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.43 HD12 ' C ' ' D' ' 46' ' ' LEU . 0.9 OUTLIER -48.4 -36.62 15.09 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.979 -178.523 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' D' ' 48' ' ' GLN . 6.6 p30 -67.23 -44.18 80.1 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.93 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.538 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 37.8 mt-30 -63.87 -55.18 24.72 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-O 121.109 0.48 . . . . 0.0 111.635 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.878 HG23 ' H ' ' D' ' 50' ' ' LYS . 4.8 tp -59.07 -68.63 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.11 -179.334 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.878 ' H ' HG23 ' D' ' 49' ' ' ILE . 9.2 ptmm? -166.73 122.01 1.14 Allowed 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.007 0.432 . . . . 0.0 110.473 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -80.35 4.9 16.41 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.683 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.897 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.6 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -162.35 58.84 0.87 Allowed Pre-proline 0 C--N 1.308 -1.222 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -77.73 -3.15 13.28 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.785 2.323 . . . . 0.0 112.085 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 12.4 tp -62.15 -48.88 78.15 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.186 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.0 p -70.33 -32.39 50.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.532 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.4 t -70.29 -43.33 78.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 120.78 0.324 . . . . 0.0 110.929 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.46 -40.06 58.7 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.158 -179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -31.23 69.74 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.362 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -62.38 -37.8 87.12 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.008 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -57.37 -35.04 47.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.075 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.7 mt -67.99 -32.42 56.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.539 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.498 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.48 -44.72 82.69 Favored Glycine 0 C--N 1.302 -1.329 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.425 -178.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 70.4 mt -70.14 -29.74 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.888 0.375 . . . . 0.0 111.202 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.438 ' O ' HG22 ' A' ' 39' ' ' ILE . 54.5 tp -62.72 -47.66 82.62 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.704 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -58.27 -28.69 65.18 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.468 -179.054 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.9 t80 -54.13 -44.06 71.03 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 36' ' ' LEU . 8.9 tp -58.02 -43.12 84.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.378 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.426 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.5 -35.12 73.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.984 0.421 . . . . 0.0 110.976 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.484 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 3.2 t-105 -49.21 -37.85 24.23 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.151 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.37 -29.53 68.99 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.287 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mm -60.42 -48.86 86.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.104 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.87 -32.28 11.28 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 121.294 -0.479 . . . . 0.0 112.015 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-160 -49.39 -28.37 5.02 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.865 0.333 . . . . 0.0 111.369 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.581 HD12 ' N ' ' A' ' 47' ' ' ASN . 3.0 pp -46.03 -40.84 11.17 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -177.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.581 ' N ' HD12 ' A' ' 46' ' ' LEU . 26.3 t-20 -56.09 -43.71 78.29 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 120.399 -0.52 . . . . 0.0 111.493 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -64.78 -59.12 4.59 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 120.896 0.379 . . . . 0.0 111.098 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.51 ' CG1' ' N ' ' A' ' 50' ' ' LYS . 1.1 pt -58.14 -51.73 67.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.51 ' N ' ' CG1' ' A' ' 49' ' ' ILE . 54.2 tttp -49.13 -74.95 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 120.721 0.296 . . . . 0.0 110.768 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -72.42 139.69 47.92 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.654 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.223 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.809 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . 0.465 ' OG ' ' N ' ' B' ' 24' ' ' ASP . 46.5 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' B' ' 26' ' ' LEU . 3.8 m-20 41.08 71.43 1.29 Allowed Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.528 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -66.69 30.07 0.11 Allowed 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.779 2.319 . . . . 0.0 111.647 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.539 ' H ' ' C ' ' B' ' 24' ' ' ASP . 22.7 tp -70.7 -42.98 69.94 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -70.35 -44.85 77.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.519 -179.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 39.8 t -68.82 -43.83 82.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.74 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.483 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -49.89 -40.9 44.44 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.151 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -54.6 -28.57 47.36 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -48.77 -40.39 28.68 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.483 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.0 tp -49.2 -36.64 9.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.447 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.401 ' N ' HG23 ' B' ' 32' ' ' ILE . 8.3 mt -70.18 -29.54 40.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.532 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.54 -51.02 55.86 Favored Glycine 0 C--N 1.307 -1.074 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.022 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 29.7 pt -65.46 -37.99 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.132 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.508 ' O ' HD23 ' B' ' 36' ' ' LEU . 1.7 tt -59.68 -48.68 80.73 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 121.307 0.575 . . . . 0.0 109.547 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -48.98 -46.72 44.12 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.249 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -68.64 -39.17 80.83 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.946 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 80.1 mt -61.42 -46.33 96.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.04 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.12 -40.89 95.13 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.843 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 -48.42 -33.1 8.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.407 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -52.26 -49.51 63.92 Favored 'General case' 0 C--N 1.3 -1.575 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.266 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.16 -51.45 71.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 C-N-CA 121.004 -0.279 . . . . 0.0 111.416 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.12 -29.4 36.12 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 3.9 t-160 -60.72 -30.0 69.7 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 120.89 0.376 . . . . 0.0 110.996 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.525 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.6 OUTLIER -48.67 -33.22 9.62 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.58 -178.49 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.465 ' ND2' ' OD1' ' C' ' 47' ' ' ASN . 20.5 m120 -64.37 -49.62 70.93 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -178.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.4 OUTLIER -59.79 -51.59 69.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-O 120.828 0.347 . . . . 0.0 111.928 -178.552 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.734 HG23 ' H ' ' B' ' 50' ' ' LYS . 5.6 tt -56.09 -67.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.529 -179.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.734 ' H ' HG23 ' B' ' 49' ' ' ILE . 20.0 pttp -136.75 172.21 13.36 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 120.874 0.368 . . . . 0.0 110.426 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.622 HH22 HD21 ' C' ' 47' ' ' ASN . 60.7 ttm-85 -152.22 147.73 26.74 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.367 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.22 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.927 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.9 m . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -172.6 60.23 0.27 Allowed Pre-proline 0 C--N 1.306 -1.285 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.689 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -77.52 15.46 1.23 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.836 2.357 . . . . 0.0 112.039 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.509 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -70.11 -40.59 74.8 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.835 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.16 -45.59 75.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.384 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.8 t -66.66 -45.41 88.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.902 0.382 . . . . 0.0 110.758 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -58.09 -44.24 87.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.84 -29.43 70.62 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.315 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 22.7 t -53.54 -41.3 66.29 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.328 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.3 tt -49.91 -29.15 4.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-O 120.94 0.4 . . . . 0.0 111.175 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 16.1 mt -64.55 -37.43 80.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.12 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.55 -47.8 83.69 Favored Glycine 0 C--N 1.302 -1.321 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.408 -178.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -69.58 -30.02 43.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.72 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -62.2 -50.62 71.08 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -178.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -52.92 -29.17 27.07 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.642 -178.523 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.636 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.7 t80 -61.16 -42.28 98.27 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.572 -0.285 . . . . 0.0 111.522 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 76.9 mt -58.25 -49.72 80.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.824 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.59 -34.65 74.44 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.036 0.446 . . . . 0.0 110.649 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.1 -32.71 10.31 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.233 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -60.51 -36.08 77.51 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.258 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.39 -50.41 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.469 -179.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.89 -30.05 35.89 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 121.206 -0.521 . . . . 0.0 111.979 -179.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -50.87 -29.55 12.19 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 120.661 0.267 . . . . 0.0 111.627 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.783 HD21 HE21 ' D' ' 48' ' ' GLN . 1.6 pp -47.46 -34.95 7.9 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.739 -177.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.622 HD21 HH22 ' B' ' 51' ' ' ARG . 30.8 t-20 -50.24 -50.17 50.75 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.552 -179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.6 tp-100 -56.47 -47.38 79.32 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.459 HG23 ' O ' ' C' ' 49' ' ' ILE . 9.5 tt -102.2 96.21 4.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.432 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -158.5 -74.9 0.08 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.349 179.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -62.02 -41.81 98.48 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.028 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.103 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 179.863 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.1 p . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -70.51 138.79 86.29 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.363 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.33 55.97 3.73 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.015 1.81 . . . . 0.0 112.002 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.58 -45.51 68.49 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.597 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 t -70.48 -38.21 72.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.425 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 85.1 t -68.57 -43.22 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.848 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -31.9 12.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.021 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.09 69.5 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.959 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.2 t -54.22 -42.15 69.48 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.025 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 mm -50.7 -34.47 12.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.68 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.0 mt -71.43 -29.27 34.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.358 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.59 -50.99 51.52 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.645 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . 0.833 HD12 ' N ' ' D' ' 36' ' ' LEU . 2.8 pp -62.87 -28.97 46.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.07 0.435 . . . . 0.0 110.628 -179.442 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . 0.833 ' N ' HD12 ' D' ' 35' ' ' ILE . 4.5 tp -60.88 -41.61 96.32 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.305 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 25.2 m170 -56.07 -41.3 74.89 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.613 -179.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -61.43 -47.86 83.81 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -178.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 12.3 pt -63.46 -43.73 98.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.163 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.484 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -63.33 -42.87 98.99 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.967 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -49.67 -33.83 16.8 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.521 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 54.5 p -59.21 -42.18 90.34 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.785 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.542 ' O ' HD12 ' D' ' 46' ' ' LEU . 4.7 mp -71.56 -53.1 21.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.4 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.39 -29.07 10.26 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -58.72 -28.18 65.59 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.964 HD13 ' H ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -48.26 -32.31 7.08 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 112.654 0.613 . . . . 0.0 112.654 -177.543 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.964 ' H ' HD13 ' D' ' 46' ' ' LEU . 4.7 t-20 -62.32 -50.79 70.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.783 HE21 HD21 ' C' ' 46' ' ' LEU . 4.2 mm100 -59.53 -50.35 74.23 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.534 ' O ' HG23 ' D' ' 49' ' ' ILE . 12.6 tt -70.78 89.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 CA-C-O 121.588 0.708 . . . . 0.0 110.408 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 26.4 ttmt 45.62 -139.3 0.46 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.474 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 ptt-85 -174.11 -15.92 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.253 0 CA-C-O 120.846 0.355 . . . . 0.0 110.6 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.916 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.0 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -168.9 62.16 0.48 Allowed Pre-proline 0 C--N 1.306 -1.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.5 7.16 4.65 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.817 2.345 . . . . 0.0 112.069 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.3 tp -66.84 -46.49 74.95 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.686 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.5 p -70.47 -38.46 73.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.373 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.457 ' N ' HG13 ' A' ' 27' ' ' VAL . 89.0 t -70.03 -43.28 79.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.948 0.404 . . . . 0.0 110.674 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.73 -36.47 25.73 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.096 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.43 -29.25 69.92 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -56.39 -43.83 79.65 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.4 pt -50.59 -29.51 6.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-O 120.746 0.308 . . . . 0.0 111.204 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -67.94 -29.95 46.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.592 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.99 -49.85 51.05 Favored Glycine 0 C--N 1.303 -1.275 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.181 -179.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.778 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.4 -29.53 46.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-O 120.696 0.284 . . . . 0.0 111.063 -179.364 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 34.0 tp -62.02 -49.25 76.78 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.634 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.3 p80 -57.91 -29.21 64.92 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.937 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.634 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 68.1 t80 -59.31 -44.29 92.58 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 120.742 -0.383 . . . . 0.0 111.031 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 77.9 mt -57.34 -48.89 81.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.89 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.6 -35.49 77.41 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-O 120.911 0.386 . . . . 0.0 110.747 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.67 -33.31 9.77 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.788 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 54.1 p -62.42 -33.2 74.31 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.003 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.535 ' O ' HD23 ' A' ' 46' ' ' LEU . 16.1 mm -70.12 -46.65 71.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.886 -0.325 . . . . 0.0 110.583 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -44.23 -24.28 0.56 Allowed Glycine 0 C--N 1.301 -1.379 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.423 ' N ' ' O ' ' A' ' 43' ' ' ILE . 5.7 t-80 -46.3 -26.54 0.83 Allowed 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.535 HD23 ' O ' ' A' ' 43' ' ' ILE . 4.2 mm? -44.15 -49.8 8.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 118.73 0.695 . . . . 0.0 110.602 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -50.21 -33.86 20.86 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.173 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -73.69 -58.57 3.22 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.868 0.366 . . . . 0.0 111.734 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.451 HD11 HD13 ' A' ' 46' ' ' LEU . 1.7 pt -58.42 -26.37 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.0 tttp -87.37 -69.56 0.68 Allowed 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.869 0.366 . . . . 0.0 110.232 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -85.27 147.25 26.65 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.448 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.215 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.982 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' B' ' 26' ' ' LEU . 1.4 m-20 -88.05 150.98 48.69 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.115 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -71.92 37.43 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 122.281 1.987 . . . . 0.0 111.676 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.429 ' H ' ' C ' ' B' ' 24' ' ' ASP . 40.1 tp -69.55 -47.46 63.62 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.861 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -70.43 -35.14 60.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.03 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 45.5 t -70.15 -47.09 69.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.358 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -37.85 30.87 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.162 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.08 -31.61 69.04 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.667 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 5.7 t -57.09 -36.02 70.11 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.57 -35.11 37.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.5 mt -71.29 -29.69 36.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.471 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.68 -44.7 88.97 Favored Glycine 0 C--N 1.307 -1.058 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.017 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -64.46 -43.42 96.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.825 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.2 tp -57.45 -42.7 83.03 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -49.21 -47.64 46.05 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.101 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -70.06 -37.25 75.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.421 ' O ' ' OG1' ' B' ' 42' ' ' THR . 96.1 mt -63.39 -43.59 98.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.587 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.63 -37.82 80.02 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 120.927 0.394 . . . . 0.0 110.681 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.63 -31.15 10.18 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.283 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 41.0 p -50.96 -36.06 36.87 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.158 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.598 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.5 mp -64.48 -50.29 76.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.66 -0.246 . . . . 0.0 111.078 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.3 -29.3 10.05 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.735 -0.546 . . . . 0.0 111.735 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.582 ' O ' HG22 ' B' ' 49' ' ' ILE . 7.7 t-160 -53.56 -27.01 23.87 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' B' ' 50' ' ' LYS . 2.1 pp -48.92 -37.54 20.16 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -64.36 -51.15 64.75 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.586 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -68.45 -53.99 19.91 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -178.246 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.932 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -50.04 -71.93 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 C-N-CA 120.684 -0.407 . . . . 0.0 111.391 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.932 ' H ' HG23 ' B' ' 49' ' ' ILE . 81.2 tttt -139.73 154.69 47.5 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 120.899 0.381 . . . . 0.0 110.905 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 8.6 tpp85 -152.22 83.11 1.26 Allowed 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.292 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.201 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' C' ' 26' ' ' LEU . 23.1 t70 -172.23 57.27 0.23 Allowed Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.933 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.59 20.24 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.576 2.184 . . . . 0.0 111.765 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.503 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -63.95 -47.16 81.54 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.368 -179.718 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -69.67 -43.14 80.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.148 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -64.36 -43.32 97.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.575 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.579 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -62.13 -44.63 96.21 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.011 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.38 -29.49 70.56 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.789 0.328 . . . . 0.0 111.349 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -55.82 -43.02 76.54 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.432 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.579 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.4 tp -49.71 -28.9 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 120.804 0.335 . . . . 0.0 111.341 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.0 -31.03 46.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.104 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.99 -50.28 41.78 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.271 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 5.8 tp -68.41 -29.48 44.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 CA-C-O 120.849 0.357 . . . . 0.0 110.482 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.16 -48.77 80.32 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.777 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -58.78 -29.24 66.65 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.561 -0.456 . . . . 0.0 111.886 -178.538 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 66.7 t80 -60.33 -45.49 93.27 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.939 -0.305 . . . . 0.0 111.361 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.414 ' O ' ' OG1' ' C' ' 42' ' ' THR . 73.7 mt -54.98 -46.4 76.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.562 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -34.56 72.77 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.411 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -48.55 -29.69 4.49 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.879 -178.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' C' ' 39' ' ' ILE . 29.5 p -63.06 -33.21 74.95 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.743 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.615 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.5 mp -65.28 -47.84 85.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.859 0.361 . . . . 0.0 110.598 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.78 -29.12 5.83 Favored Glycine 0 C--N 1.3 -1.466 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.504 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -53.41 -29.33 34.46 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.874 0.337 . . . . 0.0 111.732 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.601 HD13 ' O ' ' C' ' 43' ' ' ILE . 7.5 mp -46.33 -45.39 17.51 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 120.415 0.15 . . . . 0.0 111.05 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.473 HD21 ' CB ' ' D' ' 47' ' ' ASN . 18.1 m120 -52.02 -50.25 61.78 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 120.511 -0.476 . . . . 0.0 111.615 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 43.7 tt0 -96.84 59.26 1.69 Allowed 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -178.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.704 HG23 ' O ' ' C' ' 49' ' ' ILE . 0.1 OUTLIER -171.71 91.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 CA-C-O 121.889 0.852 . . . . 0.0 110.079 178.355 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.6 pttt -179.92 -43.65 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.671 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 82.6 mtt85 -70.08 173.46 6.53 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.861 0.362 . . . . 0.0 110.751 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.177 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.825 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 38.3 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -75.64 151.19 84.78 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.204 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -72.33 40.18 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.221 1.947 . . . . 0.0 111.968 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.74 -43.59 68.54 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.68 -40.67 77.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.061 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . 0.469 HG13 ' N ' ' D' ' 29' ' ' ALA . 14.3 p -70.46 -42.25 78.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.599 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.489 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -56.51 -40.02 74.32 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.791 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.86 -29.37 70.14 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.649 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -49.32 -36.41 21.03 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.489 HG22 ' O ' ' D' ' 29' ' ' ALA . 3.7 tp -53.75 -33.84 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 121.059 0.457 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.6 mt -71.16 -29.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.429 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.51 -43.92 91.27 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 121.358 -0.449 . . . . 0.0 112.503 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 28.3 pt -68.39 -32.68 56.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.653 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -53.24 -41.44 65.42 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 18.7 m170 -54.48 -42.92 71.27 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.704 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -56.96 -47.19 81.3 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -178.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.7 pt -65.01 -46.04 92.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 119.932 -0.707 . . . . 0.0 111.503 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.43 -37.92 77.62 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.63 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.472 ' O ' ' CD1' ' D' ' 41' ' ' TRP . 13.1 t-105 -49.07 -28.46 4.15 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.35 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 4.0 m -59.61 -30.95 69.05 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 96.1 mt -62.46 -50.55 79.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.487 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.22 -29.48 9.77 Favored Glycine 0 C--N 1.303 -1.281 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -62.89 -29.13 70.53 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.76 0.281 . . . . 0.0 111.76 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -47.99 -34.27 9.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -177.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.473 ' CB ' HD21 ' C' ' 47' ' ' ASN . 3.7 m120 -58.87 -52.29 66.36 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.166 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -92.04 66.93 5.04 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 122.237 -0.289 . . . . 0.0 111.647 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.442 ' O ' ' N ' ' D' ' 51' ' ' ARG . 1.6 tp -175.66 103.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 121.187 0.517 . . . . 0.0 110.409 179.051 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' D' ' 51' ' ' ARG . 19.1 tptp 61.88 -76.38 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.258 179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' D' ' 49' ' ' ILE . 17.3 ptt180 38.45 -162.32 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.325 -179.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.893 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.458 ' C ' ' H ' ' A' ' 26' ' ' LEU . 5.8 p-10 -173.39 56.53 0.2 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.23 18.55 0.32 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.813 2.342 . . . . 0.0 111.573 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 24' ' ' ASP . 50.8 tp -70.16 -44.53 68.62 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.754 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.7 -36.27 64.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.122 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.7 t -70.07 -44.7 78.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.976 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.49 -31.05 9.25 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.582 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.5 -30.11 66.8 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 35' ' ' ILE . 41.2 t -60.7 -44.45 96.54 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.592 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.682 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -52.12 -29.79 12.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.804 0.335 . . . . 0.0 110.353 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.4 mt -70.6 -29.62 39.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.211 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.501 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -64.04 -45.93 92.62 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.555 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -69.9 -29.56 40.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.053 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 39' ' ' ILE . 8.0 tt -61.84 -42.48 99.09 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.54 -179.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -68.03 -28.59 67.53 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 120.239 -0.584 . . . . 0.0 111.456 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 76.7 t80 -66.49 -47.86 71.66 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.434 HG22 ' O ' ' A' ' 36' ' ' LEU . 7.2 tt -57.61 -35.9 52.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.24 -0.584 . . . . 0.0 110.442 -179.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.64 -36.11 73.25 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.659 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -52.95 -35.5 58.77 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.809 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.0 p -59.49 -37.12 77.43 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.669 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.604 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -69.25 -50.9 48.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.673 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.68 -28.32 6.87 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 111.991 -0.444 . . . . 0.0 111.991 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.544 ' CD2' ' OE1' ' A' ' 48' ' ' GLN . 33.7 t-80 -49.54 -27.31 4.26 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -179.382 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.422 HD23 ' O ' ' A' ' 43' ' ' ILE . 1.2 pt? -47.99 -33.93 8.57 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -176.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.412 ' N ' ' HG ' ' A' ' 46' ' ' LEU . 7.8 t-20 -48.56 -52.87 20.63 Favored 'General case' 0 C--N 1.311 -1.084 0 C-N-CA 120.056 -0.658 . . . . 0.0 110.403 -178.116 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.604 ' C ' ' H ' ' A' ' 50' ' ' LYS . 4.6 mp0 -67.52 -140.8 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 178.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.479 HG23 ' C ' ' A' ' 48' ' ' GLN . 0.1 OUTLIER 54.14 -8.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 179.878 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.604 ' H ' ' C ' ' A' ' 48' ' ' GLN . 61.4 pttt -171.89 -163.94 0.28 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 118.217 0.462 . . . . 0.0 110.648 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.655 HH21 ' NH2' ' C' ' 51' ' ' ARG . 25.4 tpt85 47.79 96.56 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.256 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.879 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . 0.433 ' O ' ' CB ' ' B' ' 24' ' ' ASP . 34.1 t . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.512 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.9 m-20 81.1 52.04 0.08 OUTLIER Pre-proline 0 C--N 1.31 -1.145 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.06 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.472 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 17.9 Cg_endo -58.26 68.79 0.05 OUTLIER 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.85 2.367 . . . . 0.0 112.113 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' B' ' 24' ' ' ASP . 51.6 tp -70.85 -48.84 51.72 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.793 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 93.9 t -70.19 -39.43 76.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.095 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 53.1 t -70.17 -45.45 75.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.959 179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -49.07 -30.39 6.3 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.438 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.05 -29.54 69.79 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.057 0.456 . . . . 0.0 110.313 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -54.26 -37.23 64.46 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.649 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 70.4 mt -55.28 -33.9 32.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.1 mt -70.9 -31.5 45.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.223 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.71 -45.42 92.84 Favored Glycine 0 C--N 1.306 -1.127 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.045 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -65.59 -41.95 91.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.205 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 37.8 tp -59.42 -46.39 88.86 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -49.87 -42.88 48.7 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.856 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -68.15 -39.07 82.75 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.364 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.71 -40.97 86.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.919 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.06 -40.85 74.81 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.023 0.44 . . . . 0.0 110.402 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -49.52 -31.09 9.5 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.858 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 62.7 p -60.77 -35.68 77.05 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.41 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.2 mm -67.38 -51.16 55.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.837 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.8 -39.38 31.88 Favored Glycine 0 C--N 1.305 -1.144 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.575 ' O ' HG22 ' B' ' 49' ' ' ILE . 23.3 t-80 -49.05 -26.55 2.7 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 120.741 0.305 . . . . 0.0 111.563 -179.648 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.413 HD22 ' OE1' ' C' ' 48' ' ' GLN . 1.0 OUTLIER -48.1 -32.55 6.98 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.778 -178.485 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' B' ' 44' ' ' GLY . 11.1 p30 -70.37 -50.32 40.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -177.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.522 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 4.1 pt20 -69.54 -52.43 26.33 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -177.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.906 HG23 ' H ' ' B' ' 50' ' ' LYS . 10.6 tt -45.47 -71.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 C-N-CA 120.661 -0.416 . . . . 0.0 110.638 -179.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.906 ' H ' HG23 ' B' ' 49' ' ' ILE . 18.0 pttp -148.7 149.27 31.15 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 120.803 0.335 . . . . 0.0 110.316 179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.477 ' CZ ' ' O ' ' C' ' 51' ' ' ARG . 0.0 OUTLIER -163.55 106.26 0.98 Allowed 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.996 -179.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.907 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.1 t . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -133.41 65.79 73.02 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.349 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -78.9 46.21 2.12 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.834 2.356 . . . . 0.0 111.919 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 45.8 tp -66.46 -47.72 72.23 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.471 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.5 t -69.98 -32.17 50.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.991 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.94 -49.5 56.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.588 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.552 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.25 -35.32 17.29 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.293 -179.007 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.22 -29.79 71.06 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 120.915 0.388 . . . . 0.0 110.904 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 34.7 t -50.0 -38.91 39.43 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.157 -179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.552 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.1 tp -53.69 -29.47 17.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.187 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.24 -36.93 69.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.014 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' NE2' ' C' ' 37' ' ' HIS . . . -63.72 -49.4 68.98 Favored Glycine 0 C--N 1.305 -1.156 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.687 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 tp -70.05 -29.86 41.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 CA-C-O 121.032 0.444 . . . . 0.0 110.105 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 27.2 tp -59.81 -49.41 77.83 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.64 -179.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.3 p80 -59.62 -29.03 67.72 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.68 -178.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 65.0 t80 -61.16 -43.36 99.0 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.031 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 66.2 mt -58.8 -45.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.087 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.16 -38.96 75.55 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.585 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.6 -29.89 7.86 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.807 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 64.6 p -60.9 -37.7 83.16 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.748 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.5 mm -63.05 -50.54 79.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.31 -179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.434 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -50.12 -31.3 18.58 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 111.899 -0.48 . . . . 0.0 111.899 -179.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -49.86 -28.09 6.03 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.438 ' O ' ' O ' ' C' ' 49' ' ' ILE . 2.0 pp -48.58 -38.88 21.84 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.696 -0.401 . . . . 0.0 111.451 -178.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.453 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 9.7 p30 -51.94 -49.26 63.51 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.594 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.453 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 4.1 tp-100 -46.92 -38.57 10.75 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.042 0.449 . . . . 0.0 110.956 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.519 ' O ' ' CB ' ' C' ' 50' ' ' LYS . 12.8 tt -112.52 112.49 40.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.727 -179.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.55 ' O ' ' N ' ' C' ' 52' ' ' GLY . 0.8 OUTLIER 94.32 119.34 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.497 -1.228 . . . . 0.0 110.713 179.591 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . 0.655 ' NH2' HH21 ' A' ' 51' ' ' ARG . 62.4 ttt180 38.78 -86.89 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.553 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.307 -1.053 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 36.0 m . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' D' ' 26' ' ' LEU . 10.5 m-20 -161.82 151.06 13.32 Favored Pre-proline 0 C--N 1.306 -1.297 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.144 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.56 21.02 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.244 1.963 . . . . 0.0 111.752 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.462 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.9 tp -67.95 -47.15 69.44 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.532 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.97 -37.8 73.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 84.5 t -69.93 -43.57 79.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.525 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.39 -32.16 11.01 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.651 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.81 -29.68 69.68 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.964 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.0 t -56.27 -42.17 77.03 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.053 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.678 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -55.32 -35.63 37.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.448 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -71.06 -32.58 48.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.412 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.74 -44.29 98.1 Favored Glycine 0 C--N 1.305 -1.141 0 C-N-CA 121.336 -0.459 . . . . 0.0 112.123 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.6 pt -68.44 -29.35 43.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.841 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.6 tp -57.35 -43.04 83.13 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.037 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 4.1 m170 -60.76 -35.02 75.35 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.123 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 t80 -62.34 -48.53 79.41 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.6 -42.19 93.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.989 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.21 -40.27 74.64 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.86 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -48.46 -29.81 4.49 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.605 -179.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 73.3 p -64.86 -30.87 71.89 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.621 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.5 mp -69.87 -51.74 37.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.26 -31.73 27.79 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.55 ' O ' HG22 ' D' ' 49' ' ' ILE . 5.7 t-160 -60.4 -28.28 68.12 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.549 0.214 . . . . 0.0 111.276 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -46.61 -31.23 2.71 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.487 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.437 ' ND2' ' OE1' ' D' ' 48' ' ' GLN . 37.9 t30 -61.03 -50.7 72.26 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.095 0.406 . . . . 0.0 112.095 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.534 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -74.04 -68.39 0.52 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.187 0.517 . . . . 0.0 111.427 -178.718 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.713 ' O ' HG23 ' D' ' 49' ' ' ILE . 20.6 tt -54.24 88.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.643 -179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.443 ' N ' ' O ' ' D' ' 48' ' ' GLN . 7.1 tppt? 58.12 116.72 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.734 179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.03 129.38 34.45 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.32 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.772 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -170.34 58.73 0.3 Allowed Pre-proline 0 C--N 1.306 -1.307 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.951 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -78.22 25.51 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.818 2.345 . . . . 0.0 111.594 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -70.39 -43.83 69.25 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.043 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.6 p -70.89 -42.62 77.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.487 -179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.507 ' N ' HG13 ' A' ' 27' ' ' VAL . 66.1 t -68.41 -43.64 83.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.815 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.81 -34.45 53.74 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -30.54 67.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.5 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -60.36 -44.83 95.22 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.621 -179.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.2 mp -50.29 -29.08 5.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-O 120.825 0.345 . . . . 0.0 110.71 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -69.95 -29.32 39.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.809 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.54 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -68.61 -50.18 38.7 Favored Glycine 0 C--N 1.305 -1.172 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.324 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.569 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.2 mp -65.98 -29.56 47.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.999 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.22 -46.02 88.96 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.705 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.7 OUTLIER -57.7 -28.35 63.74 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.625 -178.787 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 30.9 t80 -55.5 -45.76 77.02 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 40' ' ' ALA . 3.4 tp -57.36 -44.56 84.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.299 -178.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.453 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -70.9 -35.4 72.28 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 120.824 0.345 . . . . 0.0 110.827 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.3 t-105 -48.95 -32.02 8.36 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.353 -178.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 61.2 p -57.56 -30.23 65.07 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.198 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 67.1 mt -64.2 -46.29 93.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.086 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.89 -27.56 3.4 Favored Glycine 0 C--N 1.297 -1.608 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.592 -178.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.596 ' NE2' ' NE2' ' A' ' 48' ' ' GLN . 13.4 t-80 -49.76 -32.91 14.8 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.427 HD22 ' OE1' ' B' ' 48' ' ' GLN . 6.4 mp -46.02 -40.15 10.14 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.938 -0.476 . . . . 0.0 111.633 -177.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -47.47 -52.68 16.41 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.455 -177.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.596 ' NE2' ' NE2' ' A' ' 45' ' ' HIS . 6.8 pt20 -72.41 -130.11 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.477 ' CG1' ' O ' ' A' ' 48' ' ' GLN . 3.8 pt 56.93 -13.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -179.129 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.569 ' H ' ' C ' ' A' ' 48' ' ' GLN . 42.6 pttt -170.12 19.94 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.012 0.434 . . . . 0.0 110.05 179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.493 HH21 ' CB ' ' D' ' 51' ' ' ARG . 64.9 ttt180 -150.22 80.36 1.36 Allowed 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.236 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.151 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.864 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 73.39 73.18 0.23 Allowed Pre-proline 0 C--N 1.307 -1.271 0 CA-C-O 121.059 0.457 . . . . 0.0 110.389 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.434 ' O ' ' HB2' ' B' ' 29' ' ' ALA . 46.8 Cg_exo -53.35 89.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.641 0 C-N-CA 122.72 2.28 . . . . 0.0 111.91 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 tp -70.66 -49.15 50.36 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.417 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.444 HG13 ' N ' ' B' ' 28' ' ' VAL . 11.6 p -70.3 -38.95 76.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.573 -179.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.444 ' N ' HG13 ' B' ' 27' ' ' VAL . 8.2 t -70.56 -45.24 75.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 120.602 -0.439 . . . . 0.0 109.891 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.434 ' HB2' ' O ' ' B' ' 25' ' ' PRO . . . -48.63 -33.41 9.86 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.242 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.28 69.96 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.482 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.2 t -49.69 -41.82 44.1 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.032 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mm -50.97 -29.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-O 120.904 0.383 . . . . 0.0 110.456 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.16 -29.55 36.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.204 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.91 -47.08 89.38 Favored Glycine 0 C--N 1.307 -1.067 0 C-N-CA 121.308 -0.472 . . . . 0.0 112.06 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.1 pt -62.12 -44.87 99.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.861 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 55.4 tp -59.97 -45.9 91.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.997 0.427 . . . . 0.0 109.905 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 33.8 t-80 -50.39 -47.56 56.33 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.142 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -66.95 -38.81 86.82 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.516 -179.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.08 -42.16 93.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.762 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.86 -39.74 76.17 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.964 0.412 . . . . 0.0 110.627 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -49.05 -29.32 4.9 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.956 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 77.8 p -54.67 -37.46 65.77 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.903 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 35.6 mm -61.16 -49.07 86.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.729 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.88 -29.91 8.66 Favored Glycine 0 C--N 1.305 -1.152 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.743 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 19.3 t-80 -53.96 -27.48 31.49 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.5 pp -46.43 -32.11 3.07 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -61.41 -50.31 73.38 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 120.705 -0.398 . . . . 0.0 112.039 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.427 ' OE1' HD22 ' A' ' 46' ' ' LEU . 47.5 mm-40 -56.26 -53.95 51.1 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.732 HG23 ' H ' ' B' ' 50' ' ' LYS . 7.8 tt -60.59 -66.6 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.761 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.31 -179.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.732 ' H ' HG23 ' B' ' 49' ' ' ILE . 15.9 ttpp -117.85 134.51 54.86 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.815 0.34 . . . . 0.0 110.585 -179.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 11.5 tpp180 -158.78 117.76 3.03 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.124 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.189 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 179.972 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -172.91 61.04 0.27 Allowed Pre-proline 0 C--N 1.306 -1.286 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.512 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -78.78 4.02 6.82 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.822 2.348 . . . . 0.0 112.211 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -60.0 -50.67 72.83 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.035 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -70.98 -33.76 53.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 120.937 0.399 . . . . 0.0 111.178 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 84.7 t -70.3 -42.91 78.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.912 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.536 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.98 -39.35 40.61 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.51 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.19 -29.48 69.84 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 120.842 0.353 . . . . 0.0 111.292 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -53.05 -40.87 64.29 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.395 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.536 HG22 ' O ' ' C' ' 29' ' ' ALA . 3.4 tp -49.68 -31.53 6.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.751 0.31 . . . . 0.0 111.428 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.3 mt -70.23 -29.84 41.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.94 -179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.526 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.26 -50.13 57.97 Favored Glycine 0 C--N 1.304 -1.218 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.908 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 36.8 pt -65.72 -29.65 47.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 CA-C-O 120.776 0.322 . . . . 0.0 111.01 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 17.6 tp -61.29 -49.44 77.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.754 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.63 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.61 -29.69 62.42 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.767 -178.287 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.63 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 70.8 t80 -63.3 -44.37 95.21 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.258 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 72.5 mt -56.14 -48.21 79.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.155 -179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.86 -35.97 81.25 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -50.29 -36.34 31.24 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.346 -179.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.4 p -54.28 -47.13 72.69 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 120.741 0.305 . . . . 0.0 111.009 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.441 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -62.44 -49.82 82.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.76 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.448 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -49.75 -29.74 13.39 Favored Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.031 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . 0.432 ' C ' HD22 ' C' ' 47' ' ' ASN . 56.3 t-80 -56.68 -29.02 61.9 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.929 ' O ' HG22 ' C' ' 49' ' ' ILE . 3.8 pp -47.12 -35.91 7.72 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.625 0.231 . . . . 0.0 111.625 -177.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.703 HD22 ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -48.51 -40.59 27.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.599 -0.841 . . . . 0.0 110.365 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.584 ' H ' ' ND2' ' C' ' 47' ' ' ASN . 49.4 tt0 -90.53 67.1 6.45 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.845 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.929 HG22 ' O ' ' C' ' 46' ' ' LEU . 17.7 tt -160.7 86.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 121.401 0.619 . . . . 0.0 111.285 179.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -175.06 160.91 2.83 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.786 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 65.8 mtp85 47.97 -121.54 1.37 Allowed 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.433 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.153 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.976 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 69.4 p . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -76.32 136.76 68.37 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -75.09 43.87 1.07 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.069 1.846 . . . . 0.0 112.166 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.47 -45.79 65.05 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.82 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.67 -41.08 77.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.912 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . 0.446 HG13 ' N ' ' D' ' 29' ' ' ALA . 8.1 p -70.73 -41.83 77.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.334 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.446 ' N ' HG13 ' D' ' 28' ' ' VAL . . . -49.8 -38.49 34.7 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.664 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.09 -31.54 72.8 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.258 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.5 t -56.22 -37.93 70.35 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.746 0.308 . . . . 0.0 110.793 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 mm -53.5 -29.59 17.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.387 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.4 mt -71.33 -29.24 34.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.465 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.33 -33.64 81.53 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 116.326 -0.397 . . . . 0.0 112.919 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.8 pp -63.72 -38.48 82.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-N 117.402 0.601 . . . . 0.0 110.707 -179.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 43.6 tp -54.72 -43.09 72.28 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.8 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.705 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 19.3 m170 -51.13 -50.01 59.68 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.412 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -61.21 -42.45 98.61 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.557 -179.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.2 mt -60.28 -48.17 89.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.913 -179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.56 -34.73 72.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.82 0.343 . . . . 0.0 111.178 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.0 t-105 -49.0 -28.04 3.62 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.141 0.496 . . . . 0.0 110.017 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.7 p -57.92 -34.88 70.33 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.854 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.588 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.4 mp -65.75 -50.92 67.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 120.759 0.314 . . . . 0.0 110.577 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.85 -29.67 62.08 Favored Glycine 0 C--N 1.302 -1.359 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.882 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.483 ' O ' HG22 ' D' ' 49' ' ' ILE . 11.6 t-160 -70.64 -32.91 70.39 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' D' ' 50' ' ' LYS . 0.7 OUTLIER -53.29 -30.18 37.38 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.612 -178.542 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -63.38 -50.26 70.6 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -178.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.532 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -67.1 -61.13 2.08 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.293 0.568 . . . . 0.0 111.632 -178.561 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.834 HG23 ' H ' ' D' ' 50' ' ' LYS . 7.2 tp -52.88 -67.17 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.975 -178.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.834 ' H ' HG23 ' D' ' 49' ' ' ILE . 34.7 ttpt -106.9 154.91 20.36 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 120.809 0.338 . . . . 0.0 110.545 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.493 ' CB ' HH21 ' A' ' 51' ' ' ARG . 0.0 OUTLIER -162.13 9.49 0.07 Allowed 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.782 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.202 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 179.935 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.409 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 16.6 p-10 -173.3 57.75 0.22 Allowed Pre-proline 0 C--N 1.306 -1.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.081 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -77.38 25.74 0.47 Allowed 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.763 2.309 . . . . 0.0 111.755 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.4 tp -64.82 -44.89 88.4 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.202 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.5 p -70.29 -41.42 78.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-O 120.756 0.312 . . . . 0.0 111.307 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.489 ' N ' HG13 ' A' ' 27' ' ' VAL . 16.6 t -63.32 -39.89 86.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-O 120.94 0.4 . . . . 0.0 110.921 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.08 -44.12 82.8 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.551 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.59 -37.13 75.16 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.785 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.2 t -57.84 -43.48 85.86 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.137 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 69.4 mt -49.32 -37.82 11.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 120.814 0.34 . . . . 0.0 110.778 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -64.77 -29.67 48.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.406 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.537 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -63.27 -50.04 65.94 Favored Glycine 0 C--N 1.305 -1.17 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.164 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.759 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -59.64 -29.62 43.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 122.686 -0.303 . . . . 0.0 111.34 -179.047 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tt -63.67 -50.83 67.71 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.672 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 0.5 OUTLIER -51.26 -29.44 14.6 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.272 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 63.8 t80 -58.35 -48.1 81.67 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.718 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.6 tp -49.67 -43.53 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.252 -179.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' N ' ' CG2' ' A' ' 39' ' ' ILE . . . -72.88 -30.03 63.64 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.76 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.507 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 10.9 t-105 -49.02 -32.38 9.25 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -177.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 42' ' ' THR . 0.2 OUTLIER -66.14 -33.01 74.79 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.463 -179.452 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.497 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.4 mp -51.09 -43.86 27.51 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.03 0.443 . . . . 0.0 109.839 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.44 -28.71 4.93 Favored Glycine 0 C--N 1.299 -1.505 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.048 -178.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -51.7 -33.78 35.69 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 117.251 0.526 . . . . 0.0 111.645 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.491 HD13 ' O ' ' A' ' 43' ' ' ILE . 6.5 mp -45.69 -45.21 14.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 119.551 -0.262 . . . . 0.0 111.531 -177.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -46.65 -49.86 18.55 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.201 -178.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.438 ' NE2' HD22 ' D' ' 46' ' ' LEU . 28.4 mm-40 -67.28 -130.11 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.42 ' H ' ' HB3' ' A' ' 48' ' ' GLN . 4.9 tt 35.78 56.28 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-O 121.373 0.606 . . . . 0.0 111.867 179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.405 ' H ' ' H ' ' A' ' 51' ' ' ARG . 19.3 pttp -169.27 4.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.799 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.405 ' H ' ' H ' ' A' ' 50' ' ' LYS . 91.8 mtt180 -145.47 152.27 39.52 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.854 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.174 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 54.2 m . . . . . 0 N--CA 1.488 1.465 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.403 ' O ' ' OD2' ' B' ' 24' ' ' ASP . 5.6 p-10 -140.21 60.69 15.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.484 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.32 56.95 1.69 Allowed 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.602 2.201 . . . . 0.0 111.78 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 tp -70.13 -49.86 46.43 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.076 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -70.19 -33.02 52.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.943 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 87.7 t -69.68 -46.2 75.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.989 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.9 -33.02 9.93 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.639 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.26 -31.51 72.74 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.772 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 37.4 t -58.9 -40.93 85.96 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.623 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 mm -51.71 -29.23 10.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -70.41 -29.95 40.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.42 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.32 -48.4 69.72 Favored Glycine 0 C--N 1.307 -1.043 0 C-N-CA 121.185 -0.531 . . . . 0.0 111.948 -179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 32.8 pt -67.32 -29.79 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 120.871 0.367 . . . . 0.0 110.678 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 53.3 tp -59.45 -47.59 84.89 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.661 -179.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.636 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 7.2 m-70 -49.82 -49.78 47.65 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.648 -179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -50.92 -42.98 59.85 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.617 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 79.1 mt -61.12 -50.43 80.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.598 -178.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.32 -38.4 74.92 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.949 0.404 . . . . 0.0 111.076 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.6 t-105 -49.18 -28.73 4.72 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.035 -179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 44.1 p -59.9 -38.63 82.83 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.001 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 29.2 mm -65.77 -51.39 62.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 C-N-CA 120.836 -0.345 . . . . 0.0 111.379 -179.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.417 ' O ' ' OD1' ' B' ' 47' ' ' ASN . . . -50.21 -29.75 16.26 Favored Glycine 0 C--N 1.305 -1.193 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.558 ' O ' HG22 ' B' ' 49' ' ' ILE . 8.6 t-160 -56.72 -27.66 59.59 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.446 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.5 pp -47.78 -35.9 10.75 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.672 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 25.0 p-10 -63.26 -49.62 73.38 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 -178.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.451 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 1.4 tm0? -68.89 -57.45 5.52 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.929 HG23 ' H ' ' B' ' 50' ' ' LYS . 13.0 tt -51.13 -71.35 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -178.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.929 ' H ' HG23 ' B' ' 49' ' ' ILE . 33.5 ttpt -111.78 147.3 35.96 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-O 120.827 0.346 . . . . 0.0 110.63 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 63.3 ttm-85 -146.49 143.33 28.88 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.387 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.92 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.18 61.83 1.93 Allowed Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.444 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -78.32 0.34 10.0 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.894 2.396 . . . . 0.0 111.999 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 59.7 tp -61.11 -42.21 98.1 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.739 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 96.2 t -70.13 -42.33 79.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.347 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 98.7 t -60.13 -43.48 93.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 120.955 0.407 . . . . 0.0 110.328 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.448 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.22 -48.25 79.27 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.638 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.28 -35.05 69.3 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.847 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.9 t -56.8 -43.66 81.18 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.724 0.297 . . . . 0.0 111.453 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.602 ' O ' HD13 ' C' ' 32' ' ' ILE . 0.3 OUTLIER -48.66 -34.6 5.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-O 120.884 0.373 . . . . 0.0 110.459 -178.892 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 5.8 mt -64.18 -29.69 48.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.702 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.548 ' O ' ' CE1' ' C' ' 37' ' ' HIS . . . -67.9 -51.37 35.06 Favored Glycine 0 C--N 1.306 -1.129 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.579 -178.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 tt -63.1 -29.29 46.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 122.419 -0.46 . . . . 0.0 111.195 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 55.9 tp -62.22 -51.4 67.95 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.589 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.636 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 1.2 p80 -53.92 -29.5 42.39 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.815 -178.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 68.9 t80 -57.17 -49.52 75.7 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.564 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -49.88 -43.38 19.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.505 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.77 -31.98 70.23 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.144 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -54.3 -42.68 70.38 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 116.592 -0.276 . . . . 0.0 111.309 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 17.3 p -56.58 -40.36 75.1 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 120.987 0.422 . . . . 0.0 110.434 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 27.4 mm -59.06 -50.86 78.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.318 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.8 -28.16 6.93 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . 0.786 ' NE2' HD13 ' C' ' 49' ' ' ILE . 6.5 t-160 -50.41 -40.13 49.22 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.477 ' CD1' ' N ' ' C' ' 47' ' ' ASN . 0.1 OUTLIER -56.27 -28.05 57.31 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 -177.77 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.477 ' N ' ' CD1' ' C' ' 46' ' ' LEU . 25.0 p-10 -45.81 -51.5 12.71 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -174.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.427 ' CD ' HD11 ' B' ' 46' ' ' LEU . 6.5 tt0 -141.27 49.83 1.63 Allowed 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 119.205 0.911 . . . . 0.0 112.392 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.786 HD13 ' NE2' ' C' ' 45' ' ' HIS . 11.2 tp -96.68 41.12 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.56 0.695 . . . . 0.0 109.207 178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.63 25.58 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.942 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 11.1 tpt180 -155.38 126.14 6.96 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.855 0.36 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.7 m . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.9 m-20 47.7 57.73 17.69 Favored Pre-proline 0 C--N 1.304 -1.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.983 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.11 12.6 0.98 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.85 2.366 . . . . 0.0 111.447 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' D' ' 24' ' ' ASP . 39.3 tp -70.74 -44.75 66.17 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.607 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.4 p -70.54 -35.06 59.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.39 -50.04 49.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.528 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.66 -33.46 15.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.87 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.46 -34.77 74.87 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 120.865 0.364 . . . . 0.0 111.132 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 36.7 t -51.85 -38.47 56.08 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.161 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 mm -61.3 -29.64 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-O 120.89 0.376 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.405 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 5.1 mt -71.33 -39.17 71.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.418 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.38 -42.2 96.12 Favored Glycine 0 C--N 1.307 -1.068 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.198 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 9.9 tt -70.27 -39.27 76.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.301 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 44.3 tp -49.48 -36.36 22.62 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.437 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.672 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 45.6 m170 -49.93 -43.11 49.65 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.164 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -57.6 -38.29 74.66 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.442 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mm -61.67 -50.81 78.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.157 -179.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.507 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.68 -35.62 72.91 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.956 -179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -48.57 -28.65 3.56 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.109 0.48 . . . . 0.0 110.403 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.4 p -51.05 -36.66 41.05 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.057 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 32.2 mm -68.23 -51.13 51.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.127 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.95 -29.48 55.39 Favored Glycine 0 C--N 1.305 -1.184 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -57.23 -27.57 62.14 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.438 HD22 ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -47.3 -28.94 2.18 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.819 -178.021 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -50.74 -52.57 39.27 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 120.36 -0.536 . . . . 0.0 112.302 -178.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.574 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -84.32 -64.22 1.2 Allowed 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 120.68 0.276 . . . . 0.0 111.64 -179.001 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 15.4 tt -62.77 14.54 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.492 ' H ' ' C ' ' D' ' 48' ' ' GLN . 12.2 ttmm -169.62 121.55 0.71 Allowed 'General case' 0 C--N 1.308 -1.22 0 O-C-N 121.844 -0.535 . . . . 0.0 110.524 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 20.9 tpt85 -162.95 80.62 0.48 Allowed 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.546 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.969 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.95 60.93 0.24 Allowed Pre-proline 0 C--N 1.305 -1.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.709 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -79.11 10.04 3.11 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.821 2.347 . . . . 0.0 112.123 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 tp -66.52 -44.32 82.82 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.63 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.3 p -70.07 -35.14 62.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.311 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 74.9 t -69.63 -43.91 79.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.938 0.399 . . . . 0.0 110.762 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.67 -39.13 35.34 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.115 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.59 -34.38 76.86 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.726 0.298 . . . . 0.0 111.165 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.4 ' O ' ' CD1' ' A' ' 35' ' ' ILE . 33.5 t -59.88 -41.79 92.35 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.797 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mm -52.55 -32.21 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.152 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.6 mt -70.25 -29.78 40.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.702 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.62 -45.1 93.92 Favored Glycine 0 C--N 1.304 -1.23 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.253 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.905 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -66.82 -29.13 45.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 122.589 -0.359 . . . . 0.0 111.189 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.603 ' O ' HG22 ' A' ' 39' ' ' ILE . 35.9 tp -62.92 -46.96 85.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -178.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.69 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.4 p80 -58.96 -28.42 66.29 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 120.201 -0.6 . . . . 0.0 111.423 -178.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.619 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 33.7 t80 -56.74 -48.66 77.29 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 36' ' ' LEU . 6.4 tt -59.4 -41.17 83.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.171 -178.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.35 -35.94 73.88 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.47 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.425 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 5.2 t-105 -49.67 -34.19 17.77 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.412 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.2 p -62.19 -29.98 70.75 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.036 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.403 HG21 ' NE2' ' B' ' 48' ' ' GLN . 58.4 mt -61.33 -47.1 95.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.385 -179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.71 -28.36 5.19 Favored Glycine 0 C--N 1.307 -1.051 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.167 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.448 ' O ' ' O ' ' A' ' 48' ' ' GLN . 4.9 t-160 -48.88 -27.71 3.26 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 116.762 0.281 . . . . 0.0 111.271 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 pp -45.47 -41.89 9.98 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.54 -0.3 . . . . 0.0 111.745 -177.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.444 ' CG ' HD21 ' D' ' 47' ' ' ASN . 5.8 m120 -48.22 -50.22 30.21 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.615 ' O ' HG22 ' A' ' 49' ' ' ILE . 2.4 tt0 -93.65 175.39 6.76 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.016 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.615 HG22 ' O ' ' A' ' 48' ' ' GLN . 0.4 OUTLIER 75.7 -30.58 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 CA-C-N 118.154 0.433 . . . . 0.0 111.434 179.805 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.409 ' H ' ' C ' ' A' ' 48' ' ' GLN . 36.1 ttpt -92.09 -62.75 1.35 Allowed 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 120.558 0.218 . . . . 0.0 111.1 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -67.24 -38.33 85.02 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.507 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.266 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.835 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' B' ' 24' ' ' ASP . 1.5 p30 -85.83 151.95 55.88 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.079 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -71.33 38.6 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.365 2.043 . . . . 0.0 111.774 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.415 ' H ' ' C ' ' B' ' 24' ' ' ASP . 43.9 tp -68.06 -47.96 66.89 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.695 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -70.52 -34.0 55.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -70.0 -45.88 75.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.265 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.04 -35.37 15.46 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.629 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.21 -29.81 70.64 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.679 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 7.0 t -57.88 -41.36 82.34 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.766 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.7 mm -50.44 -30.61 7.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.584 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.63 -29.34 37.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.4 -49.93 58.3 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 121.047 -0.596 . . . . 0.0 111.787 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.408 HG12 ' H ' ' B' ' 35' ' ' ILE . 10.5 pt -63.42 -42.84 97.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.691 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 58.1 tp -60.26 -45.18 94.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.279 0.561 . . . . 0.0 109.615 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -61.08 -41.17 96.16 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.347 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 88.9 t80 -70.67 -46.58 62.94 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.474 ' O ' ' OG1' ' B' ' 42' ' ' THR . 18.0 tt -68.07 -29.97 46.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.317 -178.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -39.98 72.02 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.213 0.53 . . . . 0.0 110.139 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -54.35 -37.45 64.94 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.432 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 31.6 p -55.16 -36.58 65.97 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.603 -0.439 . . . . 0.0 110.934 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -65.04 -50.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.015 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.542 ' O ' ' ND2' ' B' ' 47' ' ' ASN . . . -49.51 -30.36 12.8 Favored Glycine 0 C--N 1.305 -1.185 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.43 ' CD2' ' CD ' ' B' ' 48' ' ' GLN . 31.7 t-80 -59.81 -27.04 66.26 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.7 0.286 . . . . 0.0 111.562 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.89 -31.65 12.69 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.774 -0.371 . . . . 0.0 111.943 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' B' ' 48' ' ' GLN . 6.9 p30 -68.95 -50.06 52.56 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -177.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.546 ' N ' ' OD1' ' B' ' 47' ' ' ASN . 7.5 pt20 -69.28 -48.51 61.5 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.821 HG23 ' H ' ' B' ' 50' ' ' LYS . 16.4 tt -53.95 -67.18 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.214 -179.154 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.821 ' H ' HG23 ' B' ' 49' ' ' ILE . 1.5 pptp? -131.07 164.06 26.26 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 120.853 0.359 . . . . 0.0 110.762 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 60.1 ttm-85 -153.52 -48.33 0.09 Allowed 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.543 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.164 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 -179.96 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 91.0 p . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -173.08 60.13 0.25 Allowed Pre-proline 0 C--N 1.305 -1.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.788 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -77.31 6.34 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.767 2.311 . . . . 0.0 111.885 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.3 tp -64.11 -48.44 76.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 59.5 t -70.42 -37.02 69.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 85.8 t -70.12 -43.71 78.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.742 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.56 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -57.48 -38.47 74.6 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.549 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.08 -30.38 71.45 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 120.906 0.384 . . . . 0.0 110.903 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -50.74 -36.47 36.61 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.178 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.56 HG22 ' O ' ' C' ' 29' ' ' ALA . 11.8 tt -55.27 -29.76 23.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.603 -179.174 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.41 -36.92 76.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.429 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.61 -46.41 84.49 Favored Glycine 0 C--N 1.303 -1.261 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.16 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 11.0 tt -70.28 -29.06 37.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.778 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 31.8 tp -61.94 -47.23 85.83 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.99 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -56.7 -29.94 62.95 Favored 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 120.421 -0.512 . . . . 0.0 111.876 -178.474 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 77.4 t80 -62.33 -40.63 96.99 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.393 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -57.43 -46.93 85.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.54 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.18 -34.62 73.19 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 120.81 0.338 . . . . 0.0 110.812 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.2 -30.68 7.31 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.354 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 42.2 p -53.97 -44.02 70.41 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.923 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.479 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.0 mp -63.66 -48.86 84.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.617 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.23 -33.56 15.67 Favored Glycine 0 C--N 1.304 -1.217 0 C-N-CA 121.259 -0.496 . . . . 0.0 111.881 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -50.58 -28.57 8.95 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 116.814 0.307 . . . . 0.0 111.628 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.448 ' C ' HD12 ' C' ' 46' ' ' LEU . 2.2 pp -46.82 -39.55 12.11 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.931 -177.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 32.1 p30 -49.95 -35.03 22.63 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.191 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.524 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 1.9 tm0? -73.91 -53.4 10.23 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 112.473 0.545 . . . . 0.0 112.473 -178.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.602 HG23 ' N ' ' C' ' 50' ' ' LYS . 13.2 tt -62.7 -56.74 15.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.602 ' N ' HG23 ' C' ' 49' ' ' ILE . 52.5 pttt -37.51 147.46 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 117.934 0.333 . . . . 0.0 111.287 -179.31 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . 0.466 ' N ' ' CD ' ' C' ' 51' ' ' ARG . 10.5 mpt_? 45.79 -90.72 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.593 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' C' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.163 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 14.9 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' D' ' 24' ' ' ASP . 4.2 p30 -71.65 151.81 93.57 Favored Pre-proline 0 C--N 1.305 -1.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.223 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.72 45.56 0.9 Allowed 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.322 2.015 . . . . 0.0 111.753 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 53.9 tp -69.97 -44.02 70.31 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.282 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.52 -38.62 74.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.979 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 95.6 t -67.08 -47.71 81.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.696 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.78 -34.37 19.18 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.015 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.31 -29.73 67.65 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.138 -179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.2 t -57.17 -42.79 81.8 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.127 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mm -51.46 -33.34 14.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 120.881 0.372 . . . . 0.0 110.481 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 4.6 mt -71.51 -29.04 33.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.282 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.36 -47.47 79.08 Favored Glycine 0 C--N 1.309 -0.937 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.118 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.9 pt -61.15 -42.07 91.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.786 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.5 tp -49.13 -32.24 9.63 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.69 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 29.5 m170 -65.35 -42.88 92.39 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.554 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.69 -50.07 66.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.3 pp -62.83 -39.04 83.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.847 -0.741 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.425 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -69.08 -40.75 78.24 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.335 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.1 t-105 -49.78 -30.2 9.18 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.73 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.2 m -69.59 -35.78 75.64 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 115.604 -0.726 . . . . 0.0 111.116 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.519 ' O ' HD12 ' D' ' 46' ' ' LEU . 60.7 mt -70.6 -51.54 36.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.012 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.97 -27.8 65.19 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -55.99 -26.56 48.97 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.758 HD13 ' N ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -47.07 -25.11 0.77 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -177.642 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.758 ' N ' HD13 ' D' ' 46' ' ' LEU . 13.7 m120 -49.23 -51.51 32.81 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.066 -0.654 . . . . 0.0 111.402 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.526 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -85.07 -69.32 0.66 Allowed 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.997 0.427 . . . . 0.0 111.098 -179.443 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.629 ' O ' HG23 ' D' ' 49' ' ' ILE . 7.3 tp -57.94 92.45 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 CA-C-O 121.546 0.689 . . . . 0.0 110.603 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' D' ' 46' ' ' LEU . 17.2 ttpp 59.13 145.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.765 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.928 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 25.1 ptt-85 -152.5 -22.69 0.17 Allowed 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.429 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.261 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.981 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.5 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -174.37 57.58 0.2 Allowed Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.38 9.74 2.41 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.828 2.352 . . . . 0.0 111.991 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.9 tp -67.75 -45.11 75.89 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.2 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.0 p -70.1 -37.2 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.655 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.429 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.6 t -68.91 -43.7 82.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 120.982 0.42 . . . . 0.0 110.989 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.82 -38.3 21.79 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.629 -179.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.08 -35.86 81.67 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.32 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 35' ' ' ILE . 44.8 t -60.4 -44.75 95.41 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.333 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.0 mm -50.01 -29.72 5.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.042 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.9 mt -70.5 -30.96 44.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.813 -179.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.53 -48.49 72.82 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.379 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.698 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.4 mp -68.07 -29.5 44.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.74 0.305 . . . . 0.0 111.057 -179.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 39' ' ' ILE . 45.2 tp -61.8 -47.43 85.17 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.464 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.1 p80 -61.1 -28.59 69.2 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.243 -0.583 . . . . 0.0 111.41 -178.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 51.4 t80 -60.18 -48.74 80.47 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.509 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -60.73 -39.96 83.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.083 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -39.47 72.44 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 120.926 0.393 . . . . 0.0 110.968 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.497 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.0 t-105 -48.94 -30.83 6.42 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.856 -178.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -57.83 -37.54 73.99 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.8 mm -61.04 -48.88 87.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.804 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -48.27 -28.12 6.01 Favored Glycine 0 C--N 1.305 -1.163 0 N-CA-C 111.709 -0.557 . . . . 0.0 111.709 -179.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 -48.2 -27.87 2.68 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.614 ' O ' HG23 ' A' ' 49' ' ' ILE . 2.6 pp -45.8 -37.46 6.1 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.732 -0.387 . . . . 0.0 111.656 -177.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -55.77 -50.24 70.97 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.431 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -86.52 68.44 10.18 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 111.612 0.227 . . . . 0.0 111.612 -179.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.614 HG23 ' O ' ' A' ' 46' ' ' LEU . 18.3 pt -110.22 -122.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.619 0.247 . . . . 0.0 111.083 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -63.54 -36.66 84.53 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 120.837 0.351 . . . . 0.0 110.693 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -69.41 -21.54 63.75 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.95 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.216 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.988 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 27.2 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.425 ' C ' ' H ' ' B' ' 26' ' ' LEU . 21.4 m-20 50.01 56.13 17.38 Favored Pre-proline 0 C--N 1.304 -1.409 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.974 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 60.7 Cg_endo -71.53 38.68 0.35 Allowed 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.731 2.288 . . . . 0.0 111.567 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.425 ' H ' ' C ' ' B' ' 24' ' ' ASP . 18.1 tp -70.27 -45.07 67.12 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.013 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 95.5 t -70.64 -38.12 72.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.545 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.44 -42.47 78.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.739 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.17 -29.74 14.76 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.595 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.74 -31.55 69.59 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.702 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.5 t -52.17 -40.25 61.2 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.749 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.415 ' O ' HD13 ' B' ' 35' ' ' ILE . 20.3 mm -51.37 -32.79 13.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-O 121.224 0.535 . . . . 0.0 110.368 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.0 mt -72.35 -29.17 30.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.36 -52.01 24.12 Favored Glycine 0 CA--C 1.528 0.899 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.731 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.415 HD13 ' O ' ' B' ' 32' ' ' ILE . 0.2 OUTLIER -70.95 -29.48 37.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 117.971 0.886 . . . . 0.0 110.267 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 57.4 tp -64.7 -44.97 88.56 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.167 0.508 . . . . 0.0 110.113 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -52.91 -43.24 66.07 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.547 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -69.8 -36.7 75.9 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.406 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.33 -42.94 98.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.978 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.41 -36.04 78.53 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.85 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -53.44 -33.48 54.2 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.087 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.0 p -54.91 -40.12 69.51 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.775 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.52 -47.64 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.614 -179.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.12 -29.35 9.04 Favored Glycine 0 C--N 1.305 -1.161 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -49.46 -27.06 3.82 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.551 0.215 . . . . 0.0 111.484 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 1.9 pp -47.43 -38.2 13.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.45 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -48.42 -51.06 28.51 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.315 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.572 ' C ' ' H ' ' B' ' 50' ' ' LYS . 16.4 tt0 -82.08 -143.99 0.06 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.052 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.479 HG22 ' O ' ' B' ' 48' ' ' GLN . 12.4 tt 46.57 1.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 N-CA-C 113.085 0.772 . . . . 0.0 113.085 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.572 ' H ' ' C ' ' B' ' 48' ' ' GLN . 20.7 pttp -175.18 132.1 0.3 Allowed 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 56.6 ttm-85 -164.95 123.73 1.75 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.848 0.356 . . . . 0.0 110.969 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.081 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.781 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 26.3 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -162.09 58.8 0.9 Allowed Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.491 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -76.17 8.02 3.05 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.841 2.361 . . . . 0.0 111.988 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 30.8 tp -70.0 -44.71 68.83 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.721 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.8 t -70.68 -39.33 75.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.348 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 13.6 t -69.7 -44.56 79.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.499 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -60.92 -39.15 88.29 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.265 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.85 -29.92 71.11 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.975 0.417 . . . . 0.0 110.786 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -50.51 -34.23 24.45 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.949 -0.568 . . . . 0.0 111.255 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.499 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.9 tp -53.18 -30.23 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.449 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.53 -32.03 51.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.013 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -67.58 -47.46 62.07 Favored Glycine 0 C--N 1.304 -1.233 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.312 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 13.1 tt -69.4 -29.82 43.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.026 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 28.5 tp -62.62 -48.95 77.13 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -53.42 -29.44 35.14 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.59 -178.7 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 58.0 t80 -61.57 -41.42 97.37 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 92.4 mt -57.61 -48.86 82.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 121.032 -0.267 . . . . 0.0 111.535 -178.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.45 -32.83 72.02 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.967 0.413 . . . . 0.0 110.316 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.8 -35.03 21.28 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.145 -179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -58.77 -32.31 69.17 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.372 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.1 -48.66 80.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.309 -179.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.447 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -49.93 -36.56 27.28 Favored Glycine 0 C--N 1.305 -1.141 0 CA-C-N 116.387 -0.37 . . . . 0.0 112.721 -178.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -51.47 -27.84 11.58 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 117.296 0.548 . . . . 0.0 111.283 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.597 HD21 ' CB ' ' D' ' 48' ' ' GLN . 1.7 pp -45.95 -41.22 11.35 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.187 -177.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.686 HD22 ' N ' ' C' ' 48' ' ' GLN . 0.5 OUTLIER -54.14 -39.0 66.1 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.017 179.744 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.686 ' N ' HD22 ' C' ' 47' ' ' ASN . 5.3 tp-100 -63.73 -51.59 64.26 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.007 0.432 . . . . 0.0 111.408 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.659 HG23 ' N ' ' C' ' 50' ' ' LYS . 0.6 OUTLIER -96.54 -144.62 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.935 -179.344 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.659 ' N ' HG23 ' C' ' 49' ' ' ILE . 46.9 tttp 53.57 161.03 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.754 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 50.38 69.46 0.62 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.442 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.17 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.946 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.487 ' C ' ' H ' ' D' ' 26' ' ' LEU . 16.0 m-20 -153.84 150.64 23.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.139 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.83 22.0 0.21 Allowed 'Trans proline' 0 N--CA 1.495 1.573 0 C-N-CA 122.1 1.867 . . . . 0.0 111.972 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.487 ' H ' ' C ' ' D' ' 24' ' ' ASP . 55.5 tp -71.87 -39.93 69.31 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.923 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.7 t -70.03 -45.24 77.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -178.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . 0.437 HG23 ' N ' ' D' ' 29' ' ' ALA . 17.1 m -67.91 -35.87 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.059 0.457 . . . . 0.0 110.439 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.437 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.66 -36.36 56.77 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.302 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.67 -39.46 73.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.316 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -61.86 -48.59 79.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.744 ' O ' HD12 ' D' ' 35' ' ' ILE . 12.5 pt -50.35 -28.21 5.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.751 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.77 -28.69 34.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.301 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -44.55 84.49 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-N 116.337 -0.392 . . . . 0.0 113.632 -178.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . 0.999 HD13 ' N ' ' D' ' 36' ' ' LEU . 0.0 OUTLIER -56.36 -28.43 26.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-N 117.411 0.605 . . . . 0.0 110.516 -178.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . 0.999 ' N ' HD13 ' D' ' 35' ' ' ILE . 4.1 tp -60.47 -43.1 97.3 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 120.892 0.377 . . . . 0.0 110.565 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.627 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 7.0 m170 -55.14 -49.16 72.52 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.526 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -56.46 -50.08 72.75 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -178.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 11.6 pt -61.29 -44.93 99.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.919 -0.712 . . . . 0.0 111.045 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.497 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.3 -37.51 74.79 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.187 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.7 t-105 -48.63 -30.13 5.09 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.843 0.354 . . . . 0.0 110.653 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.4 p -60.09 -36.75 78.11 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.842 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.64 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -69.23 -51.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.231 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' D' ' 47' ' ' ASN . . . -53.44 -28.74 37.11 Favored Glycine 0 C--N 1.304 -1.228 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.495 ' O ' HG22 ' D' ' 49' ' ' ILE . 10.6 t-80 -65.29 -33.33 75.72 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.6 pp -59.41 -41.33 89.23 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.446 ' OD1' ' O ' ' D' ' 44' ' ' GLY . 0.7 OUTLIER -64.43 -50.33 67.97 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.948 -178.771 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.597 ' CB ' HD21 ' C' ' 46' ' ' LEU . 0.2 OUTLIER -63.63 -61.56 2.24 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.955 0.407 . . . . 0.0 111.233 -179.251 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.653 HG23 ' N ' ' D' ' 50' ' ' LYS . 4.2 tp -47.42 -60.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.126 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.653 ' N ' HG23 ' D' ' 49' ' ' ILE . 46.4 mtpt -125.86 153.53 44.01 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.91 21.63 1.12 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.838 0.351 . . . . 0.0 110.403 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.898 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.4 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 43.2 m . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-20 -161.62 64.0 1.73 Allowed Pre-proline 0 C--N 1.307 -1.246 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.638 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -79.55 0.48 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 122.876 2.384 . . . . 0.0 112.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.3 tp -66.12 -46.61 76.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.956 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.411 HG13 ' N ' ' A' ' 28' ' ' VAL . 14.0 p -70.34 -36.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.649 -179.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.411 ' N ' HG13 ' A' ' 27' ' ' VAL . 74.3 t -69.55 -42.27 80.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 120.918 0.389 . . . . 0.0 110.855 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.55 -38.12 29.8 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.828 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.42 75.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.303 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -59.93 -42.74 94.64 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.112 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.6 mm -49.69 -31.49 6.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.876 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.5 mt -70.48 -29.59 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.547 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -65.57 -49.83 58.07 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.461 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.866 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.1 mp -65.64 -29.73 47.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 122.576 -0.367 . . . . 0.0 111.089 -179.187 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 39' ' ' ILE . 56.5 tp -61.41 -46.11 91.5 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.643 -179.024 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.0 OUTLIER -61.34 -28.99 69.61 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 120.195 -0.602 . . . . 0.0 111.358 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 91.6 t80 -62.78 -50.16 72.12 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.465 HG22 ' O ' ' A' ' 36' ' ' LEU . 5.8 tt -57.79 -40.38 75.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 C-N-CA 120.089 -0.644 . . . . 0.0 110.521 -178.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.99 -36.15 72.37 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.629 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' D' ' 40' ' ' ALA . 4.9 t-105 -48.83 -34.08 11.76 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.744 -179.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 39' ' ' ILE . 38.1 p -58.9 -33.67 70.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.814 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.605 ' CG2' ' NE2' ' B' ' 48' ' ' GLN . 96.6 mt -65.36 -44.24 94.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.201 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.0 -26.13 1.15 Allowed Glycine 0 C--N 1.306 -1.124 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -46.94 -25.02 0.7 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 123.016 -0.108 . . . . 0.0 111.104 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.567 ' CD1' ' NE2' ' B' ' 48' ' ' GLN . 1.1 mt -44.34 -50.58 9.02 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.208 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -56.94 -42.28 79.78 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.564 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.413 ' O ' ' OE1' ' A' ' 48' ' ' GLN . 0.1 OUTLIER -66.47 -57.67 6.86 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 120.897 0.38 . . . . 0.0 111.62 -179.054 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.743 HG23 ' H ' ' A' ' 50' ' ' LYS . 7.3 tp -59.91 -64.03 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.221 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.743 ' H ' HG23 ' A' ' 49' ' ' ILE . 34.4 ttmt -47.02 146.5 1.69 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 49.7 ptt85 37.74 -154.66 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.983 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.729 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . 0.49 ' O ' ' CB ' ' B' ' 24' ' ' ASP . 14.9 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' B' ' 26' ' ' LEU . 4.0 t70 84.79 52.58 0.04 OUTLIER Pre-proline 0 C--N 1.312 -1.044 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.38 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.466 ' CD ' ' N ' ' B' ' 24' ' ' ASP . 13.5 Cg_endo -56.06 70.46 0.03 OUTLIER 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 122.985 2.457 . . . . 0.0 112.29 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' B' ' 24' ' ' ASP . 20.6 tp -71.47 -50.88 27.28 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.504 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 t -70.69 -35.5 61.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-O 121.127 0.489 . . . . 0.0 111.514 -179.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 99.3 t -70.39 -44.18 77.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.274 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -29.52 5.71 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.813 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.53 -29.71 69.18 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.939 0.4 . . . . 0.0 110.524 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.0 t -49.98 -37.13 31.08 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.828 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -54.7 -29.51 21.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 120.978 0.418 . . . . 0.0 110.443 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -71.02 -29.84 38.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.323 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.45 -46.6 76.31 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.17 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 12.3 pt -66.01 -42.35 91.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.164 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.4 tp -62.32 -46.54 88.28 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.143 0.497 . . . . 0.0 109.818 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 54.4 t-80 -51.6 -42.03 61.65 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.444 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.13 -36.03 74.5 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.539 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -41.85 93.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.129 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.41 -40.42 77.32 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.01 0.434 . . . . 0.0 110.817 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.26 -32.05 10.0 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.067 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 68.8 p -51.38 -33.91 32.02 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.264 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 34.3 mm -65.74 -50.46 70.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.61 -30.11 26.6 Favored Glycine 0 C--N 1.306 -1.089 0 C-N-CA 121.232 -0.509 . . . . 0.0 111.928 -179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.443 ' O ' ' OE1' ' B' ' 48' ' ' GLN . 0.1 OUTLIER -63.78 -27.73 69.39 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 122.574 0.349 . . . . 0.0 111.342 -179.286 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.596 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.0 OUTLIER -48.75 -29.03 4.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.498 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.403 ' ND2' HH21 ' B' ' 51' ' ' ARG . 17.7 t-20 -58.18 -51.7 68.66 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -177.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.618 ' CD ' ' H ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -75.38 -47.82 25.78 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.25 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.909 HG23 ' H ' ' B' ' 50' ' ' LYS . 8.6 tt -55.05 -73.41 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 C-N-CA 120.301 -0.56 . . . . 0.0 110.474 -179.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.909 ' H ' HG23 ' B' ' 49' ' ' ILE . 0.0 OUTLIER -147.84 149.41 32.25 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.015 0.436 . . . . 0.0 110.939 179.672 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.403 HH21 ' ND2' ' B' ' 47' ' ' ASN . 57.8 ttm-85 -141.47 -53.45 0.45 Allowed 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.086 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.931 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 16.8 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -175.34 57.99 0.18 Allowed Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.39 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -75.68 7.58 3.06 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.881 2.387 . . . . 0.0 112.061 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 48.4 tp -69.35 -47.97 62.73 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.49 -36.61 66.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.058 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 64.2 t -70.33 -46.74 70.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.84 -36.61 27.38 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.18 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.5 -29.64 67.32 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.787 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -51.7 -41.94 61.85 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.278 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' C' ' 29' ' ' ALA . 7.4 tt -53.93 -27.13 15.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.018 0.437 . . . . 0.0 111.031 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 1.6 mm -59.89 -37.72 73.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.754 -178.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.446 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.4 -46.66 76.3 Favored Glycine 0 C--N 1.304 -1.212 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.991 -178.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -70.16 -29.13 38.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.533 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 34.4 tp -61.64 -50.62 71.79 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.667 -179.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.637 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -57.62 -29.0 64.17 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 120.546 -0.462 . . . . 0.0 111.652 -178.741 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 42.2 t80 -59.94 -42.64 94.44 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.638 0.256 . . . . 0.0 111.294 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' C' ' 42' ' ' THR . 19.6 mm -58.14 -45.71 88.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.071 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.01 -30.28 65.06 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.225 0.536 . . . . 0.0 111.056 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -52.6 -38.02 59.28 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -57.77 -29.99 65.27 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.48 -178.262 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.607 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.6 mp -61.24 -48.97 86.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.165 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.42 -29.74 11.32 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 12.9 t-80 -50.84 -28.09 8.73 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.69 0.281 . . . . 0.0 111.207 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.624 ' C ' HD12 ' C' ' 46' ' ' LEU . 3.3 pp -45.85 -33.6 3.28 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.892 -177.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.591 ' N ' HD12 ' C' ' 46' ' ' LEU . 71.1 m-20 -62.36 -49.03 77.18 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.732 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -82.04 71.03 9.08 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-O 120.604 0.24 . . . . 0.0 111.58 -178.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.768 HG23 ' H ' ' C' ' 50' ' ' LYS . 1.5 tp -179.51 -78.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 O-C-N 122.088 -0.382 . . . . 0.0 110.687 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.768 ' H ' HG23 ' C' ' 49' ' ' ILE . 51.5 pttt -50.86 -27.12 6.76 Favored 'General case' 0 C--N 1.309 -1.191 0 O-C-N 122.067 -0.395 . . . . 0.0 110.457 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -156.69 145.3 19.91 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.205 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.218 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 60.3 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -81.6 150.02 65.7 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.316 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.54 42.23 0.56 Allowed 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.201 1.934 . . . . 0.0 111.743 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.4 tp -70.15 -47.08 63.2 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.574 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.3 t -70.68 -34.42 56.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.093 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 91.8 t -69.96 -47.67 67.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.648 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -31.45 10.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.839 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.01 -33.76 74.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.5 t -58.06 -41.21 82.85 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 68.3 mt -58.36 -30.15 39.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-O 120.976 0.417 . . . . 0.0 110.816 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.441 ' O ' ' NE2' ' D' ' 37' ' ' HIS . 6.0 mt -71.43 -31.96 44.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.515 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.6 -39.61 90.68 Favored Glycine 0 C--N 1.307 -1.07 0 C-N-CA 121.429 -0.415 . . . . 0.0 112.579 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 19.9 pt -69.99 -35.76 65.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.601 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 27.6 tp -49.34 -36.09 20.39 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.484 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 8.7 m170 -58.99 -34.73 72.18 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -62.05 -45.96 91.25 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 -177.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 1.5 pp -67.22 -40.23 84.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.522 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.87 -41.28 71.59 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.211 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -48.96 -28.72 4.07 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 60.1 p -60.3 -32.5 71.26 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 84.8 mt -66.01 -51.57 58.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.174 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.84 -29.5 42.35 Favored Glycine 0 C--N 1.304 -1.215 0 N-CA-C 111.685 -0.566 . . . . 0.0 111.685 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 9.0 t-80 -55.77 -28.21 54.91 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.436 ' O ' ' O ' ' D' ' 50' ' ' LYS . 1.0 OUTLIER -47.02 -31.81 3.52 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.522 -177.618 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' D' ' 47' ' ' ASN . 19.5 p-10 -54.07 -48.25 70.82 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.107 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . . . . . . . . . 36.2 mm-40 -65.02 -53.33 47.64 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-O 120.936 0.398 . . . . 0.0 111.006 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.455 ' O ' HG23 ' D' ' 49' ' ' ILE . 3.6 tp -87.35 95.59 5.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-O 121.797 0.808 . . . . 0.0 110.389 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' D' ' 46' ' ' LEU . 5.7 ttpm? 64.32 161.42 0.11 Allowed 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.645 -1.161 . . . . 0.0 111.234 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.12 3.11 0.44 Allowed 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.771 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.413 ' H ' ' HG2' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.303 -1.28 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 79.2 p . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -177.73 60.28 0.15 Allowed Pre-proline 0 C--N 1.307 -1.244 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.847 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -78.62 4.1 6.68 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.891 2.394 . . . . 0.0 112.024 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.3 tp -66.48 -48.52 69.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.03 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.34 -35.56 63.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.586 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.0 t -70.36 -43.63 78.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 120.868 0.366 . . . . 0.0 110.684 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.2 -35.82 18.13 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.997 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.14 -35.26 79.69 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 120.734 0.302 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -61.07 -41.78 97.27 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.124 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -55.92 -29.76 26.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.114 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.3 mt -70.39 -32.47 50.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.397 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -61.21 -40.24 98.3 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.375 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 mt -69.98 -29.6 40.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.937 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.509 ' O ' HD23 ' A' ' 36' ' ' LEU . 1.7 tt -60.6 -47.83 84.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.314 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 1.5 p80 -61.61 -28.76 69.59 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.45 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 56.1 t80 -60.97 -48.24 82.76 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 10.2 pt -62.64 -40.53 88.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.074 -0.65 . . . . 0.0 111.098 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -39.58 75.31 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.69 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.6 t-105 -49.09 -30.96 7.1 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.016 -179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 70.4 p -63.78 -30.9 71.94 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 76.7 mt -59.69 -49.57 83.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.815 0.341 . . . . 0.0 111.016 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.26 -28.99 9.45 Favored Glycine 0 C--N 1.305 -1.175 0 N-CA-C 111.618 -0.593 . . . . 0.0 111.618 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.479 ' CD2' ' NE2' ' A' ' 48' ' ' GLN . 3.1 t-80 -49.76 -27.63 5.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 120.764 0.316 . . . . 0.0 110.897 -179.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.505 ' O ' ' CD1' ' A' ' 49' ' ' ILE . 2.5 pp -44.63 -36.96 3.33 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 52' ' ' GLY . 21.0 m120 -70.5 -36.19 73.67 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.573 ' C ' ' H ' ' A' ' 50' ' ' LYS . 11.0 tt0 -67.55 -57.92 5.62 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.505 ' CD1' ' O ' ' A' ' 46' ' ' LEU . 0.0 OUTLIER -60.63 15.39 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -177.658 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.581 ' CG ' ' H ' ' A' ' 51' ' ' ARG . 0.4 OUTLIER -164.2 -80.45 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 178.686 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.581 ' H ' ' CG ' ' A' ' 50' ' ' LYS . 60.8 ttt180 -57.18 -9.09 0.83 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.975 0.417 . . . . 0.0 110.166 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 47' ' ' ASN . . . . . . . . 0 C--N 1.308 -0.996 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 32.9 t . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.426 ' C ' ' H ' ' B' ' 26' ' ' LEU . 6.1 p-10 42.09 57.56 10.27 Favored Pre-proline 0 C--N 1.306 -1.309 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.963 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.27 12.1 0.52 Allowed 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.744 2.296 . . . . 0.0 111.753 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.426 ' H ' ' C ' ' B' ' 24' ' ' ASP . 36.0 tp -70.44 -46.14 64.46 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.039 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 91.9 t -70.28 -38.69 75.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.323 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 16.6 t -70.35 -45.95 73.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.56 -35.38 20.35 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.656 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.01 -36.8 77.99 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.5 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 19.8 t -51.57 -37.48 49.89 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.311 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.6 -36.12 47.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.847 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -70.63 -33.12 51.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.481 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.86 -44.72 78.5 Favored Glycine 0 C--N 1.305 -1.176 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.284 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 16.6 pt -70.04 -37.41 72.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.553 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.525 ' O ' HD13 ' B' ' 36' ' ' LEU . 0.2 OUTLIER -49.15 -42.63 40.26 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.035 -179.75 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' C' ' 37' ' ' HIS . 0.5 OUTLIER -53.2 -45.79 68.74 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.783 -179.761 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -57.85 -45.07 86.8 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.537 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.6 mp -61.28 -45.72 98.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.838 -179.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.33 -39.92 74.44 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.181 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.58 -28.64 5.91 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.435 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 43.4 p -62.01 -38.62 89.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.43 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.653 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.45 -50.17 80.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.607 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.74 -29.65 58.6 Favored Glycine 0 C--N 1.304 -1.218 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -56.0 -28.41 57.12 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.916 HD21 HE21 ' C' ' 48' ' ' GLN . 1.9 pp -47.61 -29.44 2.91 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.738 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.491 ' OD1' ' NH2' ' B' ' 51' ' ' ARG . 83.5 m-20 -62.92 -45.58 91.83 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -61.29 -53.11 60.96 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.011 0.434 . . . . 0.0 111.86 -179.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.673 HG23 ' H ' ' B' ' 50' ' ' LYS . 1.5 tp -55.85 -66.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.673 ' H ' HG23 ' B' ' 49' ' ' ILE . 18.0 pttp -150.89 172.23 15.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.995 0.426 . . . . 0.0 110.71 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.491 ' NH2' ' OD1' ' B' ' 47' ' ' ASN . 32.9 ttm-85 -152.23 135.21 15.65 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.233 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.227 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.932 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 41.6 t . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -106.08 100.05 26.48 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.372 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -83.12 10.51 3.62 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 122.145 1.897 . . . . 0.0 112.37 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.493 HD13 ' O ' ' C' ' 26' ' ' LEU . 0.2 OUTLIER -55.24 -50.31 69.79 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.762 -179.312 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 80.0 t -69.87 -39.91 78.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.829 0.347 . . . . 0.0 111.198 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 66.9 t -62.3 -44.21 98.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.618 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.541 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -64.03 -50.19 69.43 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.609 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.43 -29.34 67.7 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.488 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.0 t -54.71 -42.6 71.69 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.448 -179.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.541 HG22 ' O ' ' C' ' 29' ' ' ALA . 9.7 tp -50.75 -30.58 8.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.97 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.2 mt -70.45 -34.26 57.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.342 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -66.49 -49.25 57.53 Favored Glycine 0 C--N 1.303 -1.291 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.128 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . 0.412 ' O ' HD12 ' C' ' 39' ' ' ILE . 14.4 tt -64.81 -37.45 80.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 122.52 -0.4 . . . . 0.0 110.713 -179.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . 0.695 ' C ' HD12 ' C' ' 36' ' ' LEU . 0.1 OUTLIER -53.29 -47.11 69.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.151 -178.807 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.625 ' CE1' ' NE2' ' B' ' 37' ' ' HIS . 0.8 OUTLIER -61.0 -28.58 69.14 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.555 -178.258 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.621 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.2 t80 -58.88 -48.01 82.9 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.615 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.597 ' H ' HD12 ' C' ' 39' ' ' ILE . 4.3 mp -60.73 -45.58 97.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.484 -0.487 . . . . 0.0 111.078 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.03 -29.88 65.92 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.472 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' C' ' 41' ' ' TRP . 10.7 t-105 -48.93 -50.36 35.71 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.769 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.523 HG22 ' O ' ' C' ' 39' ' ' ILE . 12.2 t -47.79 -28.05 2.34 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.515 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tp -49.83 -49.32 20.83 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 120.299 -0.56 . . . . 0.0 110.358 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.515 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -54.18 -28.44 42.1 Favored Glycine 0 C--N 1.302 -1.321 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.93 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-80 -49.66 -33.39 15.48 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.818 0.309 . . . . 0.0 111.415 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.609 HD12 ' N ' ' C' ' 47' ' ' ASN . 2.0 pp -60.7 -44.56 96.42 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.609 ' N ' HD12 ' C' ' 46' ' ' LEU . 0.5 OUTLIER -61.57 -49.69 75.63 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 120.188 -0.605 . . . . 0.0 111.143 -178.976 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.916 HE21 HD21 ' B' ' 46' ' ' LEU . 1.9 mm100 -44.64 -15.63 0.02 OUTLIER 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.834 0.35 . . . . 0.0 111.096 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.812 HG23 ' H ' ' C' ' 50' ' ' LYS . 2.0 tt -136.43 -98.37 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -179.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.812 ' H ' HG23 ' C' ' 49' ' ' ILE . 58.7 pttt 42.7 32.89 0.42 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 120.764 0.316 . . . . 0.0 111.005 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -141.99 87.43 2.04 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.408 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.987 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 12.6 p . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -63.85 137.1 97.0 Favored Pre-proline 0 C--N 1.305 -1.365 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.213 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -74.55 45.36 1.24 Allowed 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.979 1.786 . . . . 0.0 111.935 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 41.6 tp -70.52 -44.39 67.65 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 11.0 t -70.7 -41.96 77.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.164 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.75 -38.39 72.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.329 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -35.13 21.41 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.69 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.17 -29.41 70.76 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.022 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 37.0 t -52.71 -42.54 64.93 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.199 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.664 HD12 ' N ' ' D' ' 32' ' ' ILE . 1.9 mp -54.97 -37.35 41.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.733 0.301 . . . . 0.0 110.5 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.412 ' O ' ' CD2' ' D' ' 37' ' ' HIS . 6.0 mt -71.45 -29.71 36.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.401 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.5 -48.92 47.97 Favored Glycine 0 C--N 1.306 -1.108 0 C-N-CA 121.361 -0.447 . . . . 0.0 113.025 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 pp -66.34 -32.47 58.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-N 117.194 0.497 . . . . 0.0 110.579 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 tp -51.06 -37.68 46.98 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.198 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.624 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 20.3 m170 -58.63 -40.44 83.37 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.858 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.02 -48.27 82.56 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . 0.408 ' O ' ' OG1' ' D' ' 42' ' ' THR . 12.6 pt -61.53 -41.88 91.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.175 -0.61 . . . . 0.0 111.422 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.6 -38.34 73.99 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.083 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.4 -30.77 8.39 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . 0.408 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 77.7 p -64.65 -34.11 77.52 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.252 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.643 ' N ' HD12 ' D' ' 43' ' ' ILE . 1.6 mp -70.49 -52.08 32.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.688 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.52 -29.35 24.01 Favored Glycine 0 C--N 1.306 -1.105 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 -179.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.44 ' O ' HG22 ' D' ' 49' ' ' ILE . 5.6 t-80 -56.4 -27.03 55.21 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 111.528 0.195 . . . . 0.0 111.528 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -46.3 -31.9 2.82 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.429 -177.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 30.5 t-20 -59.49 -50.86 72.29 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.767 -0.373 . . . . 0.0 111.558 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.551 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -73.31 -66.22 0.71 Allowed 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.159 0.504 . . . . 0.0 111.417 -178.789 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.721 ' O ' HG23 ' D' ' 49' ' ' ILE . 17.9 tt -63.63 93.6 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 CA-C-O 121.717 0.77 . . . . 0.0 110.046 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 33.5 ttpt 60.6 106.67 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.62 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -76.51 -169.17 1.15 Allowed 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.496 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.989 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.6 m . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -129.45 65.4 74.44 Favored Pre-proline 0 C--N 1.312 -1.032 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.153 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -78.65 48.41 2.75 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.767 2.311 . . . . 0.0 111.599 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.9 tp -70.52 -42.85 70.71 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.21 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.15 -40.92 78.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.589 -179.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.7 t -68.16 -46.21 81.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.822 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.84 -38.43 34.96 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.879 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.47 79.01 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.428 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.29 -39.92 80.59 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.949 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.1 mt -51.26 -29.67 9.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.263 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.9 mt -69.75 -29.82 42.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.623 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.26 -48.17 66.27 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 121.182 -0.532 . . . . 0.0 112.287 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.859 ' H ' HD12 ' A' ' 35' ' ' ILE . 4.1 mp -67.14 -29.68 46.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 120.681 -0.407 . . . . 0.0 111.126 -179.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.73 -46.3 90.94 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.574 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.695 ' HE2' ' CE1' ' D' ' 37' ' ' HIS . 1.1 p80 -61.78 -28.79 69.7 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.385 -178.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.637 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 64.1 t80 -60.62 -50.14 74.72 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.8 -39.17 69.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.952 -0.699 . . . . 0.0 111.007 -178.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.42 -36.04 73.77 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.891 0.377 . . . . 0.0 110.944 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.8 t-105 -49.68 -38.05 31.22 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.103 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.1 p -52.47 -39.76 61.52 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.91 -49.32 84.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.834 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.36 -28.6 9.49 Favored Glycine 0 C--N 1.304 -1.205 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 -48.85 -28.22 3.59 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.478 ' O ' HG22 ' A' ' 49' ' ' ILE . 2.4 pp -46.15 -33.77 3.8 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.292 -177.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 11.2 m-20 -46.12 -28.03 1.12 Allowed 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.597 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.539 ' O ' ' N ' ' A' ' 50' ' ' LYS . 12.1 tt0 -92.26 -45.62 8.13 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 120.66 0.267 . . . . 0.0 111.25 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.478 HG22 ' O ' ' A' ' 46' ' ' LEU . 1.8 tp -42.62 -15.19 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -178.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.539 ' N ' ' O ' ' A' ' 48' ' ' GLN . 0.0 OUTLIER -94.65 -74.76 0.53 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 120.86 0.362 . . . . 0.0 110.034 179.336 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -52.31 -71.03 0.07 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.707 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.074 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -179.866 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 34.3 p . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.475 ' C ' ' H ' ' B' ' 26' ' ' LEU . 0.9 OUTLIER -77.86 152.17 79.88 Favored Pre-proline 0 C--N 1.304 -1.377 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.147 179.853 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 35.43 0.24 Allowed 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.14 1.893 . . . . 0.0 111.681 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.475 ' H ' ' C ' ' B' ' 24' ' ' ASP . 48.4 tp -70.42 -46.62 63.56 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.067 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 48.7 t -70.42 -37.55 70.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.582 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.17 -44.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.598 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -33.22 12.04 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.356 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.92 -33.67 76.59 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.766 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.2 t -57.56 -41.03 80.23 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.782 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.8 mm -56.71 -35.94 47.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.279 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.57 -33.74 50.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.441 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.17 73.38 Favored Glycine 0 C--N 1.305 -1.183 0 C-N-CA 121.249 -0.5 . . . . 0.0 111.898 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.418 HG23 ' N ' ' B' ' 36' ' ' LEU . 3.7 tp -68.47 -43.99 83.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.745 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.418 ' N ' HG23 ' B' ' 35' ' ' ILE . 53.9 tp -49.97 -38.12 35.42 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.136 0.493 . . . . 0.0 110.078 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -49.64 -41.9 43.73 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.012 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -67.41 -38.71 85.04 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.726 -179.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.56 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.5 mp -62.01 -43.91 98.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.65 -179.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.56 74.96 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.152 0.501 . . . . 0.0 110.788 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -49.49 -29.56 6.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.819 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' B' ' 39' ' ' ILE . 25.3 p -61.62 -36.14 79.89 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.464 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 28.2 mm -63.67 -50.79 76.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.093 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.21 -29.48 29.48 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.493 ' O ' HG22 ' B' ' 49' ' ' ILE . 29.2 t-80 -61.46 -28.92 69.62 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 120.616 0.246 . . . . 0.0 111.327 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.533 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.8 OUTLIER -49.4 -34.66 16.83 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.397 -178.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -64.45 -50.43 67.53 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.478 ' CD ' ' CD2' ' B' ' 45' ' ' HIS . 9.5 pt20 -69.66 -50.05 47.8 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.864 HG23 ' H ' ' B' ' 50' ' ' LYS . 15.9 tt -58.43 -68.88 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.93 -179.272 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.864 ' H ' HG23 ' B' ' 49' ' ' ILE . 17.8 ptmt -114.84 155.39 26.88 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.671 0.272 . . . . 0.0 110.442 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 61.5 ttm-85 -147.54 -61.42 0.27 Allowed 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.362 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.135 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 93.3 p . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 m-20 -162.32 57.32 0.72 Allowed Pre-proline 0 C--N 1.307 -1.262 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -76.21 0.78 9.01 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.723 2.282 . . . . 0.0 112.116 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 34.8 tp -66.6 -45.07 80.4 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.994 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.22 -34.34 58.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.301 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.57 -47.3 80.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.51 -37.38 26.42 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.788 -179.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.4 -29.8 70.85 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.47 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 38.4 t -57.26 -42.85 82.34 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.693 0.283 . . . . 0.0 111.321 -179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.674 ' N ' HD12 ' C' ' 32' ' ' ILE . 2.2 mp -54.77 -30.28 22.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 mt -68.14 -36.38 75.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.525 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -63.61 -45.29 94.96 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.396 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 tp -69.96 -29.6 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 116.964 0.382 . . . . 0.0 110.824 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 33.0 tp -61.75 -49.26 77.13 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.916 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -55.66 -28.83 57.62 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 120.566 -0.454 . . . . 0.0 111.552 -178.61 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 51.4 t80 -61.07 -42.44 98.5 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.696 -0.229 . . . . 0.0 111.509 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 57.2 mt -58.1 -45.36 88.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.348 -178.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.26 -35.4 76.05 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.854 0.359 . . . . 0.0 110.743 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -49.47 -35.26 19.13 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 29.1 p -55.42 -39.07 69.79 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.031 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 85.1 mt -62.1 -48.49 88.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.901 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.517 ' O ' ' ND2' ' C' ' 47' ' ' ASN . . . -48.17 -27.79 5.58 Favored Glycine 0 C--N 1.305 -1.189 0 N-CA-C 111.613 -0.595 . . . . 0.0 111.613 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -47.71 -28.1 2.28 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 122.744 -0.268 . . . . 0.0 111.511 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.418 HD12 ' N ' ' C' ' 47' ' ' ASN . 3.2 pp -46.15 -43.73 15.29 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.323 -178.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.678 ' ND2' ' H ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -50.14 -37.93 36.72 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.24 179.704 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.678 ' H ' ' ND2' ' C' ' 47' ' ' ASN . 44.9 tt0 -63.19 -49.1 75.58 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.921 0.391 . . . . 0.0 111.445 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.703 HG23 ' N ' ' C' ' 50' ' ' LYS . 0.5 OUTLIER -94.56 -142.7 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.474 -179.499 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.703 ' N ' HG23 ' C' ' 49' ' ' ILE . 8.4 mtpm? 39.72 26.55 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.727 -179.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' C' ' 49' ' ' ILE . 11.3 tpt180 -157.31 112.22 2.75 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.177 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.086 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 95.8 p . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.483 ' C ' ' H ' ' D' ' 26' ' ' LEU . 2.2 m-20 -53.11 150.94 9.84 Favored Pre-proline 0 C--N 1.306 -1.314 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.058 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.8 34.59 0.25 Allowed 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 122.081 1.854 . . . . 0.0 111.841 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.483 ' H ' ' C ' ' D' ' 24' ' ' ASP . 48.4 tp -71.99 -38.25 69.7 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.801 179.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.73 -40.7 77.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . 0.413 HG23 ' N ' ' D' ' 29' ' ' ALA . 31.0 m -70.11 -40.23 78.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 CA-C-O 120.687 0.28 . . . . 0.0 110.836 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.413 ' N ' HG23 ' D' ' 28' ' ' VAL . . . -52.45 -30.93 32.19 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.48 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.19 -34.61 68.53 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.237 179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 35.4 t -63.68 -44.85 92.49 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 pt -56.71 -28.17 27.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 120.852 0.358 . . . . 0.0 110.696 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.97 -29.02 35.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.315 179.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.07 -38.5 95.45 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 116.36 -0.382 . . . . 0.0 113.263 -178.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 pp -68.96 -29.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 117.49 0.645 . . . . 0.0 110.366 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . 0.544 ' O ' HD23 ' D' ' 36' ' ' LEU . 0.9 OUTLIER -57.31 -29.49 63.97 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.382 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.695 ' CE1' ' HE2' ' A' ' 37' ' ' HIS . 8.7 m170 -69.75 -35.6 75.09 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.539 -179.187 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -66.18 -46.68 76.51 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -178.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 pp -66.33 -39.14 83.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.416 -178.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -38.92 74.6 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.054 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -52.96 -30.74 36.58 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 120.952 0.406 . . . . 0.0 111.0 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 67.6 p -63.95 -32.08 73.49 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.023 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 18.1 mm -70.66 -51.63 35.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.461 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.42 -29.74 31.68 Favored Glycine 0 C--N 1.307 -1.082 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.435 ' O ' ' OE1' ' D' ' 48' ' ' GLN . 6.2 t-80 -54.62 -27.19 37.65 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 120.715 0.293 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -48.83 -33.38 10.43 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.668 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 51.0 t-20 -48.72 -51.82 26.75 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.733 -178.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.447 ' H ' ' CD ' ' D' ' 48' ' ' GLN . 3.0 pm0 -88.46 -132.53 0.08 Allowed 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.693 ' O ' HG23 ' D' ' 49' ' ' ILE . 0.2 OUTLIER 29.78 89.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.959 0.885 . . . . 0.0 112.203 179.139 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt 42.83 77.68 0.06 Allowed 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.835 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 33.7 ptt-85 -49.29 -38.7 28.23 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.153 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.84 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.4 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 26' ' ' LEU . 49.5 m-20 -160.85 58.25 0.98 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.761 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.89 20.33 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.761 2.307 . . . . 0.0 111.912 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' A' ' 24' ' ' ASP . 1.4 tt -65.32 -49.54 69.06 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 -179.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' N ' ' A' ' 28' ' ' VAL . 11.9 p -70.6 -39.43 75.97 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.005 179.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.468 ' N ' HG13 ' A' ' 27' ' ' VAL . 69.0 t -62.95 -29.95 48.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.754 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.87 69.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.522 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.34 -36.0 80.53 Favored 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.596 -179.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.2 t -56.52 -46.19 80.72 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.565 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.696 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.35 -39.85 22.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.935 0.398 . . . . 0.0 110.166 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.8 mt -70.46 -28.61 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.289 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.527 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -64.96 -50.68 56.81 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.199 -0.524 . . . . 0.0 112.796 -178.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' N ' ' A' ' 36' ' ' LEU . 2.8 pp -66.04 -29.15 45.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.065 0.432 . . . . 0.0 111.413 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 35' ' ' ILE . 7.2 tt -62.74 -41.13 99.05 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.451 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.632 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.5 OUTLIER -65.56 -28.74 69.37 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.659 -178.976 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 60.3 t80 -64.49 -50.44 67.42 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -178.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' A' ' 42' ' ' THR . 7.4 pt -51.56 -40.46 25.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.149 -179.024 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.32 -33.25 65.05 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 120.97 0.414 . . . . 0.0 111.272 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.453 ' CD1' ' O ' ' A' ' 41' ' ' TRP . 11.8 t-105 -49.23 -31.06 7.99 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -177.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -69.39 -29.6 67.4 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.331 -179.443 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.5 mp -56.17 -44.98 80.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.847 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.15 -28.43 4.25 Favored Glycine 0 C--N 1.304 -1.236 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -178.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 -48.88 -28.48 3.81 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 120.806 0.336 . . . . 0.0 110.398 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.844 ' O ' HG23 ' A' ' 49' ' ' ILE . 2.8 pp -45.44 -44.22 12.05 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.905 -177.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.438 ' HB3' HD21 ' D' ' 47' ' ' ASN . 55.8 m-20 -49.98 -51.76 39.05 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.689 -0.632 . . . . 0.0 111.102 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.408 ' OE1' ' CG2' ' D' ' 43' ' ' ILE . 1.7 pt20 -96.94 59.46 1.68 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -178.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.844 HG23 ' O ' ' A' ' 46' ' ' LEU . 0.1 OUTLIER -64.1 -55.2 23.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.585 179.299 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.4 ' N ' HG12 ' A' ' 49' ' ' ILE . 0.0 OUTLIER -138.2 -12.87 1.4 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 120.854 0.359 . . . . 0.0 110.073 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -67.73 -22.54 65.24 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.561 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.095 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 80.5 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.436 ' C ' ' H ' ' B' ' 26' ' ' LEU . 48.7 m-20 54.02 57.54 12.88 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.818 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.49 24.55 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.702 2.268 . . . . 0.0 111.618 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.436 ' H ' ' C ' ' B' ' 24' ' ' ASP . 52.2 tp -70.23 -43.21 71.08 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.503 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 96.3 t -70.16 -41.77 78.99 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.738 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 50.2 t -70.21 -41.11 78.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.176 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.8 -37.31 18.82 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.349 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.9 -29.52 65.14 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.72 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.6 t -58.64 -41.73 86.66 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 23.9 mm -50.66 -36.65 14.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.684 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 7.2 mt -69.99 -29.76 41.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.15 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.68 -50.16 63.61 Favored Glycine 0 C--N 1.306 -1.131 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.622 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 13.0 pt -62.5 -43.65 98.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.998 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.5 tp -62.28 -49.16 76.76 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.019 0.438 . . . . 0.0 109.828 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -49.79 -39.45 38.21 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.95 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 74.8 t80 -69.99 -39.74 75.71 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.48 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.37 -43.67 94.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.968 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -66.05 -40.76 91.23 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.995 0.426 . . . . 0.0 110.594 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.9 t-105 -49.81 -32.74 14.74 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.285 -179.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 58.0 p -60.98 -38.16 84.99 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.993 -179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.594 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.6 mp -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.503 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.19 -29.81 16.24 Favored Glycine 0 C--N 1.304 -1.224 0 C-N-CA 121.335 -0.46 . . . . 0.0 112.089 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -58.07 -28.5 64.62 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 111.849 0.315 . . . . 0.0 111.849 -179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.565 ' CD1' HH21 ' B' ' 51' ' ' ARG . 1.0 OUTLIER -47.03 -32.22 3.83 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.321 -177.605 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.635 HD21 HD22 ' C' ' 47' ' ' ASN . 86.6 m-20 -62.29 -44.99 95.26 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.405 HE21 HD22 ' A' ' 46' ' ' LEU . 34.6 mm-40 -61.74 -53.33 57.43 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 120.916 0.389 . . . . 0.0 112.027 -178.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.736 HG23 ' H ' ' B' ' 50' ' ' LYS . 1.9 tp -58.75 -67.53 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.135 -179.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.736 ' H ' HG23 ' B' ' 49' ' ' ILE . 24.0 pttm -136.15 149.3 48.57 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.959 0.409 . . . . 0.0 110.709 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.565 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.3 tpm_? -153.93 -43.93 0.09 Allowed 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.314 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.223 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -172.0 56.18 0.22 Allowed Pre-proline 0 C--N 1.306 -1.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.956 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -76.21 11.57 1.76 Allowed 'Trans proline' 0 N--CA 1.495 1.602 0 C-N-CA 122.747 2.298 . . . . 0.0 111.729 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.42 HD21 HG13 ' D' ' 28' ' ' VAL . 41.4 tp -70.07 -43.68 70.68 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.754 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -70.36 -40.92 78.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.923 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.2 -47.76 80.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -49.73 -37.18 28.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.976 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.97 -29.55 70.49 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-O 120.83 0.347 . . . . 0.0 111.07 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 6.2 t -52.49 -43.72 65.19 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -50.1 -29.1 5.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-O 120.75 0.31 . . . . 0.0 111.324 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -70.1 -31.83 48.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.116 -179.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.62 -50.16 38.78 Favored Glycine 0 C--N 1.303 -1.267 0 C-N-CA 120.654 -0.784 . . . . 0.0 111.753 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.2 tp -69.54 -29.49 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 120.852 0.358 . . . . 0.0 110.281 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.11 -48.86 79.71 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.79 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.5 OUTLIER -55.59 -29.14 58.55 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 120.646 -0.422 . . . . 0.0 111.935 -178.491 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -59.04 -42.61 90.67 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.375 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.439 ' H ' HD12 ' C' ' 39' ' ' ILE . 3.8 mp -58.38 -47.57 87.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.577 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.93 78.63 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 120.889 -0.325 . . . . 0.0 110.847 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -49.13 -29.99 6.06 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 67.7 p -57.13 -37.39 71.94 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.248 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 75.9 mt -63.22 -50.23 79.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.912 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.41 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -48.15 -28.83 6.3 Favored Glycine 0 C--N 1.305 -1.182 0 N-CA-C 112.059 -0.416 . . . . 0.0 112.059 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -49.12 -27.96 3.89 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.856 0.328 . . . . 0.0 111.341 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.581 HD21 HE22 ' D' ' 48' ' ' GLN . 3.4 pp -46.04 -44.39 15.26 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.917 -177.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.635 HD22 HD21 ' B' ' 47' ' ' ASN . 28.4 p-10 -52.05 -46.54 65.13 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.046 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.459 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 7.4 tm0? -53.84 -48.14 70.24 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.645 -179.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.677 ' CG1' ' H ' ' C' ' 50' ' ' LYS . 0.9 OUTLIER -94.43 -143.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.637 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.677 ' H ' ' CG1' ' C' ' 49' ' ' ILE . 50.1 mttm 43.0 -167.19 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 120.663 0.268 . . . . 0.0 110.31 -179.222 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -43.09 133.28 3.89 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.839 0.352 . . . . 0.0 110.878 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . 0.468 ' C ' ' NH1' ' B' ' 51' ' ' ARG . . . . . . . . 0 C--N 1.305 -1.163 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' D' ' 26' ' ' LEU . 4.1 m-20 -67.92 151.13 97.43 Favored Pre-proline 0 C--N 1.306 -1.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.124 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -72.21 27.08 0.26 Allowed 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 122.218 1.945 . . . . 0.0 111.829 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' D' ' 24' ' ' ASP . 47.7 tp -70.17 -44.86 67.91 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.582 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -70.17 -36.97 70.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.998 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . 0.42 HG13 HD21 ' C' ' 26' ' ' LEU . 87.9 t -67.97 -46.76 81.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.412 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.67 -34.35 11.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.46 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.96 -29.65 69.56 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 34.6 t -58.82 -43.72 90.69 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.218 -179.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.674 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -53.98 -29.9 19.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 120.835 0.35 . . . . 0.0 110.351 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.36 -29.91 37.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.265 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.93 -43.94 95.26 Favored Glycine 0 C--N 1.308 -1.024 0 C-N-CA 121.34 -0.457 . . . . 0.0 112.188 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 13.6 pt -67.19 -37.64 79.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.499 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.1 tt -49.81 -43.31 48.55 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.616 ' NE2' ' NE2' ' A' ' 37' ' ' HIS . 26.4 m170 -57.8 -44.19 86.14 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.923 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -61.56 -47.26 86.34 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -178.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . 0.415 ' O ' ' OG1' ' D' ' 42' ' ' THR . 14.6 pt -63.79 -41.76 93.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.301 -0.56 . . . . 0.0 111.425 -178.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.432 ' HB3' ' CZ2' ' A' ' 41' ' ' TRP . . . -70.16 -40.76 74.53 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.804 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.53 -29.32 6.65 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.042 0.449 . . . . 0.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.2 p -62.25 -33.21 74.18 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.345 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.602 ' O ' HD12 ' D' ' 46' ' ' LEU . 90.7 mt -65.56 -50.72 70.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.03 -28.15 47.84 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -56.85 -28.06 61.17 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 112.628 0.603 . . . . 0.0 112.628 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.898 HD13 ' N ' ' D' ' 47' ' ' ASN . 0.0 OUTLIER -49.21 -28.08 4.23 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -178.342 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.898 ' N ' HD13 ' D' ' 46' ' ' LEU . 16.0 m120 -65.09 -50.61 65.47 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.759 ' N ' HE21 ' D' ' 48' ' ' GLN . 0.0 OUTLIER -64.21 -53.79 43.64 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -177.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.87 HG23 ' H ' ' D' ' 50' ' ' LYS . 14.7 tt -55.6 -68.63 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.237 -179.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.87 ' H ' HG23 ' D' ' 49' ' ' ILE . 14.7 tptm -121.79 156.03 34.05 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 120.814 0.34 . . . . 0.0 110.497 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 37.8 ptt-85 -151.02 16.94 0.76 Allowed 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.406 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.165 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.978 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 68.7 m . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -173.58 60.55 0.25 Allowed Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.41 24.7 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.716 2.277 . . . . 0.0 111.851 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.2 tp -70.14 -42.89 71.98 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.084 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.3 p -70.69 -39.19 75.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.65 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.471 ' N ' HG13 ' A' ' 27' ' ' VAL . 58.0 t -66.77 -42.57 89.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-O 120.85 0.357 . . . . 0.0 110.971 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -34.54 18.85 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.683 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.61 82.54 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.739 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -59.31 -44.03 92.6 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.392 -179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 70.8 mt -49.81 -34.68 9.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 120.95 0.405 . . . . 0.0 110.759 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.0 mt -69.8 -29.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.555 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -66.13 -50.27 52.6 Favored Glycine 0 C--N 1.306 -1.109 0 C-N-CA 121.105 -0.569 . . . . 0.0 112.363 -179.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 40.5 mt -61.04 -29.63 46.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 122.509 -0.407 . . . . 0.0 110.918 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.469 ' O ' HG22 ' A' ' 39' ' ' ILE . 46.3 tp -61.88 -44.43 96.83 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.361 -179.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -61.56 -28.83 69.62 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.501 -178.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 40.4 t80 -63.19 -50.63 69.54 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.253 0.464 . . . . 0.0 112.253 -178.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 42' ' ' THR . 5.8 tt -57.07 -38.83 62.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.23 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -30.62 64.77 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 120.936 0.398 . . . . 0.0 111.448 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -55.09 -36.49 65.7 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 -177.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.52 ' O ' ' ND1' ' A' ' 45' ' ' HIS . 0.1 OUTLIER -59.06 -34.01 71.45 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.995 -178.946 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 mp -60.68 -38.21 77.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.114 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -45.87 -25.81 1.75 Allowed Glycine 0 C--N 1.306 -1.111 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.52 ' ND1' ' O ' ' A' ' 42' ' ' THR . 39.1 m170 -46.96 -23.65 0.49 Allowed 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 122.77 0.428 . . . . 0.0 111.173 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mt -42.21 -47.32 4.67 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 120.984 -0.287 . . . . 0.0 110.504 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -53.59 -51.1 64.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -178.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' HG3' ' H ' ' A' ' 49' ' ' ILE . 8.5 pt20 -69.74 -55.16 10.68 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -178.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.414 ' H ' ' HG3' ' A' ' 48' ' ' GLN . 4.5 pt -54.23 -38.31 38.88 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.998 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -76.03 -72.61 0.31 Allowed 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.834 0.35 . . . . 0.0 110.527 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.514 HH22 ' HZ1' ' C' ' 50' ' ' LYS . 98.8 mtt180 -83.26 139.53 33.04 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.431 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.125 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.974 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 71.9 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.407 ' C ' ' H ' ' B' ' 26' ' ' LEU . 51.8 m-20 -77.74 149.6 77.78 Favored Pre-proline 0 C--N 1.305 -1.359 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.203 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -72.7 39.55 0.44 Allowed 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.104 1.87 . . . . 0.0 111.549 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.407 ' H ' ' C ' ' B' ' 24' ' ' ASP . 1.6 tt -63.35 -49.62 73.18 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.69 -179.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.08 -33.77 56.52 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.375 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 47.6 t -69.93 -44.5 78.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.516 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.86 -39.37 39.01 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.672 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.25 -33.47 74.67 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.846 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 6.8 t -57.8 -41.82 82.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.849 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mm -51.79 -34.33 16.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.727 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -70.88 -29.76 38.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.224 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.15 -48.74 62.54 Favored Glycine 0 C--N 1.305 -1.159 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 11.3 mm -61.54 -46.22 97.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.64 -179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 32.3 tp -52.39 -42.49 64.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.019 0.438 . . . . 0.0 109.933 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -49.92 -44.67 50.38 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.835 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -66.65 -41.6 87.98 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.555 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 93.3 mt -60.85 -45.16 98.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.899 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.416 ' HB3' ' CZ2' ' C' ' 41' ' ' TRP . . . -67.81 -36.88 81.18 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.467 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.66 -34.85 19.57 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.534 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 25.0 p -52.43 -41.05 62.92 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.349 -179.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.659 ' N ' HD12 ' B' ' 43' ' ' ILE . 1.8 mp -62.66 -50.3 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.929 -0.308 . . . . 0.0 111.121 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.16 -29.72 15.88 Favored Glycine 0 C--N 1.305 -1.167 0 C-N-CA 121.187 -0.53 . . . . 0.0 111.964 -179.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -60.69 -28.1 68.37 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.5 ' CD1' HH21 ' B' ' 51' ' ' ARG . 1.0 OUTLIER -46.81 -31.08 2.79 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.863 -177.364 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -60.0 -48.96 79.54 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -63.14 -54.48 37.09 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -178.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.601 HG23 ' H ' ' B' ' 50' ' ' LYS . 2.6 tt -58.42 -68.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.07 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.601 ' H ' HG23 ' B' ' 49' ' ' ILE . 60.7 pttt -121.85 161.77 22.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.846 0.355 . . . . 0.0 110.668 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.5 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.6 tpm_? -167.92 -57.61 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.611 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.173 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.953 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 40.9 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -174.92 56.42 0.17 Allowed Pre-proline 0 C--N 1.307 -1.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.708 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.07 11.49 1.45 Allowed 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 122.692 2.261 . . . . 0.0 112.156 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 40.5 tp -64.21 -48.33 76.28 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.097 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 23.4 t -70.22 -40.21 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.222 -179.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 97.4 t -69.47 -44.18 80.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.806 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.535 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -51.25 -43.1 61.43 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.957 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.73 -29.44 69.37 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.093 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 5.8 t -51.22 -43.42 61.43 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.493 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.535 HG22 ' O ' ' C' ' 29' ' ' ALA . 10.2 tp -49.5 -29.61 4.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.344 -179.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.5 mt -69.03 -30.55 47.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.912 -179.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.546 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -65.64 -49.71 58.38 Favored Glycine 0 C--N 1.303 -1.292 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.312 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.5 tp -66.41 -29.34 46.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.841 -179.444 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 10.4 tp -62.02 -50.71 70.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 116.528 -0.306 . . . . 0.0 111.823 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.6 OUTLIER -52.51 -29.24 24.11 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.665 -178.401 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 57.7 t80 -58.06 -44.5 87.5 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 120.578 0.228 . . . . 0.0 111.481 -179.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.0 mt -54.55 -48.99 69.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.587 -178.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.53 -30.49 67.25 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-O 120.994 0.426 . . . . 0.0 110.761 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . 0.416 ' CZ2' ' HB3' ' B' ' 40' ' ' ALA . 2.7 t-105 -49.28 -36.67 21.3 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.058 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 33.6 p -59.23 -36.94 76.34 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.088 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -63.16 -50.98 77.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.283 -179.483 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.55 -29.8 25.4 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.916 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -51.76 -29.73 19.92 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.4 ' HG ' ' N ' ' C' ' 47' ' ' ASN . 1.5 pp -46.54 -35.8 6.13 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.472 -177.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.443 ' OD1' ' N ' ' C' ' 48' ' ' GLN . 7.5 p30 -48.96 -44.86 41.17 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.371 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.443 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 5.5 tp-100 -63.15 -48.71 77.28 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.695 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.465 HG23 ' O ' ' C' ' 49' ' ' ILE . 3.0 tp -111.58 101.13 12.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 CA-C-O 121.452 0.644 . . . . 0.0 110.252 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.514 ' HZ1' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER -170.1 -39.76 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.682 179.605 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -74.81 -43.93 52.06 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.496 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.209 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -179.903 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 46.9 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -82.22 149.92 63.2 Favored Pre-proline 0 C--N 1.307 -1.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.347 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.12 42.52 0.64 Allowed 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.164 1.909 . . . . 0.0 111.745 179.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 51.7 tp -70.22 -47.92 59.32 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.649 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 10.5 t -70.87 -35.97 62.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.145 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -70.14 -46.29 72.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.659 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -29.8 7.71 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.005 -179.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.72 66.86 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 38.8 t -58.22 -40.38 81.52 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.22 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -55.22 -29.77 23.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 120.899 0.38 . . . . 0.0 110.836 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.23 -29.67 37.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.49 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.74 -44.43 80.87 Favored Glycine 0 C--N 1.307 -1.04 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.444 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.0 pt -67.03 -36.15 76.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.64 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 tp -49.91 -36.68 28.37 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.457 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -59.17 -47.04 86.79 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.85 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -57.54 -46.14 84.24 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 14.9 pt -66.39 -43.14 91.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.436 -178.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -39.78 72.87 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.367 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 t-105 -49.39 -28.86 5.53 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 120.974 0.416 . . . . 0.0 110.673 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 81.5 p -62.0 -29.92 70.59 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.755 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 82.1 mt -70.21 -52.25 31.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-O 121.025 0.44 . . . . 0.0 111.053 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.538 ' O ' ' ND2' ' D' ' 47' ' ' ASN . . . -53.09 -28.21 32.79 Favored Glycine 0 C--N 1.302 -1.321 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.457 ' O ' HG23 ' D' ' 49' ' ' ILE . 0.0 OUTLIER -68.22 -29.34 68.14 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.527 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.467 HD12 ' N ' ' D' ' 47' ' ' ASN . 2.4 pp -52.76 -46.67 67.61 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.478 -179.021 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.55 ' H ' ' ND2' ' D' ' 47' ' ' ASN . 0.2 OUTLIER -60.8 -45.63 93.67 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.609 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.464 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 2.1 mm100 -67.42 -110.57 0.0 OUTLIER 'General case' 0 N--CA 1.429 -1.517 0 C-N-CA 122.287 0.235 . . . . 0.0 111.214 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.457 HG23 ' O ' ' D' ' 45' ' ' HIS . 32.1 pt 32.69 50.59 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.379 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' D' ' 49' ' ' ILE . 50.5 mtpt 47.99 -178.11 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.422 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 ppt_? -158.51 -3.29 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 120.761 0.315 . . . . 0.0 110.51 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.252 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 179.956 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 49.9 m . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -161.64 59.17 1.0 Allowed Pre-proline 0 C--N 1.306 -1.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.735 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -77.55 -3.38 13.55 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.754 2.303 . . . . 0.0 112.003 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 57.7 tp -63.69 -45.73 88.72 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.83 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 28' ' ' VAL . 13.2 p -70.37 -37.61 71.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.453 -179.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.418 ' N ' HG13 ' A' ' 27' ' ' VAL . 62.6 t -70.08 -35.99 66.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 CA-C-O 120.982 0.42 . . . . 0.0 110.784 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.68 -38.16 31.66 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.62 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.57 -34.0 76.16 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.341 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.2 t -63.01 -50.34 71.11 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -178.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 11.2 pt -51.99 -29.49 11.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.636 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.1 mt -67.25 -29.58 46.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -59.76 -46.24 94.38 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.4 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' D' ' 33' ' ' ILE . 10.0 mm -61.24 -35.75 68.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 CA-C-O 120.77 0.319 . . . . 0.0 111.145 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.65 -49.75 76.4 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.954 -178.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.7 OUTLIER -57.72 -28.86 64.25 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.812 -178.768 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 71.2 t80 -59.63 -50.11 75.16 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.711 ' O ' HG22 ' A' ' 42' ' ' THR . 1.5 pp -59.22 -41.67 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.768 -178.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.92 -34.03 68.76 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.106 0.479 . . . . 0.0 111.002 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.474 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 10.1 t-105 -48.23 -35.3 11.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.517 -178.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.711 HG22 ' O ' ' A' ' 39' ' ' ILE . 14.9 t -56.86 -29.34 62.81 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.508 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 80.0 mt -55.28 -46.08 77.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.04 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' O ' ' OD1' ' A' ' 47' ' ' ASN . . . -45.5 -28.63 2.42 Favored Glycine 0 C--N 1.305 -1.185 0 C-N-CA 120.762 -0.733 . . . . 0.0 111.534 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 -48.59 -25.98 2.0 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.928 0.364 . . . . 0.0 110.79 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.664 ' O ' HG23 ' A' ' 49' ' ' ILE . 0.3 OUTLIER -45.2 -50.21 11.69 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.399 -178.175 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.542 ' OD1' ' NE2' ' A' ' 48' ' ' GLN . 0.1 OUTLIER -59.41 -44.02 92.92 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.507 -179.024 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.673 ' OE1' HD21 ' D' ' 46' ' ' LEU . 9.0 mm-40 -85.0 68.18 10.47 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.887 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.0 OUTLIER -115.93 -137.63 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 CA-C-O 120.873 0.368 . . . . 0.0 111.972 -179.699 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.418 ' N ' HG12 ' A' ' 49' ' ' ILE . 22.4 pttp -102.94 12.31 36.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.156 -179.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.8 ttt-85 -63.51 -41.04 98.54 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.23 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.146 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 179.651 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 41.2 m . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' B' ' 26' ' ' LEU . 0.8 OUTLIER -79.77 152.22 74.66 Favored Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.167 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 40.72 0.32 Allowed 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.226 1.951 . . . . 0.0 111.63 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.432 ' H ' ' C ' ' B' ' 24' ' ' ASP . 37.4 tp -69.35 -45.93 68.24 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.535 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 79.9 t -70.43 -41.1 78.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 57.3 t -68.65 -46.85 79.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.321 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.76 -38.37 33.72 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.663 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.89 -31.53 72.18 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.31 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 31.9 t -56.04 -42.11 76.05 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.991 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.6 mm -49.67 -29.86 4.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.649 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.9 mt -71.92 -29.82 34.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.51 -50.61 42.34 Favored Glycine 0 C--N 1.307 -1.076 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.324 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.5 pt -64.53 -47.1 90.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.831 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -51.51 -41.26 60.87 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.059 0.457 . . . . 0.0 110.074 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -49.58 -39.79 36.38 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.813 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.46 -40.03 92.71 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.688 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.566 HD12 ' N ' ' B' ' 39' ' ' ILE . 1.7 mp -57.48 -42.84 81.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.51 -179.26 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.98 -37.18 69.93 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.228 0.537 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.8 t-105 -54.91 -39.65 69.02 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.471 HG22 ' H ' ' B' ' 42' ' ' THR . 0.0 OUTLIER -57.69 -34.14 69.11 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.243 -178.903 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.586 ' O ' HD12 ' B' ' 46' ' ' LEU . 28.8 mm -62.14 -47.72 91.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.603 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.09 -28.67 8.2 Favored Glycine 0 C--N 1.306 -1.089 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -61.23 -27.05 68.17 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.978 HD13 ' H ' ' B' ' 47' ' ' ASN . 0.0 OUTLIER -47.71 -30.63 3.98 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.676 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.978 ' H ' HD13 ' B' ' 46' ' ' LEU . 29.4 p-10 -61.5 -50.5 72.47 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -59.27 -53.07 62.47 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 120.978 0.418 . . . . 0.0 112.112 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.798 HG23 ' H ' ' B' ' 50' ' ' LYS . 2.5 tp -60.67 -67.2 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.162 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.798 ' H ' HG23 ' B' ' 49' ' ' ILE . 57.4 mttp -71.57 116.21 11.65 Favored 'General case' 0 C--N 1.309 -1.175 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.149 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -166.3 129.61 2.02 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.474 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.16 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.938 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -162.02 56.37 0.66 Allowed Pre-proline 0 C--N 1.306 -1.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -77.82 8.57 3.36 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.692 2.261 . . . . 0.0 111.738 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 44.5 tp -70.13 -42.64 72.33 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.091 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 92.8 t -70.12 -44.22 78.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.192 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 96.0 t -67.09 -46.64 84.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.545 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.55 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -54.87 -44.37 73.99 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.941 -179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.54 -29.63 70.71 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 120.777 0.322 . . . . 0.0 110.925 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 7.1 t -50.56 -41.86 54.68 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.181 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.55 HG22 ' O ' ' C' ' 29' ' ' ALA . 16.2 tt -49.8 -29.06 4.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-O 120.851 0.357 . . . . 0.0 111.295 -179.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 6.9 mt -65.81 -33.45 63.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.144 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.57 -50.33 37.93 Favored Glycine 0 C--N 1.303 -1.256 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.202 -178.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.05 -29.48 44.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-O 120.868 0.366 . . . . 0.0 110.529 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -61.28 -50.62 72.26 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.782 -179.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.642 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.0 OUTLIER -55.08 -28.65 54.06 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.742 -178.577 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.642 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 43.9 t80 -57.9 -44.38 86.72 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 121.031 -0.268 . . . . 0.0 111.456 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 79.4 mt -56.34 -48.37 79.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.943 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.05 -34.28 73.02 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.855 0.359 . . . . 0.0 110.755 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 -48.4 -30.25 4.83 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.565 -179.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 40.7 p -56.38 -38.74 71.89 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.634 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.632 HD12 ' N ' ' C' ' 43' ' ' ILE . 1.7 mp -64.05 -49.93 79.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.013 -179.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.436 ' O ' ' OD1' ' C' ' 47' ' ' ASN . . . -47.82 -28.28 5.34 Favored Glycine 0 C--N 1.304 -1.198 0 C-N-CA 121.301 -0.476 . . . . 0.0 112.024 -178.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -49.07 -27.84 3.64 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.4 ' O ' ' O ' ' C' ' 49' ' ' ILE . 3.0 pp -46.04 -41.41 12.02 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.399 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.451 ' N ' ' OD1' ' C' ' 47' ' ' ASN . 20.8 p-10 -49.13 -50.24 38.32 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.174 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -58.09 -49.14 77.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.162 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.607 HG23 ' O ' ' C' ' 49' ' ' ILE . 0.1 OUTLIER -120.8 110.39 28.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.909 -179.565 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.523 ' N ' HD13 ' C' ' 49' ' ' ILE . 3.4 ttmp? -131.78 -76.74 0.51 Allowed 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.12 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 84.3 mtt85 -89.24 9.55 25.4 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.485 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.963 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 74.1 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' D' ' 26' ' ' LEU . 1.4 m-20 -88.5 150.89 47.42 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.232 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.69 33.6 0.37 Allowed 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.189 1.926 . . . . 0.0 111.756 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' D' ' 24' ' ' ASP . 2.1 tt -63.9 -50.54 68.32 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.613 -179.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 t -70.49 -33.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.113 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 92.5 t -69.95 -45.1 77.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.692 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.58 -32.71 8.51 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.718 -178.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.31 -32.17 73.69 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 120.769 0.319 . . . . 0.0 110.912 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 43.0 t -60.4 -42.93 96.95 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.217 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 mm -58.05 -35.21 51.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 CA-C-O 121.148 0.499 . . . . 0.0 110.346 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.434 ' CD1' ' CD1' ' A' ' 35' ' ' ILE . 8.8 mt -71.67 -29.98 36.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.303 179.243 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.36 91.73 Favored Glycine 0 CA--C 1.53 1.002 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.589 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 12.8 pt -68.51 -38.13 78.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.782 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tp -49.69 -38.63 33.76 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 120.946 0.403 . . . . 0.0 110.455 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.533 ' CE1' ' NE2' ' A' ' 37' ' ' HIS . 16.4 m170 -57.53 -39.78 77.36 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.371 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -58.23 -46.55 85.72 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.6 pt -66.63 -42.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.125 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -41.96 77.18 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.723 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -48.74 -29.46 4.5 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.745 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 2.5 m -66.8 -29.85 69.89 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.515 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 30.0 mm -65.48 -50.8 70.22 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.988 -0.285 . . . . 0.0 111.181 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.48 -34.17 63.34 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.451 ' O ' ' OE1' ' D' ' 48' ' ' GLN . 10.7 t-80 -55.98 -28.05 55.44 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 120.653 0.263 . . . . 0.0 111.522 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.673 HD21 ' OE1' ' A' ' 48' ' ' GLN . 0.4 OUTLIER -53.58 -29.82 39.26 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.17 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.537 ' OD1' ' N ' ' D' ' 48' ' ' GLN . 6.5 p30 -59.75 -49.88 76.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.405 -0.518 . . . . 0.0 112.313 -178.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.607 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 0.1 OUTLIER -83.31 53.02 2.35 Favored 'General case' 0 C--N 1.309 -1.184 0 O-C-N 122.208 -0.307 . . . . 0.0 111.616 -179.056 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.418 ' O ' ' O ' ' D' ' 50' ' ' LYS . 0.0 OUTLIER -177.2 127.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.119 0 CA-C-O 121.18 0.515 . . . . 0.0 110.229 179.085 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' D' ' 49' ' ' ILE . 54.1 tttp 60.18 131.01 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.833 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -161.46 136.57 7.47 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.467 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.173 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.919 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -171.23 60.11 0.31 Allowed Pre-proline 0 C--N 1.305 -1.329 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.827 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.68 28.68 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.788 2.325 . . . . 0.0 112.04 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' N ' HD12 ' A' ' 26' ' ' LEU . 10.3 mp -69.5 -40.91 76.71 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.711 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.544 HG13 ' N ' ' A' ' 28' ' ' VAL . 12.4 p -70.76 -44.15 76.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.475 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.544 ' N ' HG13 ' A' ' 27' ' ' VAL . 88.5 t -63.63 -41.75 93.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.737 -179.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.77 -37.38 29.53 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.476 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.76 -36.8 84.24 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.471 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -53.81 -47.14 71.13 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 120.994 -0.283 . . . . 0.0 111.233 -179.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.692 ' H ' HD12 ' A' ' 32' ' ' ILE . 2.1 mp -51.56 -40.17 24.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.462 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.87 -29.5 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -67.1 -50.66 44.37 Favored Glycine 0 C--N 1.306 -1.125 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.907 -179.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 57.3 mt -64.74 -29.71 48.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 122.652 -0.322 . . . . 0.0 111.047 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.474 ' O ' HG22 ' A' ' 39' ' ' ILE . 33.4 tp -61.47 -45.18 95.33 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.331 -179.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.632 ' CE1' ' NE2' ' D' ' 37' ' ' HIS . 0.6 OUTLIER -61.66 -28.79 69.64 Favored 'General case' 0 C--N 1.301 -1.529 0 C-N-CA 120.151 -0.62 . . . . 0.0 111.497 -178.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 78.2 t80 -63.47 -50.82 68.17 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.772 ' O ' HG22 ' A' ' 42' ' ' THR . 5.4 tt -54.91 -39.67 49.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.135 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.14 -35.3 69.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.922 0.392 . . . . 0.0 111.215 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.462 ' C ' ' CD1' ' A' ' 41' ' ' TRP . 11.3 t-105 -49.78 -35.07 21.2 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.244 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 39' ' ' ILE . 9.8 t -65.4 -29.4 70.1 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -179.275 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 36.5 mm -60.87 -45.15 98.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.777 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -46.16 -27.03 2.44 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.037 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -49.41 -29.62 6.69 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.2 mp -46.06 -43.17 14.33 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 121.181 -0.208 . . . . 0.0 111.036 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.752 HD21 HD22 ' B' ' 47' ' ' ASN . 18.9 m120 -58.02 -51.92 67.65 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.905 -0.718 . . . . 0.0 112.122 -178.166 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.87 ' NE2' HD11 ' D' ' 46' ' ' LEU . 0.6 OUTLIER -61.89 -53.22 58.72 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -177.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 40.1 pt -48.64 -3.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -177.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 48' ' ' GLN . 17.9 pttp -143.78 -44.85 0.27 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 118.301 0.5 . . . . 0.0 111.077 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -76.69 -143.27 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.797 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.133 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.765 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -133.72 62.63 59.73 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.498 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -76.1 45.32 1.51 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.75 2.3 . . . . 0.0 111.574 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.01 -48.74 67.49 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.552 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.59 -30.35 42.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.48 HG22 HD23 ' A' ' 26' ' ' LEU . 58.0 t -70.14 -46.7 71.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.392 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.11 -31.5 8.2 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.613 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.69 -29.64 70.22 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.538 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 38.6 t -54.44 -38.08 65.89 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.796 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 25.8 mm -55.6 -36.94 44.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-O 120.923 0.392 . . . . 0.0 110.456 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 5.9 mt -71.24 -29.98 38.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.337 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.96 -48.41 54.47 Favored Glycine 0 C--N 1.306 -1.11 0 N-CA-C 111.659 -0.576 . . . . 0.0 111.659 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -63.93 -42.44 95.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.611 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 35.9 tp -60.61 -44.26 96.51 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 24.2 t-80 -49.86 -44.36 49.68 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.696 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 55.8 t80 -70.12 -37.55 75.34 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.272 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' B' ' 42' ' ' THR . 91.8 mt -63.41 -42.64 97.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.856 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.412 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.66 -37.47 70.78 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.009 0.433 . . . . 0.0 111.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -49.55 -44.84 46.94 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.81 -27.83 5.55 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.655 -178.528 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.517 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 9.3 tp -56.17 -48.57 79.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.252 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.517 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -57.65 -29.73 61.58 Favored Glycine 0 C--N 1.304 -1.229 0 C-N-CA 121.32 -0.466 . . . . 0.0 111.963 -179.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -53.17 -29.53 32.11 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.653 ' C ' HD12 ' B' ' 46' ' ' LEU . 2.7 pp -50.58 -34.0 24.13 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 120.836 -0.346 . . . . 0.0 111.519 -178.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.752 HD22 HD21 ' A' ' 47' ' ' ASN . 5.3 m120 -63.19 -50.38 70.55 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.096 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 0.0 OUTLIER -67.41 -55.89 11.88 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.142 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.815 HG23 ' H ' ' B' ' 50' ' ' LYS . 7.7 tp -50.51 -67.71 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.815 ' H ' HG23 ' B' ' 49' ' ' ILE . 23.0 ttpp -139.82 146.49 39.48 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.997 0.427 . . . . 0.0 111.114 -179.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.675 HH21 ' ND2' ' B' ' 47' ' ' ASN . 48.2 ttm-85 -162.53 115.06 1.66 Allowed 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.383 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.978 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -175.74 59.68 0.19 Allowed Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.778 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.95 19.74 0.57 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.862 2.375 . . . . 0.0 111.97 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.552 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.3 mp -67.1 -42.71 84.13 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.637 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . 0.508 HG13 ' N ' ' C' ' 28' ' ' VAL . 12.9 p -70.28 -40.9 78.46 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.206 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . 0.508 ' N ' HG13 ' C' ' 27' ' ' VAL . 92.2 t -64.47 -46.63 92.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.746 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.555 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -55.96 -40.69 73.6 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.92 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.56 -29.65 70.67 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.746 0.308 . . . . 0.0 111.138 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 15.1 t -52.56 -44.27 65.76 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.617 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.555 HG22 ' O ' ' C' ' 29' ' ' ALA . 12.3 tt -49.68 -29.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.269 -179.101 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 8.4 mt -69.02 -31.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.037 -179.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -68.15 -50.43 39.79 Favored Glycine 0 C--N 1.306 -1.085 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.016 -179.214 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . 0.439 HG22 ' H ' ' C' ' 35' ' ' ILE . 0.0 OUTLIER -66.72 -29.48 46.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.722 -179.76 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 30.4 tp -60.72 -48.77 80.31 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.687 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.8 OUTLIER -56.79 -29.99 63.24 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.863 -178.367 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.2 t80 -62.18 -44.26 96.99 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.098 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 96.6 mt -55.65 -45.61 79.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.723 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.15 -33.79 72.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.015 0.436 . . . . 0.0 110.779 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -49.29 -34.68 16.0 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.173 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 18.5 p -57.3 -45.05 84.53 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.376 -179.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.486 ' H ' HD12 ' C' ' 43' ' ' ILE . 4.2 mp -66.45 -51.09 61.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.603 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.47 -29.52 17.42 Favored Glycine 0 C--N 1.303 -1.267 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -59.77 -28.96 67.85 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.116 0.414 . . . . 0.0 112.116 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.433 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 0.9 OUTLIER -46.1 -28.27 1.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.446 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.643 HD21 HE22 ' D' ' 48' ' ' GLN . 28.0 m120 -47.43 -51.48 19.95 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.383 -178.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.702 ' H ' ' NE2' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -73.24 -45.74 54.24 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.269 -179.622 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 1.1 tp -47.93 -5.73 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.515 ' N ' ' O ' ' C' ' 48' ' ' GLN . 49.8 mttm -92.08 153.65 19.25 Favored 'General case' 0 C--N 1.317 -0.833 0 O-C-N 122.046 -0.408 . . . . 0.0 110.234 179.425 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . 0.428 ' O ' ' O ' ' C' ' 50' ' ' LYS . 2.1 mpt_? 48.28 -176.96 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.162 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 47.2 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -76.82 148.35 79.05 Favored Pre-proline 0 C--N 1.305 -1.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.113 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.34 41.0 0.64 Allowed 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.1 1.867 . . . . 0.0 111.872 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . . . . . . . . . 59.3 tp -63.85 -48.97 74.63 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.617 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 47.3 t -70.42 -34.21 57.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 57.6 t -70.05 -44.14 78.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.584 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.6 -35.08 19.7 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.722 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.23 -29.63 70.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 33.2 t -55.54 -41.5 73.28 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.035 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.666 HD12 ' N ' ' D' ' 32' ' ' ILE . 2.0 mp -54.87 -35.62 34.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.491 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 mt -70.76 -30.05 40.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.352 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.25 -46.02 88.88 Favored Glycine 0 C--N 1.306 -1.096 0 C-N-CA 121.249 -0.501 . . . . 0.0 112.07 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 22.1 pt -66.68 -29.79 47.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-O 120.815 0.341 . . . . 0.0 110.753 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tp -56.29 -42.39 77.46 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.708 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 37' ' ' HIS . 15.3 m170 -56.62 -43.52 80.28 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -59.52 -47.09 86.88 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 13.4 pt -64.03 -43.8 97.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.491 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.12 -39.37 75.5 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.058 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -48.81 -29.4 4.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.859 0.361 . . . . 0.0 110.502 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 64.8 p -61.99 -31.51 71.88 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.769 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 33.7 mm -67.38 -51.33 53.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.76 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -50.99 -29.95 21.66 Favored Glycine 0 C--N 1.304 -1.245 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -59.02 -29.61 67.39 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 120.648 0.261 . . . . 0.0 111.274 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.87 HD11 ' NE2' ' A' ' 48' ' ' GLN . 2.6 pp -49.52 -43.49 45.68 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.395 -178.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.656 ' N ' HD12 ' D' ' 46' ' ' LEU . 0.9 OUTLIER -62.32 -49.42 75.68 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 -179.055 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.709 ' N ' HE21 ' D' ' 48' ' ' GLN . 2.9 mm-40 -54.22 -40.27 67.5 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-O 120.943 0.402 . . . . 0.0 111.603 -179.401 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.601 ' O ' HG23 ' D' ' 49' ' ' ILE . 20.4 tt -102.55 113.24 38.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 CA-C-O 121.531 0.681 . . . . 0.0 109.973 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt 62.76 144.98 0.02 OUTLIER 'General case' 0 C--N 1.292 -1.914 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.805 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.95 18.96 1.44 Allowed 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.315 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.16 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.999 . . . . . . . . 0 0 . 1 stop_ save_